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Abstract 
Autoimmune Polyendocrinopathy Syndrome type 1 (APS1) results from homozygous 
AIRE mutations that cripple thymic deletion of T cells that recognise a wide array of 
organ-specific self-antigens. For unknown reasons, APS1 nevertheless exhibits a highly 
variable onset and pattern of discrete organs affected by autoimmunity. The studies 
presented in this thesis test the hypothesis that this variable and limited organ 
involvement reflects the failsafe action of discrete post-thymic mechanisms for 
imposing self-tolerance in peripheral T cells, so that autoimmunity only manifests when 
one of these peripheral mechanisms also breaks down.  
Aire-deficient mice were crossed with mice carrying specific genetic defects in one of 
four distinct peripheral tolerance mechanisms: activation-induced cell death (Faslgld/gld), 
anergy and requirement for CD28 co-stimulation (Cblb-/-), inhibition of ICOS and TFH 
cells (Rc3h1san/san), or decreased numbers of Foxp3+ T regulatory cells (Card11unm/unm). 
Cblb-deficiency was unique among these four in precipitating rapid clinical 
autoimmune disease when combined with Aire-deficiency, resulting in lethal exocrine 
pancreatitis and sialoadenitis within weeks after T cells emerged from the thymus. 
Adoptive transfer experiments established that CD4+ and CD8+ subsets were both 
necessary to transfer lethal disease, although CD8 cells alone were sufficient to cause 
extensive pancreatitis. These findings supported a multistep model for autoimmune 
disease pathogenesis and established a simplified experimental model for spontaneous 
autoimmunity that depends on just two inherited genetic changes on an otherwise 
uniform genetic background. 
The remarkably uniform organ-specificity of autoimmunity in Aire-/-Cblb-/- mice was 
hypothesised to reflect an underlying property of the T cell repertoire in the mouse. 
Varying the nascent T cell repertoire by substituting the H2k MHC haplotype with the 
H2b haplotype, or by holding the MHC constant but introducing a TCR transgene that 
skewed the repertoire towards the pancreatic islet beta cells failed to redirect the 
   
 
xvi 
exocrine pancreatic autoimmunity in Aire-/-Cblb-/- mice, albeit these strategies slowed 
down the intensity and tempo of the disease. This indicated that the organ-specific 
pattern was not simply governed by the numbers of precursor self-reactive T cells 
against a particular antigen in the repertoire but must reflect a unique property of the 
disease-driving T cells that escaped tolerance in Aire-/-Cblb-/- mice.  
To illuminate the unique properties of the autoimmune driver cells in Aire-/-Cblb-/- mice, 
a new approach to isolate pancreas-specific T cell clones was successfully established. 
This involved enriching for the driver T cells by serial adoptive transfer, followed by 
RT-PCR amplification and sequencing of mRNAs encoding the paired TCRα and 
TCRβ chains from single T cells sorted from the pancreas or spleen. A remarkably 
oligoclonal expansion of CD8 T cells within the pancreas was revealed, comprising 
several clones within an animal bearing highly related TCRs. The TCR from one of the 
expanded CD8 T cell clones, 3.5, was expressed in retroviral transgenic (retrogenic) 
bone marrow chimeras. T cells expressing TCR3.5 were positively selected into the 
CD8 T cell lineage, showed no evidence of negative selection in Aire-wildtype thymi, 
and accumulated as mature naïve CD8 T cells in the axillary and inguinal lymph nodes. 
TCR3.5 CD8 T cells were nevertheless activated in the pancreatic lymph node and 
accumulated in the pancreas, and retrogenic expression of TCR3.5 was sufficient to 
precipitate extensive exocrine pancreatitis in animals with wild-type Aire and Cblb 
genes. These results suggest that Aire may not directly regulate the driver CD8 T cells, 
raising novel possibilities about how the defects in Aire and Cblb co-operate to 
precipitate organ-specific autoimmunity. 
These findings support the hypothesis that organ-specific autoimmunity manifests only 
when a defect in thymic deletion is paired with a defect in peripheral T cell tolerance. 
Even with two inherited defects, other tolerance mechanisms continue to operate so that 
in the case of Aire deficiency combined with FasL, Rc3h1 or Card11 mutations, no 
rapidly emergent autoimmune disease was observed. In Aire and Cblb double 
deficiencies, only rare self-reactive CD8 T cells with particular TCR specificities 
escaped the other tolerance mechanisms, causing an extremely rapid but very discrete 
   
 
xvii 
pattern of organ-specific autoimmunity directed at the exocrine pancreas and salivary 
glands. The results illuminate the stringent nature of the mechanisms that protect the 
body from autoimmune diseases, and provide a framework and experimental approach 
for interpreting patterns of genetic and phenotypic variability in human autoimmune 
diseases. 
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1.1 Preamble 
Four hundred and fifty million years ago, just as microbial pathogens were rapidly 
evolving to evade the non-specific immune responses, our ancestors responded by co-
evolving pathogen-specific immune responses – the acquired or adaptive arm of 
immune defence. The two main cellular protagonists of the adaptive immune defence 
are the B and T lymphocytes. Specificity is achieved through thymus-derived T 
lymphocytes that express T cell receptors (TCRs), and bone marrow-derived B 
lymphocytes that express B cell receptors (BCR), each recognizing unique molecules 
produced by pathogens, referred to as antigens. One of the challenges of the adaptive 
immune system is to eradicate foreign pathogens while minimally disturbing the host 
tissue. Hence, the ability to distinguish between self and foreign proved to be of utmost 
importance in directing immune effector mechanisms.  
In 1901, Paul Ehrlich was the first to propose the concept of immune attack against self 
(autoimmunity) and tolerance mechanisms that protect the body against it. His “horror 
autotoxicus” theory envisioned that individuals produce immune cells specific for any 
imaginable antigen and that cells specific for the body’s own elements (“autotoxins”) 
would be “dysteleogic” and not produced (Erhrlich, 1901). Subsequently, Burnet and 
Fenner postulated that there was a temporal window early in embryonic life where the 
immune system may tolerise cells that are foreign to the host (Burnet and Fenner, 
1948). This paradigm was suggested following Owen’s observations of two types of 
non-identical twin cattle; those that shared a haematopoietic system in utero were 
tolerant of blood cells from each other, while those who had not were not cross-tolerant 
(Owen, 1945).  
Medewar then extended Owen’s findings utilising his expertise as a transplant scientist 
investigating the effects of transferring allogenic blood cells from one mouse to another 
at different times after birth. Cells transferred within the first few days of life, but not 
later, rendered the recipient mouse tolerant to the donor antigen throughout life 
(Billingham et al., 1953). This was the first demonstration of highly specific tolerance 
to a foreign tissue that was encountered neonatally and triggered Burnet to published his 
2
   
landmark clonal selection theory of acquired immunity with clonal deletion as a caveat 
to guard against “horror autotoxicus” (Burnet, 1959). The idea was that each 
lymphocyte has a receptor on its surface with specificity towards a particular antigen, 
and binding to this antigen results in clonal proliferation of only those cells within the T 
and B cell that have recognized their specific pathogen (Burnet, 1976; Talmage, 1957), a 
concept later proven experimentally (Nossal and Lederberg, 1958). Self-reactive 
“forbidden clones” are clonally deleted during development. These concepts and key 
experiments foreshadowed the discovery of autoimmune diseases and tolerance 
mechanisms. 
Today, autoimmune diseases can be broadly classified into two: (i) Systemic 
autoimmunity directed towards systemic antigens with disease manifestation occurring 
at a variety of different sites in the body. Examples of this are rheumatoid arthritis (RA) 
and systemic lupus erythematosus (SLE); (ii) Organ specific autoimmunity directed 
towards tissue-specific antigens such as type 1 diabetes (T1D), psoriasis (PS), and 
multiple sclerosis (MS), inflammatory bowel disease (IBD) [which includes Crohn's 
disease (CrD) and ulcerative colitis (UC)], and celiac disease (CD). Collectively, 
autoimmune diseases affect 5-8% of the population but their etiology remains poorly 
understood. While it has been shown that individuals carrying genetic loci that alter 
tolerance mechanisms may be at higher risk of developing the disease than those not 
carrying these alleles, current knowledge of the genetic contributions fail to account for 
the development of autoimmune diseases. The challenge to understand these diseases 
are further complicated by the heterogenous clinical presentation, variable timing of 
onset and inconsistent target organs in patients carrying specific autoimmune-
predisposing mutations.  
To explain the complex genetics and heterogenous nature of autoimmune diseases, the 
work in this thesis tests a multistep model for autoimmune disease progression, whereby 
combined inherited or somatic deficiencies in two or more tolerance mechanisms must 
cooperate. This introduction section will review lymphocyte development, tolerance 
mechanisms controlling self-reactive cells and the spectrum of autoimmune diseases 
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that arise from genetic defects throughout this process. The focus will be on T cells, 
although similar concepts could be applied to the B cell counterparts. 
1.2 T cell development 
A schematic of T cell development in Fig. 1.1 (adapted from (Miller, 2011)) 
accompanies this section. T cells originate from haematopoietic stem cells (HSC) in the 
bone marrow (Wu et al., 1991). Hereafter, common lymphoid progenitor cells (CLPs) 
from the bone marrow migrate to the thymus, a bi-lobe lymphoid organ above the heart, 
where the cells undergo further maturation processes (Miller, 1959, 1961). The 
importance of the thymus in T cell development is illustrated by the abolishment of T 
cells in both mice and humans due to congenital deficiencies in the thymic epithelium 
when the whn gene is mutated (Frank et al., 1999). In the thymus, HSCs develop into 
common lymphoid progenitors (CLPs) and progressively acquire the characteristic 
feature of a T cell – the unique T cell receptor (TCR) that determines their specificity. 
The TCR is a disulphide-bonded heterodimeric glycoprotein composed of a 
combination of either an α (alpha) and β (beta) chain or a δ (delta) and γ (gamma) chain 
(Havran and Allison, 1988). The αβ T cells are essential mediators of antigen-specific 
immunity, while γδ T cells are directed towards early immunity and surveillance of 
microbial and non-microbial tissue stress (Hayday, 2009; Hein and Mackay, 1991). The 
remainder of the section will focus on the αβ T cells. 
Entering the thymus via the cortico-medullary junction, the CLPs establish themselves 
in the subcapsular zone in the cortex and begin development into a functional T cell 
defined by several stages based on the expression of CD4 and CD8 co-receptors – CD4-
CD8- double negative (DN), CD4+CD8+ double positive (DP) and CD4+CD8- or CD4-
CD8+ single positive (SP) stages (Owens et al., 1987). Two additional markers, CD25 
and CD44 further segregate the DN thymocytes into four distinct stages: DN1 (CD25-
CD44+), DN2 (CD25+CD44+), DN3 (CD25+CD44-) and DN4 (CD25-CD44-) (Godfrey 
et al., 1993; Nikolic-Zugic, 1991; Pearse et al., 1989). The DN1 early thymic precursors 
originate from multipotent progenitor stem cells (CLPs) from the bone marrow with the 
capacity of developing into dendritic, natural killer or myeloid cell lineages (Bell and 
Bhandoola, 2008; Porritt et al., 2004). These cells gradually lose their multipotency to 
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form distinct T cell precursors that are charaterised by additional expression of the Kithi 
surface marker. 
At the DN2 stage, the cells begin the construction of a TCR. The uniqueness or 
variability of the TCR is an important feature of adaptive immunity as the diversity of 
the TCRs within an individual ultimately determines the ability to recognise and 
counteract an antigen. Diversity is achieved by the generation of the α and β chains by 
somatic recombination of non-contiguous variable (V), and joining (J) gene segments, 
with an additional diversity (D) segment in the β chain, assembled together in a single 
functional reading frame (Fig. 1.2). Rearrangement of these gene segments generates a 
functional VDJβ exon that is transcribed and spliced to join Cβ, and the resulting mRNA 
is translated to yield the β chain. The human β chain genes are located on chromosome 
7 (position 7q35) and comprise of 54 TRBV elements, 2 TRBD elements, 13 TRBJ 
elements and 2 TRBC genes (Miles et al., 2011). VDJ recombination can rearrange 
these 71 genes into 2808 unique β-chain VDJC recombinations. The mouse β chain is 
encoded on chromosome 6 from 22 Trbv elements, 2 Trbd, 11 Trbj and 2 Trbc genes, 
giving rise to a possible 968 combinations (Miles et al., 2011).  
Recombination at the TCR locus requires the collaborative function of several genes. A 
complex of two proteins encoded by the recombination activating genes (Rag), Rag1 
and Rag2, recognises the coding sequence that will be joined and introduces double 
stranded breaks between the V(D)J gene segments, forming DNA hairpins. These 
double stranded breaks are repaired by non-homologous end joining proteins, such as 
DNA Ligase IV, DNA-dependent protein kinase, Ku (Ku70:Ku80 heterodimer that 
associates with DNA-PK) and Artemis. Accordingly, inherited deficiency of any of 
these proteins in mice and humans blocks this process and precludes lymphocyte 
development, resulting in severe combined immune deficiency (Li et al., 2005; 
Mombaerts et al., 1992; Shinkai et al., 1992). The combinatorial diversity from 
recombined genes fragments is further enhanced by the addition of random non-
template-dependent (N-nucleotides) or palindromic (P-nucleotides) by terminal 
deoxynucleotidyl transferase at joints between each gene segment (junctional diversity) 
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prior to joining, and by the variable position of the cleavage and joining of the V, D and 
J elements. 
By the start of the DN4 stage, each T cell precursor expresses either a pre-αβTCR 
(TCRβ chain paired with an invariant preTα) or a γδTCR on the cell surface (Hayes and 
Love, 2007; von Boehmer, 2005). As the pre-αβTCR does not possess cytoplasmic 
signalling domains, it collaborates with the invariant CD3 chains, delta (δ), epsilon (ε), 
gamma (γ) and zeta (ζ) for intracellular assembly, surface expression and signalling 
(Fig. 1.2). Signals via the pre-αβTCR selects successful functional V(D)J 
recombination of the Trb locus – a process termed β-selection. Having established a 
functional Trb rearrangement, recombination proceeds to the Tra locus encoding the 
alpha chain, and the cell proceeds to the DP stage. Similar to the TRB locus, the human 
TRA locus on chromosome 14 (position 14q11.2) houses multiple genes - 47 TRAV 
genes, 57 TRAJ genes and a single TRAC gene potentially resulting in 2679 unique α-
chain VJC gene combinations. The mouse α chain locus on chromosome 14 houses 73 
Trav genes, 38 Traj and 1 Trac genes, giving rise to a possible 2774 combinations. 
Merging all the α- and β-chain gene combination produces an estimate of 7 522 632 
and 2 685 232 possible gene combinations in humans and mouse, respectively (Miles et 
al., 2011). Collectively, coupling combinatorial and junctional diversity, the theoretical 
estimate of TCRαβ diversity amounts to 1015 genetically unique receptors (Davis and 
Bjorkman, 1988), albeit humans and mice only contain a maximum of 1012 and 108 
TCRαβ cells, respectively. Experimentally, diversity in the periphery is estimated to be 
even lower – 2 x107 for humans (Arstila et al., 1999) and 2x106 for mouse repertoires 
(Casrouge et al., 2000). This constraint is attributed to the vigorous thymic positive and 
negative selection processes ensuring the TCR on emigrating T cells binds weakly to 
self peptides bound to self-MHC. 
The DP cells acquire the expression of the chemokine CCR4 and CCR7 and migrate to 
the chemotactic gradient in the thymic medulla (Laan et al., 2009). The cells are 
retained for several days to complete the transformation from DP to SP cells. While 
continuous V-Jα recombination occurs in DP cells, the thymocytes test the resulting 
TCRαβ receptors for binding to self-peptides presented on major histocompatibility 
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complex molecules (MHC) displayed on thymic cortical epithelium. The MHCs encode 
human leukocyte antigens (HLA) genes in human and H2 genes in mice. At this stage, 
each TCRαβ comprises a heterodimer bearing six highly variable complementarity 
determining regions (CDRs)– CDR1, CDR2 and CDR3 for the α-chain and β-chain. 
Architecturally, the CDR1 and CDR2 loops are germline encoded within the TRAV and 
TRBV elements and largely fix the TCR to the MHC. On the other hand, the CDR3 
loops are hypervariable as they lie across the V(D)J junctions, engaging with the 
solvent-exposed chains of the MHC-bound peptide (Rudolph et al., 2006).  
The strength and specificity of TCR binding to self peptide-MHC (pMHC) complexes 
(pMHC) dictates the fate of each DP thymocyte. High-affinity binding results in 
elimination or deletion of the potentially autoreactive cells by a process termed negative 
selection, primarily at the SP stage but also at the DP stage. Conversely, low affinity 
binding rescues the cells from programmed cell death and results in further 
differentiation, allowing the cells to acquire functional competence and lineage 
differentiation to either CD4 or CD8 single positive (SP) cells. This process is called 
positive selection. Cells with TCRs that bind weakly to self-peptides presented by MHC 
Class I (MHC I) are positively selected into the cytotoxic CD8SP lineage, while cells 
that recognise peptides bound to MHC Class II (MHC II) become helper CD4SP cells 
(Cosgrove et al., 1991; Zijlstra et al., 1990). It is also possible for TCRs with affinities 
for self-pMHC at the high end of the positive selection range to induce the FoxP3 
transcription factor, causing the cells to differentiate into CD4SP natural T regulatory 
(nTreg) cells (Josefowicz and Rudensky, 2009). Rearrangement of the Tra loci does not 
stop until successful positive selection occurs, giving the thymocyte multiple chances to 
undergo recombination events progressing from the 5’ to 3’ of the Jα loci before the 
allele is exhausted. As continuous TCRα rearrangement is only halted when the TCR 
binds to an intrathymic ligand (Borgulya et al., 1992), all mature αβ T cells contain two 
rearranged TCRα alleles and 30% of such cells have two productive TCRα 
rearrangement (Casanova et al., 1991). Out of the 30%, only 10% of T cells are 
estimated to express dual-TCRα on the cell surface as there are unequal preferences for 
certain TCRα to pair with TCRβ (Heath et al., 1995; Padovan et al., 1993; Saito et al., 
1989). 
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Ninety percent of cells at the DP stage interact poorly with pMHC and are condemned 
to die by neglect. The transcription factors involved in CD4 or CD8 lineage 
commitment are thymus selection–associated high-mobility group box factor (Tox), c-
Myb and GATA-binding protein 3 (GATA3) which induce T-helper inducing POZ-
Kruppel factor (ThPOK or Zbtb7) that is required for CD4 lineage commitment 
(Aliahmad and Kaye, 2008; Collins et al., 2009; Pai et al., 2003; Wang and Bosselut, 
2009). ThPOK and Runx3 (the CD8 lineage commitment transcription factor) form a 
negative regulatory loop, in which they mutually prevent the expression of each other, 
resulting in lineage commitment (Collins et al., 2009).   
For the committed CD4SP and CD8SP cells to egress the thymus, the cells need to lose 
the CD69 thymic retention signal and gain expression of the sphingosine-1-phosphate 
receptor 1 (SIP1) receptor for blood-borne chemotactic sphingolipids that promotes 
thymic egress, and gain expression of the lymph node homing receptor, L-selectin or 
CD62L (Weinreich et al., 2009). CD4 lineage cells can continue to mature in the 
periphery, assuming either T helper 1 (TH1), T helper 2 (TH2) (Mosmann et al., 1986), T 
helper 17 (TH17) (Stockinger and Veldhoen, 2007), follicular T helper (TFH) (Vinuesa et 
al., 2005b) and T regulatory (Treg) (Wing and Sakaguchi, 2010) identity distinguished 
based on the transcription profiles, cytokines secreted and effector pathways induced as 
seen in Table 1.1. The CD8 cells directly kill host cells infected with viruses, 
intracellular bacteria and protozoa by secreting degradative enzymes or inflammatory 
cytokines and cell-to-cell contact-dependent signalling. The end result of this 
developmental process is a T cell repertoire with enormous diversity in TCRs capable to 
responding to any given antigen – functional diversity. 
Table 1.1. The CD4 subsets of the immune system 
Subset Master 
transcription 
factor 
Cytokines Effector pathways Physiological 
roles 
TH1 T-bet IFNγ, IL-2, 
TNFβ 
Inflammation, 
machophage 
activation, opsonising 
IgG2a and IgG3 
antibodies 
Destruction of 
intracellular 
pathogens 
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TH2 GATA3 IL-4, IL-5, IL-
13 
Eosinophil activation, 
neutralising IgE and 
IgG1 antibodies 
Destruction of 
extracellular 
pathogens 
TH17 RORγt IL-17, IL-23 Inflammation, 
neutrophil activation 
Destruction of 
extracellular 
bacteria and 
fungi 
TFH Bcl-6 IL-21 Germinal centre 
reactions, high affinity 
long-lived antibodies  
Providing help 
for germinal 
centre B cells 
to produce 
high affinity 
antibodies 
Treg FoxP3 IL-2, IL-10, 
TGFβ 
Suppression of self-
reactive T cells in the 
priphery 
Maintenance 
of peripheral T 
cell tolerance 
 
1.3 T cell tolerance 
The random process of somatic recombination that generates the functional diversity in 
the T lymphocyte repertoire brings with it a fundamental dilemma – the generation of 
self-reactive T lymphocytes. This dilemma is exacerbated by the fact that positive 
selection is designed to ensure all TCRs are at least weakly self-reactive, presumably to 
provide maximal sensitivity to one or a few foreign peptides at the outset of an infection 
(Ebert et al., 2010). Cells whose TCR binds too strongly to self-pMHC nevertheless 
have the potential to result in a T cell-mediated immune response against crucial self-
targets, causing an autoimmune disease. Elimination and deletion of these self-reactive 
T cells would have been evolutionarily necessary. A number of strategies have evolved 
to weed out high risk self-reactive T lymphocytes while still preserving the repertoire 
diversity of weakly self-reactive T cells. These strategies can be divided into 
mechanisms which occur during development in the thymus (central tolerance) and 
mechanism controlling the reactive cells that evade deletion in the thymus and escape to 
the periphery (peripheral tolerance). 
1.3.1 Central tolerance 
1.3.1.1 Clonal deletion 
Burnet was the first to envision that lymphocytes expressing self-antigen specific 
receptors would be deleted during their development (Burnet, 1959). Later, when self-
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MHC restriction of T cells was discovered by Zinkernagel and Doherty and shown to be 
acquired during their development in the thymus (Zinkernagel and Doherty, 1974a, b), 
it was predicted that the fate of thymocytes might depend on TCR signalling intensity, 
whereby strong signals correlated with high affinity and self-reactivity, while weak 
signals do not. This was experimentally confirmed by analysing the fate of thymocyte 
responses to stimulation by mouse superantigens or conventional pMHC complexes in 
transgenic mouse models. Mouse superantigens are proteins encoded by endogenous 
retroviruses that are inherited in the germline in many mouse strains. The superantigen 
proteins encoded by the mouse mammary tumour proviral genes Mtv-8 and Mtv-9 bind 
to the MHC Class II molecule I-Ek and bind with high affinity to TCRs that use the 
Vβ5, Vβ11 and Vβ17a segments (Woodland et al., 1990; Woodland et al., 1991a; 
Woodland et al., 1991b). Using a monoclonal antibody against Vβ17a TCRs, Kappler 
and colleagues demonstrated that Vβ17a usage was absent in the peripheral T 
lymphocyte population of I-Ek expressing mice, but present at the expected frequency 
amongst immature thymocytes (Kappler et al., 1987). This was the earliest evidence 
confirming that superantigen-specific T cells are deleted from the T cell repertoire. This 
observation was extended by studies in transgenic mouse models that express TCRαβ 
receptors with defined specificity for particular self-antigens (Berg et al., 1989; 
Kisielow et al., 1988; Pircher et al., 1989; Sha et al., 1988). For example, thymocytes 
that expressed a transgene-encoded TCRαβ with high affinity for MHC Class I Db 
molecules presenting a peptide derived from the product of the Smcy gene, which lies 
on the Y-chromosome and comprises the male-specific HY antigen, were deleted in 
male mice but positive selected in females that expressed Db but lacked the Smcy –
derived peptide (Teh et al., 1988). 
Key genes involved in the process of clonal deletion as shown in Fig. 1.3 (adapted from 
(Goodnow et al., 2005)). For both positive and negative selection to occur, self-peptides 
need to be presented in the context of the appropriate MHC to the developing 
thymocytes at the DP stage in the thymic cortex and the SP stage in the thymic medulla. 
In the cortex, self-peptides are displayed on the cortical thymic epithelial cells (cTEC), 
and TCRs that bind with weak affinity are triggered to cease α-chain rearrangement and 
increase homing receptors to progress towards the thymic medulla. The cell continues 
to interrogate its TCR on the surface by testing its affinity towards self-peptides 
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presented in the context of MHC. Self-peptides are presented in the medulla by 
immature dendritic cells of haematopoietic origin (Steinman et al., 2003) and by 
medullary thymic epithelial cell (mTEC) that express a plethora of organ-specific 
transcripts essential for negative selection (Derbinski et al., 2008; Hanahan, 1998).  
In a remarkable intersection of discoveries, the transcription factor Autoimmune 
regulator (Aire) was discovered to be mutated in people with the multi-organ 
autoimmune disorder autoimmune polyendocrinopathy syndrome type 1 (APS1) 
(Aaltonen et al., 1997; Consortium, 1997; Nagamine et al., 1997) and was found to 
direct the expression in mTECS of many of the mRNAs from otherwise organ-specific 
genes (Anderson et al., 2002; Derbinski et al., 2005). Consistently, mice that lack Aire 
fail to negatively select organ-specific T cells. This has been formally demonstrated in 
several TCR transgenic mouse models that have T cells recognising neo-self antigens. 
Using a transgenic model where hen-egg-lysozyme (HEL) is expressed under the 
control of the tissue-specific promoters, Liston and colleagues demonstrated that HEL-
specific TCR3A9 CD4 cells fail to be deleted in Aire-deficient mice resulting in severe 
diabetes when the HEL antigen is coupled to the insulin promoter or thyroiditis when 
HEL is coupled to the thyroglobulin promoter (Liston et al., 2004a; Liston et al., 2003). 
Similarly, ovalbumin (OVA)-specific OTII CD4 cells escape deletion and cause infant-
onset diabetes when the OVA gene is expressed by the insulin promoter in Aire-/- mice 
(Anderson et al., 2005) or Aire mice harbouring the G228W mutation (Su et al., 2008). 
Notably, the failure of thymic deletion was specific for organ-specific T cells as Aire 
showed no effect on thymic deletion when the antigen expression was driven by a 
systemic H2k-promoter (Liston et al., 2004a) or when the antigen was made available 
via a virus-mediated infection (Kedzierska et al., 2010). 
Besides the expression of the characteristic transcription regulator Aire and expression 
of tissue-specific antigens, the mTEC cells express T cell co-stimulatory molecules, 
such as CD80 (B7.1) and CD86 (B7.2), the ligand for the CD28 co-receptor that is 
present on T cells. CD28 costimulation was shown to enhance death of immature DP 
thymocytes in tissue culture (Punt et al., 1994). A role for this co-stimulatory signal in 
the process of negative selection was implied by mouse experiments where the 
CD80/CD86 molecules were missing or blocked on the mTECs. In such mice, self-
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reactive TCRs were not deleted causing graft-versus-host-disease-like inflammation in 
the periphery (Gao et al., 2002; Laufer et al., 1996).  
It is paradoxical that a single TCR can mediate two opposing fates of the thymocyte – 
positive selection and negative selection. It is clear that signalling events via the TCR 
are required for both processes but the machinery required for positive and negative 
selection may differ in several aspects to mediate these opposing outcomes. At the 
immunological synapse, p56 (Lck) and CD3ζ are recruited to the peripheral edge rather 
than the centre of the cell (Richie et al., 2002). The tyrosine kinase ζ-chain associated 
protein kinase of 70 kDa (ZAP70) is required for deletion, and SKG mice harbouring a 
spontaneous point mutation in the SH2 domain of ZAP70 have diminished negative 
selection in the HY-TCR transgenic model (Sakaguchi et al., 2003). The translation of 
the signal from the TCR also requires the growth factor receptor bound protein 2 
(GRB2) (Gong et al., 2001) and the misshapen Nck interacting kinase related kinase 
(MINK) (McCarty et al., 2005). Strong but transient activation of the extracellular 
signal regulated kinase (ERK) via ras-guanyl nucleotide exchange factors, Sos and 
RasGRP1, is required for negative selection while low levels of sustained activation is 
required for positive selection (Mariathasan et al., 2001; Priatel et al., 2002). Further 
signals are relayed by the c-Jun NH2-terminal kinase (JNK) (Rincon et al., 1998). The 
protein tyrosine phosphatase, non-receptor type 22 (PTPN22) is thought to regulate the 
strength of TCR signals and gain of function alleles weaken TCR signalling, potentially 
imparing the deletion of autoreactive T cells (Chuang et al., 2009). 
At the distal end of the signalling pathway, the signals culminate in the activation of 
thymocyte death by two possible pathways: activating the Fas-dependent death receptor 
pathway or the Bim-dependent Bcl2-inhibited mitochondrial death pathway. The death 
receptor pathway is activated when members of the tumour necrosis factor receptor 
family that possess a death domain (such as Fas or CD95 or APO-1) bind to its 
corresponding ligand (such as Fas-ligand), triggering the formation of a death inducing 
signalling complex, promoting the activation of caspase-8. A series of studies 
performed by Kishimoto and Sprent demonstrated that in vitro stimulation of early SP 
thymocytes results in a Fas-independent apoptotic response at low antigen 
concentrations but a Fas-dependent response at high concentrations (Kishimoto and 
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Sprent, 1999a, b; Kishimoto et al., 1998). Similar studies have demonstrated this Fas-
mediated deletion in vivo in transgenic DO11.10 mice (Kishimoto and Sprent, 1999a, b; 
Kishimoto et al., 1998). However, a partial loss of function mutation in Fas did not 
affect deletion in the HY-TCR transgenic model (Sidman et al., 1992) and absence of 
the caspase-8 apoptosis inducer did not affect negative selection (Salmena et al., 2003), 
opposing the view that the Fas-pathway is involved in thymic deletion. 
The alternative apoptotic pathway is the Bim/Bcl-2 pathway. In this pathway, Bim 
antagonises pro-survival proteins including Bcl-2, BclXL and Mcl-1, thereby releasing 
the pro-apoptotic proteins Bax and Bak to trigger release of cytochrome c from 
mitochondria, and culminating in the activation of caspase-9 required for deletion 
(Rathmell and Thompson, 2002). Bcl-2 overexpression and elimination of Bax/Bak has 
been demonstrated to inhibit the developmental death of autoreactive thymocytes 
specific for both superantigens (Rathmell et al., 2002; Strasser et al., 1991) and 
conventional antigens (TCR-HY transgenic system) (Strasser et al., 1994). Several 
studies have demonstrated that anti-CD3 mediated thymic apoptosis is exclusively Bim-
dependent and independent of Fas. (Bouillet et al., 1999; Bouillet et al., 2002; Villunger 
et al., 2003). Most convincingly, Bim acts in a dose-dependent fashion, in that Bim 
heterozygous thymocytes have an intermediate effect on deletion (Bouillet et al., 2002), 
suggesting that Bim induction represents the point in the pathway where signal strength 
is translated into opposing decision of survival or apoptosis. 
Deletion also involves induction of the Nur77, an orphan steroid receptor involved in 
the apoptotic pathway. Overexpression of a dominant negative Nur77 precludes 
apoptosis and thymic deletion in vivo, and loss of Nur77 prevents apoptosis (Cheng et 
al., 1997; Woronicz et al., 1994; Xue et al., 1997). The defective induction of Bim and 
Nur77 in the NOD mouse strain account for four of the diabetic susceptibility 
chromosomal loci (D1mit181, D2mit490, D7mit101, and D15mit229) in this strain 
(Liston et al., 2004b). The resistance of NOD thymocytes to deletion, thus, appears to 
be important autoimmune susceptibility contributor to a range of autoimmune 
manifestations in this strain (Kishimoto and Sprent, 2001; Lesage et al., 2002).  
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1.3.1.2 Limiting pro-survival signals 
Another possible mechanism that could regulate self-reactive T cells is regulating the 
survival signals the T cells are exposed to, such as the pro-survival cytokine interleukin-
7 (IL-7) (Barthlott et al., 2003; Marrack and Kappler, 2004). Under physiological 
conditions, IL-7 levels are low causing the cells to be in the interphase stage of cell 
division. However, when strong self-reactive TCR signals are triggered, the cells are 
forced to undergo transient proliferation that culminate in Bim-induced cell death 
(Strasser and Bouillet, 2003). In conditions where low numbers of lymphocytes are 
present, concentrations of pro-survival cytokine IL-7 increase, stimulating naïve T cells, 
including potentially self-reactive cells, into proliferation to fill up the empty niche. 
Hence, coupling the imbalance of the IL-7 survival cytokine with conditions of low T 
cell numbers (lymphopenia) may paradoxically induce an autoimmune disease. X-linked 
thrombocytopenia is a confounding blend of lymphopenia and autoimmunity caused by 
a mutations if the WASp gene (Villa et al., 1995). Another similar affliction is Omenn 
syndrome, a combination of limited T and B cell production and graft-versus-host-
disease-like autoimmunity (Villa et al., 1998). Owing to partial loss-of-function variants 
in Rag1, Rag2 and Artemis genes (Ege et al., 2005; Gennery et al., 2005), V(D)J 
recombination is impaired and T lymphocyte repertoire becomes  highly restricted in 
TCR diversity (Santagata et al., 2000). 
1.3.1.3 Inhibitory receptors 
While negative selection could purge T cells with high affinity towards the autoreactive 
cells, fine-tuning the TCR signalling could control low affinity autoreactive cells. One 
essential component in this process is the inhibitory receptor CD5 (Pena-Rossi et al., 
1999). CD5 contains a tyrosine-based inhibitory motif on its cytoplasmic tail that 
directly interacts with TCR signalling molecules such as SHP1, negatively regulating 
TCR activation (Perez-Villar et al., 1999). Self-reactive thymocytes increase the 
expression of CD5, tuning down the TCR signals (Wong et al., 2001). The regulation of 
signalling by CD5 receptor begins in the thymus and continues in the periphery (Smith 
et al., 2001). 
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1.3.2 Peripheral tolerance 
As an alternative to Burnet’s clonal deletion theory, other studies have articulated 
tolerance mechanisms that might act on mature lymphocytes, controlling self-reactive 
lymphocytes that escape negative selection. These can be broadly divided into: (i) 
recessive forms of tolerance – cis-acting tolerance that is intrinsic to the autoreactive 
cell or (ii) dominant tolerance – trans-acting tolerance processes that act extrinsically to 
control many different autoreactive cells. 
1.3.2.1 Recessive cell intrinsic tolerance 
One mechanism that regulates peripheral tolerance is the requirement for two signals to 
activate lymphocytes – TCR binding to peptide/MHC (signal 1) and CD28 binding to 
CD80 or CD86 (signal 2) (Fig. 1.4) (Bretscher and Cohn, 1970; Lafferty and 
Cunningham, 1975). Depending on the amount of peptide/MHC, self-reactive T cells 
are either not activated and remain ignorant or are induced to a state of anergy or non-
responsiveness when antigen recognition occurs in the presence of signal 1 alone, 
without the co-stimulatory signal 2 (Kundig et al., 1996; Nossal, 1983; Schwartz, 1990, 
2003). Such a mechanism may have evolved because antigen presenting cells (APCs) 
routinely present both foreign and self-peptides, meaning that antigen recognition alone 
is not sufficient to discriminate between self and non-self. Provision of the co-
stimulatory signal occurs upon the reception by APCs of danger signals from pathogens 
that are sensed through innate immune receptors such as the Toll like receptors, which 
induces the expression of CD80/CD86 on APCs. The inhibitory receptor cytotoxic T-
lymphocyte antigen 4 (CTLA-4) inhibits T cell activation by competing with CD28 for 
binding to the CD80/CD86 molecules, removing CD80 and CD86 from antigen 
presenting cells (Qureshi et al., 2011), and also by transmitting inhibitory signals to T 
cells that express CTLA-4 (Ravetch and Lanier, 2000; Sharpe and Freeman, 2002; 
Walker and Abbas, 2002). The importance of this inhibitory process is underscored by 
CTLA-4 deficient mice that display massive accumulation of self-reactive T cells in the 
peripheral lymphoid and non-lymphoid tissues (Tivol et al., 1995; Waterhouse et al., 
1995).   
When T cells are stimulated in the absence of co-stimulatory signal 2, this still allows 
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Figure 1.4. Key elements in the pathways for clonal anergy of
peripheral T cells.
Elements italicised in red correspond to genes associated with
human autoimmune diseases.
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activation of the calcium-dependent nuclear factor of activated T-cells (NFAT) pathway 
unaccompanied by full activation of the AP-1 and NFkB pathways (Macian et al., 
2002), inducing the expression of anergy associated genes including ubiquitin ligases 
such as casitas B-lineage lymphoma b (Cblb), gene related to anergy in lymphocytes 
(Grail), HECT-E3 ligase Itch and Peli1 (Paolino and Penninger, 2009). These ubiquitin 
ligases bind target substrates, tagging them for protosomal degradation, alter 
intracellular trafficking of TCRs, trigger endocytosis or allosterically interfere with 
signaling (Anandasabapathy et al., 2003; Chang et al., 2011; Heissmeyer and Rao, 
2004; Jeon et al., 2004; Liu, 2004). These processes render the T cells to a state of 
anergy or unresponsiveness. 
The ubiquitin ligase Cbl-b targets downstream molecules of the TCR signaling 
pathway, notably ubiquitination of the p85 catalytic subunit of PI3K that alters its 
intracellular localization and prevents its interaction with CD28 and CD3ζ at the plasma 
membrane (Fang and Liu, 2001). Cbl-b thus inhibits Akt and PKCθ-mediated NFκB 
activation, and additionally, prevents Vav1-mediated cytoskeleton rearrangements 
required for receptor clustering and synapse formation (Krawczyk et al., 2000). In 
anergic T cells, Cbl-b upregulation occurs together with phospholipase c gamma (PLCγ) 
and protein kinase c theta (PKCθ) ubiquitylation indicating these two molecules to be 
crucial targets for Cbl-b anergic functions (Heissmeyer et al., 2004; Jeon et al., 2004). 
Mice deficient in Cblb develop mild autoimmunity and have a decreased threshold for T 
cell activation (Bachmaier et al., 2000; Chiang et al., 2000). Coupling Cblb-deficiency 
with a particular MHC haplotype causes diabetes in the Komeda diabetes prone (KDP) 
rat strain (Yokoi et al., 2002). When T cell deficient c-cbl (the homologue of Cblb 
expressed in the thymus) mice are crossed with Cblb-/- mice, double-deficient mice 
showed drastic weight lost by 12 (females) and 16 (males) weeks, accompanied by 
multi-organ specific autoimmunity in the heart, skin and liver (Naramura et al., 2002). 
In humans, genome wide association studies (GWAS) have associated a polymorphism 
in CBLB with multiple sclerosis in Sardinian (Sanna et al., 2010) and Italian populations 
(Corrado et al., 2010), although clarification the mechanism by which the specific CBL-
B polymorphism affects autoimmunity in these disease would require further functional 
characterisation. 
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Self-reactive T cell proliferation could also be cut short by ensuring T cell death or 
apoptosis. Similar to the T cell death in the thymus, death could occur as a result of 
Fas-dependent pathway or Bim-dependent pathway. In general, the Fas-dependent 
pathway is crucial in aborting peripheral T cells that are have undergone chronic 
stimulation by antigens such as injection of cytochrome c into transgenic mice with an 
MHCII TCR (systemic self antigens) (Singer and Abbas, 1994) or in an influenza 
infection in a transgenic mice with an MHCII restricted hemagglutinin-specific TCR 
(chronic infection) (Sytwu et al., 1996). By contrast, the Bim-dependent pathway 
predominantly eliminates T cells that undergo transient or intermittent exposure to 
antigens, which frequently occurs in response to organs-specific antigens. For example, 
when HY-specific T cells recognising peripheral antigen encoded by the Smcy gene on 
the Y chromosome are introduced into male mice, the cells undergo a sequence of 
activation, proliferation, anergy and death in a Bcl2 (Bim pathway)-dependent but Fas-
independent manner (Teh et al., 1996). This same Bcl2 (Bim pathway)-dependent 
deletion of self-reactive cells is also observed for OT-1 ovalbumin-specific CD8 cells 
that recognise the ovalbumin neo-self antigen in the pancreas (Kurts et al., 1996; Kurts 
et al., 1997b). 
The importance of the Fas-dependent death receptor pathway is exemplified by studies 
of mouse models and humans deficient in molecules within the pathway. Two key 
mouse models that have been extensively studied are strains inheriting loss of function 
mutations, Faslpr/lpr and Faslgld/gld (Cohen and Eisenberg, 1991). Binding of Fas-ligand 
to its cognate receptor, Fas, activates a cascade of events that cumulates in cell death via 
apoptosis. In both the Faslgld/gld and Faslpr/lpr strains, homozygous disruption of this 
pathway results in extensive lymphoproliferation and high titres of autoantibodies 
(Krueger et al., 2003). A characteristic feature of the mice is the accumulation of 
unusual CD3+ CD4- CD8- TCRβ+ CD45R(B220)+ (double negative T, DNT) cells in the 
periphery (Takahashi et al., 1994; Watanabe-Fukunaga et al., 1992). These cells are 
thought to be cells that have been stimulated to undergo apoptosis but are unable to 
complete the process in the absence of CD95 or CD95-ligand (Steinberg, 1994). In skin 
allograft transgenic mice, wild-type (Priatel et al., 2001; Zhang et al., 2000) or Faslpr/lpr 
(Ford et al., 2002) DNT cells have been shown to down-regulate the immune response 
by killing allogenic CD8+ cells that expressed functional Fas but not CD8+ cells that 
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express non-functional Fas. The inability to kill the activated T cells is suggested to 
contribute to the development of autoimmunity in the Faslgld/gld and Faslpr/lpr mice. 
Mutations in Fas and Fas-ligand in humans result in a similar syndrome called 
autoimmune lymphoproliferative syndrome (ALPS) or Canale-Smith syndrome that 
includes systemic autoimmunity and accumulation of CD3+ CD4- CD8- T cells (Fischer 
et al., 2000; Fisher et al., 1995). 
Another E3 ubiquitin ligase that regulates peripheral tolerance is Roquin (Rc3h1). It 
regulates a subset of T cells, the TFH cells. TFH cells home to the germinal centre and 
function to provide help to germinal centre B cells. TFH cells are characterized by the 
expression of the transcription factor Bcl-6 (Johnston et al., 2009; Nurieva et al., 2009; 
Yu et al., 2009), and the co-stimulatory molecules inducible co-stimulator receptor 
(ICOS) and CD134 (Walker et al., 2000). Although complete loss of Roquin results in 
embryonic lethality (Bertossi et al., 2011), the importance of this ubiquitin ligase in 
preventing autoimmunity is demonstrated by its identification and characterization in 
the sanroque mouse model. Roquinsan/san mice carry a single point mutation in the 
Roquin gene. Roquin acts as a repressor to the inducible co-stimulator receptor, ICOS. 
The Roquinsan/san mice exhibit hyperactivation of follicular T cells that are specialized in 
delivering signals to germinal centre B cells, produce high levels of autoantibody and 
display high incidences of nephritis, phenotypes similar to the human systemic lupus 
erythematosus (Linterman et al., 2009; Vinuesa et al., 2005a). Roquinsan/san mice also 
have accelerated autoimmune diabetes in a transgenic mouse model due in part to 
excessive anti-islet autoantibody production (Silva et al., 2011). 
1.3.2.2 Dominant cell extrinsic tolerance 
The notion of dominant tolerance first arose from observations that neonatally 
thymectomised mice developed organ-specific autoimmunity that was preventable by 
adoptive transfer of splenocytes from adult mice (McIntire et al., 1964; Nishizuka and 
Sakakura, 1969). The initial description of “suppressor cells” that could prevent 
autoimmunity received surges of interest over the next decade and only gained 
popularity after Shimon Sakaguchi’s characterization of the T “regulatory cells” (Treg) 
defined by the surface markers CD4+ and CD25+ (the interleukin-2 receptor alpha chain) 
(Sakaguchi et al., 1995). The population suppresses T cell proliferation in vitro and 
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prevents autoimmunity in vivo (Sakaguchi et al., 1995). The Treg population was 
further defined and characterised upon the discovery of the master transcription factor 
for the population, the X-linked forkhead box P3 (FoxP3) that causes severe 
autoimmunity when mutated in scurfy mice (Fontenot et al., 2003; Hori et al., 2003; 
Khattri et al., 2003). Similar to the mouse counterparts, children with defects in the 
Foxp3 gene develop Immunodeficiency, Polyendocrinopathy, and Enteropathy, X-
Linked Syndrome (IPEX) (Bennett et al., 2001; Brunkow et al., 2001; Wildin et al., 
2001) characterized by watery diarrhea, eczematous dermatitis, and endocrinopathy, 
typically beginning in the first year of life (Gambineri et al., 2003; Nieves et al., 2004; 
Wildin et al., 2002). 
The Foxp3-expressing cells can originate as natural Treg (nTreg) cells generated in the 
thymus (Buckner and Ziegler, 2008). Alternatively, naïve CD4 cells can be converted 
into FoxP3+ inducible Treg (iTreg) cells in vitro upon stimulation with transforming 
growth factor beta (TGFβ) for human and mouse cells or retinoic acid for mouse cells, 
although it is unclear if these cells could mediated suppressive ability in vivo (Coombes 
et al., 2007; Lathrop et al., 2011; Tran et al., 2007; Walker et al., 2005). FoxP3+ cells 
mediate suppression either via cell-contact dependent suppression or cytokine 
dependent suppression to modulate the cytokine microenvironment, metabolically 
disrupt the target cell, changing the dendritic cell activating capacity, and cytolysis 
(Sakaguchi et al., 2010; Shevach, 2009; Vignali et al., 2008).  
All tolerance mechanism, both dominant and recessive, can be envisaged to work 
together to prevent robust autoimmunity, but very little is known about how defects in 
one tolerance mechanism may or may not be compensated by activity of another. Since 
multiple genes govern each tolerance mechanism, it seemed logical that mutations in key 
tolerance genes would lead to autoimmunity. The genetic basis of autoimmunity is 
described in the following section. 
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1.4 Genetic basis of autoimmune disease 
To examine the genetic contribution to disease susceptibility, genetic epidemiologists 
have used several measures – examining the concordance of a disease in monozygotic 
twins compared to that of dizygotic twins, the extent of familial clustering, and 
examining the increased risk of the disease for a family member of a patient compared 
to that of the general population.  
By these measures, there is a strong inherited predisposition to most autoimmune 
diseases, with 30-70% concordance in identical twins (Hyttinen et al., 2003), due in 
most cases to cumulative effects of variants in MHCs and other mostly unknown genes 
(Barrett et al., 2009; Todd and Wicker, 2001; Wandstrat and Wakeland, 2001). It is not 
known if these complex genetic factors disrupt a single tolerance mechanism, 
compromise several cooperating mechanisms, or act at other levels such as 
inflammatory responses to microbes. Many different cellular mechanisms of actively 
acquired self-tolerance described in section 1.3, including clonal deletion, clonal anergy 
and regulatory T cell differentiation are known, but it is not known if these mechanisms 
act in series as failsafes for one another such that autoimmune disease would require 
multiple mechanisms to fail (Goodnow, 2007) or if they act independently to protect 
different tissues from autoimmunity. To put it simply, it is currently unknown whether 
the compounding of inherited defects in discrete tolerance mechanisms will precipitate 
autoimmune phenotypes that are simply the sum of each individual defect or will 
exhibit highly cooperative behaviour to produce emergent autoimmune phenotypes. 
Understanding how the individual mechanisms fit together for robust tolerance is 
critical for interpreting patterns of genetic and phenotypic variability in human 
autoimmune disease. 
1.4.1 Monogenic autoimmune disease: Autoimmune polyglandular syndrome 1 as 
an example 
Major advances in understanding the pathogenesis of autoimmune disease have been 
made by studying monogenic autoimmune diseases. In these experiments of nature, 
single inborn errors resulting in rare autoimmune diseases are inherited in a simple 
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Mendelian fashion. Examples of these disease, and corresponding mouse models that 
have been discussed in section 1.3 are illustrated in Table 1.2. Studies in mice have 
revealed a great deal aiding the understanding of autoimmune disease pathogenesis. The 
remainder of the section will focus on Aire-mediated autoimmunity, highlighting key 
principles of autoimmune disease pathogenesis and puzzling disease-traits. 
Table 1.2. Single gene defects associated with autoimmune diseases. Table adapted 
from (Rioux and Abbas, 2005). 
Gene Human disease Mouse 
model 
Mechanism of 
autoimmunity 
Autoimmune 
regultor (Aire) 
Autoimmune 
polyendocrine syndrome 
type I (OMIM: 240300) 
(2007; Nagamine et al., 
1997) 
Knockout 
(Anderson et 
al., 2002; 
Ramsey et 
al., 2002b) 
Decreased expression 
of self-antigens in the 
thymus, resulting in 
decreased negative 
selection. 
Fas/Fasl Autoimmune 
lymphoproliferative 
syndrome, Canale-Smith 
syndrome (OMIM: 
601859) (Fischer et al., 
2000; Fisher et al., 1995) 
Lpr/lpr, 
gld/gld 
(Cohen and 
Eisenberg, 
1991) 
Failure of apoptotic 
death of self-reactive 
T and B cells. 
FoxP3 Immunedysregulation, 
polyendocrinopathy and 
enteropathy, X-linked 
(OMIM: 304790) 
(Bennett et al., 2001) 
Knockout 
(Fontenot et 
al., 2003; 
Hori et al., 
2003; 
Khattri et 
al., 2003) 
Decrease generation of 
CD4+CD25_ 
regulatory T cells 
 
Mutations in the AIRE gene have been identified as the cause of autoimmune 
polyglandular syndrome type 1 (APS1) or polyendocrinopathy-candidiasis-ectodermal 
dystrophy (APECED). Clinically, three abnormal features are most frequently observed 
in this syndrome: (i) chronic mucocutaneous Candida albicans infections that are now 
known to be due to autoimmune neutralization of IL-17 (Kisand et al., 2010; Puel et al., 
2010) ;(ii) chronic hypoparathyroidism; (iii) autoimmune adrenal insufficiency (Betterle 
et al., 1998), a clinical triad that was first reported in 1946 (Leonard, 1946) and defined 
in further detail by Peerhentupa (Perheentupa, 2006). A patient must present with at 
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least two components of the clinical triad to be diagnosed with APECED. Beyond these 
features, affected individuals frequently exhibit secondary symptoms including 
autoimmune endocrinopathies (hypergonadotropic hypogonadism, insulin-dependent 
diabetes mellitus, autoimmune thyroid diseases, and pituitary defects), autoimmune or 
immune-mediated gastrointestinal diseases (chronic atrophic gastritis, pernicious 
anemia, exocrine pancreatic insufficiency and malabsorption), chronic active hepatitis, 
autoimmune skin diseases (vitiligo and alopecia), ectodermal dystrophy, 
keratoconjunctivitis, immunologic defects (cellular and humoral), asplenia, and 
cholelithiasis (Betterle et al., 1998). The disease is very heterogeneous as the secondary 
clinical features vary from patient to patient and even between two siblings that inherit 
AIRE deficiency in the same genetic lesion (Ishii et al., 2000). This heterogeneity in 
clinical picture is also a common feature in many other autoimmune diseases.  
Besides the highly variable features of AIRE-deficiency, another feature of the disease 
is the presence of a latent phase during the development of the disease. Typically, the 
APS1 disease unfolds in a stepwise manner within the first 20 years of life, while 
secondary features appear until the fifth decade of life (Table 1.3). The first symptom, 
typically mucocutaneous candidiasis appears in childhood before the age of five, 
followed by chronic hypoparathyroidism within the first decade of life, and later by 
autoimmune adrenal insufficiency or Addison disease. In addition to these 
characteristics, the patients typically present with tissue-specific autoantibodies 
correlated with the manifestation of the secondary features (Table 1.3). 
Table 1.3. Table shows the clinical features in APS1 patients, average age of onset 
and putative organ-specific autoantibody associated with particular symptoms. * 
indicates primary clinical characteristics. # indicates features shared with the mouse 
models. Table adapted from (Husebye et al., 2009; Kisand et al., 2011; Marx et al., 
2010; Perheentupa, 2006; Peterson and Peltonen, 2005).  
Manifestation 
Mean 
onset age 
in 
years±SD Prevalence 
Related autoantibodies 
(% prevalence) 
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At 10 
years 
of age 
(%) 
At 30 
years 
of age 
(%)   
Chronic mucocutaneous 
candidiasis* 6±6 70 98 
IL-22 (91%), IL-17F 
(75%) 
Chronic 
hypoparathyroidism* 8±7 66 85 
NACHT leucine-rich-
repeat protein 5 (49%) 
Autoimmune adrenal 
insufficiency* 12±8 40 78 
steroid 21 hydroxylase 
(66%), steroid 17-α-
hydroxylase (44%), side-
chain cleavage enzyme 
(52%) 
Ovarian failure# 15±7 – 36   
Diabetes mellitus 27±15 1 27 
glutamic acid 
decarboxylase (37%), 
protein tyrosine 
phosphatase like 
protein(7%) 
Exocrine pancreatic 
failure 19±13 7 14  
Testicular failure# 28±10 – 25 TSGA10 (8%) 
Hypothyroidism 27±10 1 24 
thyroglobulin (36%), 
thyroid peroxidase (36%) 
Gastritis/pernicious 
anemia# 22±12 1 20 
tryptophan hydroxylase 
(45%), histidine 
decarboxylase (37%) 
Asplenia 
Early to 
late 10 20   
Autoimmune hepatitis 7±4 14 18 
cytochrome P450 1A2 
(8%),  
Chronic diarrhea 12±5 10 18   
Ectodermal 
manifestations^         
Alopecia 12±7 15 38 
tyrosine hydroxylase 
(40%)  
Vitiligo 15±11 11 30 
SRY (sex determining 
region Y)-box 9/10 
(22%), aromatic L-amino 
acid decarboxylase 
(51%) 
Keratopathy 6±4 18 24   
Dental enamel 
dysplasia 
Adult 
teeth only   75   
Nail dystrophy     50   
Myasthenia gravis       
acetylcholine receptor 
(<5%) 
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In a tour de force of functional genomics, Aaltonen and colleagues performed linkage 
studies on a cohort of Finnish patients, mapping the disease-locus to a region on 
chromosome 21q22.3 (Aaltonen et al., 1997). Two independent groups narrowed down 
the region to a single locus on human chromosome 21 using positional cloning 
strategies. The 545 amino acid gene encoded in this locus was termed the AutoImmune 
REgulator (AIRE) gene. Nagamine and colleagues isolated two common mutations 
(R257X and K83E) in the AIRE gene in the Swiss and Finnish cohort of APS1 patients 
(Nagamine et al., 1997), while the Finnish-German APECED Consortium identified an 
additional 4 mutations (Consortium, 1997). Currently, more than 60 different missense 
mutations have been localized in the AIRE gene in APECED patients (Ruan and She, 
2004). Interestingly, no single mutation has been shown to correlate with the 
manifestation of particular secondary phenotypes of the disease, with a few exceptions 
(Cetani et al., 2001; Su et al., 2008). Halonen and colleagues studied the correlation 
between HLA Class II and AIRE in APECED patients and found that adrenal 
insufficiency was associated with HLA-DRB1*03, alopecia with HLA-
DRB1*04/DQB1*0302, whereas type 1 diabetes correlated negatively with HLA-
DRB1*15/DQB1*0602 (Halonen et al., 2002). 
Knocking out the mouse homologue of the human Aire gene has created mouse models 
of the APECED disease. Three independent Aire-deficient mouse strains have been 
described in the literature (Anderson et al., 2002; Kuroda et al., 2005; Ramsey et al., 
2002a). Although it is still debatable if Aire-deficient mice provide an accurate mouse 
model for the human disease (Hubert et al., 2009; Kekalainen et al., 2007a), they share 
two, albeit milder, organ-specific autoimmunity traits with their human counterparts: 
the presence of inflammatory lymphocytic infiltrates and serum autoantibodies. Studies 
in mice show that the AIRE protein is present in the medullary thymic epithelial cells 
(mTECs) (Blechschmidt et al., 1999; Heino et al., 1999). It acts as a transcriptional 
regulator (Abramson et al., 2010) that relieves pausing of RNA polymerase shortly after 
transcript start sites (Giraud et al., 2012), allowing promiscuous expression of tissue-
specific mRNAs in thymic medullary epithelial cells (Anderson et al., 2002; Derbinski 
et al., 2001; Jolicoeur et al., 1994). Expression of the corresponding organ-specific 
proteins enables these antigens to be presented to maturing T cells to stimulate deletion 
of self-reactive T cells in the thymic medulla (Anderson et al., 2002; Liston et al., 
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2004a; Liston et al., 2003). Besides this transcription model, alternative models for the 
main mechanistic action of Aire in maintaining thymic tolerance have been suggested: 
(i) affecting mTEC organization, processing, maturating and emigration which is 
required for tissue-specific antigen expression (maturation model) (Matsumoto, 2011); 
(ii) priming T cells that develop in the thymus (autoimmunization model) (Kisand et al., 
2010). Evidence for the maturation model came from analysis of the effects of Aire-
deficiency in ovalbumin-specific TCR transgenic mice that also expressed an 
ovalbumin transgene controlled by the rat insulin promoter (Anderson et al., 2005). 
Ovalbumin-specific CD4 or CD8 T cells were not deleted efficiently, but surprisingly 
this was despite apparently normal mRNA from the RIP-mOVA transgene in thymic 
mTECs. Microarray profiling of the Aire-deficient mTECs revealed diminished 
expression of numerous genes involved in antigen processing, leading to the conclusion 
that failed thymic deletion in this case arose for inefficient presentation of the mTEC-
expressed antigens. 
Aire expression is also observed at lower levels in secondary lymphoid organs (extra-
thymic Aire-expressing cells) that regulates the expression of a subset of peripheral 
tissue-specific genes, and acts to control self-reactive peripheral T cells (Gardner et al., 
2008; Lee et al., 2007; Nichols et al., 2007), although it still remains unclear if Aire 
expression in secondary lymphoid tissues plays a physiological role in preventing 
autoimmune diseases since thymic transplants clearly indicated that it was required 
solely within the thymus (Anderson et al., 2002; DeVoss and Anderson, 2007). 
Consistent with the HLA-effect in human disease, varying the mouse strain background 
or specifically changing the H2 haplotype changes the spectrum of organs targeted by 
autoimmunity (Jiang et al., 2005; Niki et al., 2006). 
Studies of the simple monogenic Aire-deficient disease have improved our 
understanding of human autoimmune disease. Importantly, it has also highlighted two 
features common to autoimmune disease that present as a challenge in understanding 
and preventing these diseases – the variability in clinical manifestation and specific 
targets of autoimmunity, and the presence of a latent phase prior to development of 
autoimmunity. Most common autoimmune disease appears still much more complex, 
resulting from a combination of myriad inherited variants that have proved exceedingly 
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challenging to pinpoint, overlaid by stochastic or environmental factors such as diet, 
environmental toxins, and infections.   
1.4.2 Polygenic autoimmune diseases 
At the other extreme from familial syndromes like APS1 that result from complete 
disruption of single genes is the evidence that genetic susceptibility to common 
autoimmune diseases reflect interaction of multiple gene variants. This could either be a 
combination of multiple common allelic variants of low penetrance or of rare allelic 
variants with higher penetrance (Schork et al., 2009). The common variant hypothesis 
has been examined by genome wide association studies (GWAS), generally performed 
by consortiums of investigators on collections of patients and controls by tracking tag 
single nucleotide polymorphisms (SNPs) for small ancestral haplotypes distributed 
throughout the genome, to highlight haplotypes that are slightly more or less frequent in 
people with a particular autoimmune disease (reviewed in (Rai and Wakeland, 2011)).  
The strongest genetic effect has been from specific HLA haplotypes and genes (Table 
1.4), although the basis for autoimmune HLA associations are still poorly understood. 
There are several possibilities: (i) autoimmune-susceptible HLA haplotypes may 
present driver autoantigens from particular organs less efficiently for negative selection, 
Treg formation or peripheral tolerance; (ii) they may be better at presenting driver 
autoantigens to provoke autoimmunity; or (iii) they may have more indirect effects on 
positive selection against unrelated self-peptides in the thymus, resulting in higher 
frequencies of cells in the repertoire with damaging cross-reactive TCR specificities 
against other self antigens.  
Table 1.4. HLA alleles associated with particular autoimmune disease identified in 
genome wide association studies. Table adapted from (Rai and Wakeland, 2011) and 
the GWAS catalogue (http://www.genome.gov/26525384).  
HLA genes 
Strongest SNP 
risk allele Disease Reference 
B rs2523393-A Multiple sclerosis  (De Jager et al., 2009) 
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C rs10484554-T Psoriasis  (Liu et al., 2008) 
C, 
CCHCR1 
rs9263739-T 
Ulcerative colitis  (Asano et al., 2009) 
C, MSH5 
rs3131379-A Systemic lupus 
erythemathosus  (Han et al., 2009) 
DQA 
rs477515 (IBD), 
rs2187668-A 
(CD) 
Inflammatory bowel 
disease, Celiac disease 
disease 
 (Kugathasan et al., 2008 ; 
van Heel et al., 2007) 
DRA 
rs9268923-C 
(UC), rs3135388-
A (MS), 
rs3135338-A 
(MS)  
Ulcerative colitis, 
multiple sclerosis 
(Asano et al., 2009; 
Franke et al., 2008; 
Franke et al., 2010; Hafler 
et al., 2007) 
DRB 
rs660895 (RA), 
rs2647044-A 
(T1D), 
rs9271366-G 
(MS) 
Rheumatoid arthritis, 
type I diabetes, multiple 
sclerosis 
(Comabella et al., 2008; 
Sanna et al., 2010; Yang 
et al., 2006) 
 
Besides HLA, many other loci have been associated with autoimmune diseases. For 
example, for type I diabetes alone more than 40 loci contribute to increased 
susceptibility (Barrett et al., 2009) and many also predispose to other autoimmune 
diseases such as psoriasis (PS), and multiple sclerosis (MS), inflammatory bowel 
disease (IBD) [includes Crohn’s disease (CrD) and ulcerative colitis (UC)], and celiac 
disease (CD), systemic lupus erythematosus (SLE). It is intriguing that many of the tag 
SNPs so far associated with human autoimmune disease are near genes that function in 
thymic deletion or peripheral T cell anergy versus co-stimulation (Fig. 1.3, Fig. 1.4 and 
Table 1.5). 
Limitations in the GWAS method include the low statistical power caused by multiple 
testing, imperfect correlation between inheritance of tag SNPs and causative gene 
variants, heterogenous genetic backgrounds, population stratification, inability to test 
for rare alleles with large effects, uncontrolled environmental variables and constraints 
on experimental validation. However, the greatest challenge is that despite the large 
number of loci with statistical evidence of association with autoimmune disease 
susceptibility, these genotypes only account for a small fraction of the total genetic 
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heritability (Manolio et al., 2009). So, what could account for this missing heritability? 
It can be suggested that the complex set of loci that contribute to autoimmune 
susceptibility work together to compromise multiple tolerance checkpoints resulting in 
severe autoimmune diseases. This epistatic interaction has been generally ignored in 
GWAS studies as statistical methods for identifying additive and epistatic (synergistic 
or interfering) interactions between individual alleles typically require even larger 
population sizes and even then still fail to include the large number of family-specific 
alleles. Another possibility is that the missing heritability comprises variants that are 
rare in the population as a whole, and hence are not “tagged” by the common SNPs 
used in GWAS studies. 
Table 1.5. Autoimmune susceptibility loci involved in thymic deletion and T cell 
anergy. Type 1 diabetes (T1D), psoriasis (PS), and multiple sclerosis (MS), 
inflammatory bowel disease (IBD) includes Crohn’s disease (CrD) and ulcerative colitis 
(UC)], and celiac disease (CD), systemic lupus erythematosus (SLE). Table adapted 
from (Rai and Wakeland, 2011) and the GWAS catalogue 
(http://www.genome.gov/26525384). 
Thymic deletion 
– associated 
genes 
Human disease Reference 
Ptpn2 T1D, CrD, CD, UC, RA  (Barrett et al., 2009; Dubois et al., 
2010; Todd et al., 2007) 
Ptpn22  RA, T1D, SLE, CrD  (Barrett et al., 2009; 2007; Todd et 
al., 2007) 
RasGFP SLE  (Han et al., 2009) 
T cell anergy – 
associated genes 
Human disease Reference 
TLR7/TLR8 CD, SLE  (Dubois et al., 2010; Shen et al., 
2010)) 
CTLA4/ICOS/C
D28 
CD, T1D, IBD, RA, MS, 
SLE  
(Dubois et al., 2010) 
CBLB MS  (Sanna et al., 2010) 
PKCθ T1D, RA, CD (Cooper et al., 2008) 
ETS1 SLE, CD  (Dubois et al., 2010; Han et al., 2009; 
Yang et al., 2010)} 
SH2B3 TID, CD  (2007) 
CD40 RA, MS, CrD  (Stahl et al., 2010) 
CD69 T1D  (Barrett et al., 2009) 
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IL2RA RA, MS, T1D  (Hafler et al., 2007; Stahl et al., 2010) 
 
1.5 Hypothesis of the study 
1.5.1 Hypothesis 
As reviewed in previous sections, multiple tolerance checkpoints prevent self-reactive 
lymphocytes from attacking self. While complete disruption in individual genes such as 
Aire, FoxP3, or Fas are able to cause rare monogenic autoimmune disease, more 
common autoimmune diseases are associated with multiple subtle allelic variants in 
different genes or loci. Many loci associated with human autoimmune diseases are close 
to genes that function in thymic deletion or peripheral T cell anergy (Fig. 1.3 and 1.4) 
suggesting that multiple defects in immune tolerance pathways cause autoimmune 
diseases. Little is known, however about the consequence of combined defects in 
thymic and peripheral tolerance pathways. 
Understanding how multiple genetic variations in individual tolerance mechanisms 
cooperate to determine the onset and clinical course of autoimmune disease has been 
challenging in part because so many genetic variants need to come together and many 
cause subtle quantitative changes in function. Even when combined there is a 
substantial and variable latent period representing the need for unknown stochastic or 
environmental events. Additive or cooperative effects of susceptibility genes in man or 
mouse may reflect death by a thousand cuts in a single pathway, as demonstrated for 
the dysregulated B cell response to autoantigen when multiple heterozygous mutations 
in the Lyn-CD22-SHP1 pathway are combined (Cornall et al., 1998) and for the failure 
of thymic deletion in NOD mice (Choisy-Rossi et al., 2004; Liston et al., 2004b; 
Venanzi et al., 2004). Alternatively, cooperative predisposition to autoimmune disease 
may result from failure of separate pathways that function as failsafes for one another - 
death by single cuts in complimentary failsafe mechanisms. 
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This dissertation explores the latter possibility, a multi-step model for the pathogenesis 
of autoimmune diseases. Since each tolerance pathway is governed by a unique set of 
genes 
In this model, it is predicted that deficiencies in two (or more) genes that cripple 
different tolerance mechanisms would co-operate to accelerate autoimmune disease, 
hasten the tempo of the disease and unveil features not seen in individual defects. This 
requirement for co-operation in more than one tolerance defect in the development of 
fulminant autoimmune disease is an attractive explanation for why autoimmune 
manifestations are heterogeneous in nature and present with a latent period. This is 
likely scenario as the frequency of germline mutations, multiplied over the large 
number of failsafe or tolerance genes would result in virtually all individuals harbouring 
deleterious alleles in a heterozygous state in at least one of the genes involved in 
tolerance. An autoimmune-prone homozygous phenotype could easily emerge in the 
scenario of a disadvantageous breeding (inherited) or if a somatic mutation were to 
occur. The latent period in autoimmune disease pathogenesis may allow accumulation 
of successive mutations in different tolerance pathways leading to fulminant 
autoimmunity  (Goodnow, 2007).  In his 1972 monograph, Burnet himself alluded to 
the idea that the latent onset of autoimmune diseases may reflect “a conditioned 
malignancy” when “forbidden clones” failed to be eliminated or inactivated as a result 
of germline and somatic mutations that disrupt tolerance mechanisms (Burnett, 1972). 
1.5.2 Direction of the study 
To explore the multi-step model for the pathogenesis of autoimmune diseases, a 
reductionist strategy was employed. As each tolerance pathway is governed by a set of 
genes, and mouse models that are deficient in key genes involved in particular tolerance 
mechanisms have been extensively studied, the study began by testing the consequences 
of pairing defective thymic deletion due to Aire deficiency with four different 
molecularly defined defects that disrupt specific peripheral tolerance mechanisms. 
Specifically, the Aire-deficient mice – which have a profound defect in thymic deletion 
to organ specific antigens - were crossed with mice carrying genetic defects in one of 
four distinct peripheral tolerance mechanisms that have been summarized above: 
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decreased numbers of Foxp3+ T regulatory cells (Card11unm/unm), apoptosis (Faslgld/gld), 
anergy (Cbl-b-/-), or deregulated activation of T follicular helper cells (Rc3h1san/san).  
This strategy simplifies the co-operating genetic and cellular events resulting in 
spontaneous autoimmune disease to pinpoint which tolerance pathways cooperate and 
establish a mechanistic basis for cooperative pathogenesis of autoimmunity. A 
prediction of the model was that combination of Aire deficiency with a defined 
molecular lesion in peripheral tolerance would dramatically accelerate autoimmunity 
and lead to emergent autoimmune disease not seen with either individual defect. By 
contrast, no acceleration of autoimmunity and an additive combination of the individual 
autoimmune phenotypes would result from compounding Aire deficiency with a defect 
in peripheral tolerance that does not serve as a failsafe. Should cooperation be found 
between Aire deficiency and a specific peripheral tolerance defect, a virtue of this 
reductionist approach would in principle be at the level of analysing the cellular basis 
for genetic co-operation. Comparing the fate of self-reactive T cells in resistant or 
susceptible backgrounds would be simplified by the need for only two Mendelian 
defects, as compared to the myriad genetic loci with difficult to pinpoint defects that are 
needed for autoimmune susceptibility or resistance in NOD mice. 
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Chapter 2  
Mice, materials and methods 
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2.1 Mice 
All mice described were housed and maintained under specific pathogen-free conditions 
in the Animal Service Department, Australian National University. All mice used in the 
hematopoietic chimera experiments were housed in the Containment Suites, John Curtin 
School of Medical Research, Australian National University. All animal procedures 
were approved by the Australian National University Animal Ethics and 
Experimentation Committee. 
2.1.1 Basic strains 
Table 2.1 Basic mouse strains used in this study. 
Basic Strains Description 
C57BL/6  Inbred C57BL/6 strain of haplotype H2b. Imported 
from Stanford University. 
C57BL/6.SJL-
Ptprca/BoAiTac (abbreviated 
as C57BL/6 Ly5a) 
C57BL/6 strain congenic for the SJL CD45 allele, 
CD45.1/Ly5a, in place of CD45.2/Ly5b.  Originally 
imported from Jackson Laboratories (Bar Harbor, 
ME). 
B10.BR-H2k/SgSnJ (B10.BR) C57BL/10 substrain congenic for the C57BR H2 
locus, H2k. Abbreviated as B10.BR. Imported from 
Jackson Laboratories (Bar Harbor, ME). 
 
2.1.2 Knock-out strains 
Table 2.2 Knock-out mouse strains used in this study. 
Knock-out strains Description 
Airetm1Pltn The Aire-deficient mouse strain, a kind gift from Prof. 
Leena Peltonen, bears the truncating R257X nonsense 
mutation through an insertion of a neomycin resistance 
cassette, eliminating exon 6 at amino acid position 218, 
similar to the major human Finnish APS1 mutation 
(Ramsey et al., 2002b) 
37
   
Rag1tm1Mom A 1356 bp genomic fragment of Rag1 gene was 
replaced by the insertion of a neomycin resistance 
cassette. Originally produced with AB1 ES cells 
(129S7/SvEvBrd-Hprt+ background) and crossed to B6 
(Mombaerts et al., 1992). Imported from the Animal 
Resources Centre, Government of Western Australia 
and backcrossed to C57/BL6 for > 15 generations. 
Cblbtm1Pngr The Cblbtm1Pngr (abbreviated as Cblb-/-) knockout mouse 
strain was obtained from Prof. Wallace Langdon. The 
mouse was generated by introducing a neomycin 
cassette replacing the region encoding a portion of the 
tyrosine kinase-binding and RING finger domains, 
corresponding to amino acids 300 through 340 of the 
encoded protein (Bachmaier et al., 2000). The mutation 
has been and backcrossed to C57/BL6 for > 10 
generations. 
Faslgld/gld The Faslgld mouse strain was obtained from the Jackson 
Laboratories. The mouse strain harbours a spontaneous 
thymine to cytosine point mutation near the 3' end of 
the coding sequence which results in a replacement of a 
highly conserved phenylalanine with a leucine at 
position 273 in the extracellular region of the encoded 
protein (Takahashi et al., 1994).  
Card11unm/unm The Card11unm/unm  C57/BL6 mouse strain was 
generated in the Immunogenomics Laboratory from N-
ethyl-N-nitrosuria mutagenesis screen of third 
generation offspring in a pedigree which displayed high 
level of surface IgM antigen receptors on circulating 
IgD+ B cells. The mice have a point mutation changing 
a thymine to adenine nucleotide, which results in a non-
polar leucine to a polar glutamine codon substitution in 
the coiled-coiled domain of Card11 (also called Carma-
1)(Jun et al., 2003).  
Rc3h1san/san The C57BL/6.Rc3h1san/san mouse strain was also 
generated in the Immunogenomics Laboratory from an 
N-ethyl-N-nitrosuria mutagenesis screen of third 
generation offspring in a pedigree that displayed high 
amounts of anti-nuclear antibodies and 
lymphadenopathy. The mice carry a thymine to guanine 
substitution in the Rc3h1 ubiquitin ligase resulting in a 
non-conservative methionine to arginine codon change. 
 
The breeding of Aire-deficient mice to heterozygous Card11unm/unm, Cblb-/-, Faslgld/gld 
and Rc3h1san/san mouse models, and preliminary intercrosses of the first three filial 
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generations were performed by Dr. Anselm Enders. This thesis includes data from the 
fourth to ninth filial generation of mouse breeding in each strain.  
2.1.3 Transgenic strains 
Table 2.3 Transgenic mouse strains used in this study. 
Transgenic strains Description 
TCR3A9 
TCR α and β transgenic produced in C57BL/6J mice 
were backcrossed >7 generations to B10.BR (Ho et al., 
1994). 
InsHEL 
The ILK-3 transgene consists of a membrane-bound 
(class I transmembrane region) hen egg lysozyme (HEL) 
antigen driven by the rat insulin promoter. Produced in 
C57BL/6J mice (Akkaraju et al., 1997b) and backcrossed 
>7 generations to B10.BR. 
ThyrHEL 
The TLK-2 transgene consists of membrane-bound HEL 
driven by a fragment of the rat thyroglobulin promoter. 
Produced in C57BL/6J mice(Akkaraju et al., 1997b) and 
backcrossed >7 generations to B10.BR (Akkaraju et al., 
1997a; Akkaraju et al., 1997b). 
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2.2 Materials 
2.2.1 Antibodies 
Table 2.4 Antibodies used for flow cytometry. The clone designations, fluorochrome 
conjugations (if applicable) and vendors are listed for each antibody. Each antibody was 
titrated and used at the minimal concentration required for saturation. 
Antibodies Clone Conjugation Vendor 
7-Amino-actinomycin D None None BD Pharmingen™ 
Anti-human Ki-67  B56 A647 BD Pharmingen™ 
Anti-mouse Bim 3C5 A647 
Gift from Andreas 
Strasser, Walter and 
Eliza Hall Institute 
Anti-mouse CD122 Mik-β3 Biotin BD Pharmingen™ 
Anti-mouse CD134 OX40 Biotin BD Pharmingen™ 
Anti-mouse CD152 
(CTLA4) 
UC10-4F10-
11 PE BD Pharmingen™ 
Anti-mouse CD16/32 2.4G2   BD Pharmingen™ 
Anti-mouse CD24 M1/69 Alexa Fluor® 405 BD Pharmingen™ 
Anti-mouse CD25 (IL-2 
Receptor a chain, p55) PC61 
Alexa 
Fluor® 700, 
APC, APC 
Cy7, PE, 
PerCP 
BD Pharmingen™ 
Anti-mouse CD3 17A2 Alexa Fluor® 700 eBioscience 
Anti-mouse CD4 RM4-5 PE Cy7 BD Pharmingen™ 
Anti-mouse CD4 GK1.5 None BioXCell 
Anti-mouse CD44  IM7 
Biotin, 
Pacific Blue, 
PE 
BD Pharmingen™ 
Anti-mouse CD45.1 (Ly-
5.1, Ly5a) A20 
Alexa 
Fluor® 700, 
FITC 
BD Pharmingen™ 
Anti-mouse CD45.2 (Ly-
5.2, Ly5b) 104 
Alexa 
Fluor® 405, 
Alexa 
Fluor® 700, 
PerCP, PE 
Cy7 
BD Pharmingen™ 
Anti-mouse CD45R (B220) RA3-6B2 
Alexa 
Fluor® 405, 
APC Cy7, 
PerCP Cy5.5 
BD Pharmingen™ 
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Anti-mouse CD5  (Ly-1) 53-7.3 PE, PerCP BD Pharmingen™ 
Anti-mouse CD62L  (L-
selectin, LECAM-1, Ly-22) MEL-14 FITC, PerCP BD Pharmingen™ 
Anti-mouse CD69  (Very 
Early Activation Antigen) H1.2F3 PE Cy7 BD Pharmingen™ 
Anti-mouse CD8  53-6.7 
APC Cy7, 
Biotin, PE 
Cy7, PerCP 
BD Pharmingen™ 
Anti-mouse Foxp3  MF23 
Alexa 
Fluor® 700, 
e450, FITC  
BD Pharmingen™ 
Anti-mouse GITR  DTA-1 
Alexa 
Fluor® 700, 
PE Cy7 
BD Pharmingen™ 
Anti-mouse ICOS 7E.17G9 PE BD Pharmingen™ 
Anti-mouse IgG1  G235-2356 PE, APC BD Pharmingen™ 
Anti-mouse NK1.1 (NKR-
P1B and NKR-P1C) PK136 APC BD Pharmingen™ 
Anti-mouse TCR H57-597  FITC BD Pharmingen™ 
Anti-TCR3A9 clonotype 1G12 None Homemade 
Ant-mouse CD8 53-6.72 None BioXCell 
Mouse IgG2b Isotype 
control MPC-11 None BioXCell 
Rat-anti mouse CD44 IM7.8.1 Alexa Fluor® 405 
Caltag™ 
Laboratories 
Streptavidin   Qdot® 605 Invitrogen™ 
Note: Antibody conjugation to A647 was done using the Protein Labelling Kit 
(Molecular Probes, A20173). 
2.2.2 Bioinfomatic tools 
Table 2.5 Bioinformatic tools used in this study. 
Bioinformatics tools Website Description 
ENSEMBL Genome 
Browser 
http://www.ensembl.org
/index.html 
Produces and maintains automatic 
annotation on selected eukaryotic 
genomes. 
ExPASy Proteomics 
Server 
http://au.expasy.org/tool
s/dna.html 
Allows the translation of a 
nucleotide (DNA/RNA) sequence to 
a protein sequence in three reading 
frames. 
FinchTV http://www.geospiza.co
m/Products/finchtv.shtm
l 
Viewing and editing nucleotide 
sequence traces. 
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ImMunoGeneTics http://www.imgt.org/ Reference for TRAV, TRAJ, TRBV, 
TRBJ nucleotide sequences and 
translations. 
Mouse Genome 
Informatics 
http://www.informatics.j
ax.org/ 
Provides integrated access to data on 
the genetics, genomics and biology 
of laboratory mice. 
Musterer http://musterer.apf.edu.a
u/ 
Database of mouse strains used in 
the project. 
Primer3 http://frodo.wi.mit.edu/c
gi-
bin/primer3/primer3_w
ww.cgi 
PCR primer design program. 
 
2.2.3 Buffers, solution and media 
2.2.3.1 Common buffers, solutions and media 
Table 2.6 Common buffers, solution and media and the respective vendors. 
Buffer Vendors 
DMEM Ordered from GibcoBRL 
Phosphate buffer saline Obtained from the John Curtin School of Medical 
Research Media Facility 
RPMI Ordered from GibcoBRL 
 
2.2.3.2 Buffers, solution and media for cell biology assays and techniques 
Table 2.7 Buffers used for cell biology techniques and the respective compositions. 
Buffer Composition 
cDMEM DMEM (GibcoBRL), 10 % (v/v) HI-FCS (Sigma), 
2mM L-glutamine (GibcoBRL), 1mM MEM sodium 
pyruvate (GibcoBRL), 100µM MEM non essential 
amino acids (GibcoBRL), 5mM HEPES buffer 
solution (GibcoBRL), 55µM 2-mercaptoethanol 
(GibcoBRL), 100u/ml penicillin, 100µg/ml 
streptomycin (GibcoBRL) 
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Cell culture medium RPMI (GibcoBRL), 10 % (v/v) HI-FCS (Sigma), 10 
mM HEPES, pH7.4 (GibcoBRL), 0.1 mM non-
essential amino-acid solution (GibcoBRL), 1 mM 
sodium pyruvate (Sigma), 50 uM beta-
mercaptoethanol (GibcoBRL), 10 mL L-glutamate and 
penicillin/streptomycin (GibcoBRL) 
Cell culture freezing media 90 % (v/v) HI-FCS (Sigma), 10% DMSO, 2mM L-
glutamine (GibcoBRL), 1mM MEM sodium pyruvate 
(GibcoBRL), 100µM MEM non essential amino acids 
(GibcoBRL), 5mM HEPES buffer solution 
(GibcoBRL), 55µM 2-mercaptoethanol (GibcoBRL), 
100u/ml penicillin, 100µg/ml streptomycin 
(GibcoBRL) 
D20 cDMEM except 20 % (v/v) HI-FCS (Sigma) instead of 
10 % (v/v) HI-FCS (Sigma) 
ELISA Blocking Buffer 1% bovine serum albumin in phosphate buffer saline 
ELISA Coating Buffer 0.05 M carbonate, 1.59 g sodium carbonate anhydrous 
and 2.93 g sodium hydrogen carbonaye in 1 L 
deionized water adjusted to pH 9.6 with hydrochloric 
acid solution 
ELISA Developer Buffer 0.1 M glycine, 0.1 mM zinc chloride, 1.0 M 
magnesium chloride in deionized water adjusted to pH 
10.4 with sodium hydroxide solution 
ELISA Dilution buffer 1% bovine serum albumin and 0.05% Tween 20 
(Sigma, St. Louis, Illinois) in phosphate buffer saline 
ELISA Wash Buffer 0.05% Tween 20 (Sigma, St. Louis, Illinois) in 
phosphate buffer saline 
FACS Buffer 5% fetal calf serum and 0.1% sodium azide in 
phosphate buffer saline 
Low serum culture media RPMI (GibcoBRL), 2 % (v/v) HI-FCS (Sigma), 10 
mM HEPES, pH7.4 (Sigma), 0.1 mM non-essential 
amino-acid solution (GibcoBRL), 1 mM sodium 
pyruvate (Sigma), 50 uM beta-mercaptoethanol 
(GibcoBRL), 10 mL L-glutamate and 
penicillin/streptomycin (GibcoBRL) 
Magnetic cell separation 
buffer 
0.5% bovine serum albumin and 2 mM  EDTA in 
phosphate buffer saline  
OptiMEM Ordered from GibcoBRL 
Red blood cell lysis buffer 
(10×) 
8.99 g ammonium chloride,1 g potassium bicarbonate, 
37 mg sodium EDTA in 100 mL deionized water, 
adjusted to pH 7.3 with hydrochloric acid solution 
Turks solution 1% (v/v) acetic acid and gention violet in deionised 
water 
 
2.2.3.3 Buffers solutions and media for molecular biology assays and techniques 
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Table 2.8. Buffers used for molecular biology techniques and the respective 
compositions. 
Buffer Composition  
Agarose gel loading buffer 
(6×) 
Bromophenol blue and 30% glycerol in deionized 
water 
CSA Sequencing Buffer 
(5×) 
400 mM Tris-hydrochloric acid adjusted to pH 9 and 
10 mM magnesium chloride 
Sodium borate buffer 5 mM sodium tetraborate 
 
2.2.4 Cell lines 
2.2.4.1 293T cells 
The 293T cells (D. Baltimore, California Institute of Technology) (a kind gift from Dr. 
Nicole La Gruta, University of Melbourne) were used as a readily transfected cell line 
to test for gene expression from retroviral vectors and for the generation of stable 
retroviral producer cell lines. Cells were maintained in NUNC T75 flasks (Thermo 
Scientific) in complete-DMEM (cDMEM) medium at 37°C until the monolayers were 
confluent. For passage, the monolayers were washed with 10 mL PBS and treated with 
1.5 mL trypsin-EDTA at 37°C for 4-5 minutes. cDMEM was added to inactivate the 
trypsin-EDTA and the cells were seeded onto fresh tissue culture flask. 
2.2.4.2 GP+E86 cells 
The GP+E86 (American Tissue Culture Type Collection: CRL-9642) (a kind gift from 
Dr. Nicole La Gruta, University of Melbourne), a 3T3-based retroviral packaging cell 
line stably transfected with two plasmids encoding gag, pol and env genes from 
Moloney Leukaemia virus (Markowitz et al., 1988). The cells were used to establish 
stable ecotropic retrovirus producer cell lines. Culture and passage conditions were the 
same as 293T cells. 
2.2.4.3 3T3 cells 
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The 3T3 cells (American Tissue Culture Type Collection: CRL-1658) (a kind gift from 
Dr. Nicole La Gruta, University of Melbourne) are a fibroblast cell line used for 
determining the titres of retroviral producer cell lines. 
2.2.5 Chemicals 
All chemicals were of analytical grade or the highest grade available, and were 
purchased from Sigma-Aldrich unless otherwise stated. 
2.2.6 Kits 
Table 2.9 Kits and the respective vendors used in this study. 
Kits Vendor 
AccuPrime™ Taq DNA Polymerase High Fidelity Invitrogen 
CD4 (L3T4) MicroBeads Miltenyi Biotec 
CD4+ CD25+ Regulatory T Cell Isolation Kit Miltenyi Biotec 
CD8 (Ly-2) MicroBeads  Miltenyi Biotec 
CellTrace™ CFSE Cell Proliferation Kit Invitrogen 
CellTrace™ Violet Cell Proliferation Kit  Invitrogen 
DyeEx 96 Kit Qiagen 
ExoSAP-IT  USB Corporation 
Flow Cytometry Fixation and Permeablisation eBioscience 
Fugene 6 reagent  Roche Diagnostics 
iScript cDNA Synthesis Kit Bio-Rad  
 
2.2.7 Molecular weight markers 
Table 2.10 Molecular weight markers used in this study. 
Molecular Weight Markers Vendor 
1Kb Plus DNA Ladder Invitrogen 
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2.2.8 Primers 
Table 2.11. Primers used in single cell multiplex PCRs. Primer sequences were 
obtained from (Dash et al., 2011) and synthesized by Invitrogen. Each desiccated 
primer was reconstituted to 100 pmol/µL in water. 5 pmol/µL working dilutions of Trav 
external, Trav internal, Trbv external and Trbv internal forward primers were prepared 
by combining equal volumes of the appropriate primers and stored at -20°C.   
Primers   Sequence   
Trav1 external forward 5' GGTTATCCTGGTACCAGCA 3' 
Trav2 external forward 5' CATCTACTGGTACCGACAGG 3' 
Trav3.5D4.10 external forward 5' CCTGAGTGTICVRGAGGGA 3' 
Trav4 external forward 5' TCTGSTCTGAGATGCAATTTT 3' 
Trav5-1.7D-2 external forward 5' CCTSATTGTICMRGAGGGAG 3' 
Trav5(D)-4 external forward 5' CTTCCTTCCATCCTGAGAG 3' 
Trav6.12-2 external forward 5' TMMCCDDIICTKTTCTGGTATGT 3' 
Trav6.5_6.6(D) external forward 5' GAYTCVGTGACTCARACAGAAGG 3' 
Trav7.10Da13 external forward 5' SRDCAGIAAGTRCAGCAGAG 3' 
Trav8 external forward 5' GAGCRTCCASGAGGGTG 3' 
Trav9.17 external forward 5' GAGMCTCBSTGSAGCTSAGATGCA 3' 
Trav11 external forward 5' AAGACCCAAGTGGAGCAG 3' 
Trav12 external forward 5' TGACCCAGACAGAAGGC 3' 
Trav14.19 external forward 5' CAGCAGCAGGTKARACAAAG 3' 
Trav15 external forward 5' CASCTTYTTAGTGGAGAGATGG 3' 
Trav16 external forward 5' GTACAAGCAAACAGCAAGTG 3' 
Trav18 external forward 5' AACGGCTGGAGCAGAG 3' 
Trav21 external forward 5' GTGCACTTGCCTTGTAGC 3' 
Trac external reverse  5' GGCATCACAGGGAACG 3' 
Trav1 internal forward 5' CTCCACATTCCTGAGCC 3' 
Trav2 internal forward 5' ACTCTGAGCCTGCCCT 3' 
Trav3.5D4.10 internal forward 5' AACGAITCTCICTGMACMTCACAG 3' 
Trav4- internal forward 5' GGITIMAGGAACAAAGGAGAAT 3' 
Trav5-1.7D-2 internal forward 5' TGGTAIARRCARSASICTGGGAA 3' 
Trav5(D)-4 internal forward 5' AGAATCCTAAGCTCATCATTGAC 3' 
Trav6.12-2 internal forward 5' TCCAIITRCAGAARDCCTCAG 3' 
Trav6.5_6.6(D) internal forward 5' GTKCRRTATCCYGGAGAAGGTC 3' 
Trav7.10Da internal forward 5' CATGRCITCIITCAACTGCAC 3' 
Trav8  internal forward 5' AGAGCCACCCTTGACAC 3' 
Trav9.17 internal forward 5' GGCTTIGAGGCIGAGTT 3' 
Trav11 internal forward 5' AACAGGACACAGGCAAAG 3' 
Trav12 internal forward 5' GGTTCCACGCCACTC 3' 
Trav13 internal forward 5' CCTTGGTTCTGCAGGAG 3' 
Trav14 internal forward 5' CTCTGACAGTCTGGGAAGG 3' 
46
   
Trav15 internal forward 5' AYTCTGTAGTCTTCCAGAAATCAC 3' 
Trav16 internal forward 5' ATTATTCTCTGAACTTTCAGAAGC 3' 
Trav18 internal forward 5' CAAGATTTCACCGCACG 3' 
Trav19 internal forward 5' GCTGACTGTTCAAGAGGGA 3' 
Trav21 internal forward 5' AATAGTATGGCTTTCCTGGC 3' 
Trac internal reverse 5' GCACATTGATTTGGGAGTC 3' 
Trbv1 external forward 5' TACCACGTGGTCAAGCTG 3' 
Trbv16 external forward 5' CCTAGGCACAAGGTGACAG 3' 
Trbv12 external forward 5' GGGGTTGTCCAGTCTCC 3' 
Trbv5 external forward 5' GGTATAAACAGAGCGCTGAG 3' 
Trbv29 external forward 5' GCTGGAATGTGGACAGG 3' 
Trbv20 external forward 5' GGATGGAGTGTCAAGCTG 3' 
Trbv13 external forward 5' GCTGCAGTCACCCAAAG 3' 
Trbv14 external forward 5' GCAGTCCTACAGGAAGGG 3' 
Trbv15 external forward 5' GAGTTACCCAGACACCCAG 3' 
Trbv17 external forward 5' GAAGCCAAACCAAGCAC 3' 
Trbv19 external forward 5' GATTGGTCAGGAAGGGC 3' 
Trbv2 external forward 5' CAGTATCTAGGCCACAATGC 3' 
Trbv23 external forward 5' CTGCAGTTACACAGAAGCC 3' 
Trbv24 external forward 5' CAGACTCCACGATACCTGG 3' 
Trbv26 external forward 5' GGTGAAAGGGCAAGGAC 3' 
Trbv3 external forward 5' CCCAAAGTCTTACAGATCCC 3' 
Trbv30 external forward 5' CCTCCTCTACCAAAAGCC 3' 
Trbv31 external forward 5' CTAACCTCTACTGGTACTGGCAG 3' 
Trbv4 external forward 5' GACGGCTGTTTTCCAGAC 3' 
Cβa (Trbc) external reverse 5' CCAGAAGGTAGCAGAGACCC 3' 
Trbv1 internal forward 5' GTATCCCTGGATGAGCTG 3' 
Trbv16 internal forward 5' GAAGCAACTCTGTGGTGTG 3' 
Trbv12 internal forward 5' CCAGCAGATTCTCAGTCC 3' 
Trbv5 internal forward 5' GCCAGAGCTCATGTTTCTC 3' 
Trbv29 internal forward 5' GTACTGGTATCGACAAGACCC 3' 
Trbv20 internal forward 5' GCTTGGTATCGTCAATCG 3' 
Trbv13 internal forward 5' GTACTGGTATCGGCAGGAC 3' 
Trbv14 internal forward 5' GGTATCAGCAGCCCAGAG 3' 
Trbv15 internal forward 5' GTGTGAGCCAGTTTCAGG 3' 
Trbv17 internal forward 5' GAACAGGGAAGCTGACAC 3' 
Trbv19 internal forward 5' GGTACCGACAGGATTCAG 3' 
Trbv2 internal forward 5' GGACAATCAGACTGCCTC 3' 
Trbv23 internal forward 5' GCCAGGAAGCAGAGATG 3' 
Trbv24 internal forward 5' GCACACTGCCTTTTACTGG 3' 
Trbv26 internal forward 5' GAGGTGTATCCCTGAAAAGG 3' 
Trbv3 internal forward 5' GATATGGGGCAGATGGTG 3' 
Trbv30 internal forward 5' GGACATCTGTCAAAGTGGC 3' 
Trbv31 internal forward 5' CTGTTGGCCAGGTAGAGTC 3' 
Trbv4 internal forward 5' CAGGTGGGAAATGAAGTG 3' 
Trbc internal reverse 5' CCTCCTTGCCATTCACCCAC 3' 
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Table 2.12 Primers for verification of pMIGII retrogenic vector and TCR insert 
sequences. Primer sequences were obtained from the La Gruta/Doherty Laboratory, 
University of Melbourne and synthesized by Geneworks. Each desiccated primer was 
reconstituted to 100 µM in Buffer TE and 10 µM working stocks are stored at -20°C. 
Primers   Sequence   
MSCV forward 5' ACACCCTAAGCCTCCGCCTCC 3' 
Cα5 internal 5' GAACCTGCTGTGTAC 3' 
IRES reverse 5' AACGCACACCGGCCTTATTCC 3' 
 
2.2.9 T cell stimuli 
Table 2.13 T cell stimuli used in this study. The initial concentrations, final 
concentrations in tissue culture and vendor are listed for each agonist.  
Agonist 
Initial 
concentration 
Used 
concentration Vendor 
Anti-CD3 0.5 mg/mL 10 µg/mL BD Pharmingen 
Anti-CD28  0.5 mg/mL 5 µg/mL  BD Pharmingen 
HEL peptide 1 mg/mL   10 µg/mL 
JCSMR 
Biomolecular 
Resource Facility 
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2.3 Methods 
2.3.1 Cell biology assays and techniques 
2.3.1.1 Preparation of peripheral blood samples 
Blood was collected from the retro-orbital sinus of mice using a glass capillary and 
placed into 1 mL cluster tubes containing 20 µL of 1000 U/mL heparin solution. The 
red blood cells were lysed by addition of 160 µL red blood cell (RBC) lysis buffer to 40  
µL of blood, followed by 10 minute incubation at room temperature and centrifugation 
for 4 minutes at a rate of 1340 r.p.m. at 18ºC. The supernatant was discarded and the 
pellet was resuspended in 180 µL RBC lysis buffer, followed by incubation and 
centrifugation as described above. The pellet was subsequently washed with 180 µL 
FACS buffer, resuspended in 180  µL FACS buffer and kept on ice until use. 
2.3.1.2 Preparation of lymphocytes from organs 
Mice were sacrificed by cervical dislocation or carbon dioxide inhalation. Solid organs 
(spleens, lymph nodes and thymus) were collected and placed into 5 mL of ice-cold 
RPMI1640 + 5% fetal calf serum (FCS). Bone marrow cells were flushed from tibias 
and femurs, which were aseptically cut at both ends with ice-cold RPMI1640 + 5% FCS 
using a 3 mL syringe. For the isolation of pancreas infiltrating lymphocytes, the 
pancreas (free of pancreatic lymph nodes) was finely cut and incubated at 37°C for 15 
minutes in 4 mL RPMI supplemented with 10 mg Collagenase P (Roche Diagnostics) 
and 10 µg DNase1 (Roche Diagnostics). The mixture was centrifuged at 1200 r.p.m. for 
5 minutes at 8°C and resuspended in 10mL of Ficoll-Paque Plus solution. Gently, 10 
mL RPMI 1640 was layered on top of the Ficoll-Paque Plus solution without disrupting 
the bottom layer. After centrifugation at 2300 r.p.m. for 15 minutes at 20°C using slow 
acceleration and deceleration (no breaks), the lymphocytes in the interphase of the two 
layers were harvested. Single cell suspensions of splenocytes, pancreatic infiltrated 
lymphocytes, thymocytes, bone marrow  and lymph node cells were prepared by teasing 
the tissues apart through a 70 µm nylon mesh filter (BD Biosciences, NJ, USA) with a 1 
mL syringe plunger.  
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All cells mentioned above were pelleted by centrifugation for 4 minutes, 1340 r.p.m. at 
4ºC. RBCs were lysed in 5  mL of RBC lysis buffer for 10 minutes. The RBC lysis 
buffer reaction was quenched by addition of 10 mL ice-cold PBS and the cell 
suspensions were pelleted by centrifugation for 10 minutes, 1340 r.p.m. at 4ºC. RBC 
lysis was not performed for thymocytes. Cells were resuspended in 5 mL of RPMI1640 
+ 5% FCS and kept on ice until use. 
2.3.1.3 Flow cytometry analysis of cell surface markers 
The expression of cell surface markers was analyzed by flow cytometry using 
fluorochrome-conjugated antibodies, according to the following procedure. 
Lymphocytes were prepared as described above, resuspended in FACS buffer and 
aliquoted into 96-well round-bottom plates (Nunc, Roskilde, Denmark) at 5×105 to 
1×106 cells per well. The cells were incubated with 20 µL Fc blocking antibody 
(CD16/CD32, 1 in 150 dilution of the 0.5 mg/mL stock) for 20 minutes at 4ºC to block 
non-specific antibody binding through Fc-receptor interactions. In cases where biotin-
conjugated primary antibodies were used, the appropriate antibody was added to the Fc 
blocking antibody mixture (both diluted to its optimal concentration in FACS buffer). 
The cells were washed by addition of 160 µL FACS buffer and centrifugation for 4 
minutes, 1340 r.p.m. at 4ºC. 
A cocktail of premixed fluorochrome-labelled antibodies (each diluted to its optimal 
concentration in FACS Buffer) was added at 30 µL per well, followed by an incubation 
for 30 minutes at 4ºC in the dark. In cases where biotin-conjugated primary antibodies 
were used, the appropriate strepavidin-conjugated secondary reagents were added to the 
premix (diluted to its optimal concentration in FACS buffer). Intracellular staining was 
performed according to the manufacturers instructions (FoxP3 Staining Buffer Kit, 
eBioscience). Following incubation, cells were washed and resuspended in 120 µL 
FACS buffer and stored at 4ºC in the dark, not more than 2 hours, before analysis on the 
FACS Calibur (Becton, Dickinson and Co, NJ, USA) or LSRII Flow Cytometer (BD 
Biosciences, CA, USA). 
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For single cell sorting, cells were stained as described above replacing the FACS buffer 
with 0.1% FSC in PBS supplemented with magnesium and calcium (GibcoBRL). 
Samples were filtered through a 70 µm filter into 5 mL polypropylene Falcon tubes. 
Cells were sorted directly onto Eppendorf 96-well PCT plates (Twin.tec skirted PCR 
plates). For each plate, 80 cells were sorted (e.g. A1-A10, B1-B10). The last row (row 
12) is a “no sort” control. The plates were capped immediately (Cap Strips, Eppendorf), 
centrifuged for 1200 r.p.m. for 3 minutes and stored at -80°C until processed further to 
cDNA. Sorting was performed on the Aria II Flow Cytometer (BD Biosciences, CA, 
USA). 
Lymphocytes were identified based on their forward scatter (FSC) and side scatter 
(SSC) properties. Cells separately stained with each of the fluorochrome-labelled 
antibodies were used as controls to compensate for the overlap between emission 
spectra of the various fluorochromes. Flow cytometric data was analysed using FlowJo 
software (Treestar, San Carlos, California, USA). 
2.3.1.4 Embedding and cryosectioning of organ samples 
Eye, salivary gland, thyroid, heart, lung, liver, kidney, pancreas, testes/ovary samples 
from Rag1-deficient mice were excised into 5 mm segments and embedded in Tissue-
Tek® Optimal Cutting Temperature compound (Sakura). The embedded sections were 
kept at -80ºC until use. Prior to cryosectioning, the embedded samples were frozen onto 
an aluminium block by cooling on dry ice. Cryosections of 8 microns-thick were made 
with a cryomicrotome (Bright Instruments, England) adjusted to -20°C and mounted on 
silane-coated slides. The sections on the slide were immediately air-dried for 1.5 hours, 
fixed with cold acetone for 10 minutes, air-dried for another 1.5 hours and stored in a 
sealed container, which was placed in a sealed bag with silica gel and stored at -20ºC 
until use. 
2.3.1.5 Hematoxylin and eosin staining 
Tissue sections were fixed in 10% neutral buffered formalin, paraffin embedded, cut, 
mounted and stained with hematoxylin and eosin staining at the Microscopy Facility, 
John Curtin School of Medical Research. All sections were inspected for infiltrates 
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using an Olympus microscope, and images were captured with the DP70-BSW 
(Olympus) software. 
2.3.1.6 Immunofluorescent staining 
Frozen sections of the spleen were air-dried for 0.5 hours. The non-specific absorption 
sites were blocked by incubation with 50  µL Blocking Serum for 30 minutes at 37ºC in 
a moist chamber. Blocking serum was removed and 50 µL of appropriate 1 in 30 diluted 
mouse serum (primary antibody) was added to each section, followed by 30 minutes 
incubation at 37ºC in a moist chamber. Slides were washed three times with PBS, 5 
minutes per wash at room temperature. Primary antibody was removed and slides were 
washed three times with PBS, 5 minutes per wash at room temperature. Subsequently, 
50  µL of Alexa 488 goat anti-mouse IgG (Invitrogen) secondary antibody was added to 
each section, followed by 30 minute incubation at 37ºC in a moist chamber in the dark. 
Secondary antibody was removed and slides were washed three times with PBS, 5 
minutes per wash at room temperature. Nuclear staining was done by a 5 minute 
staining with 0.1 µg/ mL DAPI (Invitrogen). Slides were mounted in Fluorescent 
Mounting Medium (DakoCytomation) before affixing a coverslip. Sections were 
viewed under an Olympus IX71 Microscope (Olympus). For each organ viewed, an 
appropriate exposure time that gave bright staining with the positive control and no 
staining with the negative control was determined and used for capturing images for all 
samples tested against a particular organ allowing for accurate comparison of the 
different images.   
2.3.1.7 Generation of bone marrow chimeras 
To harvest bone marrow, cells were flushed from tibias and femurs, which were 
aseptically cut at both ends, with ice-cold RPMI 1640 using a 3 mL syringe. Single cell 
suspensions were prepared by teasing the tissues apart through a 70 µm nylon mesh 
filter (BD Biosciences, NJ, USA) with a 1 mL syringe plunger. Cells were then pelleted 
by centrifugation for 10 minutes, 1340 r.p.m. at 4ºC. Cells were resuspended in 1 mL of 
RPMI 1640 and kept on ice until use. The cells were counted and adjusted to 1×107 
cells/mL in RPMI 1640.  Samples were then mixed to the required ratios and injected 
intravenously at 200 µL (2×106 cells) per mouse into the tail veins of irradiated 
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recipients. Recipients were irradiated (X-RAD 320, CMS Alphatech, Sydney, Australia) 
with two doses of 450 cGy separated by 4 hours or a single dose of 500 cGy for Rag1-
deficient lymphopenic recipients. After bone marrow irradiation, the recipient mice 
were given 25 µg/mL Neomycin sulphate and 13 µg/mL Polymyxin B sulphate in their 
drinking water for 6 weeks. Before subsequent analysis, hematopoietic cells were 
allowed to reconstitute in the chimeras for six weeks or earlier if mice needed to be 
sacrificed after losing 20% of the mice body weight. 
2.3.1.8 Retroviral-mediated bone marrow transduction 
The retroviral-mediated bone marrow transduction was performed according to a 
published protocol (Holst et al., 2006a). Briefly, bone marrow donor mice received 0.15 
mg 5-fluorouuracil per gram weight of the mice intraperitoneally 48 hour prior to bone 
marrow harvest. Following harvest, bone marrow cells were cultured for 48 hours at 
37°C, 10% CO2 in 150 mm tissue culture dishes at 4×106 cells/mL in D20 media 
supplemented with 50 ng/mL hIL-6, 20 ng/mL mIL-3 and 50 ng/mL mSCF (all from all 
Biosource International, Camarillo, CA, USA). 
Meanwhile, the GP+E86 retroviral producer cells were irradiated with 1200 rads and 
seeded onto 150 mm tissue culture dishes (8×106 cells in 19 mL D20 per plate). The 
cells were incubated for 24 hours at 37°C, 10% CO2. After incubation, the bone marrow 
cells were treated with RBC lysis buffer for 5 minutes to lyse erythrocytes prior to 
addition to GP+E86 producer cell plates. Bone marrow cells were retrovirally 
transduced by co-culture with GP+E86 cells for 48 hours in the presence of 50 ng/mL 
hIL-6, 20 ng/mL mIL-3, 50 ng/mL mSCF and 6 µg/mL hexadimethrine bromide. 
To generate retrogenic mice, the Rag1-deficient recipient mice were sub-lethally 
irradiated with 500 rads and reconstituted with 200 µL 1.5×106 bone marrow cells 
injected intravenously with 20 U/mL heparin. Irradiated mice were administered 
antibiotics in their drinking water (25 µg/mL Neomycin sulphate and 13 µg/mL 
Polymyxin B sulphate (both Sigma-Alrich)) and allowed to recover for 2 weeks before 
analysis of peripheral blood neutrophils, monocytes and lymphocytes to assess GFP 
expression. 
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2.3.1.9 Adoptive transfer assays 
Single cell spleen suspensions were prepared in RPMI 1640 medium (Gibco) 
supplemented with 5% fetal calf serum. Where CD4+ or CD8+ purification was 
necessary, cells were purified using anti-CD4 MACS beads (Miltenyi Biotec, clone 
L3T4) or anti-CD8 MACS beads (Miltenyi Biotec, clone 53-6.7) and separated using an 
autoMACS™ Separator (Miltenyi Biotec) according to manufacturer’s instructions. The 
purity was >92% for both CD4 and CD8. Whole splenocytes, CD4 enriched, CD4 
depleted, CD8 enriched and CD8 depleted were transferred intravenously into 
B10.BR.Rag-1-/- recipients. On days 0, 1, 7 and 14 days post-transfer, recipients of 
CD8-depleted cells or CD4-depleted cells were treated with 0.3 mg of anti-CD8 (Bio X 
Cell, clone 2.43) or anti-CD4 (Bio X Cell, clone GK1.5) respectively, to deplete any 
residual CD4+ or CD8+ cells. 
2.3.1.10 Enzyme-linked immunosorbent assay 
High protein-binding 96-well flat-bottom plates (Nunc, Roskilde, Denmark) were 
coated with 100 µL/well of 5 µg/ mL appropriate coating antigen (diluted in coating 
buffer) and incubated overnight at 4ºC. The unbound antigen was removed and plates 
were washed three times with Wash Buffer. The remaining absorption sites were 
blocked by a 1.5 hour incubation at 37ºC after addition of Blocking Buffer. The 
Blocking Buffer was removed and plates were washed three times with Wash Buffer. 
Appropriate serum dilutions were prepared with Dilution Buffer and added to the first 
row of the plate except the first column (200 µL per well). Control serum (defined in 
each experiment in the section 3) was added to the first column on the first row of the 
plate. The remainders of the plate wells were filled with 100 µL dilution buffer. The 
samples were then serially diluted eight times by successive transfer of 100 µL along 
the columns of the plates, with mixing, giving a 2 fold dilution every row from top to 
bottom of plate. Plates were washed three times with wash buffer after a 1 hour 
incubation at 37ºC. Detection antibody for the different antibody isotypes were added to 
each well (100   µL per well), followed by a one hour incubation at 37ºC. Plates were 
washed three times with wash buffer. In cases where goat anti mouse IgG2ab-biotin was 
used, 1 µg/ mL strepavidin-alkaline phosphate was added (100 µL per well), followed 
by a 20 minute incubation at 37ºC. Phosphate substrate (Sigma, St. Louis, Illnois, USA) 
(1 tablet per 5 mL developer buffer) was added at 100 µL/well and plates were 
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incubated at 37ºC to induce colour development. Optical densities at 405 nm and 650 
nm were determined for each well using ThermoMax microplate reader (Molecular 
Devices, Sunnyvale, California) and SoftMAX Pro software (SD, California, USA). 
Each ELISA plate was analysed separately. For each plate, sigmoidal dose-response 
(variable slopes) nonlinear regression was performed on the dose response curves of the 
samples. Values for the top and bottom were constrained to be the plate maximum and 
minimum readings. The hill-slope was calculated for the samples with the maximum 
and minimum readings. This constant hill-slope was applied to all samples on the plate. 
The logEC50 value (point of inflection which is proportional to the antibody 
concentration) was determined. The difference between the logEC50 values of each 
sample compared to the control on each plate was calculated by subtraction. The control 
was given an arbitary unit of 100 and the samples were plotted on graphs relative to the 
control. Graphpad Prism 4 (GraphPad Software, San Diego, USA) was used for 
statistical analysis, and the differences were taken to be significant when P<0.05. 
2.3.2 Molecular biology assays and techniques 
2.3.2.1 Processing tissue samples for genomic DNA 
Ear or tails samples were harvested from mice for preparation of genomic DNA for 
initial genotyping after weaning or for confirmation after experimentations. Ear samples 
were prepared by the ANU Bioscience Services, by addition of Ear Punch Digestion 
Buffer mix (50 mM Tris HCl (pH 8.0), 2 mM NaCl, 10mM EDTA, 1% SDS, 2 mg/ mL 
Proteinase K), digestion at 55°C for 40 minutes and denaturation of Proteinase K at 
99°C for 10 minutes. Tail samples were processed using the Qiagen DNeasy 96 tissue 
kit based on manufacturers instructions.  
2.3.2.2 Genotyping by polymerase chain reaction 
Genomic DNA was used for genotyping. AccuPrime Taq DNA Polymerase High 
Fidelity was used in reactions according to manufacturer’s instructions. The reactions 
were performed in 0.2 mL thin walled 96-well plates (Quality Scientific Plastics, ON, 
Canada) using a PTC-225 Peltier Thermal cycler. The 50 µL PCR reactions contained 1 
U of polymerase, 20 ng tempate DNA, 10 µM forward and reverse primers and 10× 
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AccuPrime PCR Buffer I. Variations of the method, PCR cycling conditions and 
primers are seen in Table 2.14. Reactions were resolved by running samples on a 2% 
agarose gel. 
Table 2.14 Genotyping conditions. All primers are listed from 5’ to 3’. 
PCR Primers  Conditions  Cycle  Resolution 
5.0 µM: 
TCCTGGAACTCACTCACTCTG 
5.0 µM: 
GCCCACTTTCTGCTCATCTC 
Aire  
8.0 µM: 
AAGGTGAGATGACAGGAGATC 
Qiagen 
Multiplex 
PCR kit 
95°C 15 min 
followed by 
35 cycles of 
(95°C 20 sec, 
56°C 30 sec, 
72°C 90 sec), 
72°C 2 min 
Top band 
WT, Bottom 
band MUT  
2.0µM Cblb WT: 
CAGACAGTGCCTGCATGA 
2.0µM Cblb Rev: 
GGAAAAATATTAGTTACAACTG
G 
Cblb 
2.0µM Cblb Mut: 
TTCCTCCCACTCATGATCTATAG 
Qiagen 
Multiplex 
PCR kit 
95°C 15 min 
followed by 
35 cycles of 
(94°C 30 sec, 
61°C 30 sec, 
72°C 50 sec), 
72°C 2 min 
600bp WT, 
550bp MUT 
3.0µM GldA: 
TCTCAACTCTCTCTGATCAATTT
TGAGGAA 
Gld 
5.0µM GldC: 
ATTCCTGGTGCCCATGATAA 
Qiagen 
Multiplex 
PCR kit, 
StuI 
overnight 
digestion 
(Sedger et 
al., 2010) 
95°C 1 min 
followed by 
35 cycles of 
(95°C 15 sec, 
62°C 15 sec, 
72°C 10 sec), 
72°C 2 min 
Bottom band 
WT, Top 
band MUT 
2.0µM Eα5: 
AGTCTTCCCAGCCTTCACACTCA
GAGGTAC 
2.0µM Eα3: 
CATAGCCCCAAATGTCTGACCTC
TGGAGAG 
H2  
2.0µM K5: 
CATGGGCATAGAAAGGGCACTC
TTTGAACT 
Standard  94°C 2 min 
followed by 
35 cycles of 
94°C 30 sec, 
60°C 30 sec, 
72°C 45 sec. 
250bp H2k, 
150bp H2b 
5.0µMIg F2: 
CTGGAGCCCTAGCCAAGGAT 
5.0µMIg R1: 
ACCACAGACCAGCAGGCAGA 
0.5µM TCR F1: 
GCAGTCACCCAAAGCCCAAG 
0.5µM TCR R1: 
CCCCAGCTCACCTAACACTG 
4.0µMHEL 4F: 
ATCCTAAGCGCCCTGGTTTT 
HEL,TCR3A9 
4.0µM HEL 4R: 
TGACCTTCCCACATCAGCAC 
Standard 94°C 2 min 
followed by 
35 cycles of 
(94°C 15 sec, 
62°C 30 sec, 
72°C 45 sec), 
72°C 2 min 
371bp 
TCR3A9, 
184bp HEL, 
264bp 
endogenours 
Ig 
Ly5a/b 0.5µM Ly5a/b-1: 
GAAGGTCGGAGTCAACGGATTT
CTTGGCCTGAGCCTGC 
Amplifluor® 
SNPs HT 
Genotyping 
94°C 4 min 
followed by 
35 cycles of 
NA 
56
   
0.5µM Ly5a/b-2: 
GAAGGTGACCAAGTTCATGCTT
CTCTTGGCCTGAGCCTGT 
7.5µM Ly5a/b-R: 
GCATAAAACATATCCATGGGGT
TTAGA 
0.5µM SNP FAM Primer (amplifluor 
kit) 
 
0.5µM SNP JOE Primer (amplifluor 
kit) 
System (94°C 10 sec, 
60°C 20 sec, 
72°C 40 sec), 
72°C 3 min 
 
3µM NeoF: 
TGAATGAACTGCAGGACGAGG 
Neo  
3µM NeoR: 
AAGGTGAGATGACAGGAGATC 
Standard  94°C 2 min 
followed by 
35 cycles of 
(94°C 20 sec, 
62°C 30 sec, 
72°C 45 sec) 
Band Neo+ 
0.5µM Rag1-1: GAA 
AGGTCGGAGTCAACGGATTAGC
ACCAAACCAGGAACCTGT 
0.5µM Rag1-2: 
GAAGGTGACCAAGTTCATGCTG
CACCAAACCAGGGAACCTGC 
7.5µM Rag1-R: 
GCACACTGACAATGAGGCAT 
0.5µM SNP FAM Primer (amplifluor 
kit) 
Rag 
0.5µM SNP JOE Primer (amplifluor 
kit) 
Amplifluor® 
SNPs HT 
Genotyping 
System 
94°C 4 min 
followed by 
35 cycles of 
(94°C 10 sec, 
60°C 20 sec, 
72°C 40 sec), 
72°C 3 min 
NA 
0.5µM Sanroque-1: 
GAAGGTGACCAAGTTCATGCTTT
CAGAGCTTCCTCCTGCC 
0.5µM Sanroque-2: 
GAAGGTCGGAGTCAACGGATTC
TTCAGAGCTTCCTCTGCA 
7.5µM Sanroque-R: 
GTGTTTAGTTCATCTTTGTTCAC
CAT 
0.5µM SNP FAM Primer (amplifluor 
kit) 
San roque 
0.5µM SNP JOE Primer (amplifluor 
kit) 
Amplifluor® 
SNPs HT 
Genotyping 
System 
94°C 4 min 
followed by 
35 cycles of 
(94°C 10 sec, 
60°C 20 sec, 
72°C 40 sec), 
72°C 3 min 
NA 
0.5µM Unmod-1: GAA 
AAGGGTCGGAGTCAACCGGATT
CTCCTTCCGGGTCATGTTCCT 
0.5µM Unmod-2: GAAGGTGACCA 
AGTTCATGCTTCTCCTTCCGGTC
ATGTTCCA 
7.5µM Unmod-R: 
CAGACAAGGCCATCTTGGACAT 
0.5µM SNP FAM Primer (amplifluor 
kit) 
Unmodulated 
0.5µM SNP JOE Primer (amplifluor 
kit) 
Amplifluor® 
SNPs HT 
Genotyping 
System 
94°C 4 min 
followed by 
35 cycles of 
(94°C 10 sec, 
60°C 20 sec, 
72°C 40 sec), 
72°C 3 min 
NA 
 
2.3.2.3 Agarose gel electrophoresis 
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2.0 % (w/v) agarose gels were made by dissolving agarose (Amresco, Solon, OH, USA) 
in 5 mM sodium borate buffer, which was poured into a casting tray and allowed to 
solidify at room temperature. Electrophoresis was performed in 5 mM sodium borate 
buffer. Molecular weight markers and DNA samples were mixed with 6× loading dye 
(5:1 DNA sample: dye ratio), loaded on the solidified gel and electrophoresed at 200-
250 volts until the dye-front reached 1 cm from the end of the gel. The gels were stained 
with GelRedTM (Life Technologies) and visualized under ultraviolet light using the 
Gene Genios Bioimaging system (SynGene, Frediick, MD, USA). Gel images were 
taken using the GeneSnap software (SynGene, Cambridge, UK). 
2.3.2.4 cDNA synthesis from single cell 
cDNA synthesis was performed on single cells in the plates that they had been sorted 
into using the iScript (Biorad) cDNA synthesis kit according to the manufacturer’s 
instructions. A 2.5 µL mix comprising of 0.5 µL 5× iScript reaction mix, 0.125 µL 
iScript reverse transcriptase, 0.275 µL 1% Triton X-100 and 1.6 µL nuclease-free water 
was added to each well. The reaction was incubated for 25°C for 5 minutes, 42°C for 30 
minutes, 85°C for 5 minutes. The reaction was centrifuged at 2400 r.p.m. for 1 minute 
before proceeding to the next step or stored at -20°C before used. 
2.3.2.5 Single cell multiplex PCR 
After cDNA synthesis, TCR cDNAs were amplified by multiplex PCR according to an 
established protocol (Dash et al., 2011). Two rounds of nested PCR were done using a 
Qiagen Taq polymerase PCR kit to amplify the TCRα and TCRβ transcripts from each 
cell in a 25 µL reaction containing 2.5 µL cDNA. The first round of PCR contained 10× 
PCR buffer, 0.7 µL 50mM MgCl2, 0.5 µL 10mM dNTP mix, 0.5 µL mix of 23 Trav 
external primers (5pmol/µL ea.), 0.5 µL single Trac external primer (5 pmol/µL), 0.5 
µL mix of 19 Trbv external primers (5 pmol/µL ea.), 0.5 µL single Cβa external reverse 
primer (5 pmol/µl) and 0.75U Taq DNA Polymerase. Two parallel second rounds of 
PCR were performed using 2.5 µL of product from the initial PCR reaction: TCRα was 
amplified by adding 5 pmol/µL mix of 23 Trav internal primers and 0.5 µL single Trac 
internal reverse primer (5 pmol/µL); TCRβ was amplified separately by adding 5 
pmol/µL mix of 19 Trbv internal primers and 0.5 µL single Trbc internal reverse primer 
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(5 pmol/µL). The PCR conditions were 95°C for 5 minutes, followed by 35 cycles of 
95°C for 30 seconds, 55°C for 30 seconds, 72°C for 1 minute with a final extension of 
72°C for 5 minutes. The PCR products were visualised on a 2% agarose gel, and 
unincorporated primers and dNTPs were eliminated using by the addition of 1 µL 
ExoSAP-IT (Affymetrix) to 5  µL PCR product by incubation at 37°C for 15 minutes 
and 80°C for 15 minutes. 
2.3.2.6 DNA sequencing reaction 
DNA sequencing reactions were performed in 0.2 mL thin walled 96-well plates 
(Quality Scientific Plastics, ON, Canada) using a PTC-225 Peltier Thermal cycler. The 
20 µL sequencing reactions consist of 1 µL Big Dye 3.1 mix (Amersham, NJ, USA), 6  
µL template DNA, 5 pmol appropriate Trac internal reverse or Trbc internal reverse 
primers, 1 µL  of DMSO and 5 µL 5× CSA Buffer. The PCR conditions were 95°C for 
5 minutes, followed by 30 cycles of 96°C for 10 seconds, 55°C for 5 seconds, 60°C for 
4 minutes. Terminators were removed using the Qiagen DyeEx 96 Kit. The plates were 
dried at 95°C for 30 minutes. The samples were sequenced by the Biomolecular 
Resource Facility (JCSMR, ACT, Australia) on an ABI 3730 capillary sequencer, and 
analyzed using Finch TV and ExPASy bioinformatic tools. 
2.3.2.7 Verification of TCR expression from pMIGII.TCR vectors 
293T cells were plated at 2x106 cells in 10 mL cDMEM on 100 mm cell culture dishes 
(NUNC, Thermo Scientific) and incubated at 37°C, 10% CO2 overnight. The cells were 
transfected with 4µg pMIGII.TCR and 4µg pMIGII.CD3δγεξ vector (Szymczak et al., 
2004) using the FuGENE 6 transfection reagent (Roche Diagnostics) according to the 
manufacturer’s instructions. Following a 24 hour incubation at 37°C, 10% CO2, the 
media on the cells were replaced with 10 mL cDMEM and the cells were incubated for 
a further 24 hours. Cells were examined under a confocal microscope fitted with a UV 
filter for detection of GFP to confirm reporter expression by 293T cells. Flow 
cytometric analysis using anti-TCRβ antibody was performed to determine cell surface 
expression of TCR. 
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2.3.2.8 Generation of a stable retroviral producer cell line 
293T cells were plated in 100 mm cell cuture dishes at 1×106 cells in 10 mL cDMEM 
and incubated for 24 hours at 37°C, 10% CO2. Cells were transfected with 4 µg 
pMIGII.TCR, 4 µg pEQ-Pam3(-E) packaging and 2 µg pVSVg envelope vectors (Holst 
et al., 2006a) using the FuGENE 6 transfection reagent according to the manufacturer’s 
instructions. Following a 24 hour incubation at 37°C, 10% CO2, the media from 293T 
cells were replaced with 10 mL cDMEM. Retrovirus-containing supernatants from the 
293T cells were harvested every 12 hours over a 72 hour period. At each harvest, the 
supernatant was passed through a 0.45 µm filter and used for repeated transduction of 
GP+E86 cells (plated at 1×105 cells in 100mm cell cuture dishes) in the presence of 6 
µg/mL hexadimethrine bromide (polybrene). GP+E86 cells were analysed by flow 
cytometry to assess the GFP expression. Retroviral titres in supernatants from stably 
transduced GP+E86 producer cell lines were determined by plating 2×106 producer 
cells in 2 mL cDMEM in a 6 well plate and incubating at 37°C, 10% CO2 for 24 hours. 
The supernatant was harvested, applied to a 0.45 µm filter and added dropwise to 3T3 
cell (plated at 1×104 cells in 1 mL cDMEM in a 24 well plate) at concentrations of 1:10, 
1:33 and 1:100 in the presence of 6 µg/mL hexadimethrine bromide (polybrene). The 
cells were incubated for 72 hours prior to analysis of GFP expression by flow 
cytometry. GP+E86 retroviral producer cells were stored frozen in at -80°C in freezing 
media. 
2.4 In vivo studies 
2.4.1 Weight studies 
Mice were weighed weekly at mid-day by placing the mice in a small box on an 
electronic weighing scale. 
2.4.2 Diabetes incidence studies 
Mice were monitored for diabetes by testing urine glucose levels using Bayer Diastix 
Reagent Strips for Urinalysis to test urine glucose at weekly intervals or tri-weekly 
intervals (for CFA-HEL adoptive transfer study). Mice with two successive positive 
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readings of 500 mg/dL (++) were called diabetic. Non-diabetic mice were sacrificed at 
20 weeks of age. 
2.5 Statistical analysis 
Unless otherwise stated, the different groups were compared using the One-Way 
analysis of variance (ANOVA), followed by pair-wise comparison with a Bonferroni 
Post Test. This test was used when the data was assumed to follow a normal 
distribution. When the overall differences were significant, the Bonferroni post-test 
made pair-wise comparisons between all possible combinations of pairs and corrected 
for multiple testing amongst the permutations. When data was not expected to be 
normally distributed, as in histological disease scoring, the Krustal-Wallis test was used 
to comparethe different groups, followed by pairwise comparisons using the Dunn’s 
Multiple Comparison Test. P-values were taken to be statistically significant when less 
than 0.05. In instances of mortality or diabetes incidences, the survival log-rank Mantel 
Cox test was used. All statistical analysis was performed using GraphPad Prism 4 
(GraphPad Software, San  Diego, USA). 
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Chapter 3  
Genetic deficiency in AIRE co-
operates with genetic deficiency in 
CBLB 
Acknowledgements of assistance in the work described in this chapter: Material in this 
chapter appeared in the Proceedings of the National Academy of Science (Teh et al., 
2010). The initial breeding of Aire-deficient mice to Card11unm/wt, Faslgld/gld, Rc3h1san/wt 
or Cblb+/- mice, and preliminary intercrosses of the first three filial generations were 
performed by Dr. Anselm Enders. The mice were genotyped by the Australian 
Phenomics Facility, except that most of the Aire genotyping was performed by me. For 
section 3.4, the weekly weight measurements were done by Ms. Elizabeth Sullivan 
(Animal Staff, Australian Phenomics Facility). For sections 3.5, the hematoxylin and 
eosin section cutting and staining was done by Ms. Anne Prins (Flow Cytometry and 
Microscopy, John Curtin School of Medical Research). Cryosectioning was performed 
by Ms. Michelle Townsend (IGL Lab Manager). Technical assistance from Mehmet 
Yabas, Mandeep Singh and Hannes Bergmann were provided for the bone marrow 
chimera takedown and organ processing in Section 3.6.1 and 3.6.2.  Technical help for 
intraperitoneal injections for section 3.8 was obtained from Dr. Anselm Enders. In 
section 3.9, Experiment 1 was conducted by me and technical assistance for Experiment 
2 was obtained from Debbie Howard (IGL Lab Technician).  Unless stated, all other 
experiments were conducted by me. 
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3.1 Preamble 
To explore the multi-step model for the pathogenesis of autoimmune disease, Aire-
deficient mice (Ramsey et al., 2002b) were intercrossed on a uniform genetic 
background that is not prone to autoimmunity (B10.BR/SgSnJ; H2k) with mice carrying 
molecularly defined genetic defects disrupting one of four distinct peripheral T cell 
tolerance mechanisms: decreased numbers of Foxp3+ T regulatory cells (Card11un/un), 
apoptosis (Faslgld/gld), anergy (Cbl-b-/-), or deregulated activation of T follicular helper 
cells (Rc3h1san/san). 
It is predicted that the combination of Aire-deficiency with a defined molecular lesion 
in peripheral tolerance, that acts as a critical failsafe for the Aire-pathway, would 
dramatically accelerate autoimmunity and lead to emergent autoimmune disease not 
seen with either individual defect. By contrast, no acceleration of autoimmunity and an 
additive combination of the individual autoimmune phenotypes would result from 
compounding Aire deficiency with a mechanism that does not serve as a failsafe. This 
chapter describes the preliminary results of the crosses, focusing on one double-
deficient combination that displayed severely accelerated lethal organ-specific 
autoimmunity. 
3.2 Mouse strains used in this chapter 
3.2.1 The Aire-deficient mouse strain 
The Aire-deficient mouse strain, a kind gift from Prof. Leena Peltonen, bears the 
truncating nonsense mutation through an insertion of a neomycin resistance cassette at 
the beginning of exon 6, similar to the major human Finnish APS1 mutation (Ramsey et 
al., 2002b). RT-PCR and immunostaining using an Aire-specific antibody confirmed the 
absence of Aire transcripts and polypeptides, respectively, validating that the mutation 
was a null mutation (Ramsey et al., 2002b).  The Aire-/- mouse was generated on the 
129/Sv embryonic stem cell background, and subsequently crossed to the C57BL/6 
strain. The mice were imported as (129/Sv x C57BL6)F2 Aire+/- mice and backcrossed 
to the B10.BR/SgSnJ; H2k (B10.BR) background for three generations in our facility. 
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The final back cross was to the TCR3A9 transgenic, insHEL transgenic and Rag1-
deficient mouse strain1. The mouse colony was maintained by intercrossing 
heterozygous mice for 6 generations. Thus, the original Aire-deficient mouse that was 
used to establish the double deficient crosses had a mixed B10.BR.C57BL/6.N3F6 
background, homozygous for Aire- and Rag1-deficiency, and hemizygous for either the 
TCR3A9 on chromosome 5 or insHEL on chromosome 12.  
3.2.2 The Card11unm/unm mouse strain 
The Card11unm/unm C57/BL6 mouse strain was generated in the Immunogenomics 
Laboratory from N-ethyl-N-nitrosuria mutagenesis screen of third generation offspring 
in a pedigree that displayed high levels of surface IgM antigen receptors on circulating 
IgD+ B cells. The mice had a point mutation changing a thymine to adenine nucleotide, 
which resulted in a non-polar leucine to a polar glutamine codon substitution in the 
coiled-coiled domain of Card11 (also called Carma-1) (Jun et al., 2003). Western 
blotting with an antiserum directed towards Card11 revealed normal levels of 
expression in B cells, although this has not been tested in T cells. The mutation 
decreased TCR-CD28 signalling and decreased FoxP3+ regulatory T cells to one sixth of 
the normal frequency but allowed T cell activation and resulted in Th2-biased 
inflammatory disease (Altin et al., 2011). This contrasted with the null mutation in 
Card11 that results in a complete absence of FoxP3+ regulatory T cells, abolished T cell 
activation and caused profound immunodeficiency (Hara et al., 2003; Molinero et al., 
2009). The original mice used to establish the double deficient cross was a heterozygous 
Card11unm/wt mouse, hemizygous for TCR3A9 on a mixed B10.BR.C57BL/6.N2F3 
genetic background, having been backcrossed to B10.BR background and intercrossed 
                                                
1 The TCR3A9 and insHEL transgene were included for further study of the central and 
peripheral tolerance mechanisms. The Rag1-deficient strain was used as it was readily 
available in our laboratory. Subsequent breeding for two filial generations fixed the 
Rag1 allele to be homozygous wild-type.  
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for three generations. The mouse was crossed to an Aire-/- mouse that was hemizygous 
for insHEL (section 3.2.1). The offspring of this breeder pair was intercrossed to 
generate filial generations for analysis. 
3.2.3 The Faslgld/gld mouse strain 
The Faslgld mouse strain was obtained from the Jackson Laboratories. The mouse strain 
harboured a spontaneous thymine to cytosine point mutation near the 3' end of the 
coding sequence which resulted in a replacement of a highly conserved phenylalanine 
with a leucine at position 273 in the extracellular region of the encoded protein 
(Takahashi et al., 1994). The point mutation in the ligand disrupted activation-induced 
cell death of chronically stimulated mature T cells and caused a slow onset, subclinical 
autoimmune syndrome characterised by extensive T cell lymphoproliferation and 
antinuclear autoantibodies in B6 or B10.BR mice (Cohen and Eisenberg, 1991). A 
B10.BR.Aire-/- hemizygous for insHEL (section 3.2.1) was bred with a 
B10.BR.Faslgld/gld mouse that had been maintained in the laboratory and intercrossed for 
14 generations. The offspring of this breeder pair was intercrossed to generate filial 
generations for analysis.  
3.2.4 The Rc3h1san/san mouse stain 
The C57BL/6.Rc3h1san/san mouse strain was generated in the Immunogenomics 
Laboratory from an N-ethyl-N-nitrosuria mutagenesis screen of third generation 
offspring in a pedigree that displayed anti-nuclear antibodies and lymphadenopathy. 
The mice carried a thymine to guanine substitution in the Rc3h1 ubiquitin ligase 
resulting in a non-conservative methionine to arginine codon change. This missense 
mutation caused accumulation of activated T cells and lupus-like autoimmunity in 
B10.BR mice due to elevated expression of the co-stimulatory ICOS receptor and 
excessive formation of T follicular helper cells (Linterman et al., 2009; Vinuesa et al., 
2005a). To establish a double deficient mouse model, a heterozygous Rc3h1san/wt mouse, 
hemizygous for insHEL was crossed to an Aire-deficient mouse (section 3.2.1) that was 
TCR3A9. The Rc3h1san/wt had a mixed CBA.(B10.BR-C57BL/6).N2F4. The original strain 
produced on the C57/BL6 background was backcrossed to CBA, H2k for two 
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generations, and further crossed to CBA.B10.BR. Thus, the complete genomic 
composition of the mouse was 75% CBA, 12.5% B10.BR and 12.5% B6. The mouse 
was also hemizygous for TCR3A9 and insHEL. The offspring of this breeder pair was 
intercrossed to generate filial generations for further analysis.  
3.2.5 The Cblb knockout mouse strain 
The Cblbtm1Pngr knockout mouse strain (abbreviated as Cblb-/- in this thesis) was 
obtained from Prof. Wallace Langdon. The mouse was generated by introducing a 
neomycin cassette replacing the region encoding a portion of the tyrosine kinase-
binding and RING finger domains, corresponding to amino acids 300 through 340 of 
the encoded protein. The targeted allele appears to be a null mutation as western blot 
analysis shows an absence of protein expression in lymph nodes and splenocytes from 
homozygous mice (Bachmaier et al., 2000).  The mutation disrupts mature T cell anergy 
and releases T cell proliferation from the requirement for CD28 co-stimulation 
(Bachmaier et al., 2000; Chiang et al., 2000; Fang and Liu, 2001; Gronski et al., 2004; 
Heissmeyer et al., 2004; Jeon et al., 2004; Naramura et al., 2002; Qiao et al., 2008; 
Thien and Langdon, 2005) but is insufficient to cause any detectable accumulation of 
activated T cells, autoimmunity or autoantibodies on the B10.BR background.The Cblb-
/- mice, originally produced on the 129/B6 background were backcrossed to C57BL/6 
for ten generations, backcrossed two generations to B10.BR, and subsequently 
intercrossed for six generations (B10.BR.C57BL/6.N2F6). To generate double deficient 
mice, a heterozygous Cblb-/+ mouse, that was hemizygous for insHEL was crossed to a 
homozygous Aire-/- mouse from section 3.2.1. Breeding to subsequent fillial generations 
was performed by intercrossing mice of the appropriate genotype with each other.  
3.3 Aire-/-Cblb-/- double deficient mice have a gravely shortened lifespan 
In each of the Aire × peripheral tolerance defect crosses, offspring were monitored for 
signs of strong co-operative interaction to precipitate early autoimmunity in absence of 
a latent phase. Three of the four combinations, Aire-/-Card11unm/unm, Aire-/-Faslgld/gld and 
Aire-/-Rc3h1san/san displayed normal survival rates, remained overtly healthy up to 140 
days (Fig. 3.1A, B and C), and showed no clinical signs of accelerated autoimmune 
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Figure 3.1 Effects of combined genetic defects in central and
peripheral tolerance mechanisms.
Survival measured from birth to 140 days for mice with single and
double mutations in: (A) Aire and Card11; (B) Aire and Fasl; (C) Aire
and Rc3h1 (D) Aire and Cblb. Statistical analysis comparing the
Aire-/-Cblb-/- group with all other genotype combinations using a log-
rank Mantel-Cox test showed a P value of <0.001.
A B
C D
67
   
disease compared to control mice with each individual mutation. By contrast, Aire-/-
Cblb-/- mice either died or needed to be euthanased due to emaciation with median 
survival of 25 days (Fig. 3.1D).  Mice with single deficiencies in either Aire or Cblb 
remained healthy for at least 140 days. 
These preliminary observations allude to the possibility of a multi-step model in 
pathogenesis of autoimmune diseases but only when coupling deficiencies in certain 
tolerance genes - Aire-deficient negative selection mice and Cblb mediated T cell 
anergy. Understanding the mechanistic basis of this combination will be the focus of the 
remaining chapters of the thesis. 
3.4 Aire-/-Cblb-/- double deficient mice were produced at normal Mendelian ratios 
but displayed severe weight loss 
Due to the mixed genomic background in the Aire-/-Cblb-/- double deficient cross, 
control littermate pups were required, necessitating the breeding of all nine possible 
genotypic combinations. The F4 to F9 breeders were able to yield litter sizes of 5.5±3 
(average±standard deviation) pups. Each of the 45 litters were analysed for expected 
Mendelian ratios of the nine possible genotypes based on the genotypes of the parent 
breeders. This was different in each breeder pair depending on the availability of the 
mice that were used for breeding. The raw data for the analysis of the breeder pairs are 
shown in Appendix 3.1. The sum of the observed genotypes and the expected genotypes 
are shown in Table 3.1. A chi-squared analysis demonstrated that there were no 
significant statistical differences between the ratio of the mice observed and the 
expected Mendelian ratios as seen in Table 3.1, except for the Aire+/-Cblb-/- group (25 
mice obtained, 30 mice expected) that had a weakly statistical significant P value of 
0.0384. In particular, Aire-/–Cblb–/– mice were born at Mendelian frequencies. 
At birth, the Aire-/-Cblb-/- mice appeared indistinguishable from littermate counterparts, 
in size and activity. The weights of the mice were monitored by measurements at 
weekly intervals for a period of 140 days (Fig. 3.2A). Both male and female Aire-/-Cblb-
/- mice failed to gain any further weight after 2 weeks of age (Fig. 3.2B). Littermates that 
were deficient in only one gene appeared overtly healthy and did not exhibit any 
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Table 3.1 Table shows the sum of the obtained and expected Mendelian ratios for 
257 mice from 45 litters of the F4 to F9 intercrosses of all possible genotype 
combinations of Aire- and Cblb- sufficient and deficient mice. 
Number of breeder pairs analysed: 8      
Number of litter analysed: 45       
Number of females: 132       
Number of males: 145       
      
  Obtained Aire+/+ Aire+/- Aire-/- 
  Cblb+/+ 10 29 25 
  Cblb+/- 24 53 53 
  Cblb-/- 20 25 18 
      
  Expected Aire+/+ Aire+/- Aire-/- 
  Cblb+/+ 10 24 25 
  Cblb+/- 26 52 48 
  Cblb-/- 16 30 25 
      
  Chi-squared test   
  P values Aire+/+ Aire+/- Aire-/- 
  Cblb+/+ 0.970 0.849 0.757 
  Cblb+/- 0.774 0.996 0.505 
  Cblb-/- 0.530 0.038 0.929 
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Aire-/-Cblb+/+ (n=4)
Aire+/+Cblb-/- (n=7)
Aire+/+Cblb+/+ (n=4)
Aire-/-Cblb-/- (n=7)
Figure 3.2 Aire-/-Cblb-/- mice fail to gain weight after 2 weeks of
age.
A.  Body weight of male (left) and female (right) mice of different
Aire and Cblb genotype combinations for 20 weeks.
B.  Body weight at 2, 3, 4 and 5 weeks after birth of male (left)
and female (right) mice of the indicated genotypes:
Aire+/+Cblb+/+ (n = 4 males, 4 females); Aire+/+Cblb-/- (n = 7
males, 7 females) and Aire-/-Cblb+/+ (n = 4 males, 4 females)
or Aire-/-Cblb-/- (n = 7 males, 7 females).
A
B
Males Females
Aire-/-Cblb+/+ (n=4)
Aire+/+Cblb-/- (n=7)
Aire+/+Cblb+/+ (n=4)
Aire-/-Cblb-/- (n=7)
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significant weight difference by 5 weeks of age, although there was a trend for Aire-/- 
and to a lesser extent Cblb-/- mice to be smaller than completely wild-type mice at 3 and 
4 weeks of age (Fig. 3.2B). 
The Aire-/-Cblb-/- mice appeared runted in size, emaciated and possessed rough fur coats 
compared to control littermates (Fig. 3.3A). The mice displayed a decrease in activity 
and either die suddenly or were euthanised when moribund after losing more than 20% 
of their body weight, usually immediately after weaning. Gross pathology at necropsy 
revealed evidence of cachectic wasting including little or no body fat, an involuted 
thymus, peripheral lymphoid hypoplasia, and a thin, translucent pancreas in all Aire-/-
Cblb-/- animals (Fig. 3.3B) but no other abnormalities were detected. 
3.5 Aire-/-Cblb-/- double deficient mice had autoimmunity directed towards 
exocrine pancreas and salivary gland 
3.5.1 Histological analysis 
To determine the cause of the infant-onset morbidity and mortality, a broad 
histopathological survey of organs in Aire-/-Cblb-/- mice was conducted. Single deficient 
Aire-/- mice on various backgrounds have previously been shown to display lymphocytic 
infiltration in the salivary glands, pancreas, eye, thyroid, lung, heart, liver, kidney and 
testis or ovary (Anderson et al., 2002; Jiang et al., 2005; Niki et al., 2006). However, 
most of the B10.BR.Aire-/- mice analysed here only exhibited mild to moderate gastritis 
and little or no inflammation of other organs except mild sialoadenitis in approximately 
50% of the animals, mild pancreatitis and lung infiltration in approximately 30% and 
mild hepatitis in 20%  of the animals (Figs. 3.4 and 3.5). Hematoxylin and eosin 
staining of fixed organ sections from 3-6 week old Aire-/-Cblb-/- mice (at time of death 
or sacrifice) and 20 week old control counterparts were made and the degree of 
lymphocytic infiltration was scored blinded to genotype on a scale of 1 to 5. A 
representative hematoxylin and eosin section of each organ from Aire+/+Cblb+/+, 
Aire+/+Cblb-/-, Aire-/-Cblb+/+ and Aire-/-Cblb-/- is shown in Fig. 3.4 and the corresponding 
disease scores are shown in Fig 3.5. The scoring was conducted according to the scale 
in Appendix 3.2: score of (0) indicated no infiltration detected; (1) indicates <12.5% 
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Sp KdSto
Panc
Aire-/-Cblb-/-
Aire+/+Cblb+/+
Aire-/-Cblb-/-Aire+/+Cblb+/+
Panc
Kd
A
B
Figure 3.3 Runted appearance and pancreatic atrophy of Aire-/-
Cblb-/- mice.
A.  A representative 24 day old female Aire-/-Cblb-/- mouse
(bottom) compared to a littermate control (top).
B.  An image of the pancreatic atrophy in Aire-/-Cblb-/- mouse
(right) compared to a littermate control (left). Sto, stomach;
Sp, spleen; Kd, kidney; Panc, pancreas.
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Aire+/+Cblb+/+ Aire-/-Cblb+/+ Aire-/-Cblb-/-Aire+/+Cblb-/-
A Pancreas
B Sal. gland
C Lung
D Kidney
E Liver
F Stomach
G Thyroid
H Heart
I Testis
J Ovary
K Eye
Figure 3.4 Representative hematoxylin and eosin-stained sections
from Aire+/+Cblb+/+, Aire+/+Cblb-/-, Aire-/-Cblb+/+ and Aire-/-Cblb-/-  mice.
Hematoxylin and eosin stained organ sections taken from mouse
pancreas (A), salivary gland (B), lung (C), kidney (D), liver (E), stomach
(F), thyroid (G), heart (H), testis (I), ovary (J) and eye (K). Organ sections
were taken from 20 weeks old mice except for the Aire-/-Cblb-/- group,
which were 3-6 weeks old. Original magnification: x200 magnification
(bars:200 µm) for all organs except testis (x100 magnification, bars:500 µ
m).
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Figure 3.5 Lymphocytic pancreatitis, sialoadenitis and gastritis
in Aire-/-Cblb-/- mice.
Percentage of mice of the indicated genotypes with different grades
of infiltration in haematoxylin and eosin stained sections from
pancreas, submandibular salivary gland, lung, kidney, liver,
stomach, thyroid, heart, reproductive organs (testis or ovary) and
eye. All mice were 20 weeks of age except Aire-/-Cblb-/- mice that
were 3-6 weeks old. Pathology was scored blinded to mouse
identifier and genotype, according to the scale shown in Appendix
3.2.
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infiltration detected; (2) indicates between 12.5% and 25% infiltration; (3) indicates 
25% to 50% infiltration; (4) 50% to 90% infiltration and (5) indicates complete 
destruction of normal tissue.  
For the pancreas, submandibular salivary glands and stomach, a detailed analysis of the 
organs from all nine possible genotypic combinations of Aire  and Cblb was performed. 
Of the nine possible genotypic combinations of Aire and Cblb, all combinations 
displayed a median disease pancreatitis score of <0.5 except Aire-/-Cblb-/- (median score 
of 5) and Aire-/-Cblb+/- mice (median score of 1) (Fig. 3.6A). Pancreatitis was 
characterized by a diffused lymphocytic infiltration of the exocrine acinar tissue. This 
was accompanied by extensive or complete loss of acinar cells, leaving fibrous and 
adipose tissue interspersed with ducts lined by simple cuboidal epithelium (Fig. 3.6B). 
No evidence of pancreatic islet infiltration was observed and islets remained intact 
despite the loss of acinar cells. Consistent with these findings, the mice showed no 
evidence of hyperglycaemia or diabetes. 
Similarly, diffuse lymphocytic infiltration was observed in the submandibular salivary 
glands of Aire-/-Cblb-/- double mutant (median score of 5), mild lymphocytic infiltration 
in the Aire-/-Cblb+/- (median score of 1) and the single Aire-/- and Cblb-/- groups (both 
with a median score of 0.5)  (Figs. 3.7A), while all other combinations yielded a disease 
score of <0.5. The male and female submandibular salivary gland exhibits sexual 
dimorphism, whereby, female glands appear to have smaller serous secreting cells. 
However, consistent with the results seen for the pancreas, both male and female glands 
from Aire-/-Cblb-/- mice had infiltrations that were accompanied by partial or complete 
loss of serous secreting and mucous secreting acinar cells, leaving collapsed structures 
of the ring shaped serous-secreting acinar cells (Figs. 3.7B). The sublingual and parotid 
salivary glands remained free of ≥ grade 3 lymphocytic infiltrations.  
The stomach displayed moderate lymphocyte infiltration in Aire-/-Cblb-/- and Aire-/-
Cblb+/-, with a median disease score of 1, although this did not appear to be more severe 
than in B10.BR littermate mice harbouring single gene deficiency in Aire (median score 
of 1.5) (Fig. 3.8A). This indicated that on the B10.BR background, Aire-/- mice were 
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Figure 3.6 Lymphocytic infiltration targeted towards exocrine
acinar tissue in pancreas of Aire-/-Cblb-/- mice.
A. Histological scores for the pancreas in 3-6 week old Aire-/-
Cblb-/- mice (taken at time of death or euthanasia) and 20
week old control counterparts (endpoint of study) of the
indicated genotypes. Bars represent medians and
interquartile ranges. Data were analysed by a Kruskal-Wallis
and Dunn’s Multiple Comparison test to compare the
medians of each group.
B. Higher power images of pancreas from Aire-/-Cblb-/- mice.
Left, grade 5 pancreatitis; right, grade 3 pancreatitis. Bars:
200 µm.
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Figure 3.7 Lymphocytic infiltration targeted towards acinar
tissue in the submandibular salivary glands of Aire-/-
Cblb-/- mice.
A. Histological scores for the salivary gland from 3-6 week old
Aire-/-Cblb-/- mice (taken at time of death or euthanasia) and
20 week old control counterparts (endpoint of study) of the
indicated genotypes. Bars represent medians and
interquartile ranges. Data were analysed by a Kruskal-Wallis
and Dunn’s Multiple Comparison test to compare the
medians of each group.
B. Submandibular salivary gland from Aire-/-Cblb-/- mice. Left,
grade 5 sialoadenitis; right, grade 1 sialoadenitis. Bars: 200 µ
m.
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Figure 3.8 Lymphocytic infiltration targeted towards stomach of
Aire-/-Cblb-/- mice.
A. Histology scores for the stomach from 3-6 week old Aire-/-
Cblb-/- mice (taken at time of death or euthanasia) and 20
week old control counterparts (endpoint of study) of the
indicated genotypes. Bars represent medians and
interquartile ranges. Data were analysed by a Kruskal-Wallis
and Dunn’s Multiple Comparison test to compare the
medians of each group.
B. Higher power images of the stomach from Aire-/-Cblb-/- mice
grade 3 gastritis. Bars: 200 µm.
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prone to lymphocytic infiltration in the stomach regardless of the Cblb genotype. By 
contrast, the majority of mice harbouring the Aire-/-Cblb-/- and single Aire-/- or Cblb-/- 
mutations remained free of inflammatory infiltrates in other organs tested, which 
include the eye, thyroid, lung, heart, liver, kidney and testis or ovary (Fig. 3.4 and 3.5). 
It is however noted that the Aire-/- (regardless of Cblb genotype) mice frequently 
develop blindness in one eye, either due to autoimmunity or retro-orbital bleeding of the 
mice. In this study, the overtly healthy eye was taken for histological analysis. 
3.5.2 Indirect immunofluorescence evidence of IgG autoantibody directed 
towards the exocrine pancreas 
Another characteristic feature previously observed in Aire-/- mice on various strain 
backgrounds was the presence of IgG autoantibodies that targeted specific organs 
mirroring the pattern of lymphocyte infiltration (Anderson et al., 2002; Jiang et al., 
2005; Niki et al., 2006). Serum was collected from 3-6 week old Aire-/-Cblb-/- mice and 
20 week old control counterparts. Autoantibodies were detected by applying sera 
diluted 1:30 to frozen cryosections of tissue sections of the pancreas, salivary glands, 
lung, kidney, liver, stomach, thyroid, heart eye and testis or ovary from Rag1-deficient 
mice. Rag1-deficient mice tissue sections were used so that the sections were free from 
endogenous IgG, thereby decreasing the background staining with the secondary anti-
IgG antibody. Binding of IgG in the serum was detected by the application of an anti-
mouse IgG-Alexa-488 fluorescent antibody. Counter-staining was performed using 
DAPI to allow visualisation of the nucleus in each cell and the stained sections were 
visualised by epifluorescence microscopy or confocal microscopy. Representative 
staining and disease scores for all organs tested are seen in Fig. 3.9 and Fig. 3.10. 
 In line with the results in section 3.5.1, autoantibodies reacting with pancreas and 
salivary gland were detected in the sera of Aire-/-Cblb-/- mice and not in single mutant 
controls when tested against frozen organ cryosections (Figs. 3.9 and 3.10).  
In the pancreas, Aire-/-Cblb-/- autoantibodies reacted with exocrine acinar cells in 
pancreas and not with beta cells within the islets of Langerhans, correlating with the 
specificity of inflammatory destruction seen in histology (Fig. 3.11A).  Autoantibody 
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Aire+/+Cblb+/+ Aire-/-Cblb+/+Aire-/-Cblb-/-Aire+/+Cblb-/-
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Figure 3.9 Representative immunofluorescence staining of organs
with serum IgG from Aire+/+Cblb+/+, Aire+/+Cblb-/-, Aire-/-Cblb+/+ and Aire-
/-Cblb-/- mice.
Representative sections of immunofluorescent testing of sera from
individual Aire+/+Cblb+/+, Aire+/+Cblb-/-, Aire-/-Cblb+/+ and Aire-/-Cblb-/- mice,
tested against frozen sections of Rag1-/- pancreas (A), salivary gland (B),
lung (C), kidney (D), liver (E), stomach (F), thyroid (G), heart, (H) testis, (I)
ovary (J) and eye (K). All mice were 20 weeks of age except Aire-/-Cblb-/-
mice that were 3-6 weeks old. Original magnification: x200 magnification,
bars: 200 µm for pancreas, liver and thyroid; x100 magnification, bars: 500
µm for salivary glands, lung, kidney, ovary and eye; x40 magnification,
bars: 2 mm for stomach, heart and testis.
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Aire+/+Cblb+/+
Aire+/+Cblb-/-
Aire-/-Cblb+/+
Aire-/-Cblb-/-
Panc SG Lung Kid Liver Sto Thy Heart O/T Eye
Results
Key
Figure 3.10 Summary of the patterns of organ specific
autoantibodies detected in Aire-/-Cblb-/- mice and littermate
counterparts.
Each pie chart represents a single mouse and shaded sections
denote the detection of autoantibodies in a given organ as indicated
by the key above. Panc, pancreas; SG, salivary gland; Kid, kidney;
Sto, stomach; Thy, thyroid; O/T, ovary or testis.
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Figure 3.11 Pattern of staining of organ specific autoantibodies
in Aire-/-Cblb-/-
Representative immunofluorescent staining of frozen sections
of pancreas from Rag1-/- mice by anti-IgG in serum from Aire-
/-Cblb-/- mice.
A. In the pancreas, islet of Langerhans is marked by “I”. High
power view shows granular pattern of staining most intensely
in the apical cytoplasm of exocrine acinar cells, marked by
“*”. Nuclei are marked by “N”. Original magnification: x200 for
left panel and x600 for right panel.
B. In the salivary gland, Aire-/-Cblb-/- sera yielded diffuse
cytoplasmic staining of most cells in salivary gland. Original
magnification: x100.
C. In the stomach, Aire-/-Cblb-/- sera selective stained crypt
epithelium. Original magnification: x100.
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staining was most intense in the apical, zymogen granule-rich cytoplasm of the 
pancreatic acinar cells (Fig. 3.11A). On the contrary, the pattern of staining in the 
salivary gland appeared to be more diffuse – strong straining was observed in the 
cytoplasm of the cells, with no particular structures being stained more intensely (Fig. 
3.11B). In the stomach, autoantibodies were detected in mice harbouring the Aire-/- 
allele, regardless of the Cblb genotype. The stomach autoantibodies targeted the 
mucosal cells in the basal half of the crypts in the stomach wall (Fig. 3.11C). Hence, the 
pattern of autoantibody reactivity was consistent with the pattern of lymphocyte 
infiltration seen in section 3.5.1. 
3.6 Hematopoietic Cblb-deficiency combines with non-hematopoietic Aire-
deficiency to cause rapid onset disease 
Bone marrow chimeras were constructed to further characterize the pancreatic 
autoimmunity in the Aire-/-Cblb-/- double deficient mice. The experimental design is 
schematically illustrated in Fig. 3.12. Wild-type or Aire-/- mice were lethally irradiated, 
killing rapidly dividing cells, such as hematopoietic stem cells and cells of the immune 
system which were replaced by a bone marrow transplant. Different mixtures of donor 
bone marrow cells were transplanted by intravenous injection: 100% wild-type; 100% 
Cblb-/- marrow or an equal mixture of wild-type and Cblb-/- marrow. The donor derived 
bone marrow stem cells were allowed to reconstitute the hematopoietic system for six 
weeks. In the bone marrow chimeras, the pancreas and other radioresistant tissues 
would have had a normal Cblb gene, while the T cells would either be normal or lack 
Cblb. On the other hand, Aire-deficiency would be present only in the radioresistant 
non-haematopoietic cells. Previous studies have shown that Aire is expressed in non-
hematopoietic thymic epithelium where it is crucial for expression of organ specific 
antigens (Anderson et al., 2002; Gardner et al., 2008; Liston et al., 2003). 
The purpose of the chimeras was three-fold. Firstly, it aimed to determine if the 
selective exocrine pancreas destruction precipitated by the combination of Cblb and 
Aire deficiency could have reflected a function of Cblb in the pancreas itself, as 
opposed to its established function in peripheral T cell regulation. Secondly, if the 
wasting syndrome were recapitulated in the bone marrow chimeras, it would allow the 
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BONE MARROW
DONOR (Haematopoietic)
RECIPIENT (Non-haematopoietic)
Irradiated Irradiated
Wild-type
1:1 ratio
Cbl-b-/-
Figure 3.12 Design of the competitive bone marrow chimera
experiment.
Aire-deficient or wild-type recipients were lethally irradiated and
reconstituted with bone marrow from wild-type or Cblb-/- mice in the
following three combinations: 100% Aire-/-, 100% Cblb-/- or an equal
mixture of both. Each combination was introduced into five
recipients.
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generation of Aire-/-Cblb-/- double deficient mice in a systematic and synchronized way 
to facilitate the analysis of lymphocyte development and frequencies. In our breeding 
strategy, it proved difficult to obtain reasonable numbers of Aire-/-Cblb-/- and age-
matched littermate controls for experimentation. Thirdly, it allowed the determination 
of intrinsic quantitative defects in lymphocyte maturation or survival in competition 
with wild-type cells (in the 1:1 mixed bone marrow chimera). 
3.6.1 Survival, pancreatitis and sialoadenitis in chimeras 
A summary of survival results from three independent bone marrow chimera 
experiments are shown in Table 3.2.. Six weeks post-reconstitution, thirteen out of the 
nineteen chimeras of Aire-/- recipients of Cblb-/- marrow developed a cachectic 
appearance and either died suddenly or were euthanased due to weight lost or ill-health. 
Aire-/- recipients of Cblb+/+ and wild type recipient of Cblb-/- remained relatively healthy 
as indicated by one death in the ten and thirteen recipients monitored, respectively. Four 
out of the nine Aire-/- chimeras reconstituted with equal mixtures of Cblb-/- and Cblb+/+ 
marrow also developed wasting establishing that the cooperative autoimmunity was not 
suppressed in the presence of wild-type T cells. 
A representative result from Experiment 2 is seen in Fig 3.13. All Aire-/- recipients of 
Cblb-/- marrow did not survive beyond 42 days post reconstitution (Fig 3.13A). The 
Aire-/- recipients of a 1:1 mixture of wild-type:Cblb-/- marrow, began to appear cachectic 
by 35 days, and over the course of the experiment two recipients needed to be 
euthanased (Fig 3.13A). Histologically, Aire-/- recipients of Cblb-/- marrow exhibited 
severe exocrine pancreatitis and moderate sialoadenitis with extensive or complete loss 
of acinar cells, whereas their single defect counterparts had limited pancreatitis and 
sialoadenitis with a disease score of ≤3 for the pancreas and ≤1 for the salivary glands, 
(Fig 3.13B and C). 
Taken together, the development of the lethal wasting syndrome accompanied by 
exocrine pancreatitis and sialoadenitis in Aire-/- recipients of Cblb-/- marrows confirmed 
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Table 3.2 Results of transplanting Cblb-/- or wild-type bone marrow, or an equal 
mixture of the two, into Aire-deficient or wild-type recipients. In the mixed 
chimeras, the wild-type marrow carried a CD45.1 allelic marker, enabling flow 
cytometric analysis to confirm equal reconstitution. Numerator, numbers of mice that 
died suddenly or were sacrificed when moribund or had lost 20% of the body weight; 
denominator, total number of mice tested; n.d, not done. 
Recipients Aire-/- Aire+/+ 
Donors Cblb-/- Cblb+/+ Cblb-/-: 
Cblb+/+ 
Cblb-/- Cblb+/+ Cblb-/-: 
Cblb+/+ 
Experiment 1 2/5 n.d. 2/4 0/3 0/3 n.d. 
Experiment 2 5/5 1/5 2/5 1/5 0/5 0/5 
Experiment 3 6/10 0/5 n.d. 0/5 0/10 n.d. 
Total 13/19 1/10 4/9 1/13 0/18 0/5 
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Figure 3.13 Pancreatitis and sialoadenitis results from Cblb-
deficiency in the haematopoietic compartment and Aire-
deficiency in the non haematopoietic system.
A. Survival of Aire-deficient or wild-type recipients after
reconstitution with Cblb-/- or wild-type bone marrow, or an
equal mixture of the two. ** indicates a P<0.01 calculated
using a log-rank Mantel-Cox test.
B. Pancreatitis scores of recipient mice
C. Sialoadenitis scores of recipient mice.
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the non-hematopoietic requirement for Aire-/- and hematopoietic requirement for Cblb-/- 
in the development of the disease. 
3.6.2 Analysis of lymphocyte development in bone marrow chimeras 
To understand the effects of the single and double deficiency in Aire and Cblb, T 
lymphocyte populations in the thymus, spleen and lymph nodes were analysed. For all 
results in this section, wild-type or Cblb-/- into wild-type or Aire-/- bone marrow 
chimeras were generated, and the mice were euthanised 29 days post-reconstitution 
before any of the mice succumbed to the lethal wasting syndrome. 
3.6.2.1 Lymphocyte populations in the central lymphoid organ, the thymus 
Representative analysis of the lymphocyte populations in the thymus are shown in Fig. 
3.14 and quantified in Table 3.3. The different subpopulations were identified based on 
the expression of the cell surface markers CD4 and CD8 to distinguish double negative 
(DN, CD4-CD8-), double positive (DP, CD4+CD8+), CD4 single positive (CD4+CD8-) 
and CD8 single positive (CD4-CD8+) cells. Compared to the wild-type and single 
mutant controls, there were no significant differences in these populations (Table 3.4).  
The DN populations were further divided into four subpopulations, DN1 
(CD25−CD44high), DN2 (CD25+CD44high), DN3 (CD25+CD44low) and DN4 (CD25-
CD44low), representing successive stages of maturity. As seen in Table 3.3 and 3.4, 
higher numbers of DN1 cells appeared to be present in Aire-/- mice. Likewise, a similar 
trend of increase in DN4 in the Aire-/- groups compared to wild-type was also observed 
when comparing their percentage but not their absolute number (Table 3.4). Given the 
multiple tests performed, these subtle abnormalities in the DN1 and DN4 population 
would need to be tested in independent experiments to determine if they are indeed 
reproducible. 
Further subdivision of the CD4 cells into CD4+FoxP3- cells and CD4+FoxP3+ natural T 
regulatory cells (nTreg) demonstrated comparable total numbers and percentages of 
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Figure 3.14 Representative flow cytometric analysis of the
thymus from Aire+/+Cblb+/+, Aire+/+Cblb-/-, Aire-/-Cblb+/+ and
Aire-/-Cblb-/- bone marrow chimeras.
A. Gated on lymphocytes (Lym), showing the percentage of DN,
DP, CD4 and CD8 subsets
B. Gated on DN cells (DN), showing the percentages of DN1,
DN2, DN3, DN4 subsets
C. Gated on CD4+ single positive cells, showing the percentages
of CD4+FoxP3+ subsets
D. Gated on CD4+ (top) or CD8+ (bottom), showing CD5, CD44
and CD69 expression on each subset.
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Table 3.3 Table shows the means and standard deviations of lymphocyte 
populations in the thymus, spleen, inguinal/axillary and pancreatic lymph nodes of 
the different bone marrow chimera groups. 
  Aire+/+Cblb+/+ Aire+/+Cblb-/- Aire-/-Cblb+/+ Aire-/-Cblb-/- 
Thymus        
Total cells (x106)        
All lymphocytes 14.93±5.993 7.054±5.029 5.33±3.845 10.16±7.448 
CD25−CD44high (DN1) 0.047±0.011 0.031±0.014 0.128±0.079 0.074±0.056 
CD25+CD44high (DN2) 0.007±0.002 0.005±0.002 0.006±0.002 0.009±0.007 
CD25+CD44low (DN3) 0.219±0.065 0.153±0.097 0.134±0.059 0.202±0.116 
CD25−CD44low (DN4) 0.548±0.201 0.391±0.226 0.522±0.198 0.51±0.254 
CD4+CD8+ (DP) 12.91±5.265 5.682±4.653 3.661±3.399 8.21±6.756 
CD4+ (SP) 0.902±0.493 0.599±0.334 0.647±0.297 0.875±0.408 
CD8+ (SP) 0.265±0.114 0.168±0.089 0.181±0.06 0.239±0.08 
CD4+FoxP3+ (SP) 0.036±0.018 0.025±0.018 0.04±0.014 0.041±0.015 
         
% from total lymphocytes        
CD25−CD44high (DN1) 0.331±0.062 0.557±0.321 2.824±1.823 1.186±1.188 
CD25+CD44high (DN2) 0.051±0.019 0.079±0.032 0.131±0.058 0.119±0.072 
CD25+CD44low (DN3) 1.578±0.599 2.246±0.448 2.859±0.803 2.675±1.58 
CD25−CD44low (DN4) 3.772±1.11 6.528±3.489 11.18±3.63 6.186±2.815 
CD4+CD8+ (DP) 86.36±0.94 73.9±13.67 62.58±13.61 74.52±10.99 
CD4+ (SP) 5.902±0.987 12.79±8.433 14.9±10.01 10.91±4.005 
CD8+ (SP) 1.794±0.34 3.412±2.182 4.404±2.971 3.736±2.701 
CD4+FoxP3+ (SP) 0.245±0.059 0.506±0.381 0.948±0.457 0.811±0.76 
         
Spleen         
Total cells (x106)         
All lymphocytes 13.04±1.708 10.04±4.698 8.538±2.247 9.53±4.369 
B cells 5.996±1.116 4.026±1.711 3.231±1.206 5.144±3.722 
CD4+  0.798±0.047 0.703±0.399 0.638±0.176 0.674±0.238 
CD8+  0.255±0.056 0.269±0.114 0.354±0.18 0.278±0.085 
CD4+FoxP3+  0.296±0.032 0.256±0.142 0.215±0.066 0.234±0.096 
CD4+CD5+  0.766±0.044 0.667±0.384 0.598±0.159 0.643±0.232 
CD4+CD44+ 0.578±0.033 0.504±0.32 0.445±0.161 0.45±0.136 
CD4+CD69+  0.192±0.028 0.187±0.123 0.156±0.048 0.173±0.065 
CD8+CD5+  0.237±0.051 0.249±0.104 0.308±0.149 0.256±0.081 
CD8+CD44+  0.158±0.03 0.174±0.069 0.266±0.163 0.177±0.046 
CD8+CD69+  0.042±0.016 0.038±0.024 0.068±0.081 0.049±0.017 
          
% from total lymphocytes         
B cells 46.27±8.288 40.58±3.154 38.55±11.76 48.01±18.48 
CD4+  6.178±0.595 6.815±1.486 7.508±0.708 7.751±2.748 
CD8+  1.942±0.206 2.799±0.857 3.976±1.236 3.305±1.239 
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CD4+FoxP3+  2.287±0.296 2.476±0.382 2.497±0.145 2.592±0.753 
CD4+CD5+  5.934±0.591 6.435±1.226 7.026±0.527 7.335±2.426 
CD4+CD44+ 4.489±0.581 4.747±0.941 5.101±0.599 5.191±1.66 
CD4+CD69+  1.485±0.245 1.741±0.456 1.808±0.087 1.921±0.429 
CD8+CD5+  1.807±0.19 2.596±0.774 3.474±1.004 3.013±1.062 
CD8+CD44+  1.207±0.148 1.801±0.403 2.912±1.353 2.169±0.911 
CD8+CD69+  0.318±0.1 0.365±0.102 0.705±0.654 0.597±0.271 
          
  Aire+/+Cblb+/+ Aire+/+Cblb-/- Aire-/-Cblb+/+ Aire-/-Cblb-/- 
Lymph nodes        
Total cells (x106)        
All lymphocytes 0.596±0.207 0.706±0.265 0.428±0.358 0.54±0.173 
B cells 0.329±0.112 0.324±0.194 0.22±0.199 0.259±0.124 
CD4+  0.132±0.056 0.16±0.059 0.098±0.079 0.139±0.03 
CD8+  0.043±0.015 0.062±0.026 0.043±0.034 0.054±0.01 
CD4+FoxP3+  0.047±0.023 0.063±0.018 0.036±0.033 0.052±0.012 
CD4+CD5+  0.125±0.051 0.153±0.054 0.091±0.071 0.128±0.028 
CD4+CD44+ 0.074±0.037 0.102±0.032 0.057±0.042 0.083±0.014 
CD4+CD69+  0.038±0.019 0.056±0.023 0.031±0.022 0.048±0.01 
CD8+CD5+  0.042±0.014 0.06±0.025 0.04±0.031 0.05±0.011 
CD8+CD44+  0.018±0.007 0.039±0.013 0.024±0.019 0.031±0.003 
CD8+CD69+  0.008±0.002 0.015±0.007 0.01±0.006 0.013±0.004 
         
% from total lymphocytes        
B cells 55.37±3.634 43.3±15.65 49.59±4.345 46.2±8.663 
CD4+  21.75±3.001 23.08±3.182 23.14±2.186 26.82±6.31 
CD8+  7.369±1.299 8.767±0.8824 10.5±2.338 10.56±2.626 
CD4+FoxP3+  7.704±1.508 9.356±2.039 8.587±2.336 10.08±2.636 
CD4+CD5+  20.62±2.549 22.1±3.297 22.01±2.278 24.76±5.611 
CD4+CD44+ 12.09±2.439 15.13±3.655 13.73±1.428 16.18±4.218 
CD4+CD69+  6.242±1.226 8.14±1.664 7.735±1.736 9.274±2.55 
CD8+CD5+  7.215±1.294 8.494±1.005 10.03±2.359 9.802±2.493 
CD8+CD44+  3.025±0.7179 5.538±0.5836 6.119±1.988 6.199±2.01 
CD8+CD69+  1.331±0.2847 2.141±0.1832 2.836±1.202 2.554±0.7777 
         
Pancreatic lymph nodes         
Total cells (x106)         
All lymphocytes 0.908±0.549 0.588±0.297 0.794±0.27 0.782±0.257 
B cells 0.403±0.291 0.182±0.218 0.224±0.123 0.349±0.175 
CD4+  0.221±0.139 0.161±0.067 0.194±0.072 0.191±0.046 
CD8+  0.046±0.031 0.033±0.015 0.046±0.021 0.046±0.007 
CD4+FoxP3+  0.056±0.037 0.046±0.025 0.04±0.012 0.042±0.017 
CD4+CD5+  0.216±0.134 0.158±0.065 0.184±0.068 0.183±0.046 
CD4+CD44+ 0.175±0.115 0.134±0.063 0.154±0.064 0.15±0.041 
CD4+CD69+  0.077±0.048 0.062±0.03 0.082±0.036 0.075±0.011 
CD8+CD5+  0.043±0.029 0.031±0.015 0.04±0.019 0.042±0.006 
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CD8+CD44+  0.028±0.022 0.024±0.011 0.033±0.018 0.032±0.008 
CD8+CD69+  0.011±0.007 0.01±0.006 0.013±0.006 0.013±0.003 
          
% from total lymphocytes         
B cells 41.94±13.25 24.15±20.27 32.84±20.71 43.39±6.876 
CD4+  24.11±3.206 28.26±6.273 24.06±1.784 24.85±1.723 
CD8+  4.958±0.791 6±2.407 5.59±1.477 6.109±0.999 
CD4+FoxP3+  5.94±1.457 7.719±1.7 5.06±0.29 5.364±0.313 
CD4+CD5+  23.54±3.123 27.74±6.343 22.89±1.693 23.82±1.47 
CD4+CD44+ 18.7±3.365 23.3±7.575 18.96±2.065 19.45±1.171 
CD4+CD69+  8.302±1.818 10.59±3.096 10.01±1.303 9.913±1.391 
CD8+CD5+  4.722±0.736 5.633±2.398 4.986±1.47 5.663±0.98 
CD8+CD44+  2.863±0.836 4.345±1.593 3.897±1.51 4.232±0.319 
CD8+CD69+  1.233±0.291 1.664±0.721 1.551±0.482 1.722±0.282 
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Table 3.4 Table shows the statistical analysis of total cell numbers and percentages 
from Table 3.3 calculated from a One-way ANOVA followed by Bonferroni's 
Multiple Comparison Test comparing each group. Test are shown only for groups 
that display statistical significance in either total cell numbers of percentages. 
Description Population 
Bonferroni's Multiple Comparison 
Test t value Significance Summary 
Total cells 
(x106) 
CD25−CD44high 
(DN1) Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 0.5226 No ns 
Thymus   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 2.5790 No ns 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.8490 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 3.1020 Yes * 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 1.3720 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.7300 No ns 
% from total 
lymphocytes 
CD25−CD44high 
(DN1) Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 0.3255 No ns 
Thymus   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 3.5830 Yes * 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.2290 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 3.2580 Yes * 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.9038 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 2.3540 No ns 
Total cells 
(x106) 
CD25−CD44low 
(DN4) Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 1.1260 No ns 
Thymus   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 0.1826 No ns 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.2744 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 0.9435 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.8517 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.0918 No ns 
% from total 
lymphocytes 
CD25−CD44low 
(DN4) Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 1.4830 No ns 
Thymus   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 3.9890 Yes ** 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.3000 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 2.5060 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.1839 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 2.6900 No ns 
Total cells 
(x106) CD8+CD44+  Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 0.2755 No ns 
Spleen   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 1.8480 No ns 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.3342 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 1.5730 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.0587 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.5140 No ns 
% from total 
lymphocytes CD8+CD44+  Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 1.1150 No ns 
Spleen   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 3.1970 Yes * 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.8050 No ns 
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    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 2.0820 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.6900 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.3920 No ns 
Total cells 
(x106) CD8+CD44+  Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 2.6830 No ns 
Lymph node   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 0.8503 No ns 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.6690 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 1.8330 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 1.0140 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.8186 No ns 
% from total 
lymphocytes CD8+CD44+  Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 2.6710 No ns 
Lymph node   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 3.2890 Yes * 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 3.3740 Yes * 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 0.6181 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.7030 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.0850 No ns 
Total cells 
(x106) CD8+CD69+  Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 2.2630 No ns 
Lymph node   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 0.7440 No ns 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 1.6660 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 1.5190 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.5971 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.9222 No ns 
% from total 
lymphocytes CD8+CD69+  Aire+/+Cbl-b+/+ vs Aire+/+Cbl-b-/- 1.7410 No ns 
Lymph node   Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b+/+ 3.2350 Yes * 
    Aire+/+Cbl-b+/+ vs Aire-/-Cbl-b-/- 2.6290 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b+/+ 1.4940 No ns 
    Aire+/+Cbl-b-/- vs Aire-/-Cbl-b-/- 0.8882 No ns 
    Aire-/-Cbl-b+/+ vs Aire-/-Cbl-b-/- 0.6060 No ns 
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these subsets between all groups. These data indicate that overall T cell development in 
the thymus was not measurably altered in the Aire-/-Cblb-/- bone marrow chimeras. 
3.6.2.2 Lymphocyte populations in the secondary lymphoid organs, the spleen and lymph 
nodes 
Following development in the thymus, T lymphocytes migrate to different secondary 
lymphoid organs, including the spleen and various lymph nodes. In this section “lymph 
nodes” refer to pooled lymphocytes from the inguinal and axillary subcutaneous lymph 
nodes, whereas “pancreatic lymph nodes” refers to lymphocytes harvested from the 
lymph node that drains the pancreas – the organ that was affected by lymphocytic 
infiltration in Aire-/-Cblb-/- mice. Hence, it was interesting to compare the status of 
activation using flow cytometric cell surface markers between the pancreas-draining 
lymph node close to the site of infiltration and subcutaneous lymph nodes that were 
present at a distant site. 
In all three peripheral organs (spleen, subcutaneous lymph nodes and pancreatic lymph 
nodes), there appeared to be no significant differences in the numbers of B cells, T cells, 
CD4, CD8 and nTreg cells (Figs. 3.15, 3.16, 3.17 and Tables 3.3 and 3.4). Similarly, the 
total numbers of CD4 and CD8 cells that upregulated the activation markers CD44 and 
CD69 were comparable between groups. Increases were observed in the percentages of 
CD8+CD44+ cells in the spleen (Aire-/- compared to wild-type) and subcutaneous lymph 
nodes (Aire-/- and Aire-/-Cblb-/- compared to wild-type). Besides CD44, the Aire-/- also 
displayed higher percentages of CD8+CD69+ cells. Nevertheless, these increases in 
percentage of CD8 cells upregulating the CD44 and CD69 marker did not translate to an 
increase in the corresponding total number of cells. Taken together, the data suggest 
that the overall T cell subsets and activation status in the Aire-/-Cblb-/- chimeric mice 
were relatively comparable to the single mutant and wild-type control chimeras. 
3.6.3 Analysis of lymphocyte development in mixed bone marrow chimeras 
There is a possibility that quantitative abnormalities in lymphocyte maturation and 
survival would be masked unless the mutant T cells were placed in competition with the 
wild-type T cells. These differences would not have been detected in the flow cytometry 
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Figure 3.15 Representation of flow cytometry plots from
splenocytes of from Aire+/+Cblb+/+, Aire+/+Cblb-/-, Aire-/-
Cblb+/+ and Aire-/-Cblb-/- bone marrow chimeras.
A. Gated on lymphocytes (Lym), showing the percentage of B
cell subsets
B. Gated on non-B cells, showing the percentage of CD4 and
CD8 subsets
C. Gated on CD4+ cells, showing the percentage of CD4+FoxP3+
subsets
D. Gated on CD4+ (top) or CD8+ (bottom), showing CD5, CD44
and CD69 expression on each subset.
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Figure 3.16 Representation of flow cytometry plots from
lymphocytes of the lymph nodes from Aire+/+Cblb+/+,
Aire+/+Cblb-/-, Aire-/-Cblb+/+ and Aire-/-Cblb-/- bone marrow
chimeras.
A. Gated on lymphocytes (Lym), showing the percentage of B
cell subsets
B. Gated on non-B cells, showing the percentage of CD4 and
CD8 subsets
C. Gated on CD4+ cells, showing the percentage of CD4+FoxP3+
subsets
D. Gated on CD4+ (top) or CD8+ (bottom), showing CD5, CD44
and CD69 expression on each subset.
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analysis in section 3.6.2 but could be detected by analysing the chimeras which have 
been reconstituted with equal ratios of Cblb-/- and wild-type bone marrow. The 
experimental design of the mixed bone marrow chimeras was illustrated in Fig. 3.12. 
The genotype of the hematopoietic cells that engrafted and differentiated can be tracked 
by monoclonal antibody staining for the surface markers CD45.1 and CD45.2 
(corresponding to different CD45 allotypes). The wild-type bone marrow was obtained 
from a B10.BR.CD45.1 congenic mice that expressed the CD45.1 marker. In contrast, 
the recipient mice and Cblb-/- bone marrow expresses the CD45.2 marker.  
Twenty-nine days post-reconstitution, the mice were euthanised and tested for the 
repopulation of B cells, T cells and other lymphocyte subsets. The relative percentages 
are seen in Fig. 3.18, Fig 3.19, Fig, 3.20 and Table 3.5, showing the relative 
reconstitution of the CD45.1 and CD45.2 components in the bone marrow chimeras. 
There was no measurable preferential expansion of Cblb-/- T cells in Aire-/- recipients. 
CD45.2+ cells preferentially contributed to the peripheral T cells in the spleen and blood 
relative to the frequency in thymocytes or B cells in the same animal in all regardless of 
recipient Aire genotype. Since the recipient mice were CD45.2, and memory T cells and 
Tregs were radioresistant, it is likely the excess CD45.2 peripheral T cells were 
recipient or host derived. 
3.7 Splenocyte precursors are able to transfer the disease 
Following the establishment that the pancreatic-wasting syndrome was a result of Cblb-
deficiency in the hematopoietic system, it was of interest to determine if lymphocytes 
could transfer the disease to another mouse. To test this, 1, 3 or 8.5 × 106 splenocytes 
from either wild-type or Aire-/-Cblb-/- mice were intravenously injected into pairs of 
B10.BR.Rag1-deficient mice (Fig. 3.21A). Rag1-deficient mice were used as recipients 
as the absence of Rag1 eliminates all mature T and B cell from the repertoire. Thus, any 
autoimmunity observed in these mice could be attributed to the effect of adoptively 
transferred cells. 
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Figure 3.18 Contribution of CD45.1 and CD45.2 cells to thymus
subsets in individual chimeric mice.
Irradiated wild-type recipients (A) or Aire-/- recipients (B) received
equal mixtures of wild-type marrow carrying the CD45.1 allelic
marker and Cblb-/- marrow carrying the CD45.2 allelic marker .The
vertical axis denotes the percentage of CD45.1 or CD45.2 allotype
cells in the indicated cell type. Every bar represents a single mouse
and these are listed in the same order for each cell type analysed.
Lymphocytes (lym); double negative (DN); double positive (DP);
single positive CD4 cells (CD4+); single positive CD8 cells (CD8+)
and T regulatory cells (CD4+FoxP3+) cells.
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Figure 3.19 Contribution of CD45.1 and CD45.2 cells to blood
lymphocyte subsets in individual chimeric mice.
Irradiated wild-type recipients (A) or Aire-/- recipients (B) received
equal mixtures of wild-type marrow carrying the CD45.1 allelic
marker and Cblb-/- marrow carrying the CD45.2 allelic marker .The
vertical axis denotes the percentage of CD45.1 or CD45.2 allotype
cells in the indicated cell type. Every bar represents a single mouse
and these are listed in the same order for each cell type analysed.
Lymphocytes (lym), B cells (B), T cells (T), CD4 cells (CD4+), CD8
cells (CD8+) and Treg (CD4+CD25+) cells.
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Figure 3.20 Contribution of CD45.1 and CD45.2 cells to
splenocyte subsets in individual chimeric mice.
Irradiated wild-type recipients (A) or Aire-/- recipients (B) received
equal mixtures of wild-type marrow carrying the CD45.1 allelic
marker and Cblb-/- marrow carrying the CD45.2 allelic marker .The
vertical axis denotes the percentage of CD45.1 or CD45.2 allotype
cells in the indicated cell type. Every bar represents a single mouse
and these are listed in the same order for each cell type analysed.
Lymphocytes (lym), B cells (B), T cells (T), CD4 cells (CD4+), CD8
cells (CD8+) and Treg (CD4+CD25+) cells.
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Table 3.5 Statistical analysis of the mixed bone marrow chimeras. For this analysis, 
the lymphocyte population was used as a reference population and the percentages of 
CD45.1 and CD45.2 lymphocytes were taken to be the "expected" frequency in all other 
subsets of the same mouse. The expected frequencies were compared to the CD45.1 and 
CD45.2 allotype percentages for other subpopulations in the same organ (the 
"observed” frequencies). The p value for the chi-squared test for independence are taken 
to be significant when p<0.05 as seen in the shaded background. 
Organ Population Allotype Chi-squared P Values Significance 
      Aire+/+ Aire-/-   
Thymus DN CD45.1 0.2881 0.5511 No 
    CD45.2 0.5885 0.7711 No 
  DP CD45.1 0.9966 0.9993 No 
    CD45.2 0.9980 0.9997 No 
  CD4 CD45.1 0.2568 0.4944 No 
    CD45.2 0.4090 0.7043 No 
  CD8 CD45.1 0.8092 0.8481 No 
    CD45.2 0.9057 0.9374 No 
  Tregs CD45.1 0.0025 0.1280 No 
    CD45.2 0.0258 0.3377 No 
Blood B cells CD45.1 0.0997 0.2577 No 
    CD45.2 0.3568 0.6516 No 
  T cells CD45.1 <0.0001 <0.0001 Yes 
    CD45.2 <0.0001 0.0300 Yes 
  CD4 cells CD45.1 <0.0001 0.0068 Yes 
    CD45.2 <0.0001 0.2683 No 
  CD8 CD45.1 <0.0001 <0.0001 Yes 
    CD45.2 <0.0001 0.0110 Yes 
  CD4 CD25 CD45.1 <0.0001 <0.0001 Yes 
    CD45.2 <0.0001 0.0014 Yes 
Spleen B cells CD45.1 0.1920 0.6521 No 
    CD45.2 0.4727 0.8779 No 
  CD4 CD45.1 <0.0001 <0.0001 Yes 
    CD45.2 <0.0001 0.0146 Yes 
  CD8 CD45.1 <0.0001 <0.0001 Yes 
    CD45.2 <0.0001 0.0265 Yes 
  Tregs CD45.1 <0.0001 <0.0001 Yes 
    CD45.2 <0.0001 0.0001 Yes 
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Figure 3.21 Transfer of cachectic disease by splenocytes from
Aire-/-Cblb-/- mice to lymphopenic Rag1-deficient
recipients.
A. 1, 3 and 8.5 x 106 splenocytes from Aire-/-Cblb-/- or wild-type
B10.BR mice were injected into Rag1-deficient B10.BR
recipients.
B. Percentage of CD4+ and CD8+ cells in the blood of mice 12
days post-transfer of the indicated splenocytes.
C. Survival of Rag1-deficient B10.BR mice after adoptive
transfer of the indicated splenocytes.
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Flow cytometric analysis of peripheral blood lymphocytes in the recipients twelve days 
post transfer revealed a marked over-representation of the CD8 T cell subset in 
recipients of Aire-/-Cblb-/- spleen cells, although this difference was not statistically 
significant (Fig. 3.21B). All mice receiving Aire-/-Cblb-/- spleen cells became cachectic 
and moribund by 28 days following adoptive transfer, regardless of the number of 
transferred cells, while all mice receiving wild-type splenocytes remained healthy (Fig. 
3.21C). At necropsy, the only gross pathology detected was a small translucent pancreas 
in recipients of Aire-/-Cblb-/- spleen cells, and histology demonstrated extensive 
lymphocytic infiltration of the exocrine pancreas and loss of most or all acinar cells 
(Fig. 3.22A and B). The pancreas pathology appeared to be more severe for recipients 
that received higher number of Aire-/-Cblb-/- spleen cells. The data indicated that as few 
as one million Aire-/-Cblb-/- splenocytes were able to transfer the disease to Rag1-
deficient recipients. 
 
3.8 CD4 T helper cells and CD8 T cytotoxic cells are necessary to transfer the 
disease 
Having established that splenocytes could transfer disease, we now had to establish if 
CD4 or CD8 T cells were required to adoptively transfer disease. Thus, the cell transfer 
experiment in 3.7 was repeated with CD4 and CD8 T cell-enriched or T cell depleted 
subsets of spleen cells. Spleen cells were obtained from bone marrow chimeras with 
both tolerance defects (Aire deficient recipients of Cblb-deficient marrow; abbreviated 
as Aire-/-Cblb-/-) and from control chimeras with neither defect (abbreviated as wild-
type), because insufficient T cell subsets could be obtained from the 3 week old very 
small, cachectic Aire-/-Cblb-/- mice. The cells were pooled and divided into three groups. 
Two of the groups were MACS-enriched for the CD4 or CD8 population, respectively, 
and both the positive and negative fractions of the enrichment were used for further 
transfers. The non-enriched splenocytes served as a positive control for the experiment, 
whereby, the cells were known to be able to transfer disease.  
Groups of Rag1-deficient mice received either 2×106 whole splenocytes, 2×106 CD4- or 
CD8-depleted spleen cells, or 2×105 CD4 or 1×105 CD8 enriched cells. These numbers 
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Figure 3.22 Transfer of pancreatitis disease by limiting
numbers of splenocytes from Aire-/-Cblb-/- mice to
lymphopenic Rag1-deficient recipients.
A. Representative haematoxylin and eosin-stained sections of
the pancreas from mice in each group. Original magnification:
x100, Bars: 500 µm.
B. Percentage of recipient mice with different grades of
pancreatitis (n=6/group).
Fr
eq
ue
nc
y
106
   
were chosen as they approximated the numbers of CD4 and CD8 T cells within 2×106 
total lymphocytes (Fig. 3.23). To ensure complete deletion of the residual irrelevant 
subset, the recipients of CD4-enriched and CD8-depleted cells were treated with 
depleting antibody to CD8; and recipients of the CD8-enriched and CD4-depleted cells 
were treated with depleting antibody to CD4 on days zero, one, seven and fourteen of 
the experiment. Flow cytometric staining of the peripheral blood samples taken nineteen 
days post-transfer determined that the CD4-enriched and CD8 -depleted group had only 
CD4 cells; and the CD8-enriched and CD4-depleted group had only CD8 cells. This 
established that efficient subset deletion had been achieved. 
All Rag1-deficient mice that received unfractionated splenocytes from Aire-/-Cblb-/- 
donors died or were euthanased due to cachexia by 45 days post transfer (Fig. 3.24 A). 
By contrast, the cachectic syndrome did not develop in recipients of CD8- or CD4-
depleted splenocytes from Aire-/-Cblb-/- donors nor in recipients of CD8- or CD4-
enriched cells, establishing that both T cell subsets were required to transfer lethal 
autoimmunity. Severe exocrine pancreatitis was observed in recipients of whole Aire-/-
Cblb-/- splenocytes, while the different combinations of CD4- or CD8- enriched and 
CD4- or CD8-depleted cells displayed varying degrees of histological severity scores. 
On the contrary, the recipients of all groups of wild-type cells displayed negligible 
infiltrations (Fig. 3.2.24B). These results imply that pancreatitis can be initiated either 
by CD4 or CD8 cells, but both cell types are required for efficient autoimmune 
destruction of this organ. 
The histological analysis of the submandibular salivary gland in mice that received Aire-
/-Cblb-/- whole splenocytes, or CD4-enriched or CD8-depleted splenocytes revealed 
infiltration in the salivary glands with histological scores from 2 to 5 in majority of the 
recipients (Fig. 3.24C). By contrast, no sialoadenitis was observed in recipients of CD4-
depleted or CD8-enriched cells. From these results, it can be inferred that CD4 cells 
from Aire-/-Cblb-/- chimeras are necessary for the development of sialoadenitis in 
lymphopenic Rag1-deficient recipients.  
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Figure 3.23 Schematic explaining the experimental design to
determine the role of T cells in adoptive transfer of pancreatitis.
Adoptive transfer of 2x106 unfractionated spleen cells (containing
approximately 2x105 CD4- or 1x105 CD8 cells), 2x106 spleen cells
selectively depleted of CD4- or CD8-cells, or 2x105 CD4- or 1x105
CD8- enriched spleen cells, obtained from bone marrow chimeras of
the indicated genotypes. Recipients of CD4-depleted or CD8-
enriched cells, and recipients of CD8-depleted or CD4-enriched
cells, were also treated with depleting antibody to CD4 or CD8,
respectively, on days 0, 1, 7 and 14 to deplete any residual T cells
of the relevant subset.
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Figure 3.24 Aire-/-Cblb-/- CD4 and CD8 cells are necessary to
transfer the wasting syndrome to lymphopenic Rag1-
deficient recipients.
A. Survival of Rag1-deficient B10.BR mice after adoptive
transfer of the indicated subsets of splenocytes.
B. Percentage of recipient mice with different grades of
pancreatitis.
C. Percentage of recipient mice with different grades of
sialoadenitis.
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These experiment established that both CD4 and CD8 cells are necessary for 
development of pancreatitis and CD4 cells are necessary for development of 
sialoadenitis. It still remains to be tested if these populations are sufficient to drive the 
disease. There is a possibility that other lymphocyte populations may also be required to 
precipitate or promulgate the disease. Several studies have indicated that there is a 
possible role for B cells (Gavanescu et al., 2008) and B-cell-activating factor to the 
tumour necrosis factor family (BAFF)-secreting dendritic cells (Lindh et al., 2008) in 
the development of autoimmunity in Aire-/- mice. Since the pattern of disease was 
mirrored by the presence of autoantibodies against these same organs, it would be 
interesting to test if B cells were also needed to transfer the disease using a similar 
experimental set-up in the future. 
3.9 Wild-type T regulatory cells confer protection from lethal wasting and 
pancreatitis in Aire-/-Cblb-/- mice 
As indicated in section 3.8, the CD4 population is necessary for the development of 
both pancreatitis and sialoadenitis. However, there are many different subpopulations of 
CD4 cells such as CD4 helper cells and T regulatory cells. Notably, besides the 
conventional role of Aire in mediating negative selection of antigen-specific CD8 and 
CD4 helper cells in the thymus, it has been suggested to play a role in positive selection 
and formation of organ-specific nTreg cells. Mice that have deficiencies in the master 
transcription factor of Treg cells, FoxP3, frequently present with multiorgan specific 
autoimmunity (Fontenot et al., 2003; Hori et al., 2003; Khattri et al., 2003). It could be 
possible that the multiorgan autoimmunity caused by Aire-deficiency, at least in part is 
due to a defect in Tregs. This section will investigate if wild-type nTregs that have been 
positively selected in an Aire-dependent fashion are able to control the lethal 
pancreatitis mediated by the double genetic defects in Aire and Cblb.  
To do this, 3×106 Aire-/-Cblb-/- splenocytes (CD45.2 and CD45.1/2, for simplicity will 
be refered to as CD45.2+) and adjusted numbers of wild-type CD45.1+CD4+CD25+ 
MACS-enriched CD45.1 nTreg cells were intra-venously introduced into groups of ten 
Rag1-deficient recipients in the following ratios: 1:0, 1:1/9: 1:1/3 and 1:1 (Aire-/-Cblb-/-
:wild-type CD4+CD25+) (Fig. 3.25). The CD45.2+ Aire-/-Cblb-/- splenocytes were 
110
3x106 Aire-/-Cblb-/-
CD45.2 or CD45.1/CD45.2
Rag1-deficient
CD45.1 CD4+CD25+
Wild-type
1:1 ratio1:1/3 ratio1:1/9 ratio1:0 ratio
Figure 3.25 Schematic representation of the T regulatory
cell adoptive transfer assay.
Rag1-deficient recipients of Aire-/-Cblb-/- splenocytes were given
CD4+CD25+ wild-type cells in different ratios as indicated.
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obtained from bone marrow chimeras to circumvent potential problems of obtaining 
insufficient cell numbers from small cachectic wasting Aire-/-Cblb-/- mice obtained via 
breeding.  
The mice were bled 22 days post-adoptive transfer to verify the engraftment and 
expansion of the CD45.2+ Aire-/-Cblb-/- splenocytes and the CD45.1+CD4+FoxP3+ 
population. As seen in Fig. 3.26A, 0.16±0.04, 0.45±0.07, 0.52±0.11 and 0.28±0.08 
(mean±s.d.)% of CD4+FoxP3+ cells were detected in recipients of 1:0, 1:1: 1:1/3 and 
1:1/9 (Aire-/-Cblb-/-:wild-type CD4+CD25+), respectively. Statistical analysis indicated 
that all groups receiving co-transferred CD4+CD25+ cells had significantly elevated 
frequencies of circulating Foxp3+ CD4 cells compared to the frequency in the control 
(1:0) group, and that the frequency was higher in the groups receiving higher numbers 
of co-transferred CD25+ cells (groups 1:1 and 1:1/3) compared to the recipients of the 
lowest number (group 1:1/9). When the Foxp3+CD4+ cells in the recipients were 
subdivided according to whether they came from the Aire-/-Cblb-/- donor (CD45.2+) or 
the wild-type donor (CD45.1+), CD45.1+ cells represented 94.7±2.2, 90.9±2.43 and 
79.4±3.79 (mean±s.d.) % of the FoxP3+ cells in the 1:1: 1:1/3 and 1:1/9 (Aire-/-Cblb-/-
:wild-type CD4+CD25+) groups (Fig. 3.26B(top panel)). Thus, the co-transferred wild-
type Tregs increased the overall numbers of circulating Tregs and accounted for the 
majority of circulating Tregs.  
To establish the extend to which the wild-type CD45.1+ cells contributed to the FoxP3- 
T cell pool within the mice, the percentages of CD45.1+CD4+FoxP3- and CD8 cells in 
each group was enumerated: group 1:1 (25.3±3.9 CD4+ FoxP3- and 13.34±6.04 CD8); 
group 1:1/3 (13.84±4.1 CD4+ FoxP3- and 2.68±1.37 CD8) and 1:1/9 (8.08±7.3 CD4+ 
FoxP3- and 1.79±1.83), whereby percentages are expressed from total CD4+ FoxP3- or 
CD8 cells, respectively. Similar to the Foxp3+CD4+, there appears to be a dose-
dependent appearance of CD4+ FoxP3- and CD8 cells in the following order group 1:1 < 
group 1:1/3 < group 1:1/9, although ≥75% of FoxP3- T cells in each group represented 
disease-driving Aire-/-Cblb-/- CD45.2+ cells. This verified that most of the FoxP3-CD4 
and CD8 cells were CD45.2+ and hence derived from the Aire-/-Cblb-/- donor. 
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1:1/3 vs 1:1/9 0.2433 Yes ***
C
Figure 3.26 Representative flow cytometry plots of recipients
analysed 22 days post transfers show detectable levels
of CD45.1 FoxP3+ cells in the blood.
A. Representation of flow cytometric plots of FoxP3+ and FoxP3-
CD4 cells gated on total lymphocytes in blood from recipients
of the indicated groups.
B. Division of the CD4+FoxP3+ (top) and CD4+FoxP3- (bottom)
cells into CD45.1 and CD45.2.
C. One-way ANOVA and Bonferronni post-test comparing
percentages of CD45.1 FoxP3+ T regulatory cells from total
lymphocytes between all groups.
Percentages for (A) and (B) show the means and standard
deviation of each group for n=10 mice per group.
2.45±1.2 0.65±0.1 1.06±0.3 1.23±0.5
CD45.1
CD45.2
Lym
CD4+FoxP3+
CD4+FoxP3-
0 102 103 104 105
0
102
103
104
105
0.16±0.04 0.45±0.07 0.52±0.11 0.28±0.08
0.36±0.42 94.7±2.2 90.9±2.32 79.4±3.79
0.55±0.32 25.3±3.9 13.8±4.1 8.08±7.3
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All the Rag1-deficient mice receiving Aire-/-Cblb-/- splenocytes alone (1:0 group) either 
died spontaneously or were sacrificed due to 20% weight loss by 56 days post-adoptive 
transfer (Fig. 3.27). By contrast, recipients of Aire-/-Cblb-/- cells that received equal 
amounts of wild-type CD4+CD25+ and Aire-/-Cblb-/- splenocytes remained healthy for 
the duration of the experiment (108 days) as determined by gross observation and 
survival. Sixty percent and 70% of the Rag1-deficient recipients in the 1:1/3 and 1:1/9 
groups also survived for the 108-day course of the experiment. Statistical analysis 
supported the conclusion that there was a dose-response relationship, in that survival in 
the 1:1/9 recipient group was unlikely to be the same as in the 1:1 group. Thus, co-
transfer of wild-type CD4+CD25+ conferred protection from the lethality in a dose 
dependent manner.  
To determine the effect of co-transferred CD25+ CD4 cells on exocrine pancreatitis and 
sialoadenitis, the remaining recipients that survived on day 108 were sacrificed and 
analysed histologically. As seen in Fig. 3.28A, while 6 or the 10 recipient mice in the 
1:1/9 group survived, all of these animals had developed pancreatitis with median 
pancreatitis scores of 5. By contrast, less severe pancreatitis was observed in the 
recipients that received higher numbers of Tregs, with median scores of 2 in the 1:1/3 
group and zero in the 1:1 group. Thus, there was a dose-response relationship between 
the number of wild-type Tregs transferred and suppression of exocrine pancreatitis. A 
similar trend was observed for the salivary gland (Fig. 3.28B), albeit all recipient mice 
displayed less severe sialoadenitis scores compared to the pancreatitis. The differences 
seen in the salivary gland histology between the experimental groups were not 
statistically significant.  
Overall, this experiment demonstrates that the addition of wild-type T regulatory cells 
were able to suppress the pancreatitis in Rag1-recipients of Aire-/-Cblb-/- cells and its 
progression to lethal disease, although further experimentation will be needed to 
accurately delineate the role of Tregs in the progression of the disease. In particular, it 
will be important to determine whether suppression of disease reflected a unique quality 
of wild-type Tregs, the overall increase in Tregs or if the addition of wild-type T cells 
displaced or diluted the disease-driving Aire-/-Cblb-/- cells. 
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Group comparision P value Significance Summary
1:0 Tregs vs 1:1 Tregs <0.0001 Yes ***
1:0 Tregs vs 1:1/3 Tregs <0.0001 Yes ***
1:0 Tregs vs 1:1/9 Tregs 0.0091 Yes **
1:1 Tregs vs 1:1/3 Tregs 0.0675 No n.s.
1:1 Tregs vs 1:1/9 Tregs 0.0291 Yes *
1:1/3 Tregs vs 1:1/9 Tregs 0.4512 No n.s.
Figure 3.27 Wild-type CD4+CD25+ cells are able to suppress
cachectic wasting syndrome in Rag1-deficient recipients
of Aire-/-Cblb-/- splenocytes in a dose-dependent manner
(Experiment 1).
A. Survival measured post-transfer of Aire-/-Cblb-/- and
CD4+CD25+ wild-type cells, n = 10 per group for Experiment
1.
B. Summary of statistical analysis for survival calculated using a
log rank Mantel-Cox test.
Results are representative of two independent experiments
with n=10 in each group.
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Figure 3.28 Wild-type CD4+CD25+ cells are able to suppress
development of pancreatitis ad sialadenitis in Rag1-deficient
recipients of Aire-/-Cblb-/- splenocytes in a dose-dependent
manner.
A. Pancreatitis scores for Rag1-deficient recipients sacrificed at Day
108 of Experiment 1.
B. Sialoadenitis scores for Rag1-deficient recipients sacrificed at Day
108 of Experiment 1.
The P values and significance comparing the different groups was
determined by a Kruskal-Wallis test comparing all columns and
Dunn’s Multiple Comparison test comparing pairs of columns.
Results are representative of two independent experiments with
n=10 in each group.
Kruskal-Wallis test P value Significance Summary
All groups 0.0008 Yes ***
Dunn's Multiple Comparison Test Difference in rank sum Significance Summary
1:1/9 Treg vs 1:1/3 Treg 9.262 Yes *
1:1/9 Treg vs 1:1 Treg 12.68 Yes ***
1:1/3 Treg vs 1:1 Treg 3.421 No n.s.
Kruskal-Wallis test P value Significance Summary
All groups 0.0655 No n.s.
Dunn's Multiple Comparison Test Difference in rank sum Significance Summary
1:1/9 Treg vs 1:1/3 Treg 2.464 No n.s.
1:1/9 Treg vs 1:1 Treg 5.75 No n.s.
1:1/3 Treg vs 1:1 Treg 3.286 No n.s.
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3.10 Chapter summary and key findings  
3.10.1 CBL-B, a key failsafe for AIRE-mediated autoimmunity 
The findings in this chapter, obtained both by breeding or bone marrow transplantation, 
established that variations in the latent period and organ specificity of autoimmune 
disease in Aire-deficiency reflected the activity of a fail-safe tolerance mechanism 
mediated by the ubiquitin ligase Cbl-b. Single deficiencies in Aire and Cblb resulted in 
no clinical autoimmune disease in the animals studied here on a genetic background not 
particularly prone to autoimmunity, and resulted in variable autoimmune disease with a 
long latent phase when studied on other genetic backgrounds (Anderson et al., 2002; 
Bachmaier et al., 2000; Chiang et al., 2000; Ramsey et al., 2002b; Yokoi et al., 2007). 
When both tolerance mechanisms were crippled, an emergent phenotype of complete 
autoimmune destruction of the exocrine pancreas occurred within weeks after T cells 
began emigrating from the thymus. The cooperation between Aire and Cblb was unique: 
while the Faslgld and Rc3h1san mutations gave rise to more fully penetrant autoimmunity 
on their own, when compounded with Aire-/- they yielded autoimmune phenotypes that 
appear simply to be the sum of each individual defect. Reasons for this will be 
discussed in chapter 6. These findings are the first to reveal a higher-level architecture 
assembling individual tolerance mechanisms together for robust resistance to 
autoimmunity. 
Cbl-b has a well-defined role in the regulation of mature T cell activation. Cbl-b is only 
expressed at low levels in immature T lymphocytes (Naramura et al., 2002; Thien and 
Langdon, 2005) and consequently Cblb-deficiency does not alter thymic selection or 
Aire-dependent thymic deletion (Hoyne et al., 2011b). Cbl-b is upregulated in mature 
and anergic T cells, where it inhibits the PI3K and NF-κB signalling pathways activated 
by TCR-CD28 co-stimulation and is required for T cell anergy to prevent proliferation 
of T cells that have recognized peripheral antigens with insufficient affinity or in the 
absence of adequate CD28 co-stimulation (Bachmaier et al., 2000; Chiang et al., 2000; 
Fang and Liu, 2001; Gronski et al., 2004; Heissmeyer et al., 2004; Jeon et al., 2004; 
Naramura et al., 2002; Qiao et al., 2008; Thien and Langdon, 2005). Hence, a simple 
explanation for the rapid progression to pancreatic autoimmune disease observed here is 
that pancreas-specific T cells escape thymic deletion due to Aire-deficiency and then 
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escape anergy and the normal requirement for CD28 co-stimulation due to Cblb-
deficiency, allowing them to proliferate and differentiate into tissue-damaging effector 
T cells. 
3.10.2 Defects in nTreg and iTregs may exacerbate autoimmunity in Aire-/-Cblb-/- 
mice 
The simple explanation was made based on the assumption that Aire and Cblb only 
crippled two different tolerance pathways. However, the results in section 3.9 
demonstrated that wild-type nTreg were able to confer protection from the lethal 
pancreatitis precipitated by adoptively transferring Aire-/-Cblb-/- cells into lymphopenic 
recipients. An attractive explanation for this rescue is that Aire-/-Cblb-/- mice exhibit 
additional deficiencies in FoxP3+ T regulatory cells besides the deficiency in negative 
selection associated with Aire-/- and T cell anergy associated with Cblb-/-. Hence, 
although the combination of Aire-/- and Cblb-/- represents two genetic defects, it may 
cripple more than two tolerance pathways. There has been growing evidence that Aire 
might also promote formation of FoxP3+ natural T regulatory cells (nTregs) that 
develop in the thymus (Hinterberger et al., 2010; Kekalainen et al., 2007b; Laakso et al., 
2011; Ryan et al., 2005; Wolff et al., 2010), and that Cblb promotes differentiation of 
inducible T regulatory (iTregs) cells that upregulate FoxP3 in response to TGF-β 
stimulation (Harada et al., 2010; Hoyne et al., 2011b; Wohlfert et al., 2004; Wohlfert et 
al., 2006). Coupling Aire-deficiency with Foxp3-deficiency further accelerated the 
already rapidly lethal effect of Foxp3-deficiency on its own (Chen et al., 2005).  
The possibility that a qualitative deficiency of iTregs is necessary for autoimmune 
pancreatitis in Aire-/-Cblb-/- mice is addressed by the mixed bone marrow chimera 
experiments (Section 3.6). Here it was observed that Aire-/- recipient mice that received 
wild-type marrow (and could therefore develop normal iTreg cells) in addition to the 
Cblb-/- marrow still developed lethal pancreatitis, although this appeared to be less 
severe than Aire-/- recipient mice that received only Cblb-/- cells. The result contrasted 
with autoimmunity entirely due to nTreg defects, which are fully corrected by mixtures 
of defective and wild-type T cells (Sakaguchi et al., 2009). This suggests that the 
disease was not mediated simply by defects in the nTreg component. However Aire 
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deficiency in these mixed chimeras could potentially decrease thymic formation of 
organ-specific nTregs from both the mutant and wild-type marrow, particularly given 
the potent suppression of pancreatitis by co-transfer of nTregs that had developed in a 
wild-type thymus (Figure 3.27 and 3.28). It would be valuable in a future experiment to 
test whether or not co-transfer of nTregs from an Aire-deficient donor could suppress 
pancreatitis to the same extent. Along these lines, the presence of normal Tregs did not 
suppress organ-specific autoimmunity when Anderson and colleagues (Anderson et al., 
2005) transferred 50:50 mixtures of splenocytes from Aire-deficient and Aire wild-type 
mice into Rag-deficient mice.  
Another way of providing a source of normally educated nTregs would be to repeat the 
mixed bone marrow chimera experiment in thymectomized recipients that had been 
grafted with two thymi: a wild-type thymus as well as an Aire-deficient thymus. 
Anderson and colleagues (Anderson et al., 2005) performed this experiment in mice that 
were singly deficient in Aire and found that autoimmunity still developed, again 
providing compelling evidence against a substantial role for a qualitative defect in 
nTregs. Understanding how Aire and Cblb co-operate mechanistically will be further 
explored using transgenic mice in chapter 4, allowing accurate tracking and 
measurements of a single self-reactive clone in the Aire-/-Cblb-/- mice. 
3.10.3 Only two organs targeted in Aire-/-Cblb-/- mice: the pancreas and salivary 
glands 
It is striking that the immediate autoimmune destruction in Aire-/-Cblb-/- double mutant 
animals was not more generalized but remained limited to exocrine acinar cells in the 
pancreas and mucous acinar cells in the submandibular salivary gland. The pancreatic 
endocrine tissues and other organs (lung, kidney, liver, thyroid, heart, eye, 
ovaries/testis) remained virtually unaffected by autoimmunity in the double-deficient 
animals, although Aire deficiency interferes with thymic deletion against hundreds of 
autoantigens that are highly expressed in different organs (Anderson et al., 2005; 
Anderson et al., 2002; Liston et al., 2003), and Cblb deficiency can predispose to 
pancreatic islet autoimmune destruction (Gronski et al., 2004; Yokoi et al., 2007; Yokoi 
et al., 2002). Since both the pancreas and salivary gland have similarities in structure 
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(exocrine and endocrine) and function (production of digestive enzymes), it is possible 
that the same autoreactive immune cell clone from the Aire-/-Cblb-/- mice is targeting a 
common autoantigen in the acinar cells in the two organs (common immunogenicity). 
However, adoptive transfer assays from section 3.8 suggest that pancreatitis is both 
CD8- and CD4-dependent, while the sialoadenitis is predominantly CD4 -dependent. 
Furthermore, the pattern of autoantibody detection from the sera of Aire-/-Cblb-/- seemed 
to be largely targeted towards the apical surface of the pancreatic acinar cells, while a 
more diffuse pattern is observed for the salivary gland. Hence, experiments in chapter 5 
will set out to isolate CD8- and CD4-dependent disease driving cells in Aire-/-Cblb-/- 
mice and utilize this information to understand the nature and immunogenicity of the 
driver autoantigen(s) in this double-deficient mouse strain. 
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Chapter 4  
Varying the T cell repertoire in Aire-/-
Cblb-/- double deficient mice 
Acknowledgements of assistance in the work described in this chapter: The mice were 
genotyped by the Australian Phenomics Facility, while I performed most of the Aire 
genotyping. Glucosuria scoring in sections 4.4.1 and 4.4.2 were performed by Ken 
Chau and Luke Walker (Animal technicians). Technical assistance for mouse takedown 
in section 4.4.2 was obtained from Jennifer Koffler (IGL laboratory technician). The 
experiments in section 4.5 were a collaborative effort between Dr. Stephen Daley and 
me. Results from section 4.5.3 were published in (Hoyne et al., 2011b). All in vitro and 
in vivo experiments described in this section were designed in collaboration with Dr. 
Stephen Daley and performed by me with some help from Debbie Howard (IGL 
laboratory technician) for injections and diabetes testing. The optimised peripheral 
proliferation assay has been published (Silva et al., 2011). All hematoxylin and eosin 
section cutting and staining was done by Ms. Anne Prins (Flow Cytometry and 
Microscopy, John Curtin School of Medical Research). 
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4.1 Preamble 
Chapter 3 poses a mechanistic question: why is autoimmunity in Aire-/-Cblb-/- double 
deficient mice selectively targeted towards the acinar cells in the pancreas and salivary 
gland while other organs remained relatively untouched? This is intriguing as Aire 
regulates the expression of numerous peripheral tissue antigens (Anderson et al., 2002). 
It is hypothesized that the spectrum of the organs targeted is determined by variations in 
the T cell repertoire (repertoire/presentation hypothesis). According to this hypothesis, 
by varying the repertoire, the Aire-/-Cblb-/- double deficient mice are predicted to still 
present with infant onset autoimmune disease but targeted towards a different organ. In 
this chapter, the T cell repertoire was varied using two strategies. Section 4.3 introduced 
variations in the repertoire by changing the MHC. Sections 4.4 and 4.5 examined the 
consequence of producing high numbers of T cell precursors specific for a different 
pancreatic cell-type. 
4.1.1 Substituting the MHC 
MHC haplotypes account for the strongest genetic effects on autoimmune diseases in 
humans and mice although the basis for this remains unresolved (Todd and Wicker, 
2001; Wandstrat and Wakeland, 2001). One explanation is that particular MHC 
haplotypes may be particularly selective for positive selection of certain driver T cells. 
A second explanation is that particular MHC alleles may be better at presenting the 
driver autoantigen that provokes autoimmunity in peripheral tissues (McDevitt, 1980). 
It is also possible that the driver autoantigens are poorly presented to reduce effective 
negative selection during development in the thymus, peripheral anergy or other 
peripheral tolerance mechanisms. 
Thus, in the Aire-/-Cblb-/- double deficient mice it is possible that the driver autoantigen 
from pancreas or salivary gland presented by the H2k-encoded MHC: (i) happens to 
cross-react with T cells that are efficiently positively selected in the thymus of H2k 
mice; (ii) efficiently presented by the T cells to induced autoimmunity or (iii) poorly 
presented for tolerance in the thymus and periphery. There is evidence that varying 
MHC haplotype in Aire-/- mice alters the spectrum of the organs targeted. For example, 
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on the NOD background (but not on the NOD.H2b background) the mice are prone to 
developing pancreatitis and sialoadenitis, while on the C57BL/6 background the mice 
develop uveitis and on the BALC/c background the mice develop gastritis (Jiang et al., 
2005; Niki et al., 2006). Therefore, it seemed reasonable to test if changing the MHC 
haplotype would change the spectrum of the disease in Aire-/-Cblb-/- mice. 
4.1.2 Changing the starting frequency of cells recognising particular 
MHC:peptide complexes produced in the pancreas 
The pattern of autoimmunity in Aire-/-Cblb-/- mice is most likely highly influenced by 
the starting frequencies of T cells recognising the acinar structures in the pancreas and 
salivary gland that were positively selected during maturation in the thymus. In Aire-/-
Cblb-/- mice these driver T cells may be elevated due to the genetic deficiencies in Aire 
(failure of negative selection in the thymus) and Cblb (failure of a peripheral anergy 
control mechanism). These high frequencies of exocrine pancreas-specific cells may 
have out-competed other T cell clones causing severe autoimmunity in the pancreas 
before any other autoimmunity could develop. It is possible to vary the starting 
frequencies of the autoreactive TCR without changing the MHC haplotye using TCR 
transgenic mice. In the H2k TCR3A9 transgenic mice, the TCR repertoire is skewed to 
contain high numbers of T cells that efficiently target the hen-egg-lysozyme (HEL) 
antigen. If the repertoire/presentation hypothesis holds true, this would change the 
course of disease in the Aire:Cblb double deficient mice when HEL is expressed in 
pancreatic islet β cells, so that the mice would develop early onset diabetes instead of 
pancreatitis. The system has several advantages: (i) it provides high numbers of driver 
autoreactive cells that are scarce under physiological conditions; (ii) the autoreactive 
cells are traceable using a clonotypic antibody throughout TCR3A9 T cell development 
and function and (iii) the pattern of HEL-self antigen is varied to target specific organs 
in the body mirroring the expression of the bona fide autoantigens by controlling 
expression under the tissue-specific promoter (in this study the insulin or thyruglobulin 
promoter was used). 
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4.2 Mice used in this chapter 
4.2.1 H2b Cblb-/- and Aire-/- mice 
The Cblb-/- (H2b) mouse used in this chapter was generated by backcrossing a Cblb-/-
B10.BR.C57BL/6.N2F6 mouse to a C57BL/6 mouse, and intercrossing the offspring for 
three filial generations to fix the H2b MHC allele before being used for experimentation. 
The Aire-/- (H2b) mouse was generated by crossing a B10.BR.C57BL/6.N5F7 that was 
homozygous for the Aire-/- and heterozygous for Rag1-deficiency (H2b) to a C57BL/6 
mouse. Offspring from this cross were intercrossed for at least four filial generations 
before being used for experimentation. 
4.2.2 TCR3A9, insHEL and thyrHEL transgenic mice 
The TCR3A9 transgenic mice inherited rearranged TCR chains, utilizing the variable 
regions Vα3 and Vβ8.2 (Ho et al., 1994) that caused most T cells in the thymus to have 
high affinity for a peptide generated from position 46-61 of hen HEL, complexed to the 
MHCII molecule I-Ak (Allen et al., 1987). TCR3A9 cells are positively selected and can 
be detected in B10.BR (H2k) mice by the clonotypic anti-mouse TCR1G12 antibody 
(Peterson and Unanue) (Van Parijs et al., 1998). The strain has been maintained in the 
laboratory on the B10.BR genetic background. Cblb-/-TCR3A9 mice were produced by 
crossing a Cblb-/- B10.BR.C57BL/6/129.N3 mouse with the B10.BR.TCR3A9 mouse and 
intercrossing the offspring for at least seven generations prior to use in experimentation.   
The insHEL transgenic strain, ILK-3, expresses HEL as a self-protein under the control 
of the pancreas-specific rat insulin promoter. The pattern of HEL expression mirrors 
that of insulin. These mice express high concentrations of HEL in the beta cells of the 
pancreatic islets (140-400 ng/mg tissue), low concentrations of HEL (10-20 ng/ mL) in 
blood plasma (Akkaraju et al., 1997b) and trace levels are made by the thymic 
epithelium in a manner that is dependent on Aire (Liston et al., 2003). The Aire-/-
insHEL mouse that was used to establish the crosses studied here had a mixed 
B10.BR×C57BL/6.N3F3 background. The mouse was crossed to the insHEL strain 
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maintained in the laboratory and intercrossed for at least four filial generations prior to 
analysis. 
In double-transgenic (Dbl-Tg) TCR3A9:insHEL mice, the TCR3A9 cells were tolerized 
despite their high prevalence. This occurred through deletion of the high avidity IG12+ 
T cells during development in the thymus and export of residual T cells that were either 
functionally anergic or are FoxP3+ nTregs (Akkaraju et al., 1997b; Lesage et al., 2002). 
The anergic cells expressed low HEL-specific TCR and CD3 and increased amounts of 
CD5 (Akkaraju et al., 1997b; Lesage et al., 2002). The mice developed insulitis, but this 
remained sub-clinical or benign in a large fraction of the animals (Akkaraju et al., 
1997b). On the B10.BR background, ~20% of the Dbl-Tg mice developed diabetes by 
24 weeks of age (Lesage et al., 2002). In the absence of Aire, TCR3A9 cells escaped 
negative selection in the thymus of Dbl-Tg mice and were exported into the peripheral 
circulation in large numbers causing 50% of the Aire-/- TCR3A9:insHEL mice to present 
with diabetes by 15 weeks of age (Liston et al., 2004a).  
ThyrHEL mice, TLK-2, produced membrane-bound HEL protein at high levels in the 
thyroid epithelium (140/400 ng/mL), approximately 0.5 ng/mL levels of soluble HEL 
protein in the circulation (Akkaraju et al., 1997a; Akkaraju et al., 1997b) and higher 
levels of HEL in thymic epithelial cells than found in insHEL mice (Liston et al., 
2004a). The higher expression of HEL in the thymus of thyrHEL mice resulted in more 
severe deletion of thymocytes than in the insHEL mice (Akkaraju et al., 1997b). In the 
thymus of Aire-deficient mice, the deletion of self-reactive thyrHEL cells was 
completely abolished (Liston et al., 2004a). Crossing a B10.BR.C57BL/6.N3F2 mouse 
homozygous for Aire- and Rag1-deficiency to the B10.BR.thyrHEL strain available in 
the laboratory generated this strain. 
To generate Aire-/-Cblb-/- deficient double transgenic mice, B10.BR.C57BL/6/129.N3F14 
Cblb-/-TCR3A9 mice were crossed with Aire heterozygous mice derived from the Aire 
insHEL, Aire thyrHEL or Aire TCR3A9 strains described above. 
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4.3 Substituting the MHC allele that presents the driver autoantigen to T cells 
At the start of the chapter, three hypotheses were put forward to explain the pattern of 
autoimmunity based on MHC haplotype. To assess the contribution of MHC alleles on 
in the pattern of autoimmunity in Aire-/-Cblb-/- double deficient mice, the H2k MHC 
haplotype (I-Ak, I-Ek, Kk, Dk & Lk) from the original Aire-/-Cblb-/- double deficient mice 
was substituted with the H2b MHC haplotype (Kb, I-Ab, I-Enull, Db, Lnull). The B10.BR, 
(H2k) and C57/BL6, (H2b) are congenic strains, and genetically vary only at the MHC 
and at a small number of other background loci that differed between the B10.BR and 
C57BL/6 substrains.  
Bone marrow chimeras were constructed whereby T cell-depleted wild-type or Cblb-/- 
(H2b) bone marrow were used to reconstitute sub-lethally irradiated wild-type or Aire-/- 
(H2b) recipients. T cell depletion was performed to eliminate mature T cells from the 
marrow so that only hematopoietic stem cell-derived T cells developed in the recipient 
mice. The donor bone marrow stem cells were allowed to reconstitute the recipient 
hematopoietic system for six weeks to test the effect of MHC substitution on survival 
and development of pancreatitis in Aire-/-Cblb-/- chimeras (Fig. 4.1). 
Fig. 4.2 compares the survival curves of two separate chimeric experiments: experiment 
2 from section 3.4 for Aire-/-Cblb-/- H2k bone marrow chimeras, and experiment 1 for the 
H2b bone marrow chimeras. The survival curves focus on four groups in each chimera – 
wild-type or Aire-/- recipients of wild-type marrow and wild-type or Aire-/- recipients of 
Cblb-/- marrow. In the H2k chimeras, Aire-/- recipients of Cblb-/- marrow exhibit a 
median survival of 35 days and the mice either died suddenly or were euthanised 
because of cachexia by 41 days post reconstitution (Fig. 4.2A). On the other hand, Aire-/- 
recipients of Cblb-/- marrow in the H2b chimeras, had a median survival of 63 days, and 
there were still 2 of 7 mice surviving 165 days post reconstitution (Fig. 4.2B). This 
result suggested that the H2b background delayed the onset of the wasting disease. 
To determine the spectrum of organs targeted by autoimmunity in the H2b chimeras, a 
histological survey of the pancreas, salivary gland, lung, liver, stomach, heart, thyroid, 
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H2b DONOR
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Irradiated Irradiated
Wild-type Cbl-b-/-
Figure 4.1 Combining the Aire-/- and Cblb-/- mutations on the
H2b background.
Aire-deficient or wild-type irradiated recipients were reconstituted
with bone marrow from wild-type or Cblb-/- mice in the following
three combinations: 100% wild-type, 100% Cblb-/- or an equal
mixture of both. Each combination was introduced into five
recipients.
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Figure 4.2 Combining the Aire-/- and Cblb-/- mutations on the
H2b background causes lethal autoimmunity, but at a slower
onset and incidence compared to H2k mice.
Comparison of survival of Aire deficient or wild-type recipients post-
reconstitution with Cblb-/- or wild-type bone marrow on the H2k (A,
chapter 3) and the H2b (B) genetic backgrounds. All mice from the
H2k experiment were sacrificed by 41 days post-reconstitution.
Statistical analysis of the Aire-/-Cblb-/- H2k and H2b groups using a
log-rank Mantel-Cox test gave a P value of 0.0002.
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eye, testis/ovaries was performed on a second cohort of chimeric mice 14 weeks after 
reconstitution. Like the first cohort, there was little evidence as cachexia during the first 
eight weeks after reconstitution. Similar to that of the Aire-/-Cblb-/- H2k 5-6 week post-
reconstitution bone marrow chimeras, lymphocytic infiltration targeting the acinar cells 
of the pancreas and submandibular salivary gland were observed. The histological 
scores are shown in Fig. 4.3. All other organs remained relatively free of infiltration. 
These results indicated that Aire-/- and Cblb-/- deficiencies co-operated on the H2b 
background but compared to the H2k background the target organs remained the same 
but the tempo of the disease was slower.  
4.4 Changing the starting frequency of T cell recognising peptide/MHC 
complexes targeted towards a different self-tissue. 
4.4.1 Effect of introducing Aire- and Cblb-deficiencies to TCR3A9:insHEL 
transgenic model by breeding   
The effect of increasing the frequency of T cell, recognising a particular pancreatic 
autoantigen in Aire-/-Cblb-/- H2k mice were analysed using TCR3A9:insHEL Dbl-Tg mice. 
This system had been used in the laboratory to study the effect of single mutations in 
Aire and Cblb, both of which accelerated the age and incidence of autoimmunity 
(Hoyne et al., 2011b; Liston et al., 2004a). Depending on the availability of mice, mice 
that were either heterozygous for Aire or Cblb, and hemizygous for TCR3A9 or insHEL 
were intercrossed. 
Based on the repertoire hypothesis, it was predicted that the introduction of high 
numbers of HEL-specific TCR3A9 cells in the Aire-/-Cblb-/- H2k mice would change the 
specificity of autoimmunity from the exocrine to endocrine pancreas. As expected, the 
introduction of large numbers of CD4 TCR3A9 cells reactive to insHEL increased the 
lifespan of Aire-/-Cblb-/- mice, from a median survival of 31 days for non-transgenic 
mice to 110 days for Dbl-Tg mice in the same cross (Fig. 4.4A, P value of 0.0114). This 
lengthening of lifespan was accompanied by a change in the target cell type within the 
same organ: non-transgenic mice displayed severe destruction of the exocrine pancreas, 
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Figure 4.3 Combining the Aire-/- and Cblb-/- mutations of the H2b
background results in infiltration of the pancreas and
salivary glands.
A. Percentage of recipient mice with different grades of
pancreatitis and sialoadenitis 6 weeks post-reconstitution on
the H2k genetic background.
B. Percentage of recipient mice with different grades of
pancreatitis and sialoadenitis 14 weeks post-reconstitution on
the H2b genetic background.
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Figure 4.4 Effect of introducing the TCR3A9 and insHEL
transgenes on autoimmunity in Aire-/-Cblb-/- H2k mice.
A. Survival of the Aire-/-Cblb-/- non-transgenic and Dbl-Tg mice
measured until 20 weeks of age.
B. Representative hematoxylin and eosin staining of the
pancreas from 20 weeks old non-transgenic and Dbl-Tg Aire-
/-Cblb-/- mice euthanised when mice were cachectic. Bars:
500 µm, 100x magnification.
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whereas Aire-/-Cblb-/- double transgenic TCR3A9:insHEL mice presented with infiltration 
targeted towards the islet structures in the pancreas (Fig. 4.4B). Hence, increasing the 
CD4 TCR3A9 islet-specific precursors slowed the course of the exocrine pancreatic 
disease and lethality in the Aire-/-Cblb-/- H2k mice.  
As islet-specific autoimmunity would manifest clinically as diabetes development, a 
cohort of TCR3A9:insHEL Dbl-Tg, with either single or double deficiencies in Aire-/- 
and Cblb-/- were monitored for glucose in the urine (glucosuria) weekly from 2 weeks of 
age (Fig. 4.5). Consistent with previous studies (Hoyne et al., 2011b; Liston et al., 
2004a), no glucosuria was detected in mice carrying the TCR3A9 or insHEL transgene 
alone. The results in Fig. 4.5 focused on the TCR3A9:insHEL Dbl-Tg mice. With the 
exception of the Aire+/+Cblb+/+ wild-type group (which was a small group, n=3), all 
groups developed diabetes throughout the time course of the experiment (140 days). 
Combined Aire- and Cblb-deficiencies appeared to cause little or no increase in diabetes 
development compared to the other groups tested. While insufficient Aire-/-Cblb+/+ Dbl-
Tg mice were available in this experiment, previous studies showed these have diabetes 
onset and incidences similar to the Aire-/-Cblb-/- Dbl-Tg mice here (Liston et al., 2004a). 
Diabetes in Aire-/-Cblb-/- Dbl-Tg mice was relatively comparable to Aire or Cblb single 
deficient Dbl-Tg mice. 
Consistent with diabetes development, the mice that developed diabetes presented with 
islet-specific infiltration (Fig 4.6). This infiltration appeared comparable between mice 
from each Aire and Cblb genotypic group. A caveat in this assay is that not all groups 
were available - Aire+/-Cblb+/+, Aire-/-Cblb+/+ and Aire-/-Cblb+/- groups were missing 
from the analysis, some of which are key control groups in the study. Due to the 
difficulty in breeding mice of the appropriate genotype, the next step was to construct 
bone marrow chimeras to achieve the desired mouse genotypes and confirm the 
observations from this section. 
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Figure 4.5 Effect of introducing the Aire-/- and Cblb-/- mutations
into TCR3A9:insHEL (Dbl-Tg) mice.
Mice of the indicated genotypes were tracked for diabetes from birth
to 20 weeks. Glucosuria was monitored weekly and mice were
considered diabetic after the first evidence of diabetes if a positive
reading (diastix score of ≥2) is also obtained on the successive
reading.
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Figure 4.6 Representative hematoxylin and eosin staining of
the pancreas from Dbl-Tg mice of the indicated genotype either
at 20 weeks of age or earlier if mice were taken down after
losing 20% of their body weight.
The arrows indicate the position of lymphocyte infiltrated islets.
Bars: 500 µm, Magnification: 100x.
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4.4.2 Bone marrow chimeras 
Bone marrow from non-transgenic, wild-type TCR3A9 or Cblb-/- TCR3A9 mice were used 
to reconstitute the hematopoietic system of 10 groups of irradiated wild-type or Aire-/- 
mice which were insHEL negative, Aire+/+Cblb+/+ insHEL+ or Aire-/-insHEL+ (Fig 4.7). 
Half the recipient mice were females and the other half were males. Again, the mice 
were monitored for diabetes development. Consistent with the results in section 4.4.1, 
only TCR3A9→insHEL+ (double transgenic) chimeras that had both TCR3A9 and insHEL 
transgenes (groups 8-10) developed glucosuria (Fig 4.8A). In both the Aire-/-Cblb-/- Dbl-
Tg (group 10) and Aire+/+Cblb-/- Dbl-Tg (group 9) groups, 3 out of 10 mice had 
developed diabetes after 42 days of reconstitution at comparable rates (Fig 4.8A). One 
out of 10 mice from the Aire-/-Cblb+/+ Dbl-Tg group (group 8) developed diabetes.  
However, it is also important to note that the onset of diabetes in the chimeric mice 
occurred as early as 14 and 21 days post-reconstitution. This time seemed to be too fast 
for T cell development and emigration from the thymus in these chimeras. It is therefore 
possible that some mature TCR3A9 cells were present in the donor bone marrow, and 
these caused diabetes rapidly in the irradiated recipients in groups 9 and 10, the groups 
that received Cblb-/- donor marrow.  
Pancreas histology was examined for all male mice in the experiment Figs. 4.9 and 
4.10. In contrast to the islet-specific destruction of TCR3A9:insHEL double transgenic 
mice obtained via breeding, the bone marrow chimeras had lymphocytic infiltration 
targeting exocrine pancreas in addition to the islets (Fig. 4.10). The exocrine-specific 
infiltration was particularly obvious in the Aire-/-Cblb-/- group, whereby two of the five 
mice had complete destruction of the acinar cells, akin to the non-transgenic Aire-/-Cblb-
/- (H2k) bone marrow chimeras described in chapter 3. In addition, 4 of the 10 mice in 
the Cblb-/- TCR3A9→ Aire-/- insHEL group (group 10), but not in other groups, showed 
signs of cachectic wasting 42 days post-reconstitution and needed to be sacrificed 
moribund due to extensive loss of body weight, mirroring the non-transgenic Aire-/-
Cblb-/- H2k chimeras (chapter 3) (Fig. 4.8B).  
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Figure 4.7 Schematic representation of experimental plan to
construct Aire-/-Cblb-/- TCR3A9:insHEL bone marrow chimeras
and control counterparts.
Irradiated Aire-/- or wild-type insHEL or non-transgenic mice were
reconstituted with Cblb-/- or wildtype TCR3A9 or non-transgenic bone
marrow, yielding 10 distinct experimental groups of chimeric mice.
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Figure 4.8 Glucosuria measurements and survival of
TCR3A9:insHEL bone marrow chimeras and control
counterparts of the indicated Aire and Cblb genotypes.
A. Percentage of diabetes free mice. Mice of the indicated
genotypes were tracked for diabetes up to 42 days post-
reconstitution. Glucosuria was monitored weekly and mice
were considered diabetic after the first evidence of diabetes if
a positive reading (diastix score of ≥2) is also obtained on the
successive reading.
B. Survival of recipients up to 42 days post-reconstitution.
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Figure 4.9 Exocrine pancreatitis development in Aire-/-Cblb-/-
TCR3A9    insHEL bone marrow chimeras and control
counterparts.
Bars represent the median histological scores for each group and
error bars indicate the interquartile range.
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Figure 4.10 Representative hematoxylin and eosin staining of
the pancreas from the respective groups.
Groups refer to the Dbl-Tg groups 7, 8, 9 and 10 in Fig. 4.8 and 4.9.
The number of the left side of the figure corresponds to the disease
score. Bars: 500 µm, Magnification: x100.
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The increased incidences of exocrine pancreatitis in Cblb-/- TCR3A9→ Aire-/- insHEL 
Dbl-Tg chimeras compared to animals bred with the genotype could be attributed to 
several reasons. Firstly, it is possible that in addition to the transgenic CD4 TCR3A9 
cells, a small number of exocrine pancreas-specific mature T cells (CD4 or CD8 cells) 
were transferred in the donor marrow and these developed in the Aire-/-Cblb-/- chimera 
group when the cells were placed in a lymphopenic environment induced by the sub-
lethal irradiation. An alternative explanation is that radioresistant memory CD8 T cells 
in the Aire-/- co-operated with donor CD4 cells to cause exocrine pancreatitis. Thus, 
TCR3A9 negative T cells from the donor marrow or the recipients could have been able 
to cause an exocrine-pancreas specific effect autoimmunity not seen in TCR3A9:insHEL 
bred mice where fewer TCR specificities arise as most of the T cells were islet-specific 
T cells. 
4.4.3 Pancreas autoimmunity in mixed chimeras where only a fraction of T cells 
were Cblb-deficient 
If exocrine pancreatitis in TCR3A9→insHEL chimeras were due to other T cells in the 
Cblb-/- bone marrow inoculum, T cell depleting the donor marrow and diluting the 
numbers of Cblb-/- cells could change the pattern of autoimmunity. To achieve this, T 
cell-depleted Cblb+/+ bone marrow were mixed in a 1:1 ratio to produce either Cblb-/-
TCR3A9:Cblb+/+ TCR3A9 or Cblb+/+TCR3A9:Cblb+/+TCR3A9 control mixtures where all the 
T cells had wild-type Cblb. The mixtures were transplanted into irradiated insHEL or 
Aire-/- insHEL recipients. All Aire-/- insHEL mice receiving the control (TCR3A9: 
TCR3A9) mixture developed diabetes by 21 days post transfer, and 3 of 4 Aire-/-insHEL 
mice receiving the Cblb-/-TCR3A9:TCR3A9 developed diabetes at a slightly slower pace 
in this experiment by 28 days post reconstitution (Fig. 4.11A). All other mice tested 
remained free of diabetes for the duration of the experiment. The Cblb-/-
TCR3A9:TCR3A9→Aire-/-insHEL group developed exocrine pancreatitis scores ranging 
from 2 to 5, whereas the control TCR3A9:TCR3A9 into Aire-/-insHEL group developed 
scores of 0 to 3. All other groups had a score of 1 or below (Fig. 4.11B).  
Taken together, the results from the 100% and 50% Cblb-deficient chimera 
experiments, when Cblb-/- was combined with Aire-/- in TCR3A9→insHEL Dbl-Tg 
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Figure 4.11 Consequence of Cblb-deficiency in only a subset of
TCR3A9 T cells.
Irradiated Aire-/- or wild-type insHEL or non transgenic
counterparts were reconstituted with 50:50 mixture of CD45.1
TCR3A9 and CD45.2 Cblb-/- or Cblb+/+ TCR3A9 bone marrow.
A. Percentage diabetes free mice. Mice were tracked for
diabetes for 42 days post-reconstitution. Glucosuria was
monitored weekly and mice were considered diabetic after
the first evidence of diabetes if a positive reading is also
obtained on the successive reading.
B. Pancreatitis scores for recipient mice. Bars indicate median
value for each group and error bars indicate interquatile
range.
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transgenic animals (data from 4.4.2, 4.4.3), there was surprisingly no evidence of 
enhanced endocrine pancreas autoimmune destruction compared to single Aire-./- or 
Cblb-/- double transgenic controls. By contrast, exocrine pancreatic autoimmunity 
exhibited an intriguing 3-way interaction. It was most severe in Aire-./- recipients that 
received Cblb-/- TCR3A9 bone marrow, but only when the recipients were insHEL+. A 
possible explanation for this result is that islet-reactive CD4+ T cells in Aire-./- insHEL 
recipients may provide help for exocrine pancreas-specific CD8+ cells. The latter must 
express endogenous TCRs, and perhaps these are drawn from radioresistant memory T 
cells in the recipient mice. The nature and role of CD8 cells in the exocrine pancreatitis 
is explained further in the next chapter. 
4.5 Studying the combinatorial role of Aire and Cblb in tolerance at a cellular 
level 
The interaction between Aire and Cblb was next analysed at the cellular level, using the 
TCR3A9 transgenic system to track autoreactive CD4 T cells in both central and 
peripheral tolerance to organ-specific HEL antigen produced by the insHEL or thyrHEL 
transgenes.  
4.5.1 Studying the combined effect of Aire- and Cblb-deficiencies in central 
tolerance (thymic selection) 
The role of Aire as a transcription regulator during negative selection in the thymus has 
been firmly established (Anderson et al., 2002; Liston et al., 2003). Although Cbl-b is 
ubiquitously expressed in many tissues in the body, it has not been shown to play a role 
in thymic development, but its homologue c-cbl inhibits T cell signalling to determine 
the fate of thymocytes during development (Naramura et al., 1998; Thien et al., 1999). 
Studies have shown that Cbl-b mediates its function in mature peripheral T cells 
(Bachmaier et al., 2000; Chiang et al., 2000), but it is nevertheless unclear at what stage 
in thymic T cell maturation Cbl-b becomes necessary. Hence it was valuable to test the 
consequence of Cblb-deficiency in positive and negative selection of the CD4 TCR3A9 
transgenic cells, alone and combined with Aire-deficiency. 
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To investigate the combined effect of Aire- and Cblb-deficiency on self-reactive CD4 
cells expressing HEL-specific TCR3A9, the 100% TCR3A9 transgenic bone marrow 
chimeras in section 4.4.2 were analysed by flow cytometry 42 days post reconstitution. 
As expected for TCR3A9 cells undergoing positive selection, in the thymus of 
TCR3A9→insHEL-negative bone marrow chimeras (on the left side of Fig 4.12A), there 
were high frequencies of CD4+CD8- single positive (SP) T cells bearing the TCR3A9 
receptor stained brightly with the 1G12 anti-clonotype antibody. No 1G12 staining 
occurred on CD4 SP thymocytes from control chimeras reconstituted with non-
transgenic bone marrow, establishing the specificity of detecting T cells expressing the 
TCR3A9 receptor.  
Negative selection was observed in TCR3A9→insHEL+ chimeras that were Aire-
sufficient, reflected by a 50% decrease in the frequency of 1G12+CD4+ SP thymocytes 
(Figure 4.12A, 4.14 and Fig 4.15). There was no measurable effect of Cblb-deficiency 
on thymic negative selection measured in this way. By contrast, no decrease in 
frequency of 1G12+CD4+ SP thymocytes occurred in TCR3A9→insHEL+ chimeras that 
were Aire-deficient, as has been found previously (Liston et al., 2003), and this 
deficiency of negative selection appeared unaltered by combining it with Cblb-
deficiency. Hence there was no discernable evidence for cooperation between Cblb-
deficiency and Aire-deficiency at the level of islet-reactive CD4 cells developing in the 
thymus. 
Analysis of the pancreatic lymph node and spleen also gave no evidence for a 
compounding effect of Cblb-deficiency when combined with the failure of thymic 
negative selection in TCR3A9→insHEL+ chimeras that were Aire-deficient (Fig. 4.12B 
and C, 4.14, 4.16, 4.16). The frequency of TCR3A9-expressing CD4+Foxp3- T cells 
revealed by the 1G12 clonotypic antibody in pancreatic node or spleen was decreased 
~90% in insHEL+ chimeras that were Aire-sufficient compared to insHEL- chimeras, 
reflecting thymic negative selection in the former and positive selection in the latter. 
Aire-deficiency in the insHEL+ chimeras prevented the drop in frequency of TCR3A9-
expressing CD4+Foxp3- T cells in the spleen and pancreatic node, so that these were 
almost as high as the frequency in insHEL- chimeras (Fig. 4.12B and C, 4.15, 4.16, 
4.17, 4.18). There was nevertheless no evidence that the frequency of TCR3A9-
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Figure 4.12 Representative flow cytometry plots showing the percentages of
CD4+ and CD8+ cells from total lymphocytes (upper rows) and FoxP3+
and TCR3A9 cells from total CD4 cells (lower row) in bone marrow
chimeras with the indicated donor and recipient genotypes.
A. Thymus (percentages in Figures 4.14 and 4.15)
B. Pancreatic lymph node (percentages in Figures 4.16 and 4.17)
C. Spleen (percentages in Figures 4.19 and 4.20)
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Figure 4.14 Percentages of double negative (DN), double
positive (DP), CD4 and CD8 cells from total lymphocytes in the
thymus of bone marrow chimeras.
The bars represent the means and each point represents a single
mouse.
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Figure 4.15 Percentages of FoxP3- TCR3A9, FoxP3+ TCR3A9,
FoxP3- and FoxP3+ cells in the thymus of  bone marrow
chimeras.
The bars represent the means and each point represents a single
mouse. All percentages are expressed from total lymphocytes
except for the third panel where the FoxP3+TCR3A9 percentages are
expressed from total TCR3A9 cells.
148
Figure 4.16 Percentages of T cells, CD4 cells and CD8 cells
from total lymphocytes in the pancreatic lymph node of bone
marrow chimeras.
The bars represent the means and each scatter represents a single
mouse.
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Figure 4.17 Percentages of FoxP3- TCR3A9, FoxP3+ TCR3A9,
FoxP3- and FoxP3+ cells in the pancreatic lymph node of  bone
marrow chimeras.
The bars represent the means and each scatter represents a single
mouse. All percentages are expressed from total lymphocytes
except for the third panel where the FoxP3+TCR3A9 percentages are
expressed from total TCR3A9 cells.
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Figure 4.18 MFI of FSC,CD44, CD25 and CD5 in the pancreatic
lymph node of bone marrow chimeras in each group relative to
average MFI of respective markers in non-transgenic controls.
The bars represent the means and each point represents a single
mouse.
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expressing CD4+Foxp3- T cells was further increased by combining Cblb-deficiency 
with Aire-deficiency in either the pancreatic node or spleen, as might have been 
expected if these cells were induced to proliferate by HEL-antigen reaching the 
pancreatic node from the pancreatic islets. Analysis of markers of T cell activation, 
including forward scatter as a measure of cell size, CD44, CD25 and CD5, also showed 
no difference between Cblb-deficient or sufficient TCR3A9+CD4+Foxp3- T cells in 
TCR3A9→insHEL+ Aire-/- chimeras (Fig. 4.19, 4.20 and 4.21). 
4.5.2 Impact of Aire and Cblb-deficiency on the formation of islet-specific Foxp3+ 
CD4 cells.  
Co-operation between Aire and Cblb deficiency could be hypothesized to occur at the 
level of the Foxp3+ T cell subset, since Cblb-deficiency diminishes Foxp3 induction in 
mature T cells (Harada et al., 2010).  In TCR3A9:insHEL double-transgenic mice, like 
many other MHC II-restricted TCR transgenic models (Jordan et al., 2001; Kawahata et 
al., 2002; Lerman et al., 2004; Liston et al., 2007), a subset of autoreactive CD4 cells 
escape thymic negative selection and become Foxp3+CD25+ natural T regulatory cells. 
The numbers of T regulatory cells in the bone marrow chimeras were quantified by 
intracellular staining for FoxP3+ in CD4+ TCR3A9 clonotype positive (1G12+) cells. In 
the thymus of insHEL-negative recipients, very few TCR3A9 CD4 cells expressed 
Foxp3, and those that did had lower staining with the 1G12 anti-clonotypic antibody 
compared to Foxp3-negative cells (Fig 4.12). This is likely to be due to co-expression of 
an endogenous TCR alpha chain on these cells. By contrast, in the thymus of insHEL+ 
recipients with wild-type Aire, a small but distinct population of 1G12highFoxp3+ cells 
was formed that accounted for a higher percentage of the TCR3A9 CD4 cells (Fig 4.12A 
and Fig 4.14). This population of 1G12highFoxp3+ CD4 cells was more dramatically 
increased in the spleen and pancreatic lymph node of the TCR3A9→insHEL chimeras, 
both as a percentage of all lymphocytes and as a percentage of 1G12high CD4 cells (Fig. 
4.14, 4.16 and 4.18). Cblb deficiency in the donor marrow did not interfere with the 
accumulation of 1G12high Foxp3+ CD4 cells in the thymus, spleen and pancreatic node 
of insHEL+ Aire+/+ recipients, and there was a tendency for Cblb-deficient nTreg cells 
to be more frequent in these animals. By contrast, Aire-deficiency greatly reduced the 
frequency of 1G12high Foxp3+ CD4 cells in the thymus, spleen and pancreatic node of 
insHEL+ Aire+/+ recipients, although their frequency was slightly increased when Aire- 
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Figure 4.19 Percentages of T cells, CD4 cells and CD8 cells
from total lymphocytes in the spleen of bone marrow chimeras.
The bars represent the means and each point represents a single
mouse.
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Figure 4.20 Percentages of FoxP3- TCR3A9, FoxP3+ TCR3A9,
FoxP3- and FoxP3+ cells in the spleen of bone marrow
chimeras.
The bars represent the means and each point represents a single
mouse. All percentages are expressed from total lymphocytes
except for the third panel where the FoxP3+TCR3A9 percentages are
expressed from total TCR3A9 cells.
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Figure 4.21 MFI of FSC,CD44, CD25 and CD5 in the spleen of
bone marrow chimeras in each group relative to average MFI of
respective markers in non-transgenic controls.
The bars represent the means and each point represents a single
mouse.
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and Cblb- deficiency were combined.  Collectively, the data above indicate that Cblb-
deficiency had little measurable effect on the regulation of self-reactive CD4 cells that 
recognized HEL expressed in the endocrine pancreas, even when it is combined with 
Aire-deficiency.  
Cblb-deficiency nevertheless had been shown to inhibited the formation of iTreg cells 
(Harada et al., 2010). This was tested in the TCR3A9 transgenic system with the 
experimental strategy illustrated in Fig, 4.22. Naïve CD4 cells from non-transgenic and 
TCR3A9 mice that were Cblb-sufficient and deficient were stimulated with anti-CD3 and 
anti-CD28 in the absence and presence of varying 0.1 ng/ mL or 0.5 ng/ mL TGFβ. 
Wild-type and TCR3A9 transgenic mice induced upregulation of the iTreg transciption 
factor FoxP3 by 20.3% and 12.4% of the cells following 0.1 ng/ mL TGFβ stimulation 
and 62.5% and 42.5% after 0.5 ng/ mL TGFβ stimulation. By contrast, the induction of 
FoxP3 was severely impaired in the Cblb-/- mutants cells with only 1.57% and 7.95% of 
cells expressing the marker after stimulation with 0.1 ng/ mL or 0.5 ng/ mL TGFβ, 
respectively (Fig 4.23). In Fig. 4.24, when the iTregs were tested for functional activity 
suppress proliferation of CFSE-labelled CD4+CD62L+CD25- T effector cells co-
cultures with antigen presenting cells, wild-type and TCR3A9 iTregs were able to 
mediated suppression of T effector as measured by CFSE-dilution. However, Cblb-/- 
TCR3A9 iTregs were less suppressive demonstrating that Cblb-/- organ specific T cells 
displayed impaired ability to form functional iTreg cells following stimulation by 
TGFβ. It is unclear if this in vitro observation is physiologically relevant and may 
contribute to the disease observed in the Aire-/-Cblb-/- mice. 
The finding here that the individual defects caused by Aire- and Cblb-deficiency do not 
result in a co-operative breakdown of tolerance in insHEL-reactive CD4 T cells from 
double mutant chimeras may mean that additional peripheral tolerance mechanisms 
exist to prevent activation of TCR3A9–expressing T cells. By contrast, these additional 
peripheral tolerance mechanisms may not apply to the T cells that caused exocrine 
pancreatitis in the double mutant mice, and this possibility is explored further in the 
next chapter.   
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Figure 4.22 Schematic representation of experimental set-up
for induction of FoxP3 and functionality of wild-type and Cblb-/-
cells.
Sorted naïve T cells (CD4+CD62+CD25-) were stimulated with anti-
CD3 and anti-CD28, together with TGF-ß to induce FoxP3
expression. Four days after initial culture, the cells were co-cultured
with CFSE-labelled naïve T cells and antigen presenting cells to
assay for suppression of proliferation.
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Figure 4.23 Cblb-deficient TCR3A9 cells are resistant to TGF-ß
induced iTreg formation.
Naive CD4+CD62L+CD25- T cells from non-transgenic or Cblb+/+ and
Cblb-/- TCR3A9 transgenic mice were stimulated with anti-CD3 and
anti-CD28 in the presence of the indicated concentrations of TGF-ß.
Development of Foxp3+ iTreg cells was assessed by flow cytometry
after 5 days.
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Figure 4.24 iTreg assay showed Cblb-deficient TCR3A9 cells are
resistant to TGF-ß induced iTreg formation.
CFSE-labelled CD4+CD62L+CD25- naive T cells from Cblb+/+
TCR3A9 mice were used as responder cells in suppression assays,
mixed with irradiated T cell-depleted splenocytes as a source of
antigen presenting cells and with the cultured CD4 cells shown in
Fig. 4.23. The cells were mixed in the two indicated ratios (CFSE-
labelled responder cells:APCs:TGF-ß treated CD4 cells). Anti-CD3
antibody was added to the cultures and CFSE dilution was
assessed by flow cytometry 3 days later.
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4.5.3 Impact of Aire- and Cblb-deficiencies on peripheral tolerance in CD4 T cells 
While the following chapter develops a new retrogenic experimental model to examine 
the T cells responsible for exocrine pancreatitis in Aire-/-Cblb-/- double deficient mice, 
the remainder of this chapter describes a set of preliminary experiments focussing on 
the role of Aire and Cblb in CD4 T cell peripheral tolerance using the TCR3A9 
transgenic system. Although Aire is predominantly expressed in the medullary thymic 
epithelial cells, it is also expressed in dendritic cells and extrathymic splenic and lymph 
node cells in the periphery (Adamson et al., 2004; Gardner et al., 2008; Halonen et al., 
2001; Lee et al., 2007; Ramsey et al., 2006). Hence in this section I explored how 
deficiency of Aire affected the fate of mature peripheral HEL-specific CD4 T cells, and 
how it interacted with a defect in Cblb in this context.  
4.5.4 Aire-deficiency interferes with mature CD4 T cell activation by organ-
specific antigen.   
To focus on the role of AIRE in peripheral CD4 T cell tolerance, an in vivo adoptive 
transfer T cell activation assay was developed. Spleen cells from CD45.1 TCR3A9 
transgenic mice were labelled with carboxyfluorescein succinimidyl ester (CFSE) and 
intravenously transferred into unirradiated CD45.2 insHEL-transgenic recipient mice or 
into non-transgenic control recipients (Fig 4.25). This regime enabled a trace number of 
organ-specific CD4 T cells to be tracked at a single cell level (Fig. 4.26A) in a host with 
a normal lymphocyte repertoire and tolerance mechanisms. Three to four days post-
transfer, the mice were sacrificed and the transferred cells were analysed by flow 
cytometry. Measurement of CFSE dilution and intracellular staining for Ki-67, a cell 
cycle protein, showed that a large fraction of the HEL-reactive T cells bearing the 
clonotypic receptor were stimulated into proliferation (Fig. 4.26B,C,D). This was 
observed in the pancreatic lymph node, which was expected due to drainage of the islet-
HEL neo-self antigen either free in the lymph or transported by antigen presenting 
dendritic cells. Interestingly, many CD4 TCR3A9 cells in the spleen were also stimulated 
into cycle, albeit to a lesser extent than in the pancreatic node (Fig. 4.27). This was 
surprising given that previous studies have indicated that HEL expression in the 
recipient mice was limited to the pancreas and thymus. When the insHEL-transgenic 
recipients were Aire-deficient, fewer CD4 TCR3A9 cells were induced to divide in the 
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Figure 4.25 Adoptive transfer of CFSE-labelled T cells:
experimental strategy.
Splenocytes from CD45.1 TCR3A9 transgenic or non-transgenic
control mice, were labelled with CFSE before adoptive transfer into
CD45.2 insHEL+ recipient mice expressing HEL controlled by insulin
or thyroglobulin intravenously. 10 - 20 x 106 cells were injected into
each recipient. Three or four days post-injection, the mice were
sacrificed and spleen, subcutaneous lymph nodes and pancreatic
lymph nodes were analysed for cell division by flow cytometry.
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Figure 4.26 Aire-deficiency causes decreased activation of HEL-
specific CD4 pancreatic lymph node T cells by insHEL
transgene.
A. Representative flow cytometry plots of B cells and CD4 cells from
donor CD45.1 cells (upper panels) and TCR3A9 cells from total CD4
cells in recipient mice four days after cell transfer gated on
CD45.1+CD4+ (lower panels)
B. CFSE dilution and Ki-67 upregulation of 1G12+TCR3A9 cells.
Percentages of divided cells seen in Figure 4.28 are calculated
from quadrants seen in red.
C. Histograms gated on CD4 cells showing CFSE dilution of
1G12+TCR3A9 (unshaded dark red) and 1G12- counterparts
(shaded light red) in the same recipient.
D. Histograms gated on CD4 cells showing Ki-67 upregulation of
1G12+ TCR3A9 (unshaded dark blue) and 1G12- counterparts
(shaded light blue) in the same recipient.
Data are representative of two independent experiments with n =
1-3 mice per group (see Figure 4.28: Experiment 1).
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Figure 4.27 Aire-deficiency causes decreased activation of
HEL-specific CD4 splenic T cells by insHEL transgene.
A. Representative flow cytometry plots of B cells and CD4 cells
from donor CD45.1 cells (upper panels) and TCR3A9 cells
from total CD4 cells in recipient mice four days after cell
transfer gated on CD45.1+CD4+ (lower panels).
B. CFSE dilution and Ki-67 upregulation of 1G12+TCR3A9 cells.
C. Histograms gated on CD4 cells showing CFSE dilution of
1G12+TCR3A9 (unshaded dark red) and 1G12- counterparts
(shaded light red) in the same recipient.
D. Histograms gated on CD4 cells showing Ki-67 upregulation of
1G12+ TCR3A9 (unshaded dark blue) and 1G12- counterparts
(shaded light blue) in the same recipient
Data are representative of two independent experiments with
n = 1-3 mice per group (see Figure 4.28: Experiment 1).
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pancreatic node (Fig 4.26) and in the spleen (Fig 4.27). The effect of Aire-deficiency on 
peripheral activation of the CD4 cells was consistent, although somewhat variable, in 
multiple insHEL-transgenic recipients in two independent experiments (Fig 4.28). 
To determine if the peripheral expression of the insHEL transgene occurred in 
hemopoietic cells (e.g. dendritic cells) or in non-hemopoietic cells such as pancreatic 
beta cells and lymph node stromal cells, the T cell transfer experiments were repeated in 
bone marrow chimeras. Irradiated insHEL-transgenic or non-transgenic mice were 
reconstituted with bone marrow from either insHEL-transgenic or non-transgenic 
donors. This experiment created four different groups of chimeric mice, where the 
insHEL transgene was present only in the hematopoietic cells, only in non-
hematopoietic cells, in both or not present at all (Fig 4.29). Twelve weeks after bone 
marrow transplantation, CFSE-labelled spleen cells from CD45.1 TCR3A9 transgenic 
mice were injected into the bone marrow chimeric mice. Four days later, flow 
cytometry revealed proliferation of 1G12+CD45.1+CD4 T cells only in recipient mice 
(in pancreatic lymph node and spleen) with the insHEL transgene in the non-
hematopoietic compartment, whereas no proliferation was induced by the insHEL 
transgene when present exclusively in the hematopoietic compartment (Fig 4.30). Thus, 
the autoantigen responsible for peripheral activation of naïve TCR3A9 CD4 T cells is 
made and presented exclusively in non-hematopoietic cells. These could either be 
pancreatic islet beta cells, whose HEL-expression is unaffected by Aire-deficiency, or 
the Aire+ peripheral antigen expressing lymph node stromal cells (Gardner et al., 2008). 
The peripheral T cell activation studies above were extended to animals bearing a 
second transgene driven by a different organ-specific promoter: thyrHEL transgenic 
mice where the thyroglobulin promoter causes HEL expression in thyroid epithelium 
and, in an Aire-dependent manner, in thymic medullary epithelium. After four days of 
transfer of CFSE-labelled spleen cells from CD45.1+TCR3A9 mice, flow cytometry 
showed that 1G12+ HEL-specific T cells were stimulated to divide in the lymph nodes 
(Fig 4.31) and spleen (Fig 4.32) of thyrHEL-transgenic mice. Fewer T cells were 
induced to divide in Aire-deficient thyrHEL-transgenic mice (Fig. 4.31, 4.32 and 4.33). 
When the donor cells were left for 14 days prior to analysis in recipient mice, it was 
difficult to trace any 1G12+ and 1G12+ cells in the mice. This indicated that Aire is 
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Figure 4.28 Aire-deficiency reduces proliferation of TCR3A9 cells
induced by the insHEL transgene.
Graph shows the percentage of CD4+1G12+CD45.1 donor cells that
have divided four (A) and three (B) days after adoptive transfer in
CFSElow cells. Data show two independent experiments (A and B)
with n = 1-3 mice per group.
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Figure 4.29 Adoptive transfer of CFSE labelled T cells into HEL-
chimeric mice experimental strategy.
A. Bone marrow chimeras with HEL transgene restricted to the
haematopoietic or non-haematopoietic cells were generated
by reconstituting irradiated wild-type or insHEL+ CD45.2+
recipients with wild-type or insHEL+ bone marrow from
CD45.2+ donors.
B. Splenocytes from CD45.1 TCR3A9 or non-transgenic control
mice were labelled with CFSE, and 10 - 20 x 106 cells were
injected into each chimeric recipient. Three days post-
injection, the mice were sacrificed and spleen, subcutaneous
lymph nodes and pancreatic lymph nodes were analysed for
cell division by flow cytometry.
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Figure 4.30 Induction of division in TCR3A9 donor cells require the
insHEL transgene in the haematopoietic compartment.
A. Profiles gated on CD45.1+CD4+1G12+ showing CFSE dilution and
Ki-67 upregulation of TCR3A9 cells in the pancreatic lymph node.
B. Percentage of donor CD45.1+CD4+1G12+ cells three days post
adoptive transfer in the quadrants that have diluted CFSE in the
pancreatic lymph node.
C. As (A) in the spleen.
D. As (B) in the spleen
Data are representative of two independent experiments with n = 3
mice per group. HC, haematopoietic component; NHC, non-
haematopoietic component.
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Figure 4.31 Aire-deficiency causes decreased activation of HEL-
specific CD4 splenic T cells by thyrHEL transgene.
A. Representative flow cytometry plots of B cells and CD4 cells from
donor CD45.1 cells and TCR3A9 cells from total CD4 cells in
recipient mice four days after cell transfer gated on
CD45.1+CD4+1G12+.
B. CFSE dilution and Ki-67 upregulation of 1G12+TCR3A9 cells.
C. Histograms gated on CD4 cells showing CFSE dilution of
1G12+TCR3A9 (unshaded dark red) and 1G12- counterparts
(shaded light red) in the same recipient.
D. Histograms gated on CD4 cells showing Ki-67 upregulation of
1G12+ TCR3A9 (unshaded dark blue) and 1G12- counterparts
(shaded light blue) in the same recipient.
Data are representative of two independent experiments with n =
3-5 mice per group (see Figure 4.33: Experiment 1).
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Figure 4.32 Aire-deficiency causes decreased activation of HEL-
specific CD4 subcutaneous lymph node T cells by thyrHEL
transgene.
A. Representative flow cytometry plots of B cells and CD4 cells from
donor CD45.1 cells and TCR3A9 cells from total CD4 cells in
recipient mice four days after cell transfer gated on
CD45.1+CD4+1G12+.
B. CFSE dilution and Ki-67 upregulation of 1G12+TCR3A9 cells.
C. Histograms gated on CD4 cells showing CFSE dilution of
1G12+TCR3A9 (unshaded dark red) and 1G12- counterparts
(shaded light red) in the same recipient.
D. Histograms gated on CD4 cells showing Ki-67 upregulation of
1G12+ TCR3A9 (unshaded dark blue) and 1G12- counterparts
(shaded light blue) in the same recipient.
Data are representative of two independent experiments with n =
3-5 mice per group (see Figure 4.33: Experiment 1).
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Figure 4.33 Aire-deficiency reduces proliferation of TCR3A9 cells
induced by the thyrHEL transgene.
Graph shows the percentage of CD4+1G12+CD45.1 donor cells four
(A and B) days days after adoptive transfer of CFSElow cells. Data
show two independent experiments with n = 3-5 mice per group.
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required for efficient activation of organ-specific T cells in peripheral lymphoid tissues 
of two different transgenic strains (insHEL and thyrHEL). The activation observed 
could be suggested to cumulate in activation induced cell death of antigen-specific cells 
by 14 days post-transfer. 
4.5.5 Impact of Cblb-deficiency on peripheral tolerance in CD4 T cells 
To test the effect of Cblb-deficiency, alone or combined with Aire-deficiency, in the 
transfer assay for peripheral T cell proliferation, CD45.2 Cblb-/- TCR3A9 spleen cells 
were mixed in a 1:1 ratio with CD45.1 Cblb+/+ TCR3A9 spleen cells. The mixture was 
labelled with CFSE and injected into CD45.1/CD45.2 wild-type or Aire-/-insHEL 
recipients. After four days, flow cytometry was used to compare CFSE-dilution and Ki-
67 expression in wild-type and Cblb-/- TCR3A9 cells in the same recipients. In the 
pancreatic lymph node and spleen of insHEL+ Aire+/+ recipients, divided T cell progeny 
accounted for a larger percentage of the Cblb-/- T cells compared to their Cblb-sufficient 
counterparts (Fig. 4.34 and 4.35), consistent with published studies of Cblb-deficient T 
cells (Jeon et al., 2004). In the Aire-deficient insHEL recipients in this experiment, the 
percent of the wild-type or Cblb-/- TCR3A9 cells that had divided varied greatly from 
mouse to mouse (Fig. 4.35). While this variability made it impossible to interpret the 
results from the Aire-deficient experimental group accurately, there appeared to be no 
consistent enhancement of proliferation of Cblb-deficient T cells within individual 
recipients.   Due to limited numbers of mice and time, repeating this experiment was not 
deemed a sufficiently high priority at this time compared with the retrogenic 
experiments described in the next chapter.  
4.5.6 The consequences of adding an adjuvant on peripheral tolerance 
In the experiments above, organ-specific CD4 cells were activated into several rounds 
of cell division as a result of endogenous HEL antigen presentation. This proliferation 
was nevertheless self-limiting and did not precipitate diabetes. Since autoimmune 
disease may also require an inflammatory trigger, the adoptive transfer system was 
varied by giving the recipient mice exogenous HEL emulsified in a strong adjuvant 
several days after TCR3A9 T cell transfer.   
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Figure 4.34 Aire- and Cblb-deficiency do not co-operate to alter
the proliferation of pancreas specific TCR3A9 cells.
Representative flow cytometry plots of B cells and CD4 cells from
donor CD45.1 TCR3A9 (top panel) and CD45.2 Cblb-/- TCR3A9 cells
(middle panel) in recipient mice four days after cell transfer. The
bottom panel shows representative histograms gated on CD4 cells
showing CFSE dilution of CD45.1+CD4+ (shaded grey) and
CD45.2+CD4+ Cblb-/- (unshaded black) cells in the pancreatic lymph
node (A) and spleen (B) of the same recipient.
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Figure 4.35 Aire- and Cblb-deficiency do not co-operate to alter
the proliferation of pancreas specific TCR3A9 cells.
Graph represent the percentage of donor
CD45.1+CD4+1G12+ wild-type and CD45.2 Cblb-/- donor cells
that has diluted CFSE four days post adoptive transfer. The
lines join connect the samples from the same recipient
mouse.
A. Pancreatic lymph node
B. Spleen
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Dose optimisation experiments were performed to establish the number of wild-type 
TCR3A9 CD4 cells needed to precipitate diabetes in insHEL-transgenic recipients. 
3×105, 1×106 or 3×106 MACS-enriched CD4 cells from TCR3A9 single transgenic mice 
were intravenously transferred into groups of 4-5 insHEL-transgenic recipients. On the 
same day, the recipients were intraperitoneally immunised with HEL protein emulsified 
in complete Freund’s adjuvant (CFA) and the mice were monitored for glucosuria three 
times a week (Fig. 4.36).  As seen in Fig. 4.37A, all mice receiving TCR3A9 CD4 cells 
developed glucosuria within 2-3 weeks after immunization, whereas no diabetes 
occurred in control animals that were immunized with HEL in CFA but did not receive 
TCR3A9 cells. While the immunized control recipients developed HEL-specific IgG 
antibodies compared to nonimmunized animals, transfer of TCR3A9 CD4 cells increased 
the titres of these autoantibodies ~20-fold (Fig. 4.37B). The diagnosis of diabetes in 
recipients of TCR3A9 cells, and not in the immunized control recipients, was confirmed 
by elevated blood glucose 36 days after transfer (Fig. 4.37C). This experiment 
established that as few as 3×105 TCR3A9 CD4 cells were sufficient to induce diabetes 
when stimulated with exogenous HEL in Freund’s adjuvant. 
The next step was to delay the HEL/CFA immunization until three days after 
transferring 3×105 MACS-enriched CD4 TCR3A9 cells. During this tolerisation period, 
the transferred T cells would be exposed only to endogenous HEL, which in the 
previous section 4.5.4 was established to induce an abortive round of proliferation that 
was followed theoretically by T cell anergy and deletion. As seen in Fig. 4.38A, 
delaying HEL/CFA immunisation ameliorated the development of diabetes and 
recipient mice presented with only trace amounts of glucose in the urine.  HEL-specific 
IgG Fig. 4.38B and blood glucose levels Fig. 4.38C tested 50 days after T cell transfer 
were also reduced when HEL/CFA immunization was delayed. These effects may 
reflect active tolerance to endogenous HEL during the 3 days delay period, or the short-
lived nature of unstimulated TCR3A9 CD4 cells. To evaluate the latter possibility, a third 
group of animals were immunized on day 0 but received ten times fewer TCR3A9 CD4 
cells. These also developed less glucosuria and did not have elevated blood glucose on 
day 50, but their serum titres of anti-HEL IgG were comparable to animals receiving the 
higher T cell dose. Regardless, these experiments established an experimental system to 
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Figure 4.36 Experimental design to test organ destruction by
TCR3A9CD4 cells
Varying numbers of MACS-enriched CD4 cells from single
transgenic TCR3A9 mice were injected intravenously into groups of
4-5 insHEL transgene recipients. On the same day, the recipients
were intraperitoneally immunised with HEL protein emulsified in
complete Freund’s adjuvant (CFA). Urine glucose was measured
three times a week for the duration of the experiment.
175
AB
C
Figure 4.37 Effect of titrating the number of donor TCR3A9CD4 cells to
be used for an adoptive transfer model of islet destruction.
A. The indicated numbers of CD4-enriched splenocytes from TCR3A9
transgenic mice were intravenously injected into insHEL-transgenic
recipients which then received 200 µg HEL protein emulsified in
CFA intraperitoneally on day 0. Glucosuria was monitored twice a
week and mice were considered diabetic after two subsequent
positive readings (Diastix score of ≥2).
B. Measurement of HEL-specific IgG in the serum of mice in day 36.
Concentrations are expressed in arbitrary units relative to
reference anti-HEL IgG serum from the Porthos IgGHEL transgenic
strain.
C. Measurement of blood glucose in the mice on day 36.
cut-off for diabetes
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Figure 4.38 Effect of delaying HEL+CFA injection after adoptive
transfer of islet-specific TCR3A9CD4 cells.
A. The indicated numbers of CD4-enriched splenocytes from TCR3A9
transgenic mice were intravenously injected into insHEL-transgenic
recipients which then received 200 µg HEL protein emulsified in
CFA intraperitoneally on day 0 or day 3. Glucosuria was monitored
twice a week and mice were considered diabetic after two
subsequent positive readings (Diastix score of ≥2).
B. Measurement of HEL-specific IgG in the serum of mice on day 50.
Concentrations are expressed in arbitrary units relative to
reference anti-HEL IgG serum from the Porthos IgGHEL transgenic
strain.
C. Measurement of blood glucose in the mice on day 50.
cut-off for diabetes
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examine the effects of Aire- and Cblb-deficiencies on pancreatic islet destruction 
mediated by limiting numbers of CD4 T cells. 
The experimental design established above was next used to compare Cblb-/- deficient 
TCR3A9 CD4 cells with Cblb–wild-type controls, after transfer into insHEL-transgenic 
recipients that were either Aire-deficient or Aire-wild-type creating 7 different groups. 
Most of the recipients were immunized with HEL in CFA, but a subset was immunized 
at the time of T cell transfer (day 0). The groups immunized on day 0 developed 
comparable urine glucose scores in the following weeks when they received 3×105 
TCR3A9 CD4 cells that were either Cblb-/- deficient or Cblb-wildtype (Fig. 4.39). In the 
groups where immunization was delayed, there also appeared to be no difference in the 
induction of glucosuria between groups of recipients receiving Cblb-/- deficient or Cblb-
wild-type T cells, nor between groups of recipients that were Aire-deficient or Aire-
wild-type. Hyperglycemia >15mM occurred only in the experimental group comprising 
Aire-deficient recipients of Cblb-/- deficient T cells: in two of the four animals on day 14 
and one of the four on day 36 (Fig. 4.40B) consistent with the time course results of 
glucosuria detection in Fig. 4.39. There were no detectable differences in HEL-specific 
IgG antibodies in the serum of mice from all groups receiving TCR3A9 cells (Fig. 
4.40A). Thus, even under the pressure of acute stimulation by antigen in adjuvant, 
combining Aire and Cblb defects did not display a significant co-operative effect 
leading to the breakdown of peripheral CD4 T cell tolerance to pancreatic islet beta 
cells, although there was a possible trend to precipitate diabetes in a subset of animals 
that would require further analysis in much larger experimental groups than were 
available for these preliminary studies. 
4.6 Chapter summary and key findings 
4.6.1 Changing the strain background from B10.BR H2k to C57BL/6 H2b 
The experiments in this chapter aimed to understand the pattern of autoimmune disease 
that occurred spontaneously in Aire-/-Cblb-/- double-deficient mice. The experiments in 
the first section tested the hypothesis that variations in the efficiency of antigen 
presentation by MHC molecules determined the spectrum of organs targeted in an 
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Figure 4.39 Aire and Cblb-deficiencies have little effect on islet
destruction by TCR3A9CD4 T cells.
3x105 of CD4-enriched splenocytes from TCR3A9 Cblb+/+ or TCR3A9
Cblb-/- transgenic mice were injected intravenously into Aire+/+ or
Aire-/- insHEL-transgenic recipients which then received 200 µg HEL
protein emulsified in CFA intraperitoneally on day 0 or 4. Glucosuria
was monitored twice a week and mice were considered diabetic
after two subsequent positive readings (Diastix score of ≥2).
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Figure 4.40 Aire and Cblb-deficiencies have little effect on
autoantibody (HEL-specific IgG) formation or islet
destruction by TCR3A9CD4 T cells.
A. Measurement of HEL-specific IgG in the serum of mice on
days 14 and 36.
B. Measurement of blood glucose in the mice on days 14 and
36.
A
B
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autoimmune disease. As a test, the MHC of the Aire- and Cblb-deficient mice was 
changed from H2k haplotype, with k alleles of Class II I-A & I-E and Class I molecules 
K, D & L, to the H2b haplotype, with the alleles Kb, I-Ab, I-Enull, Db, Lnull. Surprisingly, 
the change in MHC haplotype did not change the organs that were targeted by 
spontaneous autoimmune disease, but it reduced the incidence, intensity and severity of 
pancreatitis. There are several possible explanations for the differing severity but not 
specificity of autoimmune disease in Aire- and Cblb-deficient mice with the two MHC 
haplotypes. These explanations could be broadly divided into differences in 
MHC:peptide interactions between the strains (section 4.6.1.1) and non-MHC 
differences (section 4.6.1.2). 
4.6.1.1 Differences in MHC:peptide-dependent interactions 
Firstly, it is possible that the MHC molecules encoded by H2k and H2b may both present 
the same driver autoantigen(s) from the pancreas and salivary glands, resulting in 
autoimmunity in the same organs, but the efficiency of presentation varied between the 
two MHCs. It is possible that thymic presentation of the driver antigen(s) on the MHC 
molecules encoded by the susceptible H2k MHC molecule interacted highly efficiently 
with the driver T cell. In the thymus, this more efficient interaction would have resulted 
in more efficient positive selection of the driver T cells. In the periphery, the highly 
efficient H2k MHC:driver T cell interaction would provoke more severe autoimmune 
disease in the Aire-/-Cblb-/- mice. Mathis and colleagues have demonstrated that T cells 
recognising the HEL46 – 61 peptide in the context of MHC Class II were strongly selected 
when both Aα and Aβ MHC molecules were derived from the CBA H2k genetic 
background, but not the C57BL/6 H2b genetic background (Tourne et al., 1999), 
highlighting the particular MHCs can be more efficient for positive selection of the 
particular T cells.  
The reverse is also equally likely, where the same “driver antigen could be less 
efficiently presented by MHC molecules encoded by susceptible H2k compared to H2b, 
resulting in less efficient presentation of the driver-antigens for peripheral tolerance - 
the classical Ir (Immune response)-gene effect (McDevitt and Chinitz, 2004; McDevitt 
and Sela, 1965). It would be interesting to test this further on other MHC backgrounds 
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such as the B10.NOD-H2g7 background (H2g7 haplotype, encoding Kd, I-Ag7, I-Enull, Db, 
Lnull). The NOD H2g7 haplotype is of particular interest because lethal exocrine 
pancreatitis occurred when Aire-deficiency was bred to the NOD strain background, and 
on this background homozygosity for H2g7 caused a high incidence of the disease 
whereas heterozygosity or homozygosity for H2b was powerfully protective (Jiang et 
al., 2005). The dominant behaviour of the resistant H2b haplotype in the Aire-/- 
NOD.H2g7 × H2b cross would be consistent with the Ir (Immune response)-gene effect. 
Other examples of weakened or less efficient MHC:peptide-TCR interactions are those 
where one of two weakening mutations in the driver peptides result in major changes in 
tolerance and autoimmunity. For example, the hemagglutinin-specific CD4 that is 
usually fully activated is induced into a long-lived tolerant state by an alanine to serine 
substitution (Sloan-Lancaster et al., 1993). Another example is that a natural 
polymorphism in the insulin gene promoter that causes only a twofold to threefold 
decrease in thymic insulin gene expression but is strongly linked to diabetes 
susceptibility (Pugliese et al., 1997; Vafiadis et al., 1997). Similarly, a splice variant in 
proteolipid protein lacking the 116-151 region in thymus results in high frequencies of 
PLP-specific cells in the peripheral repertoire, increasing experimental autoimmune 
encephalitis susceptibility (Anderson et al., 2000). In theory, this weakened 
peptide:MHC interaction cause by mutations in the peptide would have the same effect 
as a weakened interactions caused by the present of absence of particular MHC alleles 
in different strains, suggesting that less efficient binding of peptide:MHC to driver T 
cells could cause rapid autoimmunity. 
Explanation of the MHC haplotype effects along these lines must also take into account 
the finding in the previous chapter that both CD8 and CD4 cells were required to 
transfer pancreatitis from Aire- and Cblb- double-deficient mice into lymphopaenic 
recipients, anticipating a role for MHC I and MHC II molecules.  To examine the role 
of specific MHC I and MHC II molecules, it would be interesting to cross the Aire- and 
Cblb-deficiencies onto C57BL/6 mouse strains with MHC Class I mutations (eg Kbm1) 
or MHC Class II mutations (eg I-Abm12). If the severity of pancreatitis persist in the 
presence of the MHC Class I mutation or MHC Class II mutation, it would suggest that 
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the driver antigen is presented in the context of MHC Class I or MHC Class II, 
respectively. 
4.6.1.2 Differences in MHC:peptide-independent susceptibility loci 
A complexity in the MHC congenic crosses is the possibility that any disease 
suppression might result from differences in immune regulatory genes on the different 
C57BL/6 and C57BL/10 backgrounds. Although genetically, the strains should have 
very little genetic variation except at the MHC loci, these strains have been maintained 
as separate lines for many generations, making it plausible that they have accumulated 
single nucleotide polymorphisms or genetic variations in other immune regulatory 
genes that might influence the timing of disease onset. These variations in non-MHC 
immune regulatory loci could be detected by performing an Aire-/-Cblb-/- B10.BR H2k 
and C57BL/6 H2b intercross. If the pancreatitis and sialoadenitis susceptibility occurred 
in the F1 H2kb offspring, the dominant susceptibility effect would be consistent with 
effects of MHC alleles presenting the autoantigen(s) more efficiently to induce 
autoimmunity in the periphery. However, if the susceptibility is absent in F1 offspring 
but present in a minor selection of F2 offspring (recessive susceptibility), it could be 
indicative of less efficient presentation by the H2k MHC for central and peripheral 
tolerance, which is usually recessive. Alternatively, as the F2 offspring also contain 
random shuffles of the B10.BR and C57BL/6 genomes at this stage, a genome wide 
scan could be performed to samples DNA from pancreatitis or sialoadenitis susceptible 
mice to identify susceptible non-MHC alleles that contribute towards development of 
pancreatitis of sialoadenitis. An F2 cross performed between the NOD.Aire-/- 
pancreatitis prone strain and the non-pancreatitis prone C57BL/5.Aire-/- strain 
established five regions that were responsible for pancreatitis, none of which spanned 
the Cblb gene (Jiang et al., 2005). This result, however demonstrated that the 
combination of Aire-/- and other genetic homozygous genetic deficiencies, perhaps in the 
same pathway as the Cblb gene, could precipitate rapid pancreatitis. 
A second possible explanation for the MHC effects is that entirely different driver 
autoantigen peptides are being presented by the H2k and H2b haplotypes, but some other 
factor accounts for the targeting of autoimmunity against the exocrine pancreas in both 
strains. For example, the content of digestive enzymes in the exocrine pancreas and 
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salivary gland acinar cells could serve as an inflammatory co-factor that serves as a 
positive feedback when rare autoreactive T cells become activated.  In support of this 
possibility, inspection of the H2k, H2g7 and H2b haplotypes reveals no shared classical 
MHC molecules between the first two pancreatitis susceptible haplotypes. Likewise, the 
exocrine pancreas is also a major target of spontaneous autoimmune disease in BALB/c 
(H2d) mice that lack CTLA-4 (Ise et al., 2010; Waterhouse et al., 1995). However, the 
same highly abundant, pancreas-specific autoantigen – PDIA2 – has been identified as a 
target autoantigen in Ctla4-deficient BALB/c mice and in Aire-deficient NOD mice (Ise 
et al., 2010; Niki et al., 2006). Clearly, a key issue for future studies is to identify the 
driver autoantigen(s) in H2k Aire-/-Cblb-/- double-deficient mice. 
4.6.2 Effect of T cell frequency in the primary repertoire using transgenic mice. 
This chapter also tested a second, related repertoire/presentation hypothesis to explain 
the pattern of autoimmunity in Aire-/-Cblb-/- double-deficient mice: that the targeting of 
the exocrine pancreas and submandibular salivary gland reflects an underlying elevated 
frequency of T cells produced in the thymus that happen to have TCRs that recognize 
an autoantigen that is abundant in these cell types. This hypothesis was tested by 
breeding the Aire- and Cblb-deficiencies to a TCR:insHEL double-transgenic strain that 
produced high frequencies of a CD4 T cells that recognised an efficiently presented 
HEL45-61/I-Ak complex expressed in the endocrine pancreas beta cells. This increased 
the precursor frequency of self-reactive CD4 T cells, but recognizing the endocrine 
islets instead of the exocrine acinar cells in the pancreas. Double transgenic mice devoid 
of both Aire and Cblb were protected from exocrine pancreatitis, establishing that 
specific T cells against the exocrine acinar cells are required for this spontaneous 
disease. However, there was no drastic acceleration of diabetes development in Aire- 
and Cblb- double-deficient mice with the high frequency of islet-reactive T cells 
compared to counterparts with single deficiency of Aire or Cblb. Although introducing 
high frequencies of TCR3A9 cells into insHEL recipients could result in severe insulitis 
instead of pancreatitis and TCR3A9 cells have been shown to be regulated by both Aire 
and Cblb individually (Hoyne et al., 2011a; Liston et al., 2003), the spontaneous 
autoimmunity in Aire-/-Cblb-/- TCR3A9:insHEL mice did not display the strong epistatic 
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co-operation of Aire- and Cblb- deficiencies observed in the pancreatitis prone Aire-/-
Cblb-/- non-transgenic mice.   
One explanation for the failure to redirect the specificity of robust autoimmunity in the 
TCR3A9 transgenic mice is that the antigen is highly efficiently presented in the thymus 
and periphery to induce tolerance. It would be interesting to extend the experimental 
approach by breeding Aire-/-Cblb-/- to the TCR7 transgenic strain, which produces high 
frequencies of CD4 T cells recognizing a sub-dominant HEL74-88 peptide that is less 
efficiently presented by I-Ab. TCR7 T cells do not encounter sufficient peptide in 
TCR:insHEL animals to be deleted within the thymus. Whereas peripheral 3A9 T cells 
transferred into insHEL transgenic mice are triggered into an abortive cycle of 
proliferation and activation-induced cell death (AICD) or anergy, there is insufficient 
pMHC in pancreatic lymph node to activate TCR7 cells. In insHEL+ mice, the TCR7 
cells develop in a state of “immunological ignorance” representative of many T cells 
that recognize self-pMHC with too low an abundance or avidity for actively acquired 
tolerance. In contrast to the TCR3A9:insHEL strain that develops diabetes 
spontaneously, this TCR7:insHEL strain is resistant to diabetes development unless it is 
coupled to a simultaneous block in CTLA-4 signalling (Neighbors et al., 2006). The 
strain thus would serve as a valuable transgenic model to analyse the co-operation 
between tolerance defects where the driver antigen is inefficiently presented. 
Another explanation for the failure to redirect autoimmunity in the TCR3A9 transgenic is 
that the autoreactive repertoire was only enriched for CD4 cells, whereas the adoptive 
transfer experiments in chapter 3 demonstrated that both CD4 and CD8 cells were 
necessary to precipitate the lethal pancreatitis seen in non-transgenic Aire-/-Cblb-/- mice. 
It would thus be valuable to extend the transgenic experiments to include a TCR that 
recognizes an MHC I-restricted islet autoantigen, such as the TCROT-1 transgenic strain 
where many CD8 cells would recognise the ovalbumin peptide SIINFEKL complexed 
with the Class I protein, Kb (Hogquist et al., 1994). The OVA self-antigen could be 
presented in the islets under the control of the rat-insulin promoter (Kurts et al., 1996). 
This system would provide valuable insight to determine if changes in driver 
autoreactive precursor CD8 cells were able to redirect spontaneous autoimmunity to the 
endocrine pancreas when Aire and Cblb were deficient. Since single deficiency for Aire 
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precipitates diabetes within a few days after birth in TCROT-1 × Rip-OVA transgenic 
mice (Anderson et al., 2005) the experiments would require lowering the frequency of 
islet-reactive CD8 cells using mixed bone marrow chimeras. 
A third explanation for the failure to redirect autoimmunity in the TCR3A9:insHEL 
transgenic animals was suggested by the results of the flow cytometric analyses in this 
chapter, which showed that islet-reactive CD4 T cells remained quiescent in the 
pancreatic node of Aire-/-Cblb-/- double deficient chimeras, despite escaping thymic 
deletion and having an intrinsically lower activation threshold. Since the peripheral 
transfer experiments demonstrate that insHEL is being presented in the draining node in 
a way that can promote T cell activation, these T cells appeared to be kept quiescent by 
other mechanisms. It may be that the driver T cells that recognize the exocrine pancreas 
in Aire-/-Cblb-/- double deficient mice are not able to be controlled by these other 
mechanisms, due either to some special characteristic of the autoantigen they recognize 
or the exocrine pancreas as discussed above. Rather than attempt to emulate these 
factors with available TCR transgenic mice, a better strategy to understand how Aire-/- 
and Cblb-/- interact to precipitate lethal autoimmunity devoid of a latent period would be 
to isolate the driver T cells themselves and use their TCRs to construct transgenic 
animals. The following chapter will describe efforts to isolate the exocrine pancreas-
specific T cells responsible for spontaneous disease in the Aire-/-Cblb-/- mice, and begin 
tracing their control by AIRE and CBL-B in TCR retrogenic mice.  
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Chapter 5  
Clonal expansion of pancreas-
specific T cells in Aire-/-Cblb-/- mice 
Acknowledgements of assistance in the work described in this chapter: Mice were 
genotyped for Cblb by the Australian Phenomics Facility. For the analysis of plates in 
section 5.2, DNA sequence traces for 10/29 plates were translated by Nadine Barthel 
(IGL technical staff) and 1/29 were translated and assigned to unique TCRαs or TCRβs 
by Mandeep Singh (IGL PhD student). All hematoxylin and eosin section cutting and 
staining was done by Ms. Anne Prins (Flow Cytometry and Microscopy, John Curtin 
School of Medical Research).  
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5.1 Preamble 
The previous chapter explored the hypothesis that the acinar pancreas- and 
submandibular salivary gland-specific autoimmunity in Aire-/-Cblb-/- mice was due to 
variations in the frequency of T cells that recognise different autoantigens. However, 
varying either the MHC in which the T cells were selected upon or increasing the 
precursor frequency of self-reactive CD4 T cells against the pancreatic islets using 
transgenic mice altered the incidence but failed to change the specificity of the 
autoimmunity. These results indicate that there is something unique about the 
antigen(s), tissues or T cells that escape tolerance in Aire-/-Cblb-/- mice. This chapter 
analyses the T cells responsible for autoimmunity in the Aire-/-Cblb-/- mice, and 
establishes an experimental system to determine their specificity and track their fate in 
wild-type animals. 
To enrich for the T cells responsible for exocrine pancreatitis or sialoadenitis in Aire-/-
Cblb-/- mice, I made use of the finding in Chapter 3 that spleen cells could adoptively 
transfer the disease into lymphopaenic Rag1-deficient mice. When normal T cells are 
transferred into Rag1-deficient recipients, the T cells proliferate in two characteristic 
phases. Initially, rapid expansion occurs in a subset of T cells which are driven to 
proliferate by gut commensal antigens (Kieper et al., 2005). There is also a slower 
homeostatic proliferation of clones driven by self-MHC restricted T cells (Ernst et al., 
1999; Goldrath and Bevan, 1999; Moses et al., 2003). Based on the rapid onset of 
pancreas destruction after adoptive transfer, it was assumed that the pancreas-damaging 
T cells would rapidly proliferate in the Rag1-deficient recipients, forming larger clones 
than any triggered by homeostatic proliferation, and preferentially accumulate in the 
pancreas. By conducting serial adoptive transfers of T cells obtained from the pancreas 
of Aire-/-Cblb-/- mice, it would therefore be possible to enrich for the T cell(s) against 
the driver autoantigen(s) in Aire-/-Cblb-/- mice. 
The serial transfer strategy was combined with a powerful new approach to analyse 
individual T cells in immune or autoimmune responses by a multiplex RT-PCR method 
that simultaneously amplifies the TCRα and TCRβ chains from single T cells (Dash et 
al., 2011). This method was selected as it allowed for an unbiased analysis of the clonal 
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diversity and recurring motifs by looking at the complete nucleotide sequence of the 
TCRα and TCRβ in single cells. It also enabled specific TCRs to be cloned and 
expressed in retrogenic mice (Holst et al., 2006a; Holst et al., 2006b; Lennon et al., 
2009), opening up a way to analyse their antigen specificity and regulation by Aire and 
Cbl-b. 
5.2 TCR profiling of original donor, primary and secondary recipients from 
serial adoptive transfers of Aire-/-Cblb-/- and wild-type cells 
5.2.1 Serial transfer system to enrich pancreas-reactive T cells from using bone 
marrow chimeric Aire-/-Cblb-/- mice 
The in vivo serial adoptive transfer assay to enrich for autoimmune driver T cells in 
exocrine pancreatitis is shown systematically in Fig, 5.1. In the experiment described in 
this section, the original donor mice were bone marrow chimeras. Two chimeric Aire-/- 
recipients of Cblb-/- bone marrow (termed MUT1 and MUT2 donors) and two 
corresponding chimeric wild-type recipients of wild-type bone marrow (termed WT1 
and WT2 donors) were used. Cells from each of the four original donors were 
transferred separately to different recipients, although it is important to note that the 
donor chimeras were constructed from the same Cblb-/- or wild-type bone marrow.  
Cells were harvested for the primary transfer six weeks after bone marrow 
reconstitution, by which time the MUT donor chimeras had developed exocrine 
pancreatitis while the WT donor mice were free of pancreatic lymphocyte infiltration 
(Fig. 5.2). Both CD4 and CD8 cells were detected in the pancreas of MUT donor mice, 
with a CD4/CD8 ratio of 2 (MUT1:7.44%/3.55% ; MUT2: 11.9%/5.76%), while spleen 
from WT mice showed a CD4/CD8 ratio of 3 (WT1: 9.08%/2.95%) and 2.6 (WT2: 
8.74%:3.06%), respectively (Figure 5.3A). For the primary transfer, 0.5×106 pancreas-
infiltrating lymphocytes (P0 cells) isolated from MUT donors or 2×106 splenocytes (S0 
cells) isolated from WT counterparts were injected into the bloodstream of individual 
Rag1-deficient recipients. 
189
S0 spleen cells
Primary recipient
Rag1-deficient
DAY 36
Original donor
DAY 0
Secondary
recipient
Rag1-deficient
DAY 84
A
B
Figure 5.1 Schematic representation of the in vivo pancreas-specific
T cell enrichment assay.
A. 2x106 splenocytes from wild-type recipients of wild-type bone
marrow were adoptively transferred into primary Rag1-deficient
recipients
B. Half of the pancreas infiltrating lymphocytes from Cblb-/- recipients
of Aire-/- bone marrow were adoptively transferred into primary
Rag1-deficient recipients. When the Aire-/-Cblb-/- recipients began
to lose weight, 2x106 splenocytes and one third of the pancreas
infiltrating lymphocytes were harvested and transferred to a second
group of Rag1-deficient recipients.
For both A. and B. single cells from all groups were sorted for
muliplex sequencing analysis. 0, original donors; 1, primary
recipients; 2, secondary recipients; P, pancreas; S, spleen. For
secondary recipients, the first letter indicates the organs the cells
were recovered from while the second letter indicates origin of the
transferred cells.
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Figure 5.2 Hematoxylin and eosin sections of the pancreas of mice of
Figure 5.1 at time of takedown.
Images were taken at x100 magnification and bars represent 500 µm. The
respective pancreatitis scores are quantified and listed at the top right
corner of each image. 0, original donors; 1, primary recipients; 2,
secondary recipients; P, pancreas; S, spleen. For secondary recipients,
the first letter indicates the organs the cells were recovered from while the
second letter indicates origin of the transferred cells.
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Figure 5.3 Flow cytometric plots and histograms of
lymphocytes from mice used in the single cell sorts.
A. CD4 and CD8 cells from total lymphocytes in spleen and
pancreas of recipient mice. 0, original donors; 1, primary
recipients; 2, secondary recipients; P, pancreas; S, spleen.
For secondary recipients, the first letter indicates the the
organs the cells were recovered from while the second letter
indicates origin of the transferred cells.
B. Forward side scatter on the CD8 cells in the pancreas of
secondary recipients.
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In the primary recipients, the animals that received MUT pancreas (P0) cells began to 
display signs of rough coats and weight lost on day 36 of the experiment, whereas the 
recipients of WT spleen (S0) cells remained healthy. The mice were sacrificed and 
spleen (S1) and pancreas (P1) were harvested. Consistent with their weight loss, the 
MUT1 and MUT2 primary recipient mice had developed severe pancreatitis with a 
score of ≥4, while no pancreatitis was present in the WT1 and WT2 primary recipients 
(Fig. 5.2). The pancreatic infiltration in MUT1 comprised of both CD4 and CD8 cells, 
while only CD8 cells were detected in MUT2 (Fig. 5.3A). From each primary recipient 
2×106 S1 spleen cells were transferred to each secondary Rag1-deficient recipient. As 
the numbers of pancreatic infiltrating cells recovered from each MUT primary recipient 
mice varied, each pancreas was divided into three portions – 1/3 for histological 
analysis, 1/3 for single cell sorting and 1/3 was used to prepare pancreatic lymphocytes 
(P1 cells) that were injected into the circulation of single Rag1-deficient secondary 
recipients.  
The secondary recipients were sacrificed 48 days following secondary transfer, before 
gross signs of weight loss had developed, with the aim of catching the early infiltrating 
T cells in the pancreas. The secondary recipients of MUT1 S1 splenocytes or MUT1 P1 
pancreatic lymphocytes displayed mild pancreatitis with a score of 1, while no 
pancreatitis had developed in secondary recipients of MUT2 cells (Fig. 5.2). The 
pancreas of secondary recipients of WT cells remained free of infiltration. CD4 and 
CD8 T cells were present at the normal ratio in the spleen (S2<S1) of WT secondary 
recipients, while only CD8 cells were detected in spleen (S2<P1) and pancreas (P2<P1) 
of the MUT1 secondary recipients and in the spleen (S2<P1) of the MUT2 secondary 
recipient. Additionally, the CD8 cells that were detected within the pancreas (P2<P1) of 
the MUT1 secondary recipient appeared to be larger as indicated by an increase in 
forward scatter of the cells (Fig.5.3B).  
Single CD4 and CD8 cells were sorted for TCR sequencing from the original donors, 
and from the primary and secondary recipients. For all spleen and pancreatic 
lymphocyte samples from each mouse, 80 CD4 and CD8 cells were sorted unless lower 
numbers of cells were recovered. For the pancreas samples in primary and secondary 
recipients, all CD4 and CD8 cells that could be recovered were sorted. 
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5.2.2 Strategy for analysis of TCRα and TCRβ  chains in single T cells from 
donors and recipients 
The variable regions of individual TCRα and TCRβ chains from each sorted T cell were 
PCR amplified and sequenced. The work-flow for the process in shown systematically 
in Fig 5.4. The mRNA of sorted single cells was first reverse-transcribed into cDNA, 
and TCR-encoding cDNA was selectively amplified through two rounds of nested PCR 
with degenerate internal and external primer combinations. The first round amplified 
TCRα and TCRβ cDNAs together, and the second round amplified TCRα and TCRβ 
cDNAs separately. A total of 23 nested forward primers complementary to different T 
cell receptor alpha chain variable (Trav) sequences and 19 nested forward primers 
complementary to different T cell receptor beta chain variable (Trbv) sequences were 
coupled with single, nested reverse primers complementary to the 5’ ends of the T cell 
receptor alpha chain constant region (Trac) and T cell receptor beta chain constant 
region (Trbc). The final PCR products were resolved by gel electrophoresis and were 
scored for successful amplification of TCRα, TCRβ or both  (Fig. 5.5). For MUT1;WT1 
and  MUT2:WT2 combination a total of 669 (64.01% of total PCRs) and 573 (53.75% 
of total PCRs) samples, respectively, yielded products for both TCRα and TCRβ 
(Tables 5.1 and 5.2). The PCR products were Sanger sequenced by priming with the 
internal constant region reverse primers, yielding the unique VJ or VDJ junction 
sequences of the TCRα and TCRβ chains, respectively in each sorted single cell.  
For each T cell, the T cell receptor alpha chain variable (Trav) and joining (Traj) 
segments, and the T cell receptor beta chain variable (Trbv) and joining (Trbj) segments 
were translated and assigned by comparison with known genomic sequences available 
from the International ImMunoGeneTics information system (IMGT) database 
(Giudicelli et al., 2006). The complementarity determining region three (CDR3) 
sequence and length were also determined. Sequences in which not all components 
could be assigned to a particular Trav/Traj or Trbv/Trbj were excluded from further 
analysis with some exceptions discussed in section 5.5.2. A caveat in this assignment is 
that some families of Trav elements display very similar 3’ sequences close to the 
CDR3 region that was amplified, making it difficult to accurately assign it to a 
particular Trav. In instances where this occurred, two or more Travs were listed as 
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Figure 5.4 Illustration of the work flow for single cell sequencing of T cells from Rag1-deficient mice.
CD4 and CD8 cells were singly sorted. cDNA was made from the mRNA in the cells. The cells were then
subjected to two rounds of nested PCR using degenerate primers.The first round amplified both TCRα and TCRβ 
together, while the second round amplified TCRα and TCRβ separately. Products were electrophorised on a gel
and subsequently sequenced.
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Figure 5.5 Confirmation of product in single cell multiplex PCR
reactions.
A. Resolution on a 2% agarose gel electrophoresis of the Trav
(left) and corresponding Trbv (right) products from the single
cell multiplex secondary nested PCR reaction. The negative
controls are indicated on the gel. The 1kb DNA ladder is ran
on the far left.
B. Score of the number of Trav and Trbv reactions which yielded
a product on each plate. The products for each cell were
sequenced only when both Trav and Trbv yeilded a product.
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196
   
Table 5.1 Frequency of Trav and Trbv reactions that yielded a product for each sample from the WT1 and MUT1 mice. For 
secondary recipients, in instances where there are two fractions, the first fraction is recipients of S1 and the second recipients of P1. 
Wild-type spleen    Aire-/-Cblb-/- spleen   Aire-/-Cblb-/- pancreas  
Plate Chain Frequency  Plate Chain Frequency  Plate Chain Frequency 
CD4WT  Trav 0/80  CD4WT  Trav 8/80  CD4WT  Trav 1/40 
S0 Trbv 21/80  S0 Trbv 16/80  P0 Trbv 6/40 
  Trav and Trbv 58/80    Trav and Trbv 47/80    Trav and Trbv 31/40 
CD4WT Trav 1/20  CD4WT Trav N.D.  CD4WT Trav 1/8 
S1 Trbv 4/20  S1 Trbv N.D.  P1 Trbv 1/8 
  Trav and Trbv 10/20    Trav and Trbv N.D.    Trav and Trbv 3/8 
CD4WT Trav 1/80  CD4WT Trav 4/80, 2/80  CD4WT Trav 0/5, 0/20 
S2 Trbv 13/80  S2 Trbv 13/50, 8/80  P2 Trbv 0/5, 0/20 
  Trav and Trbv 55/80    Trav and Trbv 
48/80, 
41/80    Trav and Trbv 2/5, 3/20 
CD8WT Trav 1/80  CD8WT Trav 7/80  CD8WT Trav 2/40 
S0 Trbv 16/80  S0 Trbv 19/80  P0 Trbv 4/40 
  Trav and Trbv 53/80    Trav and Trbv 37/80    Trav and Trbv 32/40 
CD8WT Trav 0/20  CD8WT Trav N.D.  CD8WT Trav 0/5 
S1 Trbv 5/20  S1 Trbv N.D.  P1 Trbv 0/5 
  Trav and Trbv 7/20    Trav and Trbv N.D.    Trav and Trbv 0/5 
CD8WT Trav 2/80  CD8WT Trav 2/80, 2/80  CD8WT Trav 2/75, 2/79 
S2 Trbv 6/80  S2 Trbv 15/80, 8/80  P2 Trbv 5/75, 1/79 
  Trav and Trbv 24/80    Trav and Trbv 
50/80, 
38/80    Trav and Trbv 
51/75, 
79/95 
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Table 5.2 Frequency of Trav and Trbv reactions that yielded a product for each sample from the WT2 and MUT2 mice. For 
secondary recipients, in instances where there are two fractions, the first fraction is recipients of S1 and the second recipients of P1. 
Wild-type spleen    Aire-/-Cblb-/- spleen   Aire-/-Cblb-/- pancreas  
Plate Chain Frequency  Plate Chain Frequency  Plate Chain Frequency 
CD4WT  Trav 3/80  CD4WT  Trav 3/80  CD4WT  Trav 1/80 
S0 Trbv 15/80  S0 Trbv 10.80  P0 Trbv 7/80 
  Trav and Trbv 61/80    Trav and Trbv 65/80    Trav and Trbv 72/80 
CD4WT Trav 4/40  CD4WT Trav N.D.  CD4WT Trav no cells 
S1 Trbv 3/40  S1 Trbv N.D.  P1 Trbv no cells 
  Trav and Trbv 14/40    Trav and Trbv N.D.    Trav and Trbv no cells 
CD4WT Trav 3/80  CD4WT Trav 2/80, 6/80  CD4WT Trav 0/1, 0/1 
S2 Trbv 14/80  S2 Trbv 
15/80, 
16/80  P2 Trbv 0/1, 0/1 
  Trav and Trbv 50/80    Trav and Trbv 
25/80, 
35/80    Trav and Trbv 0/1, 0/1 
CD8WT Trav 0/80  CD8WT Trav 3/80  CD8WT Trav 0/80 
S0 Trbv 11/80  S0 Trbv 5/80  P0 Trbv 10.80 
  Trav and Trbv 69/80    Trav and Trbv 66/80    Trav and Trbv 69/80 
CD8WT Trav 2/40  CD8WT Trav N.D.  CD8WT Trav 5/20 
S1 Trbv 10/40  S1 Trbv N.D.  P1 Trbv 1/20 
  Trav and Trbv 14/40    Trav and Trbv N.D.    Trav and Trbv 1/20 
CD8WT Trav 0/80  CD8WT Trav 2/80. 1/80  CD8WT Trav 0/4 
S2 Trbv 10/80  S2 Trbv 1/80, 0/80  P2 Trbv 0/4 
  Trav and Trbv 16/80    Trav and Trbv 4/80, 12/80    Trav and Trbv 0/4 
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possibilities. 
5.2.3 Results of analysis of TCRα or TCRβ  chains from single CD4 cells in 
original donors, primary and secondary recipients  
A summary of the results from the serial transfer experiment is shown in Fig. 5.6. Each 
unique Trav/CDR3α/Traj paired to Trbv/CDR3β/Trbj combination is termed a single 
TCR “clonotype” and those that occurred in two or more T cells within a recipient or 
donor mouse were shaded in colour and listed in Table 5.3 (for WT1 and MUT1) and 
Table 5.4 (for WT2 and MUT2), along with the fraction of T cells that displayed this 
TCR clonotype. Raw data are seen in the Appendix Tables 5.10 to 5.26.  
For the original MUT or WT donor spleen or pancreatic cells (S0 or P0), the sorted CD4 
T cells exhibited a diverse range of TCR clonotypes, with no two cells bearing the same 
TCR. In the primary recipients, very few cells were recovered from each group, 
although the TCR clonotypes detected in WT1 S1 spleen CD4 cells (n=5) and MUT1 P1 
pancreas CD4 cells (n=2) were unique (Fig. 5.6). In WT2 S1 CD4 cells, one clonotype 
(2.1) was found in 2/12 cells, while all other CD4 cells from the same mouse carried 
unique TCRs. No cells were recovered from the pancreas of the MUT2 primary 
recipient (Fig. 5.6), consistent with the absence of histological evidence of lymphocytic 
infiltration in this mouse (Fig 5.2).  
Expansion or enrichment of particular CD4 clones became apparent in both MUT and 
WT secondary recipients. In MUT1 secondary recipients of P1 pancreas-infiltrating 
cells, seven TCR clonotypes were detected in two or more of the 34 CD4 cells analysed 
in the spleen (S2<P1): clonotypes 1.4, 1.5, 1.6, 1.7, 1.8, 1.9 and 1.10 (Fig. 5.6). One of 
these, clonotype 1.4, was also carried by two of four P2<P1 pancreas CD4 cells in the 
same mouse, compared to 6/34 S2<P1 spleen CD4 cells. The MUT1 secondary recipient 
of S1 splenocytes had five TCR clonotypes, clonotypes 1.11, 1.12, 1.13, 1.14 and 1.15, 
which were carried by two or three CD4 cells from 23 CD4 cells sequenced in the S2<S1 
spleen  (Fig. 5.6). TCR sequence data was only obtained for two CD4 cells in the P2<S1 
pancreas of the same recipient, and both carried TCRs that differed from the TCRs 
detected in the spleen CD4 cells (Fig. 5.6). Thus, the MUT1 secondary recipients 
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Figure 5.6 Analysis of distinct TCRα and TCRβ combinations
found in CD4 cells of  original donor and primary/secondary
Rag1-/- recipients of wild-type or Aire-/-Cblb-/- lymphocytes.
Segment sizes are proportional to the percentages of different
clones with a unique combination of Vα, Jα, Vß, Jß and
complementarity determining regions. For the wild-type donor and
recipient mice, only splenocytes were transferred and assayed. For
the Aire-/-Cblb-/-, both pancreas infiltrating lymphocytes and
splenocytes were assayed. n.c. indicated no detection of cells.
Clones that were represented ≥2 times are represented by a
coloured region and given a unique identification number. 0, original
donors; 1, primary recipients; 2, secondary recipients; P, pancreas;
S, spleen. For secondary recipients, the first letter indicates the
organs the cells were recovered from while the second letter
indicates origin of the transferred cells.
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Table 5.3 The frequencies of recurring (≥2) CD4 clones and their respective Trav, CDR3α, Traj and Trbv, CDR3β, Trbj regions 
from WT1 and MUT1 mice. Each clonotype of interest is given a unique "clonotype number". Numerator represents number 
of clones of the respective clonotype and denominator represents the total number of clones isolated. 
 
Table 5.4 The frequencies of recurring (≥2) CD4 clones and their respective Trav, CDR3α, Traj and Trbv, CDR3β, Trbj regions 
from WT2 and MUT2 mice. Each clonotype of interest is given a unique "clonotype number". Numerator represents number of 
clones of the respective clonotype and denominator represents the total number of clones isolated. 
Trav  Va  CDR3a Ja Traj Trbv  Vb  CDR3b Jb Trbj Clonotype S0 P0 P1 S2<S1 P2<S1 S2<P1 P2<P1
Trav7-6 or 7D-6 YLCAV RGNMGYKL TFGTGTSLLVDP Traj9 Trbv14 YLCAS SKTGINQAP LFGEGTRLSVL Trbj1-5 1.1 12/25 WT1
Trav8-2 YFCAT DDTNTGKL TFGDGTVLTVKP Traj27 Trbv13-2 YFCAS GGTGGAETL YFGSGTRLTVL Trbj2-3 1.2 2/25 WT1
Trav10, 10D YFCAA SNYGNEKI TFGAGTKLTIKP Traj48 Trbv5 YFCAS SPDRGGWEQ YFGPGTRLTVL Trbv2-7 1.3 2/25 WT1
Trav5-1 YFCSA SGTGNYKY VFGAGTRLKVIA Traj40 Trbv13-3 YFCAS RAGVAEQ FFGPGTRLTVL Trbj2-1 1.4 6/34 2/4 MUT1
Trav13-1 or 13D-4 YLCAM HQGGSAKL IFGEGTKLTVSS Traj57 Trbv13-2 YFCAS GGPGQGANERL FFGHGTKRSVL Trbj1-4 1.5 4/34 MUT1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDQGGSAKL IFGEGTKLTVSS Traj57 Trbv3 YFCAS SLGLGIQNTL YFGAGTRLSVL Trbj2-4 1.6 3/34 MUT1
Trav8-2 YFCAT DNNYAQGL TFGLGTRVSVFP Traj26(1) Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 1.7 3/34 MUT1
Trav7-5, 7D-5 YLCAP LSSNTDKV VFGTGTRLQVSP Traj34 Trbv13-2 YFCAS GDRPGRAEV FFGKGTRLTVV Trbj1-1 1.8 2/34 MUT1
Trav7-3, 7D-3 YLCAV SDNNNAP RFGAGTKLSVKP Traj43 Trbv13-2 YFCAS GDAGTGGYEQ YFGPGTRLTVL Trbv2-7 1.9 2/34 MUT1
Trav13-2 YFCAI NYGSSGNKL IFGIGTLLSVKP Traj32 Trbv13-2 YFCAS GAGQSNTEV FFGKGTRLTVV Trbj1-1 1.10 2/34 MUT1
Trav6-1, 6-2, 6-4, 6D-04, 6-
5, 6D-5, 6-6, 6D-6, 6-7/DV9 YYCVL ATGNTGKL IFGLGTTLQVQP Traj37 Trbv13-2 YFCAS GDAGLGDTGQL YFGEGSKLTVL Trbj2-2 1.11 3/23 MUT1
Trav6-6 or D-6 YYCAL ARNNNNAP RFGAGTKLSVKP Traj43 Trbv19 FLCAS RTQGNTEV FFGKGTRLTVV Trbj1-1 1.12 2/23 MUT1
Trav7-5 or D-5 YLCAP LSSNTDKV VFGTGTRLQVSP Traj34 Trbv13-2 YFCAS GDRPGRAEV FFGKGTRLTVV Trbj1-1 1.13 2/23 MUT1
Trav8-2 YFCAT DNNYAQGL TFGLGTRVSVFP Traj26(1) Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 1.14 2/23 MUT1
Trav12D-1, 12-2, 12D-2, 12-3, 12D-3YYCAL SDQGGSAKL IFGEGTKLTVSS Traj57 Trbv3 YFCAS SLGLGIQNTL YFGAGTRLSVL Trbj2-4 1.15 2.23 MUT1
Trav  Va  CDR3a Ja Traj Trbv  Vb  CDR3b Jb Trbj Clonotype S0 P0 P1 S2<S1 P2<S1 S2<P1 P2<P1
Trav8D-2 YFCAT DNTNTGKL TFGDGTVLTVKP Traj27 Trbv31 YLCAW IRDNQDTQ YFGPGTRLLVL Trbj2-5 2.1 2/12 WT2
Trav14-1 YFCAA YTGGLSGKL TFGEGTQVTVIS Traj2 Trbv31 YLCAW SPRDGSAETL YFGSGTRLTVL Trbj2-3 2.2 2/16 WT2
Trav4-3 or 4D-3 YFCAA ENYAQGL TFGLGTRVSVFP Traj26(1) Trbv5 YFCAS SQDRGQDTDV FFGKGTRLTVV Trbj1-1 2.3 1/20 10/23 MUT2
Trav6D-7, 6-5 YFCAL SKGHKCLP-HPEPRTCCA Trbv5 YFCAS SQDRGQDTEV FFGKGTRLTVV Trbj1-1 2.4 17/20 13/23 MUT2
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displayed an oligoclonal CD4 expansion, but these TCRs did not appear to share any 
specific features in common (Table 5.3). 
By contrast, in the spleen of MUT2 secondary recipients two TCR combinations 
accounted for most of the CD4 cells for which sequence data was obtained. Clonotype 
2.3 was carried by 10 of 23 CD4 spleen cells in the mouse that received P1 pancreas 
infiltrating cells (recipient S2<P1), but only 1 of 20 CD4 splenocytes in the recipient of 
S1 spleen cells (recipient S2<S1). Clonotype 2.4 was carried by 13/23 CD4 spleen cells 
in the recipient of P1 pancreas cells (recipient S2<P1) and also carried by 17/20 CD4 
splenocytes in the recipient of S1 cells (recipient S2<S1)  (Fig. 5.6). No cells were 
detected in the pancreas of the MUT2 secondary recipient, consistent with the absence 
of pancreatitis in this animal.  
Expanded clones of CD4 cells were also evident in the secondary recipients of WT 
cells. In the WT1 secondary recipient, the spleen CD4 repertoire was dominated by 
clonotype 1.1 (frequency of 12/25 cells), with two other clonotypes also recurring: 1.2 
(frequency of 2/25) and 1.3 (frequency of 2/25) (Fig. 5.6). Similarly, in the secondary 
recipient of WT2 spleen cells, clonotype 2.2 occurred at a frequency of 2/16 CD4 cells 
in the spleen (Fig. 5.6). No similarities could be discerned between the expanded 
clonotypes in MUT or WT secondary recipients, with respect to TCRα or TCRβ 
element usage or sequence motifs in the complementarity determining regions (Table 
5.3 and Table 5.4). 
These results indicate that particular CD4 clones become selectively expanded after 
two-rounds of serial transfers for both WT and MUT mice, and hence clonal expansion 
per se is unlikely to be sufficient to identify autoimmune driver clones. The 
autoimmune driver TCRs would be best selected as clonotypes that accumulated 
preferentially in the pancreas relative to the spleen of the same MUT mouse or 
accumulated in the pancreas in more than one recipient mouse. In this experiment only 
one TCR, clonotype 1.4 from MUT1, met both those criteria. 
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5.2.4 Analysis of TCRα or TCRβ  chains on CD8 cells in original donor, primary 
recipient and secondary recipients  
Fig. 5.7, Tables 5.5, 5.6 and Appendix Tables 5.27 – 5.34 summarizes the results for the 
analysis of the CD8 clones within the repertoire. Consistent with the CD4 repertoire, the 
original WT and MUT donors had a diverse repertoire of TCRs among CD8 cells with 
each TCR only occurring once (Fig. 5.7). No TCR PCR products or sequence data was 
obtained from the few CD8 cells isolated from the pancreas of MUT1 primary 
recipients, while all eight cells analysed in the MUT2 primary recipient (P1) carried an 
identical TCR, clonotype 1.17 (Fig. 5.7 and Table 5.6). Remarkably, an identical TCR 
clonotype 1.17 was also detected on one of the 22 CD8 cells analysed in the pancreas of 
the MUT1 original donor (P0). Although complete TCR sequence data was only 
obtained from a few CD8 cells in the WT1 and WT2 primary recipients (S1), the two 
and nine cells analysed, respectively, each carried unique TCRs (Fig. 5.7).   
As with the CD4 cells above, oligoclonal repertoires were evident in the CD8 cells from 
secondary recipients of MUT or WT cells (Fig. 5.7 and Table 5.5). The MUT1 
secondary recipients displayed a striking increase in three TCR clonotypes that were 
present in both the recipient of P1 pancreas and the recipient of S1 spleen cells. 
Clonotype 1.17 was present in 1/31 CD8 cells in S2<P1 spleen, 30/73 CD8 cells in 
P2<P1 pancreas, and 2/38 CD8 cells in S2<S1 spleen. The high frequency of CD8 cells 
bearing this TCR in the pancreas makes it a strong candidate for an autoimmune driver. 
Clonotype 1.18 also represents a driver candidate, because it was present in 5/31 cells in 
S2<P1 spleen, 42/73 in P2<P1 pancreas, 14/38 CD8 cells in S2<S1 spleen, and 21/51 cells 
in P2<S1 pancreas. Clonotype 1.19 was present in 8/38 CD8 cells in S2<S1 spleen and in 
S2<P1 spleen. Other clones that were represented only in one organ of the secondary 
recipient mice occurring at a frequency of more than one were clonotypes 1.20, 1.21, 
1.22 and 1.23 (Fig. 5.7 and Table 5.5).  
Intriguingly, two TCRs detected in MUT1 were also dominant clones in MUT2 
secondary recipients. Clonotype 1.17 was carried by 100% of CD8 cells analysed in the 
pancreas of the MUT2 P1 primary recipient (n=8) and in the spleen of the secondary 
recipient of MUT2 S2<S1 spleen cells (n=3). It was also detected at a frequency of 1/5 
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Figure 5.7 Analysis of of distinct TCRα and TCRβ combinations
found in CD4 cells of original donor and primary/secondary
Rag1-/- recipients of wild-type or Aire-/-Cblb-/- lymphocytes.
Segment sizes are proportional to the percentages of different
clones with a unique combination of Vα, Jα, Vß, Jß and
complementarity determining regions. For the wild-type donor and
recipient mice, only splenocytes were transferred and assayed. For
the Aire-/-Cblb-/-, both pancreas infiltrating lymphocytes and
splenocytes were assayed. n.c. indicated no detection of cells.
Clones that were represented ≥2 times are represented by a
coloured region and given a unique identification number. 0, original
donors; 1, primary recipients; 2, secondary recipients; P, pancreas;
S, spleen. For secondary recipients, the first letter indicates the
organs the cells were recovered from while the second letter
indicates origin of the transferred cells.
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Table 5.5 The frequencies of recurring (≥2) CD8 clones and their respective Trav, CDR3α, Traj and Trbv, CDR3β, Trbj regions 
from WT1 and MUT1 mice. Each clonotype of interest is given a unique "clonotype number". Numerator represents number of 
clones of the respective clonotype and denominator represents the total number of clones isolated. 
 
Table 5.6 The frequencies of recurring (≥2) CD8 clones and their respective Trav, CDR3α, Traj and Trbv, CDR3β, Trbj regions 
from WT2 and MUT2 mice. Each clonotype of interest is given a unique "clonotype number". Numerator represents number of 
clones of the respective clonotype and denominator represents the total number of clones isolated. 
 
 
 
 
 
 
Trav  Va  CDR3a Ja Traj Trbv  Vb  CDR3b Jb Trbj Clonotype S0 P0 P1 S2<S1 P2<S1 S2<P1 P2<P1
Trav3-1 YFCAV GNSGGSNAKL TFGKGTKLSVKS Traj42 Trbv13-3 YFCAS RDRDTQ YFGPGTRLLVL Trbj2-5 1.16 9/18 WT1
Trav6-4, 6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 1.17 1/22 2/38 1/31 30/73 MUT1
Trav7-3, 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 1.18 14/38 21/51 5/31 42/73 MUT1
Trav8-2 YFCAT DNNYAQGL TFGLGTRVSVFP Traj26(1) Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 1.19 8/38 6/31 MUT1
Trav9-3,9-4, 9D-4 YFCVL TINSAGNKL TFGIGTRVLVRP Traj17 Trbv13-2 YFCAS GDNNERL FFGHGTKLSVL Trbj1-4 1.20 15/31 MUT1
Trav7-4., 7D-4 YFCAA SDANKM IFGLGTILRVRP Traj47 Trbv19 FLCAS RKLGNQDTQ YFGPGTRLLVL Trbj2-5 1.21 8/38 MUT1
Trav7-3, 7D-3 YLCAV IDYANKM IFGLGTILRVRP Traj47 Trbv13-1 YFCAS TGQNYAEQ FFGPGTRLTVL Trbj2-1 1.22 25/51 MUT1
Trav7-1 YFCAV RVGDNSKL IWGLGTSLVVNP Traj38 Trbv1 LYCTC SADRGGNTL YFGEGSRLIVV Trbj1-3 1.23 4/51 MUT1
Trav  Va  CDR3a Ja Traj Trbv  Vb  CDR3b Jb Trbj Clonotype S0 P0 P1 S2<S1 P2<S1 S2<P1 P2<P1
Trav6-6 YYCAL GDYGNEKI TFGAGTKLTIKP Traj48 Trbv29 YFCAS SRQGNTGQL YFGEGSKLTVL Trbj2-2 2.5 2/6 WT2
Trav13-2 YLCAL ELDYANKM IFGLGTILRVRP Traj47 Trbv13-3 YFCAS SDAGGANERL FFGHGTKLSVL Trbj1-4 2.6 2/6 WT2
Trav6-4 or Trav6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 1.17 8/8 3/3 1/5 MUT2
Trav7-3 or 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 1.18 2/5 MUT2
Trav7-3 or 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 Trbv5 YFCAS SQDRGQDTEV FFGKGTRLTV Trbj1-1 2.7 2/5 MUT2
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CD8 cells in the MUT2 S2<P1 spleen, representing the secondary recipient of P1 
pancreas cells. The second TCR that was detected in both MUT1 and MUT2 secondary 
recipients was clonotype 1.18 that was present at a frequency of 2/5 in MUT2 S2<P1 
spleen cells. This clone was of interest because the nucleotide sequencing 
chromatograms revealed two or more overlapping DNA sequences in the TCRα PCR 
product but a single DNA sequence for the TCRβ product from each of these CD8 cells. 
This is likely to reflect expression of two rearranged TCRα alleles in this clone, and 
will be discussed in the discussion section 5.5.2. The only clone detected in MUT2 that 
was not detected in MUT1 was clonotype 2.7 that represented 2/5 of the CD8 cells 
analysed in the S2<P1 spleen cells from the MUT2 secondary recipient. 
In WT1 secondary recipients, there was an expansion of clonotype 1.16, which was 
present in 9/18 CD8 cells in the S2<S1 spleen. Two other independent TCRs, clonotypes 
2.5 and 2.6, were each present at a frequency of 2/6 in spleen CD8 cells of the WT2 
secondary recipient mouse.  
Taken together, data from sections 5.2.3 and 5.2.4 indicate that serial adoptive transfer 
experiments enriched for clonally expanded CD4 and CD8 cells from both WT and 
MUT donors. Within the pancreas and spleen of secondary recipients, the clonal 
expansion appeared to be selective for a number of dominant clones. Although 
expansion occurred in both WT and MUT secondary recipients, the presence of two 
MUT CD8 clones (clonotype 1.17 and 1.18) in more than three different recipient mice, 
occurring at higher frequencies in the pancreas compared to the spleen is suggestive that 
these clones might have been repeatedly selected for clonal expansion by driver 
autoantigen(s) in the pancreas.  
There were two drawbacks in this experiment. Firstly, the donor mice were bone 
marrow chimeras and this could have skewed the T cell repertoire in the original donor. 
The transplanted wild-type or Cblb-/- bone marrow given to these chimeras could 
contain residual mature T cells in addition to haematopoietic stem cells. Likewise, the 
irradiated wild-type or Aire-/- marrow recipients would have a pool of radioresistant 
memory T cells. The presence of residual T cells from donor marrow or host may have 
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skewed the T cell repertoire. Furthermore, for the first several weeks following bone 
marrow transplantation, any residual mature T cells from the marrow donor or the host 
will undergo strong lymphopenia-induced homeostatic expansion. The occurrence of 
the same TCR in the CD8 cells that expand in recipients of pancreas cells from two 
separate original chimera donors, MUT1 and MUT2, could best be explained by a pre-
existing CD8 clone present in the Cblb-/- bone marrow that underwent proliferation in 
both of the chimeras. The possibility of contamination of PCR products can be firmly 
excluded because this shared TCR clonotype was never detected in CD4 cells or WT 
cells that were sorted and amplified in parallel on the same 96-well plates.  
The second caveat was that very small numbers of lymphocytes were adoptively 
transferred in some cases, particularly during secondary transfer of pancreatic cells. 
This may create a population bottleneck that exaggerates the oligoclonality of the CD4 
and CD8 T cell repertoire in the secondary recipients. Indeed, the small sample size of 
two to five sorted T cells yielding complete TCR sequences for some experimental 
groups made it difficult to draw meaningful conclusions at those time points. In MUT1 
primary recipients, TCRs from only two CD4 and no CD8 cells were analysed, while 
≥30 CD8 cells were analysed in the secondary recipients although the number of CD4 
cells remained low. However for MUT2 recipients, TCR sequences could only be 
obtained for CD8 cells in the pancreas of the primary recipients, while no CD4 or CD8 
cells were detected in the pancreas of the secondary recipients either because these 
animals were euthanased before the onset of autoimmune pancreatitis or because these 
recipients lacked the necessary mix of CD4 and CD8 cells shown both to be required 
for disease progression in Chapter 3. 
5.3 Serial transfer system for enrichment of autoreactive T cell clones using 
pooled lymphocytes from Aire-/-Cblb-/- mice 
To validate the observations from section 5.2 and circumvent the caveats of bone 
marrow chimeras, the serial transfer experiment was repeated with a few changes. 
Firstly, instead of using bone marrow chimeras, in this experiment the original donors 
were a pair of unmanipulated, age-matched 24-day-old mice, one of the B10.BR.Aire-/-
Cblb-/- genotype (MUT3) and the other B10.BR wild-type genotype (WT3) (Fig. 5.8). 
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Figure 5.8 Schematic representation of the in vivo pancreas-
specific T cell enrichment assay.
Splenocytes from Aire-/-Cblb-/- and wild-type mice were adoptively
transferred into Rag1-deficient recipients. When the Aire-/-Cblb-/-
recipients began to lose weight,the wild-type splenocytes and
mutant pancreas infiltrating lymphocytes were harvested, pooled
and transferred to a second group of Rag1-deficient recipients.
Single cells from the secondary recipients were sorted for TCR
sequencing. 0, original donors; 1, primary recipients; 2, secondary
recipients; P, pancreas; S, spleen. For secondary recipients, the first
letter indicates the organs the cells were recovered from while the
second letter indicates origin of the transferred cells.
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At the time of euthanasia to harvest cells for the primary adoptive transfer, the MUT3 
original donor mouse had a cachectic appearance typical of B10.BR.Aire-/-Cblb-/- mice, 
and histological analysis revealed grade 5 exocrine pancreatitis (Fig. 5.9). The second 
variation to the design was that 2×106 spleen cells were used for the primary transfer of 
both WT and MUT cells, and these were given to multiple primary recipients in parallel 
so that larger numbers of pancreas-infiltrating lymphocytes were available for 
secondary transfers. A total of 2×106 WT3 or MUT3 splenocytes (S0) were adoptively 
transferred to groups of four and five Rag-1-deficient primary recipients, respectively 
(Fig 5.8). 
The primary recipients were euthanased 36 days after adoptive transfer, by which time 
the recipients of MUT3 cells were exhibiting cachexia. As seen in Fig. 5.9, all MUT3 
primary recipients had developed destructive exocrine pancreatitis with a score of ≥3, 
whereas all of the WT3 primary recipients were free of lymphocytic infiltration in the 
pancreas. In order to minimise T cell population bottlenecks in the secondary transfer 
and ensure the maximum numbers of cells were transferred to the secondary recipients, 
pooled populations of cells from multiple primary recipients were used. All splenocytes 
(S1) from the four WT3 primary recipients were pooled and 10×106 cells were 
transferred into a secondary recipient. For the MUT3 group, pancreas-infiltrating 
lymphocytes (P1) from the five primary recipients were pooled and 0.5×106 cells were 
transferred to each of three secondary Rag-1-deficient recipients (Fig. 5.8). 
The WT3 secondary recipient was sacrificed for analysis on Day 68 of the experiment. 
This mouse did not show any signs of autoimmunity in the pancreas (Fig. 5.9). Both 
CD4 and CD8 cells were present in the spleen of WT3 in a 20.7%:3.29% (CD4:CD8) 
ratio (Fig.5.10A).  
By contrast, MUT3 secondary recipients were sacrificed on Day 105 of the experiment 
when the mice began to show signs of cachectic wasting. The MUT3 secondary 
recipients were sacrificed later than WT3 secondary recipients to allow more time for 
the development of pancreatitis in the mice. Histological analysis revealed varying 
degrees of exocrine pancreatitis, with disease scores of 5, 3 and 2 (Fig. 5.9). All 
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Figure 5.9 Hematoxylin and eosin sections of the pancreas in
donor and recipient mice.
Pancreatitis scores between 0 and 5 are shown for each animal.
Images were taken at x100 magnification and bars represent 500
µm.
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Figure 5.10 Flow cytometric analysis of lymphocytes isolated
from the secondary WT3 and MUT3 recipients.
A. Percentage of pooled CD4 and CD8 cells gated on total
lymphocytes in the indicated tissues of secondary recipients.
B. Forward side scatter as a measure of size of CD4 and CD8
cells.
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splenocytes (S2<P1) or pancreas infiltrating lymphocytes (P2<P1) from each recipient 
were pooled for subsequent analysis. Flow cytometric analysis of the spleen of the 
MUT3 secondary recipients revealed both CD4 and CD8 cells present at a ratio of 
10.1%:7.43% (CD4:CD8) (Fig.5.10A). T cells in the pancreas were strongly skewed in 
favour of CD8 cells, however, with only 0.45% of lymphocytes bearing CD4 while 
20.4% carried CD8 Fig.5.10A. Additionally, consistent with the results for MUT1 in the 
previous section, the CD8 cells within the pancreas appeared blasted as measured by an 
increase in forward scatter of the cells Fig.5.10B. 
In this transfer, single CD4 and CD8 cells from only the secondary recipients were 
sorted into 96-well plates for TCR analysis. The corresponding TCRα and TCRβ 
variable regions sequences for each WT3 or MUT3 T cell were determined using the 
strategy detailed in the previous section. As observed in Table 5.7, the success rate for 
amplification of both TCRα and TCRβ chains from each sorted T cell was 49.7% (293 
of 480 samples) for this experiment.  
The results for the CD4 repertoire analysis in WT3 and MUT3 secondary recipients are 
summarised in Fig. 5.11, Table 5.8, Appendix Table 5.44, 5.45 and 5.46. In the spleen 
(S2<S1) of the WT3 secondary recipient, most of the CD4 cells that were sequenced 
carried a unique TCR clonotype with the exception of two TCRs that each occurred on 
two separate CD4 cells (clonotypes 3.1 and 3.2). Similarly, the majority of the CD4 
cells isolated from the spleen (S2<P1) (13/16) and pancreas (P2<P1) (15/15) of the 
MUT3 secondary transfer recipients carried unique TCRs. Only one TCR, clonotype 
3.3, was carried by three separate CD4 cells in the spleen of the MUT3 recipients, and 
this was not found among the CD4 cells isolated from the pancreas. Thus, the CD4 
repertoire in both WT3 and MUT3 secondary recipients did not appear to be strongly 
dominated by any CD4 clone. 
The repertoire of TCRs carried by CD8 T cells in the WT3 and MUT3 secondary 
recipients is summarised in Fig. 5.12, Table 5.9, Appendix Table 5.47, 5.48 and 5.49. 
The CD8 repertoire of the WT3 secondary recipient revealed diverse TCRs with the 
expansion of one clonotype, 3.4, found in 5/24 T cells that were successfully sequenced. 
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Table 5.7 Frequency of Trav and Trbv reactions that yielded a product for each sample from the WT3 and MUT3 mice. 
 
Plate Chain Frequency 
CD4WT Trav 0/80 
 S2<S1 Trbv 8/80 
  Trav and Trbv 50/80 
CD4MUTS Trav 0/80 
 S2<P1 Trbv 20/80 
  Trav and Trbv 38/80 
CD4MUTP Trav 0/80 
 P2<P1 Trbv 19/80 
  Trav and Trbv 49/80 
CD8WTS Trav Jan-80 
 S2<S1 Trbv 13/80 
  Trav and Trbv 51/80 
CD8MUTS Trav 0/80 
 S2<P1 Trbv 19/80 
  Trav and Trbv 55/80 
CD8MUTP Trav 2/80 
 P2<P1 Trbv 13/80 
  Trav and Trbv 50/80 
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Figure 5.11 Unique TCRα and TCRβ combinations found in
single CD4 cells in the indicated tissue of WT3 (A) and MUT3
(B) secondary Rag1-/- recipients.
Segment sizes are proportional to the percentages of CD4 cells with
a unique TCR clonotype based on the combination of Vα, Jα, Vß, Jß
and complementarity determining region sequences. Clones that
were represented ≥2 times are represented by a coloured region
and given a unique identification number. 1, primary recipients; 2,
secondary recipients; P, pancreas; S, spleen. The first letter
indicates the organs the cells were recovered from while the second
letter indicates origin of the transferred cells.
WT3
MUT3
S2<P1
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Table 5.8 The frequencies of recurring (≥2) CD4 clones and their respective Trav, CDR3α, Traj and Trbv, CDR3β, Trbj regions 
from WT3 and MUT3 mice. Each clonotype of interest is given a unique "clonotype number". Numerator represents number of 
clones of the respective clonotype and denominator represents the total number of clones isolated. 
 
Table 5.9 The frequencies of recurring (≥2) CD8 clones and their respective Trav, CDR3α, Traj and Trbv, CDR3β, Trbj regions 
from WT3 and MUT3 mice. Each clonotype of interest is given a unique "clonotype number". Numerator represents number of 
clones of the respective clonotype and denominator represents the total number of clones isolated. Note that clonotype 3.8 was 
included in this table although only occurring once as it is highly related to clonotype 3.5. 
 
 
 
Trav  Va  CDR3a Ja Traj Trbv  Vb  CDR3b Jb Trbj Clonotype S2 P2
Trav14-1 YFCAA SGVSGGSNYKL TFGKGTLLTVTP Traj53 Trbv26 YLCAS SQGSQNTL YFGAGTRLSVL Trbj2-4 3.1 2/35 WT3
Trav14-2 YFCAA SSTGNYKY VFGAGTRLKVI Traj40 Trbv26 YLCAS SLQGTNERL FFGHGTKLSV Trbj1-4 3.2 2/35 WT3
Trav13D-1 YLCAM GDNNAGAKL TFGGGTRLTVRP Traj39 Trbv20 YLCGA RDNYAEQ FFGPGTRLTVL Trbj2-1 3.3 3/16 MUT3
Trav  Va  CDR3a Ja Traj Trbv  Vb  CDR3b Jb Trbj Clonotype S2 P2
Trav4-3 or Trav4D-3 YFCAA EGGSAKL IFGEGTKLTVSS Traj57 Trbv19 FLCAS SMGLGYEQ YFGPGTRLTV Trbv2-7 3.4 5/24 WT3
Trav7-1 YFCAV SSSGSWQL IFGSGTQLTVMP Traj22 Trbv1 LYCTC SGDSSGNTL YFGEGSRLIVV Trbj1-3 3.5 12/39 29/42 MUT3
Trav7-1 YFCAV SGGSNYQL IWGSGTKLIIKP Traj33 Trbv1 LYCTC SGDRGGNTL YFGEGSRLIVV Trbj1-3 3.6 8/39 9/42 MUT3
Trav12D-1, 2, D-2, 3 YYCAL SDTSSGQKL VFGQGTILKVYL Traj16 Trbv14 YLCAS SFGTGAYAEQ FFGPGTRLTVL Trbj2-1 3.7 7/39 MUT3
Trav12D-1, 2, D-2, 3 YYCAL SGNTGYQNF YFGKGTSLTVIP Traj49 Trbv1 LYCTC SGDSSGNTL YFGEGSRLIVV Trbj1-3 3.8 1/39 MUT3
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Figure 5.12 Unique TCRα and TCRβ combinations found in
single CD8 cells in the indicated tissue of WT3 (A) and MUT3
(B) secondary Rag1-/- recipients.
Segment sizes are proportional to the percentages of CD8 cells with
a unique TCR clonotype based on the combination of Vα, Jα, Vß, Jß
and complementarity determining region sequences. Clones that
were represented ≥2 times are represented by a coloured region
and given a unique identification number. 1, primary recipients; 2,
secondary recipients; P, pancreas; S, spleen. The first letter
indicates the organs the cells were recovered from while the second
letter indicates origin of the transferred cells. Note that clonotype 3.8
only occurs once but was shaded as it is highly similar to clonotype
3.5.
A
B
WT3
MUT3
3.5                                 3.6
216
   
This degree of clonal expansion among CD8 cells was consistent with that observed in 
WT1 and WT2 secondary recipients analysed in section 5.2, and reinforces the 
conclusion that clonal expansion per se cannot be taken as an accurate indicator of 
autoimmune driver TCRs.  
Thirteen unique TCRs were identified among 39 sequenced CD8 cells from the spleen 
(S2<P1) of MUT3 secondary recipients (Fig 5.12B and Table 5.8). Three TCRs were 
carried by two or more separate CD8 T cells: clonotype 3.5 was present in 12/39 CD8 
cells, clonotype 3.6 in 8/39 cells and clonotype 3.7 in 7/39 cells. Interestingly, the two 
most frequent TCRs, clonotypes 3.5 and 3.6, had identical Trav, Trbv, Trbj segments 
and differed only in their Traj gene segment and in the sequence of their CDR3α 
(S…..QL, dots represent differences) and CDR3β (SG…GNTL, dots represent 
differences). These two similar TCRs made up 30.7% and 20.5% of the CD8 splenic 
repertoire that was sequenced. Clonotype 3.8 shared exactly the same TCRß chain as 
clonotype 3.5 and occurred once. Even more impressive was the discovery of the same 
TCRs, clonotypes 3.5 and 3.6, at high frequencies in the pancreas (P2<P1) infiltrating 
CD8 cells of the same secondary recipients with an occurrence of 29/42 (69%) and 9/42 
(21.4%), respectively. Only four other TCRs were detected in the pancreatic CD8 cells 
from MUT3 secondary recipients, all of which were only found once. These clones 
were different from that observed to be expanded in the CD8 repertoire of WT3 
secondary recipients. All TCRs detected in this experiment were also different from the 
TCRs detected in the experiment described in section 5.2, and from TCRs detected in 
CD4 cells of the MUT3 secondary recipients. 
The findings from this experiment demonstrate a clear selective expansion of two 
similar CD8 clones, differing only in the CDR3α, TRAJ region and CDR3β sequences 
in the MUT3 secondary recipients. The two clones made up 51.2% and 90.4% of the 
CD8 repertoire analysed for spleen (S2<P1) and pancreas (P2<P1) of MUT3, 
respectively. The enrichment of two very similar clones in the pancreas and to a lesser 
extend in the spleen suggested that the clones were repeatedly selected most likely 
attributed to their ability to bind the driver pancreas-specific autoantigen(s) with high 
affinity. To test this hypothesis, the dominant TCR clonotype 3.5 was used to generate 
retrogenic mice as described in the following section. 
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5.4 Production and preliminary characterization of TCR retrogenic mice 
expressing the putative pancreatic autoimmunity driver TCR 3.5 clonotype 
5.4.1 Construction of a retroviral vector bearing TCRα and TCRβ  chains of 
MUT3 CD8 TCR 3.5 clonotype  
To test if the TCRs that were found enriched in pancreas-infiltrating T cells recognised 
bona fide exocrine pancreatic antigens and were capable of driving pancreatitis, CD8 
clonotype 3.5 from section 5.3 was selected as a promising clone and used to create a 
multicistronic retroviral vector encoding the TCRα and TCRβ chains of clonotype 3.5. 
For this purpose, the unique junctional nucleotide sequences of the Trav7-
1/SSSGSWQL/Traj22 and Trbv1/GDSSGNTL/Trjb1-3 segments were obtained from 
the sequence analysis of the PCR products of multiple CD8 MUT3 cells in section 5.3. 
The remaining 5’ untranslated and coding sequence of Trav7-1 and Trbv1, and the 
sequence of the Trac and Trbc-1 constant regions was obtained from ImMunoGeneTics 
(IMGT) and ENSEMBL databases, since these regions were not covered by the 
sequencing primers in section 5.3.  The accurate Trbc-1 sequence proved difficult to 
obtain from online bioinformatic tools, and was taken directly from the original 
sequencing of genomic clones of the TCRβ chain (Gascoigne et al., 1984). The TCRα 
and TCRβ chains were designed to share a single open reading frame (Fig 5.13), 
separated from each other by a self-cleaving 2A peptide sequence to serve as a cis-
acting hydrolase element mediating cleavage between the translated TCRα and TCRβ 
chains (Holst et al., 2006a). The 1824 base pair insert encompassing clonotype 3.5 
TCRα-2A peptide-TCRβ chains sequences was flanked by restriction enzymes sites 
EcoRI and XhoI allowing the insertion into the mouse stem cell virus (MSCV)-based 
retroviral vector, pMIGII (Holst et al., 2006a). The vector contained an internal 
ribosome entry sequence followed by green fluorescent protein (IRES-GFP) cassette to 
identify transfected cells. The nucleotide sequence and translation of the insert designed 
are seen in Fig. 5.13. 
The 1824 bp TCRα-2A peptide-TCRβ sequence was chemically synthesized and cloned 
into the pMIGII vector by Biomatik Corporation and the sequence was verified using 
two primers flanking the insert and one internal primer. For simplicity, the construct 
was abbreviated as pMIGII-TCRαβ3.5 for the remainder of this chapter. 
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Figure 5.13 The nucleotide sequence and corresponding
translated open reading frame of the TCRαß3.5  vector insert
synthesized by Biomatik Corporation.
The portion of the sequence indicated by each colour is as follows:
TRAV7.1 Leader sequence, TRAV7.1, TRAJ22, TRAC, 2A self
cleaving peptide, TRBV1 Leader sequence, TRBV1, TRBJ1.3,
TRBC1. In-frame translation initiation and termination codons are
underlined. Restriction sites: EcoRI, BglII, XhoI, MfeI. The EcoRI
and XhoI sites were utilised for cloning into the pMIGII vector.
GCGCCAGAATTCAGATCTACCATGAAGTCCTTGTGTGTTTCACTAGTGGTCCTGTGGCTT 
 A  P  E  F  R  S  T START K  S  L  C  V  S  L  V  V  L  W  L  
CAGCTACACTGGGTGAACAGCCAGCAGAAGGTGCAGCAGAGCCCAGAATCCCTCATTGTT 
 Q  L  H  W  V  N  S  Q  Q  K  V  Q  Q  S  P  E  S  L  I  V  
CCAGAGGGAGGCATGGCCTCTCTCAACTGCACTTTCAGTGATCGTAATTCTCAGTATTTC 
 P  E  G  G  M  A  S  L  N  C  T  F  S  D  R  N  S  Q  Y  F  
TGGTGGTACAGACAGCATTCTGGGGAAGGCCCCAAGGCACTGATGTCCATCTTCTCCAAT 
 W  W  Y  R  Q  H  S  G  E  G  P  K  A  L  M  S  I  F  S  N  
GGTGACAAGAAGGAAGGCAGATTCACAGCTCACCTCAATAAGGCCAGCCTGTATGTATCC 
 G  D  K  K  E  G  R  F  T  A  H  L  N  K  A  S  L  Y  V  S  
CTGCACATCAAAGACTCCCAACCCAGTGACTCTGCTCTCTACTTCTGTGCAGTGAGCTCT 
 L  H  I  K  D  S  Q  P  S  D  S  A  L  Y  F  C  A  V  S  S  
TCTGGCAGCTGGCAACTCATCTTTGGATCTGGAACCCAACTGACAGTTATGCCTGACATC 
 S  G  S  W  Q  L  I  F  G  S  G  T  Q  L  T  V  M  P  D  I  
CAGAACCCAGAACCTGCTGTGTACCAGTTAAAAGATCCTCGGTCTCAGGACAGCACCCTC 
 Q  N  P  E  P  A  V  Y  Q  L  K  D  P  R  S  Q  D  S  T  L  
TGCCTGTTCACCGACTTTGACTCCCAAATCAATGTGCCGAAAACCATGGAATCTGGAACG 
 C  L  F  T  D  F  D  S  Q  I  N  V  P  K  T  M  E  S  G  T  
TTCATCACTGACAAAACTGTGCTGGACATGAAAGCTATGGATTCCAAGAGCAATGGGGCC 
 F  I  T  D  K  T  V  L  D  M  K  A  M  D  S  K  S  N  G  A  
ATTGCCTGGAGCAACCAGACAAGCTTCACCTGCCAAGATATCTTCAAAGAGACCAACGCC 
 I  A  W  S  N  Q  T  S  F  T  C  Q  D  I  F  K  E  T  N  A  
ACCTACCCCAGTTCAGACGTTCCCTGTGATGCCACGTTGACCGAGAAAAGCTTTGAAACA 
 T  Y  P  S  S  D  V  P  C  D  A  T  L  T  E  K  S  F  E  T  
GATATGAACCTAAACTTTCAAAACCTGTCAGTTATGGGACTCCGAATCCTCCTGCTGAAA 
 D  M  N  L  N  F  Q  N  L  S  V  M  G  L  R  I  L  L  L  K  
GTAGCGGGATTTAACCTGCTCATGACGCTGAGGCTGTGGTCCAGTGCCACGAACTTCTCT 
 V  A  G  F  N  L  L  M  T  L  R  L  W  S  S  A  T  N  F  S  
CTGTTAAAGCAAGCAGGAGACGTGGAAGAAAACCCCGGTCCCATGTGGCAGTTTTGCATT 
 L  L  K  Q  A  G  D  V  E  E  N  P  G  P  M  W  Q  F  C  I  
CTGTGCCTCTGTGTACTCATGGCTTCTGTGGCTACAGACCCCACAGTGACTTTGCTGGAG 
 L  C  L  C  V  L  M  A  S  V  A  T  D  P  T  V  T  L  L  E  
CAAAACCCAAGGTGGCGTCTGGTACCACGTGGTCAAGCTGTGAACCTACGCTGCATCTTG 
 Q  N  P  R  W  R  L  V  P  R  G  Q  A  V  N  L  R  C  I  L  
AAGAATTCCCAGTATCCCTGGATGAGCTGGTATCAGCAGGATCTCCAAAAGCAACTACAG 
 K  N  S  Q  Y  P  W  M  S  W  Y  Q  Q  D  L  Q  K  Q  L  Q  
TGGCTGTTCACTCTGCGGAGTCCTGGGGACAAAGAGGTCAAATCTCTTCCCGGTGCTGAT 
 W  L  F  T  L  R  S  P  G  D  K  E  V  K  S  L  P  G  A  D  
TACCTGGCCACACGGGTCACTGATACGGAGCTGAGGCTGCAAGTGGCCAACATGAGCCAG 
 Y  L  A  T  R  V  T  D  T  E  L  R  L  Q  V  A  N  M  S  Q  
GGCAGAACCTTGTACTGCACCTGCAGTGGGGACAGTTCTGGAAATACGCTCTATTTTGGA 
 G  R  T  L  Y  C  T  C  S  G  D  S  S  G  N  T  L  Y  F  G  
GAAGGAAGCCGGCTCATTGTTGTAGAGGATCTGAGAAATGTGACTCCACCCAAGGTCTCC 
 E  G  S  R  L  I  V  V  E  D  L  R  N  V  T  P  P  K  V  S  
TTGTTTGAGCCATCAAAAGCAGAGATTGCAAACAAACAAAAGGCTACCCTCGTGTGCTTG 
 L  F  E  P  S  K  A  E  I  A  N  K  Q  K  A  T  L  V  C  L  
GCCAGGGGCTTCTTCCCTGACCACGTGGAGCTGAGCTGGTGGGTGAATGGCAAGGAGGTC 
 A  R  G  F  F  P  D  H  V  E  L  S  W  W  V  N  G  K  E  V  
CACAGTGGGGTCAGCACGGACCCTCAGGCCTACAAGGAGAGCAATTATAGCTACTGCCTG 
 H  S  G  V  S  T  D  P  Q  A  Y  K  E  S  N  Y  S  Y  C  L  
AGCAGCCGCCTGAGGGTCTCTGCTACCTTCTGGCACAATCCTCGCAACCACTTCCGCTGC 
 S  S  R  L  R  V  S  A  T  F  W  H  N  P  R  N  H  F  R  C  
CAAGTGCAGTTCCATGGGCTTTCAGAGGAGGACAAGTGGCCAGAGGGCTCACCCAAACCT 
 Q  V  Q  F  H  G  L  S  E  E  D  K  W  P  E  G  S  P  K  P  
GTCACACAGAACATCAGTGCAGAGGCCTGGGGCCGAGCAGACTGTGGGATTACCTCAGCA 
 V  T  Q  N  I  S  A  E  A  W  G  R  A  D  C  G  I  T  S  A  
TCCTATCAACAAGGGGTCTTGTCTGCCACCATCCTCTATGAGATCCTGCTAGGGAAAGCC 
 S  Y  Q  Q  G  V  L  S  A  T  I  L  Y  E  I  L  L  G  K  A  
ACCCTGTATGCTGTGCTTGTCAGTACACTGGTGGTGATGGCTATGGTCAAAAGAAAGAAT 
 T  L  Y  A  V  L  V  S  T  L  V  V  M  A  M  V  K  R  K  N  
TCATGACTCGAGCAATTGCGACGC 
 S STOP L  E  Q  L  R  R 
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5.4.2 Verification of TCRα-2A-TCRβ  3.5 expression on the cell surface and stable 
transfection into the GP+E86 retroviral producer cell line 
The TCRα and TCRβ expression on the cell surface was determined by transient 
transfection of the pMIGII-empty vector or pMIGII-TCRαβ3.5, with or without the 
pMIGII-CD3βγεζ co-receptor components, into 293T human embryonic kidney cells. 
As seen in Fig 5.14A, B and C, transfection of the pMIGII vector, with or without the 
TCRαβ3.5 insert resulted in GFP expression detected by confocal microscopy and flow 
cytometry. However, only the 293T cells that were transfected with both pMIGII-
TCRαβ3.5 and pMIGII-CD3βγεζ showed TCRβ expression on the cell surface as seen 
in Fig. 5.14D. This result verified that the vector successfully produced TCRα and 
TCRβ chains that assembled with CD3βγεζ subunits, since these steps are a pre-
requisite for surface TCR expression. 
The pMIGII-TCRαβ3.5 was used to stably transduce a retroviral packaging cell line, 
GP+E86. GP+E86 is a 3T3-based cell line. It constitutively expresses the Moloney 
Leukaemia virus gag and pol genes from one stably transfected plasmid and the 
Moloney ecotropic env gene from another transfected plasmid, providing a safe 
packaging vector to produce replication defective retroviral vector particles (Markowitz 
et al., 1988). These packaging cells were stably transduced with the pMIGII-TCRαβ3.5 
vector by repeatedly co-culturing the GP+E86 cell line with defective retrovirus-
containing supernatant harvested from 293T cells that were transiently co-transfected 
with pMIGII-TCRαβ3.5 together with gag, pol and env retroviral genes in separate 
vectors. This transduction system resulted in 99.9% transduction efficiency of the 
GP+E86 cell line (Fig. 5.15). The titres for the GP+E86 transduced cells were 
determined to be 2.693x105cells/mL for the pMIGII-empty vector and 
3.727x105cells/mL for the pMIGII-TCRαβ3.5 (Figures 5.16 and 5.17). The high titres 
obtained here were imperative for the construction of TCRαβ3.5 retrogenic mice. 
5.4.3 Autoimmune pancreatitis in TCRαβ3.5 retrogenic mice 
To determine if CD8 T cells expressing TCRαβ3.5 were able to drive autoimmune 
pancreatitis and recapitulate the phenotype of the original MUT3 donor and secondary 
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Figure 5.14 Verification of TCR expression 48 hours after transfection of 293T cells with pMIGII-TCRαβ3.5  and pMIGII-
CD3δγεζ or controls.
A. Brightfield images of the cells in culture viewed at x200 magnification; bars represent 200 µm.
B. GFP detection of cells under UV light viewed at x200 magnification; bars represent 200 µm.
C. Expression of GFP (green) detected by flow cytometry. Grey solid histogram is the non-transfected control.
D. Expression of cell surface TCRß (red) detected by flow cytometry. Grey solid histogram is the non-transfected control.
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Figure 5.15 The generation of stably transfected retroviral
GP+E86 producer cell lines.
A. GPF expression detected by flow cytometry for GP+E86 cells
that have been repeatedly transduced with supernatant from
293T cells that had been transiently transfected with pMIGII
or pMIGII-TCRαβ3.5 after 72 hours of culture.
B. Brightfield images of the cells in culture after cells have
grown to confluency (48 hours after (A)) viewed at x200
magnification; bars represent 200 µm.
C. GFP detection of cells under UV light viewed at x200
magnification; bars represent 200 µm.
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Figure 5.16 Determination of retroviral titres for the stably
transduced retroviral GP+E86 producer cell line.
GPF expression detected by flow cytometry for 3T3 cells
transduced with the indicated dilutions of retroviral
supernatant harvested from GP+E86 after 48 hours of
culture.
A. Non transfected
B. pMIGII-empty vector
C. pMIGII-TCRαβ3.5
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B
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Figure 5.17 Determination of retroviral titres for the stably
transduced retroviral GP+E86 producer cell line.
Graph shows the percentage of GFP+ cells resulting from exposure
to 1:10, 1:33 and 1:100 dilutions of retroviral supernatant harvested
from GP+E86 and applied onto 3T3 cells for 48 hours. A linear
regression was performed and the equation and r2 values for each
line of best fit is shown. For determination of titres, the dilution that
results in 50% GFP+ cells is interpolated from the equation and
used to calculate the total number of GFP+ transduced cells per mL
of supernatant using the formula: percent positive × 0.01 × dilution
factor × 104 cells.
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recipient B10.BR.Aire-/-Cblb-/- mice, TCRαβ3.5 retrogenic bone marrow chimeras were 
generated. The retroviral GP+E86 cell lines expressing pMIGII-TCRαβ3.5 or the 
control pMIGII-empty vector was used to transduce B10.BR.wild-type or B10.BR.Cblb-
/- bone marrow. The transduced marrow was used to reconstitute the hemopoietic 
system of irradiated Rag1-/-Aire+/+ or Rag1-/-Aire-/- recipients. This experimental design 
resulted in TCRαβ3.5 retrogenic chimeras with four relevant genotypic combinations: 
wild-type T cells and thymic epithelium, Cblb-/- T cells with wild-type thymic 
epithelium, wild-type T cells with Aire-/- thymic epithelium, or Cblb-/- T cells combined 
with Aire-/- thymic epithelium. Two control groups of chimeras were constructed in 
parallel, by reconstituting Rag1-/-Aire+/+ recipients with B10.BR wild-type bone marrow 
that was either non-transduced or transduced with pMIGII-empty vector. A detailed 
schematic of the experimental design is shown in Fig. 5.18.  
The bone marrow chimeras were closely monitored for weight loss. By 22 days post 
reconstitution, all recipients of pMIGII-TCRαβ3.5 transduced marrow began to lose 
weight regardless of their Aire or Cblb genotypes. The weight loss appeared to be more 
severe for the groups receiving the Cblb-/- bone marrow, although larger group sizes 
would be needed to test this inference statistically. By contrast, the recipients of the 
empty vector transduced bone marrow maintained relatively consistent body weight 
throughout the 29 days time course (Fig. 5.19). The severe weight loss in the Aire-/-
Cblb-/- retrogenic group may simply reflect the autoimmunity in B10.BR.Aire-/-Cblb-/- 
bone marrow chimeras described in Chapter 3, since the transplanted bone marrow 
would generate a polyclonal T cell repertoire. However, the trend towards weight loss 
in the fully wild-type retrogenic chimeras can be directly compared to the control group 
which was transduced with pMIGII-empty vector, and suggests that the TCRαβ3.5 cells 
were able to drive weight loss even with wild-type Aire and Cblb. 
Definitive evidence that TCR3.5-expressing cells drive pancreatic autoimmunity came 
from histological analysis of the retrogenic animals Fig 5.20. Empty vector transduced 
wild-type chimeras remained relatively free of pancreatitis, whereas corresponding 
wild-type chimeras that received TCRαβ3.5-transduced bone marrow displayed severe 
exocrine pancreatic lymphocytic infiltration (pancreatitis scores ranging from 3 to 5). 
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Co-culture with irradiated
retrovirus producer cells
BM 5-10% 
GFP
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500 rads
Figure 5.18 Retroviral transduction of bone marrow stem cells.
Bone marrow stem cells from 5-fluorouracil-treated wild-type or
Cblb-/- donor mice were transduced by co-culture with TCRαß3.5
transfected GP+E86 retroviral producer cells and used to
reconstitute sub-lethally irradiated Rag1-/- wild-type or Rag1-/-Aire-/-
recipient mice. This experimental design creates retrogenic
chimeras of wild-type, Aire-/-, Cblb-/- and Aire-/-Cblb-/- genotypes.
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Figure 5.19 TCRαβ3.5 retrogenic mice lose weight within 25
days post-reconstitution.
A. Weight of retrogenic mice monitored for 29 days. Every line
represents a single recipient mouse. Mice in the same groups
are coded with the same colour.
B. Percentage of weight variation comparing the weight of mice
on day 0 and day 25 (when the first group of mice were
sacrificed after losing >15% of their body weight). Each dot
represents a single mouse, bars represent means.
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Figure 5.20 TCRαβ3.5 retrogenic mice displayed pancreatitis
within 25 days post-reconstitution.
Haematoxylin and eosin stained pancreas sections from retrogenic
mice. Magnification: x100, Bars: 500µm. Pancreatitis scores are
indicated on the top right corner of each sample.
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The fact that pancreatitis was induced by TCRαβ3.5 despite the presence of normal Aire 
in the recipients’ thymic epithelium and normal Cblb in the T cells may reflect the high 
frequency of self-reactive T cells or dysregulated expression of the retrogenic TCR, as 
discussed at the end of this chapter. Regardless, this result validated the adoptive 
transfer enrichment assays described in section 5.3 by showing that one of the TCR 
clonotypes that accumulated in the pancreas was indeed an exocrine pancreas-specific 
driver clone.   
Severe pancreatitis was also present in the other TCRαβ3.5-transduced marrow 
recipient groups Fig 5.20, with those receiving Cblb-/- bone marrow displaying 
marginally more severe disease scores. This trend was consistent with the weight loss 
observation but is more problematic to interpret because of the occurrence of exocrine 
pancreatitis in conventional Rag1-/- bone marrow chimeras that receive Cblb deficient 
bone marrow or lack Aire in their thymic epithelium (unpublished data). 
5.4.4 Flow cytometric analysis of TCRαβ3.5 retrogenic mice 
To determine the impact of negative and positive selection on T cells expressing 
TCRαβ3.5 during development in the thymus, the TCRαβ3.5 retrogenic mice were 
analysed by flow cytometry at the time of sacrifice. Expression of GFP was used to 
identify T cells that expressed the retroviral vector. The intensity of GFP per cell varied 
by more than two orders of magnitude within individual chimeras, as well as from one 
chimera to another (Fig 5.21A). This is likely to be caused by variation in the 
permissiveness for retroviral transcription between different chromosomal sites of 
retroviral integration, which will be unique in each transduced hemopoietic stem or 
progenitor cell (Klug et al., 2000). Since the level of retroviral expression in any given 
cell would influence the amount of TCRαβ3.5 that was produced, the developing 
thymocytes and mature T cells in all TCRαβ3.5 retrogenic mice were divided into three 
populations – GFPneg, GFPlow and GFPhi. The percentage of cells within each population 
varied from mouse to mouse, but standardizing cells for the level of retroviral 
expression allowed cells with high expression (GFPhi) to be compared to those with 
none (GFPneg). For all the cellular phenotypes described in the remainder of this section, 
there appeared to be no observable effects of the Aire- and Cblb-deficiencies in 
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Figure 5.21 Flow cytometry plots of thymocytes in retrogenic mice.
A. Gated on double positive cells, histograms show the distribution of GFP expression on DP cells in each of the
indicated experimental groups. The percentage of GFPneg, GFPlow and GFPhi cells are shown.
B. CD4 versus CD8 plots gated on GFPneg, GFPlow and GFPhi thymocytes. Percent of cells in each window is
shown.
C. Overlaid histograms gated on GFPneg, GFPlow and GFPhi CD8 cells showing CD3 expressions.
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development and activation of T cells expressing high levels of pMIGII-TCRαβ3.5. 
Hence, for simplicity, all recipient genotypes would be described as a single retrogenic 
TCRαβ3.5 group unless otherwise stated. 
Since the TCR3.5 clonotype was isolated from CD8+ T cells, it would be expected that 
thymocytes expressing the pMIGII-TCRαβ3.5 vector at high levels would be positively 
selected into the CD8 single positive (SP) subset. Comparing the percentages of GFPhi 
thymocytes that developed into CD4+SP or CD8+SP cells tested this hypothesis. As seen 
in Fig. 5.21 and 5.22, the GFPneg DP T cells that did not express the TCRαβ3.5 receptor 
formed a lower percentage of CD8+SP than CD4+SP cells, in an ~1:3 ratio that was 
comparable to that of control chimeras reconstituted with non-transduced or empty 
vector-transduced bone marrow recipients. Likewise, GFPhi cells expressing the 
pMIGII-empty vector differentiated into CD4+SP and CD8+SP cells at the normal ratio.  
By contrast, CD8+SP cells were produced in marked excess to CD4+SP cells in the 
GFPhi cells expressing pMIGII-TCRαβ3.5 (Fig. 5.22A). Thus, expression of TCR3.5 
promotes positive selection into the CD8 lineage. 
The CD8 SP GFPhi cells expressing pMIGII-TCRαβ3.5 differed from GFPhi CD8 SP 
cells expressing pMIGII-empty vector, and from CD8 SP cells that were GFPneg, in that 
they carried less CD3 on their cell surface (Fig 5.21C and Fig 5.22B). This trait may 
reflect active downregulation of the 3.5 TCR as a result of its reactivity with self 
antigens, or it may reflect inefficient cleavage and surface expression of the retrovirally-
encoded TCR, as discussed at the end of the chapter. 
The accumulation of GFPhi thymocytes within the CD8 SP subset in the retrogenic 
animals also implied that DP and CD8 SP cells expressing the pancreas-specific 
autoreactive TCRαβ3.5 were not subjected to pronounced thymic negative selection 
regardless of the Aire or Cblb genotype. This contrasted with the marked decrease in 
CD4 SP cells bearing the insulin-specific TCR3A9:insHEL described in chapter 4, which 
underwent Aire-dependent negative selection, and with published studies of retrogenic 
mice expressing other self-reactive TCRs (Holst et al., 2006b). 
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Figure 5.22 Graphs show the comparisons for GFPneg (black
bars) and GFPhi (white bars) cells for:
A. Percentages of CD8 cells from total thymocytes
B. CD3 geometric fluorescent mean intensity for CD8 cells
C. Forward light scatter geometric mean intensity for CD8 cells
A
B
C
GFPneg
GFPhi
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The conclusion that TCRαβ3.5 expressing cells were not subject to thymic negative 
selection was reinforced by the finding of high frequencies of GFPhiCD8+ T cells in the 
peripheral lymph nodes and spleen of each of the retrogenic TCRαβ3.5 groups. A 
normal frequency of CD8+ cells, representing ~25% of gated T cells, was observed in 
GFPnegCD3+ T cells in the lymph nodes of all retrogenic animals (Fig. 5.23A-F, GFPneg 
panels; 5.24A, upper panel). Likewise, there was a normal frequency of CD8+ cells 
among GFPhiCD3+ T cells in control retrogenic animals expressing the pMIGII-empty 
vector (Fig. 5.23B and 5.24A). This normal apportioning between CD4 and CD8 subsets 
is consistent with these T cells lacking TCRαβ3.5 and expressing a normal, polyclonal 
repertoire of TCRs. By contrast, in GFPhiCD3+ T cells expressing the pMIGII-
TCRαβ3.5 vector at high levels, CD8+ T cells accounted for more than 80% of 
GFPhiCD3+ T cells in the lymph nodes regardless of Aire or Cblb genotype (Fig. 5.23C-
F and 5.24A lower panel). 
Analysis of CD3 expression revealed only a subtle decrease in CD3 expression on the 
GFPhiCD8+ T cells in lymph nodes of the TCRαβ3.5 retrogenic mice (Fig. 5.23C-F and 
5.24B lower panel). This contrasted with the much more marked decrease observed for 
GFPhiCD8+ SP cells in the thymus, suggesting that surface expression of the retroviral-
encoded TCR recovered by the time the thymocytes had emigrated and fully matured. 
Further analysis of the GFPhiCD8+ T cells accumulating in the various peripheral lymph 
nodes of the retrogenic animals provided evidence that these were not tolerant but were 
activated selectively in the lymph nodes that drain the pancreas and intestinal tract. In 
the axillary and inguinal lymph nodes of TCRαβ3.5 retrogenic mice the mean geometric 
intensity of forward scatter for GFPhiCD8+ T cells was comparable to that of GFPhi 
CD8+ T cells from the empty vector control retrogenic animals (Fig. 5.23C-F , 5.25 and 
5.27A lower panel). This measure of T cell size increased in the pancreatic lymph node 
and mesenteric lymph node of the TCRαβ3.5 retrogenic mice but not in the empty 
vector controls (Fig. 5.23C-F , 5.25 and 5.27A lower panel).  
The difference in CD8 T cell activation between pancreatic versus inguinal and axillary 
lymph nodes was most clearly revealed when CD44 expression was used as a measure 
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Figure 5.23 Representative flow cytometry plots and
histograms of peripheral lymphocytes in retrogenic mice.
For each sample, flow cytometric plots represent CD45.2, B cells, T
cells, CD4 cells, CD8 cells, FSC, CD3 expression and CD44
expression on GFPneg, GFPlow and GFPhi expressors from
experimental groups.
A. Non-retrogenic control
B. Wild-type pMIGII vector control
C. Wild-type pMIGII-TCRαß3.5
D. Cblb-/- pMIGII-TCRαß3.5
E. Aire-/- pMIGII-TCRαß3.5
F. Aire-/- Cblb-/- pMIGII-TCRαß3.5
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Figure 5.24 Graphs show the comparisons for GFPneg (black
bars) and GFPhi (white bars) cells for:
A. Percentages of CD8 cells from total T cells
B. CD3 geometric fluorescent mean intensity for CD8 cells
Each dot represents a single mouse. Bars represent means
and error bars represents standard deviations. A: Axillary
lymph node, I: Inguinal lymph node, M: messenteric lymph
node, P: Pancreatic lymph node, p: pancreas, S: spleen
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Figure 5.25 Histograms of forward size scatter measurement on
CD8+GFPhiCD3+CD45.2+ cells in axillary (ALN), inguinal
(ILN), messenteric (MLN), pancreatic (PLN) lymph nodes.
pMIGII-empty pMIGII-TCRαβ3.5
WT              WT           Cblb-/-          Aire-/-      Aire-/-Cblb-/-
# cells
FSC
Gate:CD8+GFPhiCD3+CD45.2+
ALN
ILN
MLN
PLN
0 50K 100K 150K 200K 250K
0
20
40
60
80
100
243
Figure 5.26 Histograms of CD44 expression on
CD8+GFPhiCD3+CD45.2+ cells in axillary (ALN), inguinal
(ILN), messenteric (MLN), pancreatic (PLN) lymph nodes.
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Figure 5.27 Graphs show the comparisons for GFPneg (black
bars) and GFPhi (white bars) cells for:
A. Forward light scatter geometric mean intensity
B. CD44 mean geometric intensity for
C. (B) represented as percentage of CD8 GFPhi cells that are
CD44hi
Each dot represents a single mouse. Bars represent means
and error bars represents standard deviations. A: Axillary
lymph node, I: Inguinal lymph node, M: messenteric lymph
node, P: Pancreatic lymph node, p: pancreas, S: spleen
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of T cell activation (Fig. 5.23C-F , 5.26 and 5.27B-C lower panel). In the axillary and 
inguinal lymph nodes of TCRαβ3.5 retrogenic mice the majority of GFPhiCD8+ T cells 
were CD44low, bearing levels of CD44 comparable to those of antigenically naïve CD8 
T cells. By contrast, the majority of GFPhiCD8+ T cells were CD44hi in the pancreatic 
lymph nodes of the same chimeras, consistent with their having encountered pancreas-
derived autoantigen on dendritic cells in the pancreatic lymph node.  In the mesenteric 
lymph nodes and spleen of the retrogenic animals, there were intermediate frequencies 
of activated CD44hi activated T cells among the GFPhi CD8 cell subset. In the case of 
the spleen, these activated T cells are likely to have migrated to the organ via the 
bloodstream after activation in the pancreatic lymph node, since the downregulation of 
CD62L lymph node homing receptors that occurs on activated T cells still allows their 
migration to the spleen whereas migration to other lymph nodes is normally blocked. 
By the same reasoning, the activated GFPhi CD8 cells in the mesenteric lymph node are 
likely to have been activated in situ. This observation raises two possibilities. One 
possibility is that the pancreatic autoantigen recognized by TCR3.5+ CD8 cells was also 
made in the intestine, where it was captured and presented by dendritic cells that 
migrate via intestinal lymph to the mesenteric node. Evidence for pancreatic enzyme 
expression by intestinal epithelial cells exists (Ponnuraj and Hayward, 2001). 
Alternatively, some dendritic cells or activated T cells that originate in the pancreas 
may migrate to the mesenteric node, for example via the peritoneal cavity, which is 
known to drain especially to the pancreatic lymph nodes and thence to the mediastinal 
intrathoracic lymph nodes, but also to the mesenteric lymph nodes (Andrade et al., 
1996; Parungo et al., 2007; Turley et al., 2005; Watanabe et al., 2000). 
5.5 Chapter summary and key findings 
5.5.1 Multiplex single cell sequencing to isolate autoimmune driver clones in Aire-
/-Cblb-/- mice. 
The aim of this chapter was to further understand the cellular basis for co-operative 
interaction between Aire and Cblb-deficiencies by establishing an experimental system 
to determine the specificity and regulation of the autoimmune driver T cell clone(s) in 
Aire-/-Cblb-/- mice. To achieve this, two rounds of adoptive transfer of Aire-/-Cblb-/- 
splenocytes into lymphopenic Rag1-deficient were used, followed by single cell TCR 
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profiling, to isolate putative pancreas-specific TCRα and TCRβ chains carried by driver 
CD4 and CD8 clones.  
Following secondary transfers, there were cellular phenotypic differences between the 
wild-type and Aire-/-Cblb-/- cell recipients. Flow cytometry analysis (Figs. 5.3 and 5.10) 
showed an over-representation of the CD8 cells or under-representation of CD4 cells in 
the Aire-/-Cblb-/- recipients compared to wild-type counterparts. Additionally, forward 
side scatter measurements indicated that the Aire-/-Cblb-/- recipient CD8 cells were 
enlarged, a common indication of activation. Although the splenic adoptive transfer 
assays in Chapter 3 indicated that both CD4 and CD8 cells were necessary for lethal 
autoimmunity in the recipients, transfer of CD4-depleted or CD8-enriched spleen cells 
was sufficient to induce extensive exocrine pancreatitis measured histologically. Thus, 
it is possible that pancreas-specific CD8 cells are responsible for the major insult to the 
exocrine pancreas cells while CD4 cells provide help to augment CD8 cell 
accumulation and differentiation into cytotoxic effectors. This scenario is supported by 
evidence of co-operation between CD8 and CD4 cells in adoptive transfer and depletion 
studies in NOD mice (Bendelac et al., 1987; Miller et al., 1988; Mora et al., 1999; 
Nagata et al., 1994; Peterson and Haskins, 1996; Santamaria et al., 1995; Serreze et al., 
2001; Verdaguer et al., 1997; Wang et al., 1996; Wong et al., 1996; Wong et al., 1998; 
Yagi et al., 1992). Direct evidence that autoreactive CD4 cells help CD8 cell expansion 
and autoimmune destruction comes from adoptive co-transfer of autoreactive CD8 and 
CD4 cells recognizing ovalbumin or influenza haemagglutinin expressed as transgenic 
self antigens in pancreatic islet beta cells (Hernandez et al., 2002; Kurts et al., 1997a). 
CD8 T cells may also possess the ability to undergo greater clonal expansion compared 
to CD4 cells. My results have parallels with the observation that CD8-antigen specific 
but not CD4 T cells were over-represented in peripheral blood in Hashimoto’s 
thyroiditis patients, and there was a trend for a more CD8 skewed repertoire in patients 
who had suffered with the disease for an extended period of time compared to newly 
diagnosed patients (Okajima et al., 2009). 
Surprisingly, despite cellular differences in wild-type and Aire-/-Cblb-/- CD8 cells 
isolated from secondary recipients, single-cell TCR sequencing from recipients of either 
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displayed clonally expanded CD4 and CD8 cells, albeit enrichment was less 
pronounced in recipients of wild-type compared to Aire-/-Cblb-/- spleen cells. It can be 
suggested that the expansion seen in the wild-type secondary recipients may be a 
response to commensal flora within the gut (Kieper et al., 2005), a phenomenon that 
frequently occurs when lymphoid cells are initially transferred into lymphopenic 
recipients. It seemed reasonable to predict that the expansion in Aire-/-Cblb-/--recipients 
was “driven” by a pancreatic antigen for those expanded T cell clones that accounted 
for a higher fraction of T cells in the pancreas compared to the spleen. Several CD8 
TCR clonotypes fulfilled this criteria and one dominant clone, TCR 3.5, was chosen 
initially for further analysis because it represented 30.7% of the splenic and 69.0% of 
the pancreatic CD8 T cell repertoire in secondary MUT3 recipients. The spontaneous 
development of exocrine pancreatitis in retrogenic mice expressing TCR3.5, and 
selective activation of TCR3.5-expressing CD8 cells in the pancreatic but not axillary or 
inguinal lymph nodes, confirmed that this was indeed a driver clone capable of causing 
extensive exocrine pancreatitis, as will be discussed further in section 5.5.3. 
5.5.2 Discussion of other expanded T cell clones revealed by single-cell sequence 
analysis. 
5.5.2.1. TCRs 1.17 and 1.18 shared in recipients from two separate donors. It was 
interesting that the MUT1 and MUT2 secondary recipients revealed clonal expansion of 
CD8 cells bearing identical TCRs – clonotype 1.17 and 1.18 – despite receiving spleen 
cells that originated from separate MUT1 and MUT2 donor chimeric animals (section 
5.2). The possibility of contamination during the sorting, PCR and sequencing steps 
seemed unlikely, as there was no overlap with the TCRs amplified from CD4 cells in 
the MUT1 and MUT2 recipients. Contamination during processing or staining would 
have been predicted to result in the same TCRs being detected in both CD4 and CD8 
cells.     
Convergent evolution is another theoretical explanation: that the two clones arose 
independently in the MUT1 and MUT2 donors but were selected to have an identical 
TCR sequence based on binding to the same exocrine-specific antigens with high 
affinities. The likelihood of two pancreas-infiltrating CD8 clones with the same TCRα-
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TCRβ pairing and exact same CDR3s evolving independently in MUT1 and MUT2 
seems small. It would seem difficult to explain the complete identity of the TCR 
junctional nucleotide sequences by selection for TCR specificity, since antigenic 
selection can only operate on the protein sequence and not on the redundant nucleotides 
such as those in +3 positions within each codon, which would be expected to yield 
synonymous differences at the nucleotide level. In diabetogenic CD8 T cells cloned 
from the pancreatic islets of NOD mice such as NY7.2 and NY8.3 (Santamaria et al., 
1995), however, recurrent use of TCRβ and TCRα chains that were identical at the 
nucleotide level was indeed shown to result from selection for autoantigen specificity 
because the T cells were isolated from independent mice and differed at the level of co-
expressed TCR transcripts from out-of-frame rearrangements. The efficient ability of 
clonal selection to arrive at identical TCRα chain nucleotide sequences in many 
independent animals was reinforced by Tra sequence analysis of islet-infiltrating CD8 
cells from NOD mice bearing a rearranged Trb transgene from the NY8.3 clone but 
unconstrained Tra diversity (Verdaguer et al., 1996). In this light, it is noteworthy that 
the TCRα chain sequence in TCR clonotype 1.18 was also found in TCR clonotype 2.7 
but in the latter it was paired with a different TCRβ chain sequence. This again 
resembles the patterns that arose from convergent evolution in independent 
diabetogenic CD8 T cell clones (Santamaria et al., 1995). However the presence of an 
identical TCRα chain but different TCRβ chains may also have arisen in clonotype 2.7 
by divergent evolution of progeny from a single CD8 T cell, through re-expression of 
Rag1 and Rag2 genes allowing secondary Trb rearrangements as has been shown to 
occur in diabetogenic CD8 cells from NOD mice (Serra et al., 2002). 
The possibility of convergent evolution of exocrine pancreas-specific CD8 cells, 
comparable to that described for pancreatic islet-specific CD8 cells by Santamaria’s 
group (Santamaria et al., 1995; Verdaguer et al., 1997), is also supported by the 
similarities within expanded CD8 clones in MUT3 recipients. Thus clonotype 3.5, 
which used to construct retrogenic mice and shown to be a driver of exocrine 
pancreatitis, uses identical α chain and β chain V and J elements to clonotype 3.6 and 
have similar but nevertheless distinct junctional sequences, indicating that these clones 
must have arisen independently yet have been selected to have very similar TCRs 
(Table 5.9).  Clonotype 3.8 has an identical beta chain sequence to clonotype 3.5 but a 
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different alpha chain. It is conceivable that these two clonotypes have arisen from 
divergent evolution of daughter cells derived from the same founder CD8 cell as a result 
of secondary alpha chain rearrangements (Serra et al., 2002), although convergent 
evolution appears equally plausible given the evidence from Santamaria’s analyses.  
It is potentially significant that clonotype 3.5 was more frequent in pancreas than in 
spleen, whereas the related clonotype 3.6 was equally frequent in both tissues and the 
other related clonotype 3.8 was only detected in spleen. Recent analysis of recurring 
TCR clonotypes among islet-reactive CD8 T cells by Santamaria’s group (Han et al., 
2005b; Tsai et al., 2010) has revealed that T cells with small differences in their alpha 
chain but identical beta chains have identical pMHC specificity but nevertheless differ 
approximately 10-fold in affinity. The high affinity CD8 cells mediate pancreatic 
destruction provided they escape activation-induced death and their frequency becomes 
sufficiently high so that they dominate the CD8 infiltrates within the pancreatic islets. 
By contrast, the low affinity CD8 cells preferentially accumulated in the blood, spleen 
and pancreatic lymph node as activated CD44hi CD122hi CD62Lhi memory cells that 
were unable to make IL-2 or proliferate in vitro but potently suppressed proliferation of 
high affinity CD8 cells either in vitro or in the pancreatic lymph node, and powerfully 
suppressed diabetes in NOD mice. The suppressive function of low affinity islet-
specific CD8 cells was ascribed to inhibition of antigen presentation by dendritic cells 
through interferon gamma and the immunoregulatory enzyme idoleamine 2,3-
dioxygenase, and elimination of islet antigen-presenting dendritic cells by perforin-
mediated killing (Tsai et al., 2010). These results raise the possibility that clonotypes 
3.8 and 3.6 may similarly have lower affinity than clonotype 3.5, so that they 
accumulate equally or primarily in lymphoid tissues as regulatory memory CD8 cells. It 
should be possible to test this hypothesis in future experiments, by comparing 
retrogenic mice expressing clonotypes 3.5, 3.6 and 3.8.   
A third explanation for the occurrence of CD8 T cells with identical TCRs in MUT1 
and MUT2 but not MUT3 recipients is based on the fact that a single pool of Cblb-/- 
bone marrow was transplanted into irradiated Aire-/- recipients to generate the original 
bone marrow chimera donors MUT1 and MUT2, whereas the MUT3 donor was entirely 
independent (and was not a bone marrow chimera). Mature CD8 T cells bearing TCR 
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clonotypes 1.17 and 1.18 may already have been present in the Cblb-/- bone marrow, 
which was not depleted of T cells before transplantation, and these “passenger” T cells 
clonally expanded in both the irradiated Aire-/- MUT1 and MUT2 chimeras and in the 
primary and secondary recipients of spleen or pancreas cells from MUT1 and MUT2. 
For this explanation to apply, CD8 T cells bearing TCR clonotypes 1.17 and 1.18 must 
have evaded clonal deletion in the Aire+/+ thymus of the Cblb-/- marrow donor, so that 
these CD8 T cells were present in the bone marrow. This inference has interesting 
parallels with the observation that the dominant CD8 T cell clonotype from MUT3, 
TCRαβ3.5, did not appear to undergo clonal deletion in retrogenic mice with a wild-
type Aire+/+ thymus. Taken together, these data raise the possibility that the CD8 T cells 
responsible for exocrine pancreatitis in Aire-/-Cblb-/- double mutant mice are not 
regulated by Aire, and that the effects of Aire-deficiency may act through co-operating 
CD4 helper T cells or antagonistic Foxp3+ Tregs. 
5.5.2.2. Analysis of TCRs 1.18, 1.22 and 1.23 confounded by two co-expressed 
chains. The multiplex single cell PCR method is a powerful strategy to accurately 
detect clonal expansion in the T cell repertoire. However, this method did produce 
several recurring TCR clonotypes where assignment to particular TCRα or TCRβ gene 
segments proved challenging. One example is clonotype 1.18 where a large fraction of 
the single CD8 cells analysed in MUT1 recipients could only be assigned to a complete 
TCRβ but not a TCRα. The nucleotide sequence chromatogram of the TCRα region 
sequence for a typical T cell bearing clonotype 1.18 is shown in Fig 5.28 and displayed 
in the 3’→5’ direction as the Trac reverse primer was used for the sequencing. The 
sequence was characterized by a region of homogeneous nucleotide sequence that 
corresponded to the 5’ end of the Trac (constant) region, followed by many overlapping 
dual peaks in the Traj and Trav regions indicating the presence of two different variable 
domain nucleotide sequences on the single T cell (Petrie et al., 1993). Dual-TCRs occur 
at a frequency of 30% of T cells in normal mice (Casanova et al., 1991) and this dual 
specificity could result in an autoreactive TCR bypassing negative selection during 
thymic development due to the presence of a second non-autoreactive receptor (Zal et 
al., 1996). Besides clonotype 1.18, clonotypes 1.22 and 1.23 also appeared to have two 
peaks within the Trbj and Trbv regions, while each bearing a unique TCRα, highly 
suggestive of the presence of two TCRβs on each clone  (Fig. 5.29). The nature of the 
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Figure 5.28 Nucleotide chromatogram sequences for clonotype 1.18.
The 3’ to 5’ nucleotide chromatogram sequences obtained by sequencing the TCRα chain using the Trac internal
reverse primer. The shaded areas correspond to the sequences of the TCRα constant region. After the shaded region,
double peaks are present throughout the sequence.
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second TCRα or TCRβ in clonotype 1.18, 1.22 and 1.23 could be resolved by blunt-end 
cloning of the PCR product into an expression vector, transformation into competent 
bacterial cells and PCR screening the bacterial colonies for the detection of the two in 
frame TCRα or TCRβ sequences. Cloning of the individual TCRs from these clonally 
expanded T cells would enable an accurate sequence to be obtained for each Tra or Trb 
expressed, to determine if the co-expressed sequences are both in-frame or if one of the 
sequences derives from an out-of-frame rearrangement on the other TRA or TRB allele. 
It is noteworthy that a subset of T cells with clonotypes 1.18, 1.22 and 1.23 lacked 
amplification of a second Tra or Trb cDNA (Fig. 5.29). These T cells may represent 
independent clones arriving at the same TCR sequence by convergent evolution, as 
discussed above, or the second mRNA may simply have been present at lower 
abundance and failed to be co-amplified from all of the T cells.   
5.5.2.3. Analysis of TCR 2.4 confounded by apparent failure to amplify the in-
frame alpha chain. Another interesting clone, clonotype 2.4 consistently displayed a 
TCRβ similar to that of clonotype 2.1. However, the TCRα could only be assigned to a 
Trav6D-7 or 6-5. Following the Trav sequence, there appeared to be a stop codon after 
13 codons, making it impossible to assign it to the appropriate Traj gene segment. The 
nucleotide chromatogram traces did not have dual-peaks and could clearly be assigned 
to a particular bases without any ambiguity. This sequence could be translated into three 
reading frames as seen in Fig. 5.29. The frames are seen in the 3’→5’ direction as the 
Trac reverse primer was utilised for sequencing. As seen in the Fig. 5.30, when 
translated in “Frame 2”, Trav6D-7 or 6-5 could be assigned as the appropriate Trav 
sequence but when translated in “Frame 3” the sequence matched Traj30. Thus, the 
TCRα detected during sequencing represented an mRNA from an out-of-frame non-
productive TCRα rearrangement present within the cell. It is likely that there was a 
functional TCRα that was not amplified by the multiplex PCR strategy used here either 
due to the dominance of the out-of-frame TCR in the cell, no coverage of the in-frame 
TCRα by the 23 Trav forward primers used or suboptimal primer binding condition for 
the in-frame Trav forward TCRα primer. It would be useful to utilise the cloning 
strategy described in the previous paragraph to search for another in-frame TCR for this 
clone. 
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Figure 5.29 Figure shows the frequencies of clonotypes 1.18,
1.22 and 1.23 and the number of clones in which double peaks
were observed (in red).
Clonotype S0 P0 P1 S2<S1 P2<S1 S2<P1 P2<P1
1.18 14/38 21/51 5/31 42/73
1.22 25/51
1.23 4/51
Clonotype S0 P0 P1 S2<S1 P2<S1 S2<P1 P2<P1
1.18 7/38 16/51 0/31 35/73 Trav
1.22 22/51 Trbv
1.23 2/51 Trbv
WT1 & MUT1 GROUP
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Trav6D-7, 6.5
Traj30
Figure 5.30 Translation of the nucleotide sequence of
clonotype 2.4 in three different reading frames.
The translation of the nucleotide sequenced obtained by sequencing
the TCRα sequence using the Trac internal reverse primer.
Translation with reading frame 2 detects usage of Trav6D-7 or 6.5
(red) and translation with reading frame 3 detects the usage of
Traj30 (green).
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5.5.3 Evidence for positive but not negative selection the TCRαβ3.5 clonotype in 
retrogenic mice 
Given the issues complicating simple interpretation of TCR sequence data, a key 
advance established here is the use of retrogenic mice to examine in vivo the fate and 
function of the different clonally expanded TCR clonotypes revealed by the multiplex 
sequence analysis. In order to achieve this, a stably transduced retroviral producer cell 
line expressing CD8 TCR 3.5 clonotype was generated. This cell line served as a 
valuable tool to examine the mechanism of organ-specific autoimmune disease in the 
Aire-/-Cblb-/- mouse model as it allowed for T cells expressing the putative organ 
specific TCR to be tracked based on their expression of GFP, because TCRα-2A-TCRβ 
3.5 and GFP were encoded by a single, tricistronic mRNA. A preliminary retrogenic 
experiment verified that clonotype 3.5 isolated from the adoptive transfer enrichment 
assay was pancreas-specific and able to recapitulate in mice with wild-type Aire and 
Cblb the exocrine pancreatic autoimmunity caused by polyclonal CD8 T cells from 
B10.BR.Aire-/-Cblb-/- mice.  
Because of the tricistronic mRNA produced in a subset of hemopoietic cells in the 
retrogenic mice, expression of GFP would be expected to correlate with the expression 
of TCRαβ3.5. Consistent with this expectation, GFPhi thymocytes and peripheral T 
cells were greatly skewed towards the CD8 subset consistent with positive selection on 
MHC Class I, whereas GFPneg and GFPlow T cells apportioned normally to yield ~75% 
CD4 cells and only ~25% CD8 T cells. Accumulation of large numbers of GFPhi CD8 T 
cells occurred in the thymus and peripheral lymph nodes of all TCRαβ3.5 retrogenic 
mice regardless of their Aire or Cblb genotypes. Thus there was no evidence that T cells 
expressing this TCR were negatively selected medulla after positive selection in the 
thymic cortex, nor after emigration to spleen, axillary and inguinal lymph nodes. While 
negative selection occurs efficiently in many TCR transgenic mice bearing self-reactive 
TCRs against trace antigens expressed in the thymic medulla, it is nevertheless formally 
possible that the high numbers of exocrine pancreas autoimmune driver TCRαβ3.5 cells 
overwhelmed the Aire-dependent negative selection that was usually in place to keep 
this clone in-check. Hence, reducing the starting concentration of the TCRαβ3.5 cells 
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using mixed retrogenic chimeras (WT: TCRαβ3.5, 50:50 ratio) may reveal a 
requirement for Aire-deficiency in negative selection of TCRαβ3.5 cells. 
Alternatively, it could be suggested that T cells expressing the TCRαβ3.5 receptor 
escaped thymic deletion by deviating to the atypical CD8αα intraepithelial lymphocytes 
(IEL), rather than adopting a conventional CD8αβ lineage (Yamagata et al., 2004). 
Although these IEL cells usually home to the gut (Leishman et al., 2001), they have 
been found in the pancreatic infiltrate in B6 and NOD BDC2.5 transgenic mice (Holler 
et al., 2007). In BDC2.5 transgenic mice, the frequency of the IELs detected in the 
pancreas correlated strongly with the aggressively of insulitis particularly in early stages 
of the disease indicating the cells have the potential of escaping the gut, homing to a 
different tissue and inducing pathogenicity (Holler et al., 2007). However, further 
analysis of the retrogenic mice in a subsequent experiment showed that majority of the 
GFPhi CD8 cells expressed both CD8α and CD8β (Fig. 5.31). 
While the data here show that TCR3.5+ CD8αβ T cells escaped thymic deletion even in 
Aire+/+ retrogenic mice, this may be due to the low surface expression of CD3 observed 
on GFPhi CD8 SP thymocytes compared either with GFPneg CD8 SP thymocytes in 
TCRαβ3.5 retrogenic mice or to GFPhi CD8 SP thymocytes from empty vector 
retrogenic mice (Figure 5.22B). CD3 and TCR expression normally increases following 
positive selection of DP thymocytes into CD8 SP cells, but this did not appear to occur 
in the positively selected GFPhi cells expressing the retroviral TCR3.5 until the CD8 
cells had matured in the periphery (Figure 5.24B). The delayed surface accumulation of 
the retroviral-encoded TCR may stem from inefficient cleavage of the 2A peptide 
sequence that links the TCR alpha and beta chains (Holst J, personal communication 
and (Holst et al., 2006b)), resulting in sufficient cleavage and TCR expression to 
support the low levels of surface TCR on DP cells and positive selection but insufficient 
to trigger deletion of CD8 SP cells in the thymic medulla. The efficiency of 2A-
mediated cleavage of different TCRα and β chains has been found to vary, and for some 
TCRs efficient cleavage required inclusion of a flexible Gly-Ser-Gly spacer between the 
C-terminus of the alpha chain and the 2A peptide that presumably allows the 2A peptide 
to adopt its catalytic conformation. In future studies, it will be important to test this 
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Figure 5.31 Flow cytometry plots of CD8α and CD8β populations
in retrogenic mice of the indicated genotype from an independent
experiment.
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possibility by constructing a second generation of TCR3.5 retrogenic mice using a 
construct that contains a Gly-Ser-Gly spacer. 
5.5.4 Are TCR3.5+ CD8 cells sufficient to induce exocrine pancreatitis?  
The ability of the TCR3.5 to serve as an autoimmune driver was established by finding 
extensive histological destruction of the exocrine pancreas in TCR3.5 retrogenic mice 
with wild-type Aire and Cblb genes, compared to completely normal pancreas histology 
in empty vector retrogenic mice of the same wild-type genotype. While there were high 
frequencies of GFPhi CD8 T cells presumably expressing TCR3.5 in these retrogenic 
mice, these developed among many more donor and host derived CD8 and CD4 T cells 
that did not express GFP and presumably carried a diverse, polyclonal TCR repertoire. 
Given the requirement for CD8 and CD4 cells discussed above, it is conceivable that 
these endogenous CD4 cells may have cooperated with the TCR3.5+ CD8 cells to 
enhance their activation in the pancreatic lymph node and accumulation and destruction 
of the exocrine pancreas.  Cooperation with helper cells may be more critical when the 
frequency of TCR3.5+ cells is not at the extraordinarily elevated frequencies present in 
the retrogenic chimeras. These issues could be addressed in future studies where the 
TCR3.5 retrogenic construct is transduced into Rag1-/- bone marrow, and then used to 
reconstitute Rag1-/- recipients alone or to reconstitute Rag1+/+ recipients after mixing the 
transduced Rag1-/- marrow with progressively increasing proportions of non-transduced 
Rag1+/+ marrow.  The finding of relatively little weight loss in the wild-type TCR3.5 
retrogenic chimeras, compared to Cblb-/- or Aire-/-Cblb-/- retrogenic animals, may also 
suggest that one or both mutations are required to allow full activation of pancreatic 
destruction, and this will need to be addressed in mixed chimeras where the frequency 
of TCR3.5+ cells is decreased as described above.  
5.5.5 What is the autoantigen recognized by TCR3.5+ CD8 cells?  
The selective destruction of the exocrine pancreas and selective activation of GFPhi 
CD8 cells in the pancreatic lymph node in TCR3.5 retrogenic mice indicates that the 
TCR 3.5 recognises an autoantigen that is specifically expressed in the exocrine 
pancreatic epithelium. Candidate autoantigens include the pancreas-specific protein 
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encoded by Pdia2, which has been shown to be a target of autoimmunity in NOD.Aire-/- 
mice (Niki et al., 2006) and in Balb/c.Ctla4-deficient mice (Ise et al., 2010). Testing the 
specificity of TCR3.5 will be facilitated by the availability of this TCR either as a 
retroviral vector that can be introduced into T cell hybridomas or expressed on CD8 T 
cells isolated from lymph nodes and spleen of retrogenic mice. The same approach 
would also conceivably allow definition of the autoantigen(s) recognized by the other 
pancreas and salivary gland expanded CD8 and CD4 T cell clonotypes. 
5.5.6 Summary. 
This chapter described the isolation and rapid analysis of an autoimmune driver T cell 
using single cell multiplex RT-PCRs and construction of retrogenic mice. Extending 
this strategy to the other CD8 and CD4 TCR clonotypes in the pancreas and to those 
from salivary gland T cells would allow detailed characterization of other pancreas- and 
salivary gland-specific clones from B10.BR.Aire-/-Cblb-/- mice. Considering the data 
from this chapter and previous chapters, it can be suggested that pancreas- and salivary 
gland-specific clones in B10.BR.Aire-/-Cblb-/- mice have different CD4 and CD8 cell 
requirements. The resulting autoimmunity in the mice may also be a result of a complex 
co-operation between Aire- or Cblb-deficiencies in antigen-specific CD4 or CD8 cells 
(retrogenic experiment and CD4/CD8 adoptive transfer assays, Chapter 3), non-antigen 
specific CD4 helper T cells (50% TCR3A9→insHEL+ bone marrow chimeras, Chapter 
4), nTregs (wildtype nTregs adoptive transfer assay, Chapter 3) and iTregs (Cblb-/- 
TCR3A9insHEL+ iTreg assay, Chapter 4). The retrogenic strategy would permit further 
study of a complex co-operative autoimmunity pathogenesis model as the strategy 
allows for complete control over the specific T cell receptor and Aire- or Cblb- genetic 
deficiencies in each T cell population present in the retrogenic mice. This, coupled with 
the ability to track, manipulate and isolate the retrogenic T cells for further analysis 
would serve as a valuable tool enriching the current understanding of the epistatic co-
operation between Aire- and Cblb-deficiencies. 
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Chapter 6  
Discussion 
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6.1 Introductory comments 
A large body of work has aimed to provide a coherent genetic architecture that explains 
the pathogenesis of autoimmune diseases. While rare autoimmune diseases could result 
from single gene variants with a simple Mendelian pattern of inheritance (Bennett et al., 
2001; Bjorses et al., 1998; Fisher et al., 1995), more common and complex diseases 
have been shown to result from interactions between multiple alleles, each harbouring 
only a weak effect on its own but in combination would synergise to cause severe 
autoimmunity. Genome wide association studies have identified many genetic markers 
associated with autoimmune diseases (Barrett et al., 2009; Hyttinen et al., 2003; Todd 
and Wicker, 2001; Wandstrat and Wakeland, 2001), but it is unclear which genes are 
causative or how these genes interact with each other. An even more distant goal is to 
explain, with the aid of genotype, the mechanisms that account for the occurrence of 
autoimmune diseases and use that information to predict individuals at risk of the 
disease and target treatment.  
This study hypothesised that there may be a minimum set of defects that are needed in 
combination before the emergence of autoimmunity – a multistep model for the 
development of autoimmune disease. Since multiple tolerance mechanisms function to 
keep autoimmunity in-check and each mechanism is governed by a unique set of genes, 
it seemed reasonable to consider genes within the same molecular pathway as 
functionally equivalent and treat them as equal from the perspective of autoimmune 
disease pathogenesis. This assumption simplified the polygenic nature of autoimmune 
diseases and allowed robust testing for additive effects between combinations of 
pathways. With this pathway stratification in mind, mice harbouring mild genetic 
defects in two tolerance pathways were examined for the ability to develop severe 
autoimmunity, in absence of a latent phase. Specifically, Aire-deficient mice – with 
crippled thymic deletion of organ-specific T cells - were crossed with mice carrying 
genetic defects in one of four key peripheral tolerance mechanisms: decreased T 
regulatory cells (Card11unm/unm), apoptosis (Faslgld/gld), anergy (Cblb-/-), or dysregulated 
T follicular helper cells (Rc3h1san/san). Cblb-deficiency was unique among these four in 
precipitating rapid clinical autoimmunity when combined with Aire-deficiency, 
resulting in lethal destruction of the exocrine pancreas and salivary gland within weeks 
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after birth. These findings are the first to reveal a higher-level architecture assembling 
individual tolerance mechanisms together for robust resistance to autoimmunity in 
support of a multi-step model for the progression of autoimmunity. In the following 
sections, the discussion will focus on the construction of a mechanistic model to 
understand why the combination of Aire and Cblb-deficiencies synergised strongly and 
relate the principles highlighted in this mouse model to the general pathogenesis of 
autoimmunity. 
6.2 Mechanistic basis for the strong epistatic co-operation between Aire- and 
Cblb-deficiencies 
The potency of the Aire-/-Cblb-/- combination could be illustrated by considering an 
autoimmune threshold model to examine the interaction between genetic defects in 
central and peripheral tolerance pathways on development of autoimmunity. This can be 
modelled as either a binomial distribution or a linear progression of disease state.  When 
using this model to calculate relative risk of autoimmunity, several parameters were 
taken into consideration: the precursor frequency of self-reactive T cells or forbidden 
clones and the presence of tolerance pathways that buffer and control these forbidden 
clones. The balance of these two parameters determines if an individual falls below or 
above the risk threshold for autoimmunity (Fig. 6.1). As seen in the figure, there is a 
positive correlation between the number of self-reactive forbidden clones (represented 
by the y axis) and the risk of developing autoimmunity (represented by the x axis), 
whereby higher frequencies of self-reactive precursors increase the likelihood of 
developing autoimmunity (Fig. 6.1A). The scatter dot represents the disease-state in any 
individual while the autoimmune threshold determines the risk for an individual to 
develop an autoimmune disease. Multiple tolerance pathways regulate the threshold. 
Under normal conditions, when all tolerance pathways are working effectively, there are 
low frequencies of self-reactive cells and multiple tolerance pathways regulating the 
low number of self-reactive cells. 
Arguably, the most prominent feature of an organ-specific autoimmune disease is the 
existence of self-reactive (forbidden) organ-specific cell(s) that can recognise and elicit 
an immune response targeted towards tissue-specific antigens. In the Aire-/-Cblb-/- 
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Figure 6.1. Schematic illustrating the relationship between
the frequency of self-reactive cells and the risk of
developing autoimmunity, and how this relationship
is altered by different tolerance mechanisms.
A. The frequency of self-reactive cells is directly proportional
to the risk of developing autoimmunity.
B. Aire-deficiency increases the burden of self-reactive cells
although the this still falls below the high autoimmune
threshold risk in B10.BR.Aire-/- mice.
C. Cblb-deficiency decreases the threshold risk for
autoimmunity, although mice still do not present with
severe autoimmunity.
D. The combination of Aire- and Cblb-deficiencies are able to
break tolerance because of the altered frequency of self-
reactive cells and changes in the autoimmune risk
threshold.
E. The Aire-/- and Cblb-/- co-operation is unique as other
combinations seem to display comparable autoimmunity
to the single deficiency in Aire-/- mice seen in (B).
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mouse model, the forbidden clones recognise self-antigens in the pancreas and salivary 
glands. In the pancreas, the self-reactive cells comprised primarily of CD8 cells with 
more than one dominant TCR being detected and different TCRs detected in different 
mice (interindividual variability). Indeed, CD4 cells and B cells (autoantibodies) also 
contribute towards the disease pathogenesis. The potency of the forbidden clones in 
Aire-/-Cblb-/- mice is demonstrated by the observation that one dominant CD8 
(clonotype 3.5) chosen from the single cell TCR analysis could precipitate extensive 
pancreatic destruction when present at high frequencies (30-50% from total T cells) in 
retrogenic mice without the need for defects in Aire or Cblb. This indicates that high 
frequencies of forbidden clones release the dependence of the clone from control by 
tolerance mechanisms (chapter 5). This paradigm is further exemplified by the finding 
that the pancreas infiltration could be re-directed from exocrine to endocrine pancreas in 
Aire-/-Cblb-/- mice by simply changing the frequency of the predominant TCR using 
TCR3A9:insHEL transgenic models (chapter 4). Hence, as demonstrated by the model, 
high numbers of autoreactive T cells would result in skewing towards a high 
autoimmune risk zone. 
What increases the burden of self-reactive forbidden clones? During the development of 
thymocytes, forbidden T cells clones harbouring self-reactive TCRs that bind strongly 
to an array of self-antigens complexed to MHC are triggered to die. Aire is thought to 
play a vital role in this process by regulating the expression of selective tissue-specific 
antigens in the thymus, mediating negative selection of T cell recognising these 
antigens. However, when this process of negative selection is crippled by Aire-
deficiency, it increases the numbers of forbidden clones that escape deletion (Anderson 
et al., 2002; Liston et al., 2003). This could have increased the burden of pancreas- or 
salivary gland-specific clones in the Aire-/-Cblb-/- mice, posing a higher risk for the mice 
to develop pancreatitis or sialoadenitis (Fig. 6.1B).  
The second feature of the model, that sets the threshold for developing autoimmunity is 
the presence of central and peripheral tolerance mechanism that control the numbers 
and functions of the forbidden clones. As thymic deletion is not full-proof, and perhaps 
more severely affected in absence of Aire, self-reactive clones require further control by 
other peripheral tolerance failsafe mechanisms to so the individual remains within the 
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low autoimmune risk zone (Fig. 6.1B). If there is a defect in one peripheral tolerance 
pathway, such as Cblb, it decreases the autoimmune threshold, increasing the risk of 
developing autoimmune disease (Fig. 6.1C). A predisposition to high amounts of 
forbidden clones coupled with defects in peripheral tolerance pathways may act 
synergistically to cause autoimmune diseases although the defects do not manifest as a 
simple addition but some combinations (combination of Aire-/- with Cblb-/-) (Fig. 6.1D) 
interact more strongly than others (combination of Aire-/- with Faslgld/gld, Rc3h1san/san or 
Card11unm/unm) (Fig. 6.1E). This observation begs the question: why is the combination 
between Aire- and Cblb-deficiencies so potent? 
In order for the peripheral tolerance mechanism to create a large shift in the threshold 
for autoimmune development when combined with high numbers of forbidden clones, 
there are several possible explanations that have been highlighted by the Aire-/-Cblb-/- 
mouse model in this study discussed below. 
6.2.1 Aire- and Cblb-deficiencies act on two complimentary pathways that control 
the same autoreactive clone(s) 
In order for multiple tolerance mechanisms to co-operate, the mechanisms must act 
upon non-redundant pathways that control the same autoreactive cell(s). It can be 
hypothesized that the interaction between Aire and Cblb appears to be strong as both 
confer protection against organ-specific autoimmunity, whereas the Fasl and Rc3h1 are 
essential in protection against systemic forms of autoimmunity. Aire-deficiency disrupts 
expression of organ-specific antigens in medullary epithelial cells of the thymus, and 
this indirectly affects thymic clonal deletion of organ-specific T cells (Anderson et al., 
2002; Liston et al., 2003). Cblb is only expressed at low levels in immature T 
lymphocytes (Naramura et al., 2002; Thien and Langdon, 2005) and consequently Cblb-
deficiency has not been shown to alter thymic selection or Aire-dependent thymic 
deletion (Hoyne et al., 2011b). In the periphery, Cbl-b is upregulated in mature and 
anergic T cells, where it inhibits the PI3K and NFκB signalling pathways activated by 
TCR-CD28 co-stimulation and is required for T cell anergy to prevent proliferation of T 
cells that have recognised peripheral antigens with insufficient affinity or in the absence 
of adequate CD28 co-stimulation (Bachmaier et al., 2000; Chiang et al., 2000; Fang and 
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Liu, 2001; Gronski et al., 2004; Heissmeyer et al., 2004; Jeon et al., 2004; Naramura et 
al., 2002; Qiao et al., 2008; Thien and Langdon, 2005). Hence, the two pathways that 
are guarded by the Aire and Cblb genes are separate but complimentary pathways that 
regulate organ-specific T cells. The rapid progression to pancreatic autoimmune disease 
observed here can be inferred to result from pancreas-specific T cells escaping thymic 
deletion due to Aire-deficiency and then escaping anergy and the normal requirement 
for CD28 costimulation due to Cblb-deficiency, allowing them to proliferate and 
differentiate into high numbers of tissue-damaging effector T cells (Fig. 6.2B). 
On the other hand, the autoimmunity manifested by Fasl and Rc3h1-deficient mice did 
not appear to selectively target particular organs but are of a more lymphoproliferative 
nature, characterized by splenomegaly, lymphodenopathy and the presence of anti-
nuclear antibodies (Roths et al., 1984; Vinuesa et al., 2005a). Thus, it would be 
reasonable to assume that Fasl and Rc3h1 would only be an important failsafe for 
thymic deletion when the TCR reacts with a systemic autoantigen and not an organ-
specific autoantigen. In this study, Fasl was chosen to represent a key regulator in 
apoptosis. As indicated in the introduction (1.3.1.1), there are two different pathways 
that lead to apoptosis: Fas/Fasl- and Bim-dependent pathways. Deletion of organ-
specific T cells that bind to both systemic and organ-specific antigens in the thymus is 
thought to be predominantly dependent on bim (Bouillet et al., 2002). However, in the 
periphery, both bim and fas/fasl may regulate apoptosis of self-reactive T cell 
depending on T cell specificity and/or the duration and strength of TCR stimulation. 
Fas/Fasl is primarily important for aborting T cells that receive chronic recurrent TCR 
signals (Alderson et al., 1995; Brunner et al., 1995), as would occur mainly for systemic 
antigens, whereas Bim appears to be the main pathway that eliminates T cells that are 
activated by transient exposure to antigens (Bouillet et al., 1999) like organ-specific T 
cells that encounter antigen in one peripheral lymph node. Mice lacking both the pro-
apoptotic Bcl-2 family member bim and Fas developed a modest increase in 
lymphadenopathy (Fortner et al., 2010). This suggests that Fas control systemic self-
reactive cells that fail to delete in the thymus of bim-deficient mice in the periphery. To 
test if this hypothesis is accurate, the synergy between bim and Fasl or Rc3h1-deficient 
mice in response to both an organ-specific and systemic antigen could be compared. 
Using the TCR3A9 model, the Bim and Fasl double mutations could be introduce on 
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Figure 6.2. Multistep models for the pathogenesis of
autoimmune disease in the Aire-/-Cblb-/- mouse model.
A. Normally, self-reactive clones are controlled by multiple
tolerance pathways.
B. Two defects in two sequential checkpoints allows a single
clone pancreas-specific CD8 clone to bypass tolerance.
C. Two defects in two tolerance genes affecting many cell
types that regulate self-reactive cells both intrinsically and
extrinsically affecting more than two checkpoints.
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transgenic mice harboring CD4 TCR3A9 (Ho et al., 1994) coupled with either an organ-
specific (low concentration insHEL or high concentration thyrHEL) (Akkaraju et al., 
1997a; Akkaraju et al., 1997b) or systemic (low concentration ML4 or high 
concentration ML5 soluble HEL) (Goodnow et al., 1988) autoantigen. If the prediction 
holds true, the organ-specific combination would display no or mild signs of increases 
autoimmunity -diabetes (for the insHEL) or thyroiditis (for the thyrHEL) compared to 
wild-type counterparts, while the “systemic” soluble antigen would precipitate a drastic 
increase in lymphoproliferation.  
The combination of Card11unm/unm and Aire-/- was set up to reflect the combination of 
defects in the FoxP3+ T regulatory cells and central tolerance. As the FoxP3-deficient 
scurfy mice exhibit a severe lethal phenotype on its own (Fontenot et al., 2003; Hori et 
al., 2003; Khattri et al., 2003), the Card11unm/unm represented a milder defect in the 
natural T regulatory component, making it possible to identify a strong interaction 
between the two mild defects. The Card11unm/unm hypomorphic allele compromised the 
formation of Foxp3+ Treg cells in the thymus and the cells were found at one seventh 
the frequency of wild-type control animals in the periphery. Although there were low 
numbers of nTreg cells, T cells were able to retain the function of preventing 
autoimmunity but resulted in dysregulation of TH2 cells leading to the expansion of this 
particular cell type (Altin et al., 2011). Mechanistically the defect in Card11unm/unm 
could be suggested to still produce sufficient numbers of nTreg cells to confer 
protection against organ-specific autoimmunity in this system even in the absence of 
Aire. 
This concept of interdependence and non-redundancy of tolerance pathways being a 
requirement for increasing the risk of severe autoimmunity development could be 
extended by exploring if coupling any gene defect in thymic negative selection of 
organ-specific T cells and athymic T cell anergy/co-stimulation would recapitulate the 
phenotype of the Aire-/-Cblb-/- mice (Fig 6.3). Other molecules that play pivotal roles in 
the Aire-related negative selection pathway such as the differentiation receptors on the 
mTEC cells including CD40, RANK and LTbR, which signal mTEC differentiation 
through NIK and the RelB/NFκB2 transcription factors (Gray et al., 2006; Seach et al., 
2008; Venanzi et al., 2007) could be coupled with Cblb-deficiency and monitored for 
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Figure 6.3. Key genes involved in the negative selection and peripheral T cell anergy pathways.
The lines combine defects that could be tested to determine if any “functionally equivalent” gene involved in
negative selection could co-operate with any “functionally equivalent” gene involved in peripheral T cell anergy.
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development of severe autoimmunity. Likewise, it would be also interesting to test if 
other genes involved in peripheral T cell anergy or co-stimulation such as CTLA-4 or 
A20 (Tnfaip3) (Graham et al., 2008; Musone et al., 2008; Nair et al., 2009; Plenge et al., 
2007; Thomson et al., 2007; Trynka et al., 2009) would co-operate with Aire-deficiency 
to yield similar outcomes of accelerated autoimmunity, devoid of a latent phase (Fig 
6.3).   
6.2.2 Although representing two genetic lesions, Aire- and Cblb-deficiencies may 
affect more than one tolerance pathway. 
The discussion in section 6.2.1 assumed a simplistic model to explain the potency of the 
Aire- and Cblb-deficient combination, whereby two genetic lesions affect two pathways 
(negative selection and anergy) within the same autoreactive clone, precipitating 
autoimmunity. However, it is also important to consider that the two different failsafes 
could affect two interacting cells: one affecting the forbidden clone and the other 
affecting a cell that enhances or inhibits the forbidden clone. Data from adoptive 
transfer experiments in chapter 3 provide compelling evidence that both CD4 and CD8 
cells were necessary to adoptively transfer lethal pancreatitis from Aire-/-Cblb-/- mice to 
lymphopenic recipients, although CD8 cells alone appeared able to cause substantial 
subclinical damage to the pancreas. Additionally, single cell multiplex PCRs in chapter 
5 detected a large clonal expansion of CD8 cells in the pancreas, and one of the clones 
isolated was sufficient to recapitulate pancreatitis when present in high numbers 
(together with a polyclonal repertoire of other T cell specificities) in retrogenic 
chimeras without the need for Aire or Cblb deficiency (chapter 5). On the other hand, 
CD4 cells appeared to be less frequently detected in the pancreas, suggesting, albeit not 
completely ruling out the possibility that the CD4 T cells may not be self-reactive in the 
Aire-/-Cblb-/- mice. The results from the TCR3A9→insHEL bone marrow chimeras, 
especially the ones where only 50% of the TCR-transgenic marrow was Cblb-deficient 
also illustrated this. Lethality and exocrine pancreatitis was observed here when three 
variables were in alignment: Aire-deficiency, Cblb-deficiency and the presence of HEL 
in the islets. This could imply that the CD4 TCR3A9 T cells that home to the HEL-
expressing pancreatic islets were helping the small amount of exocrine-specific CD8 
cells to damage the acinar cells. Thus, although the CD4 cells may not be exocrine-
specific, these cells could still act as helper cells in mediating the disease by 
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extrinsically contributing to the immune microenvironment of exocrine-specific CD8 
cells. In the NOD diabetes mouse model, it has been clearly demonstrated that 
autoreactive CD8 T cells are the first to infiltrate the pancreas, the first wave of cell 
recognising insulin derived epitopes (Wong et al., 1999), followed by highly 
diabetogenic T cells recognising other antigens such as islet-associated glucose-6-
phosphatase with high avidity (Verdaguer et al., 1997; Verdaguer et al., 1996). The role 
of CD4 cell help to precipitate diabetes in this model remains unclear, however multiple 
studies have suggested that CD4 T cell help may be required for the antigen-specific 
CD8 cells to reach their maximum diabetogenic potential (Bendelac et al., 1987; 
Christianson et al., 1993; DiLorenzo and Serreze, 2005; Yagi et al., 1992), most likely 
by activating the APCs (CD40 on CD4/CD154 on APC ligation) that present antigen to 
the CD8 antigen-specific cells (Amrani et al., 2002). Thus, it is entirely possible that 
Aire-deficiency is only acting on non-antigen specific CD4 T helper cells, and Cblb 
deficiency only on antigen-specific CD8 cells with cell-to-cell cooperation explaining 
the strong genetic epistasis in the Aire-/-Cblb-/- mouse model. 
A further potential layer of complexity is added by experimental data that suggest Aire 
may play a role in the education of antigen-specific nTreg cells (Hinterberger et al., 
2010; Kekalainen et al., 2007b; Laakso et al., 2010; Ryan et al., 2005; Wolff et al., 
2010), and that Cblb promotes TGFβ-induced FoxP3 upregulation by naïve CD4+ cells 
to form iTregs cells (data from Chapter 4 and (Harada et al., 2010)). Interestingly, 
several mouse models that have deficiencies in Tregs have been shown to develop early 
lethality and multiorgan autoimmunity similar to Aire-/-Cblb-/- mice. (i) Neonatal mice 
thymectomized 2 to 4 days post-birth develop thyroiditis, gastritis, orchitis, prostatitis, 
and sialoadenitis (Kojima and Prehn, 1981; Nishizuka and Sakakura, 1969). This 
disease was preventable by inoculation of normal cells, containing what we currently 
know as T regulatory cells (Sakaguchi et al., 1982). (ii) Deficiency in the key 
transcription factor for Treg cells - FoxP3. In mice (Fontenot et al., 2003; Hori et al., 
2003; Khattri et al., 2003) and humans (Bennett et al., 2001; Chatila et al., 2000; Wildin 
et al., 2001) the deficiency resulted in a lymphoproliferative wasting disease 
accompanied by multi-organs lymphocytic infiltration. (iii) Mice with abolished 
production of a key Treg-related immunomodulatory cytokine - TGFβ (Li et al., 2007; 
Shull et al., 1992) demonstrated lymphoproliferative wasting disease accompanied by 
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multi-organ lymphocytic infiltration. The parallels between the autoimmunity without a 
latent phase and multiorgan infiltration, in the well-studied FoxP3-deficient scurfy 
mouse model and Aire-/-Cblb-/- mice suggested that the autoimmune phenotype in Aire-/-
Cblb-/- could occur, at least partly, as a result of defective T regulatory cells. 
Thus, it is also plausible that a co-factor for pancreatitis development is a deficiency in 
nTreg caused by the absence of Aire and/or deficiency in iTreg cells in the absence of 
Cblb. In support of this is the observation that transfer of varying doses of wild-type 
Tregs suppressed the wasting syndrome and pancreatitis in adoptive transfer recipients 
of Aire-/-Cblb-/- cells in a dose dependent manner, although I have not tested if this 
suppression will still be observed if Cblb-deficient or Aire-deficient Tregs were used 
instead (chapter 3). In contrast to that, it is also noteworthy that Aire-/- recipients that 
received equal mixtures of wild-type and Cblb-/- bone marrow still developed 
pancreatitis although this appeared to be less severe than Aire-/- recipient mice that 
received only Cblb-/- cells. This failure to correct autoimmunity with wild-type Tregs in 
trans contrasts with autoimmunity due to nTreg defects, which is fully corrected in 
animals or humans with mixtures of defective and wild-type T cells (Sakaguchi et al., 
2009). Hence the mixed chimera experiments suggest that the disease was not mediated 
simply by defects in the nTreg component but must have primarily an effector T cell-
autonomous basis. 
Taken together, although Aire and Cblb-deficiencies represented two genetic lesions in 
autoimmunity, the pleiotropic nature of the two genes suggest that the defects may have 
potentially crippled more than two failsafes or tolerance checkpoints for organ-specific 
autoimmunity in the Aire-/-Cblb-/- mice (Fig. 6.2C). Future work could provide further 
resolution of how the respective genotypic deficiencies (in Aire or Cblb) within each 
cell type contributes to the development of autoimmunity. The retrogenic technology 
described in Chapter 5 will be an invaluable tool to tackle this question as it allows for 
the introduction of defects in different tolerance genes within different cell types. The 
genotypic contribution of CD4 helper and CD8 cells could be tested by restricting Aire- 
and Cblb-deficiencies to different immune cell types and observe which combinations 
recapitulated the disease. Alternatively, in light of the TCR3A9→insHEL chimera result 
on the requirement for TCR3A9 cells in the development of exocrine pancreatitis, it is 
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also possible to combine this system with the CD8-retrogenic system. Simply, a low 
frequency of CD8 wild-type or Cblb-deficient retrogenic donor marrow could be 
introduced together equal numbers of non-transgenic:wild-type TCR3A9 marrow. In this 
system, Cblb-deficienct would be restricted to rare exocrine pancreas specific CD8 
cells, while Aire-deficiency would affect the frequency of TCR3A9 cells available to 
serve as helpers in insHEL recipients and wild-type cells would provide a buffer so 
autoimmunity does not develop rapidly. If the notion for CD4 and CD8 was correct, this 
experiment should see the requirement for three variables before the development of 
lethal exocrine pancreatitis: Cblb-deficiency in the retrogenic bone marrow, Aire-
deficiency and insHEL in the recipients. 
6.3 Comparing the Aire-/-Cblb-/- mouse model with other mouse models 
The main characteristic features of the Aire-/-Cblb-/- mouse model is the lethal wasting 
disease and autoimmunity targeted towards the pancreas and salivary gland. This 
section provides a comparison of the Aire-/-Cblb-/- mouse model with other mice 
harbouring similar histopathological characteristics that could provide insights on 
understanding the molecular basis of the severe autoimmunity in the B10.BR.Aire-/-
Cblb-/- mouse model. The mouse strains discussed are summarised in Table 6.1 and can 
be divided into three categories: mice with defects in the Aire-related pathway; in the 
Cblb-related pathway; and defects in cytokine pathways. 
Table 6.1. Comparing the Aire-/-Cblb-/- mouse model with mice that display similar 
phenotypes. 
Mouse model Aire-/-Cblb-/- Aire-/- Map3k14aly Cd28-/- Ctla4-/- 
Background B10.BR NOD B6×AEJ NOD 
(BDC2.5 
Treg-treated) 
BALB/c, 
(DO11.10
TCRβ × 
Ctla4-/-) 
Pathway AIRE, CBL-
B 
AIRE AIRE CBL-B CBL-B 
Median survival 3.5 weeks 10 weeks >48 weeks >24 weeks 7 weeks 
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Histopathological 
infiltration 
Exocrine 
pancreas, 
salivary 
gland, 
stomach 
Exocrine 
pancreas, 
eye, salivary 
gland, 
stomach 
Exocrine 
salivary 
gland, 
lacrimal 
gland, 
pancreas, 
lung 
Exocrine 
pancreas  
Heart, 
lungs 
exocrine 
pancreas 
Organ-specific 
autoantibody 
Exocrine 
pancreas, 
salivary 
gland, 
stomach 
Pancreas, 
eye, salivary 
gland, 
stomach, 
lung, thyroid 
Not 
detected 
(mice had 
defect in 
humoral 
immunity) 
Exocrine 
pancreas 
Not done 
Autoantigen 
identification 
Not 
identified 
Protein 
disulfide 
isomerase 
family 2 
Not 
identified 
Pancreatic 
amylase 
Protein 
disulfide 
isomerase 
family 2 
Autoimmunity 
driving cell 
(determined by 
adoptive transfer 
of disease to 
lymphopaenic 
recipients) 
CD4 and 
CD8 
dependent 
(pancreatitis), 
CD4-
dependent 
(sialoadenitis
) 
Not done CD4-
dependent 
(Vβ1 in 
pancreas 
and Vβ1 & 
Vβ5 in 
salivary 
glands) 
CD4-
dependent 
CD4-
dependent 
Model for human 
disease 
Autoimmune 
pancreatitis 
Autoimmune 
pancreatitis 
Sjogren's 
syndrome 
Autoimmune 
pancreatitis 
  
Other comments Wild-type 
Treg cells 
confer 
protection for 
pancreatitis 
H2b MHC 
and Idd3/ 
Idd5 
protective 
for 
pancreatitis 
 Disease 
attributed to 
a defect in 
peripheral 
survival of 
Treg cells 
CTLA-4 
expression 
by Treg 
enough to 
control 
disease 
References (Teh et al., 
2010) 
(Jiang et al., 
2005; Niki et 
al., 2006) 
(Tsubata et 
al., 1996; 
Yamamichi 
et al., 
1997) 
(Meagher et 
al., 2008) 
(Ise et al., 
2010; 
Tivol et 
al., 1995) 
 
6.3.1 Mice with deficiencies in functionally equivalent genes to Aire 
The first group of mice that exhibited a similar co-occurrence of autoimmune T cell 
mediated exocrine pancreatitis and sialoadenitis is a group of mice with deficiencies in 
the Aire-related pathway of autoantigen presentation by medullary thymic epithelium. 
B6×AEJ.Map3k14aly mice harbor a mutation in the NFκB-inducing kinase (NIK), an 
upstream activator of Rel-B through the non-canonical NFκB pathway involved in the 
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development of AIRE-expressing thymic medullary epithelial cells (Fletcher et al., 
2009). The mice survived for more than 48 weeks of age but displayed striking 
autoimmunity targeted towards the exocrine pancreas, salivary glands, lacrimal glands 
and lung (Tsubata et al., 1996). The CD4 cells that infiltrated the pancreas or salivary 
gland appeared oligoclonal, with recurrent use of particular Vβ elements and 
sequencing evidence for expansion of particular CD4 T cell clones that were distinct in 
pancreas and salivary gland of the same mouse (Yamamichi et al., 1997). Although 
similar organs were targeted in the Map3k14aly and Aire-/-Cblb-/- mouse model, CD4 
cells mediated disease in the former while both CD8 and CD4 cells were needed for the 
adoptive transfer of pancreatitis in the latter.  
Another similar mouse was the NOD mouse sub-strain lacking AIRE (Jiang et al., 2005; 
Niki et al., 2006). Wild-type NOD mice are a well-recognised model for studying 
autoimmune diabetes and displayed severe insulitis but not exocrine pancreatitis. 
Interestingly, when Aire mutations were intercrossed to the NOD mouse strain, the mice 
presented with accelerated and modified autoimmunity targeted towards the exocrine 
instead of endocrine pancreas. In comparison to the B10.BR.Aire-/-Cblb-/- mice, the mice 
had a longer median of survival (10 weeks compared to 3.5 weeks) but display similar 
B and T cell autoimmunity directed toward the exocrine pancreatitis, salivary gland and 
stomach. In the study from the Mathis laboratory (Jiang et al., 2005), congenic crosses 
made between the B6 and NOD backgrounds showed that the NOD H2g7 MHC 
haplotype together with the Idd3 and Idd5 haplotypes on chromosome 3 and 1, 
respectively, were key determinants of exocrine pancreas autoimmunity in this mouse 
(Jiang et al., 2005). While B10.BR Aire-/-Cblb-/- mice do not utilise the H2g7 MHC 
haplotype and Cblb is not located within the Idd3 or Idd5 chromosomal regions, it is 
noteworthy that the NOD Idd5 locus alters the relative splicing of Ctla-4 isoforms 
(Ueda et al., 2003), a molecule within the Cblb pathway in that Ctla-4, like Cbl-b, 
negatively regulates CD28 signalling. 
6.3.2 Mice with deficiencies in functionally equivalent genes to Cblb 
The second group of mice that displayed striking similarities to the Aire-/-Cblb-/- mice 
are groups of mice with mutations in the “Cblb-related pathway”: that is, other 
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mutations in negative regulators of CD28 co-stimulation. Similar to the NOD.Aire-/- 
mouse stain describe above, another manipulation to the NOD strain that precipitated 
exocrine pancreatitis was CD28-deficiency, which was revealed provided the animals 
were protected from diabetes by either adoptive transfer of BDC2.5 islet-specific Treg 
cells or by insulin treatment (Meagher et al., 2008). In these animals, the exocrine 
pancreas infiltration was adoptively transferable by CD4 cells that were shown to target 
the pancreatic amylase antigen, which is expressed in the pancreatic acinar cells and in 
the salivary gland (Meagher et al., 2008). On face value, Cbl-b deficiency and CD28 
deficiency should be considered as having opposite polarity: Cbl-b deficiency 
exaggerates CD28 signalling or renders T cells CD28 independent (Bachmaier et al., 
2000; Chiang et al., 2000), whereas CD28 deficiency eliminates this source of co-
stimulation. However the Bluestone group demonstrated that CD28 deficient NOD mice 
have greatly diminished Tregs, explaining the paradoxical acceleration of type 1 
diabetes in these animals (Salomon et al., 2000) and by extension also explaining the 
development of exocrine pancreatitis. An important function of Tregs is expression of 
Ctla-4, and Ctla-4 deficiency on exocrine pancreas-specific Tregs partly explains 
pancreatitis in Ctla4 knockout mice (Ise et al., 2010). Hence Treg deficiency results in 
greater or prolonged display of CD80 and CD86 on antigen presenting cells (Ise et al., 
2010; Qureshi et al., 2011; Schmidt et al., 2009; Wing et al., 2008). However, in 
NOD.Cd28-/- mice this mechanism cannot explain the development of exocrine 
pancreatitis, since no matter how much CD80 and CD86 are displayed there is no CD28 
receptor to receive these co-stimulatory signals. Deficiency of Tregs in NOD.Cd28-/- 
mice may nevertheless enhance T cell stimulation through other pathways such as the 
TCR itself. IL-10, which is an important product of Tregs, downregulates surface MHC 
II display on dendritic cells and macrophages through induction of MHC II 
ubiquitination by MARCH1 (Tze et al., 2011). Since MHC II binds to the TCR, 
decreases in IL-10 would lead to a converse increase in MHC II-TCR binding and T 
cell stimulation. Data from this mouse strain coupled with information from the 
NOD.Aire-/- mouse suggest that modifying the NOD mouse strain to have defects either 
in thymic selection (AIRE) or T cell co-stimulation (CD28) precipitates a similar 
disease to the B10.BR.Aire-/-Cblb-/- mouse. 
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As pointed out above, one of the molecules that could be influenced by the NOD 
background is Ctla-4. The role of Cbl-b has a number of parallels with the inhibitory 
cell surface receptor, Ctla-4, suggesting they are both part of a single peripheral T cell 
tolerance pathway for suppressing pancreatic and salivary gland autoimmunity. Ctla-4 
is also induced by sustained antigen exposure on mature and anergic T cells and 
opposes CD28 co-stimulation, in part by binding more avidly to the CD28 ligands 
CD80 and CD86 (Linsley and Nadler, 2009; Pentcheva-Hoang et al., 2009) and 
stripping these molecules from the surface of antigen-presenting cells (Qureshi et al., 
2011). Moreover, autoimmune exocrine pancreatic and salivary gland destruction are 
prominent features of the multi-organ inflammation that occurs in Ctla-4 deficient 
129/Sv mice or BALB/c DO11.10 TCRβ transgenic mice (Ise et al., 2010; Tivol et al., 
1995; Waterhouse et al., 1995). The autoimmune inflammation was seen to be CD4-
dependent and Ctla-4 was shown to oppose accumulation of pancreas-specific T cells 
by two routes: intrinsically by its expression on pancreas-specific effector T cells that 
showed strong reactivity towards the PDIA2 antigen (Ise et al., 2010) and extrinsically 
by its expression on Foxp3+ Treg cells where it down-regulated CD86 on antigen 
presenting cells to mediate their suppressive effects (Ise et al., 2010; Qureshi et al., 
2011; Schmidt et al., 2009; Wing et al., 2008). Since Cblb-deficiency relieves T cells of 
their dependence on CD80 and CD86, it may have a similar effect to Ctla4-deficiency 
by allowing pancreas-reactive T cells to proliferate vigorously despite stimulation by 
immature dendritic cells with low MHC II, CD80 and CD86. Experiments in vitro 
showed that Cblb-deficient T effector cells were refractory to growth inhibition by 
CD4+CD25+ T regulatory cells, although the basis of this effect is unresolved (Wohlfert 
et al., 2004; Wohlfert et al., 2006).  
6.3.3 Mice with deficiencies in genes that alter the “microenvironment” of the 
self-reactive cells 
The third group of mice developing exocrine pancreatitis and sialoadenitis are animals 
with an altered cytokine environment in the pancreas. NOD mice treated with 
interferon-gamma (IFNγ) and tumour necrosis factor-alpha (TNFα) demonstrated a 
reduction in insulitis and a propensity towards exocrine pancreatitis (Campbell et al., 
1991). Besides this mouse model, LP-BM5 murine leukemia virus-treated C57BL/6 
mice developed exocrine pancreatitis and sialoadenitis (Watanabe et al., 2003). The 
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infiltrating cells were CD4 T cells, Mac-1+ cells and B cells, of which most cells were 
apoptotic cells characterized by expression of Fas ligand and TNFα. The major 
inflammatory cytokines found in the exocrine pancreas were IFNγ and interleukin-10 
(Watanabe et al., 2003). Aire-deficiency also could cause general dysregulation of a 
constellation of pro-inflammatory cytokines, changing the cytokine milieu and 
environment within the mice. Evidence for this comes from APECED patients that 
present with high titres of neutralising auto-antibodies against type I interferons (IFN-α 
and -ω (Husebye et al., 2009; Meager et al., 2006; Meloni et al., 2008) and IL-17A, IL-
17F and/or IL-22 (Kisand et al., 2010; Puel et al., 2011; Puel et al., 2010). In mouse 
models, IL-17 cytokines seemed to be important for the control of various other 
pathogens, particularly in the lungs and gastrointestinal track (Khader et al., 2009). 
Th17 cells, especially their downstream cytokines, mediate major pathogenic functions 
in many other autoimmune diseases such as multiple sclerosis, rheumatoid arthritis, 
inflammatory bowel disease and psoriasis (Hu et al., 2010), providing evidence that 
accumulation of these cytokines can contribute towards the development of 
autoimmunity. This represents another layer of dysregulation that could influence the 
phenotype of the Aire-/-Cblb-/- double-deficient mouse. 
Comparing the mouse models in sections 6.3.1, 6.3.2 and 6.3.3 to double-deficient Aire-
/-Cblb-/- highlighted several themes that reinforced the conclusions or hypotheses that 
were drawn about the mechanistic interactions between Aire-/- and Cblb-/- in section 7.2. 
Firstly, most of the mouse models that shared similar histopathological characteristics to 
Aire-/-Cblb-/- harbour genetic deficiencies in the genes associated with Aire or Cblb 
pathways on various mouse genetic backgrounds. This provides compelling evidence 
that the Aire and Cblb pathways may represent important failsafes for pancreas- and 
salivary gland-specific autoimmunity. Secondly, the data from these different mouse 
models suggest that the genetic deficiencies in the mice affect the self-reactive cells and 
cells that affect the microenvironment of the self-reactive cells (e.g. Tregs or cytokines). 
It is however interesting to note that adoptive transfer of only CD4 cells from the 
B6×AEJ.Map3k14aly, NOD.Cd28-/- and BALB/c.DO11.10TCRβ×Ctla4-/- mouse models 
to lymphopenic recipients caused pancreatitis. This contrasted with the Aire-/-Cblb-/- 
mouse model whereby the pancreatitis was largely CD8-dependent. It would thus be 
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interesting to further characterize the CD8 cells that are mediating pancreatitis in this 
model and identify the target antigen recognised by these self-reactive clones. 
Overall, the observations from mouse models with similar autoimmunity to Aire-/-Cblb-/- 
mice support the notion that lethal autoimmunity, devoid of a latent phase resulted from 
unifying genetic defects affecting both self-reactive cell intrinsic and cell extrinsic 
regulation of the self-reactive cells.  
6.4 Exploring organ specificity in Aire-/-Cblb-/- mice 
6.4.1 Why is the pancreas and salivary gland specifically targeted? 
An intriguing feature of the Aire-/-Cblb-/- mice is that the mice present with 
autoimmunity targeted towards the exocrine pancreas and salivary glands. This specific, 
reproducible pattern contrasts with the single gene deficiency in Aire in both man and 
mice that affects multiple organs. Although, APS1 patients are diagnosed by the clinical 
triad of mucocutaneous candidiasis, hypoparathyroidism and adrenal insufficiency, they 
also displayed wide variability in secondary autoimmune manifestations including type 
I diabetes, premature ovarian failure, alopecia, vitiligo, malabsorption, and pancreatic 
insufficiency (Betterle et al., 1998; Perheentupa, 2006; Peterson and Peltonen, 2005). 
Consistent with numerous organ-specific genes that depend upon Aire for expression in 
thymic medullary epithelium (Anderson et al., 2002), mice with Aire-deficiency 
gradually develop autoantibodies and lymphocytic infiltration in numerous organs, 
including the salivary glands, eye, liver, kidney, stomach, lungs, thyroid gland and 
reproductive organs. Thus, it is intriguing that Aire and Cblb double-deficient mice 
would display autoimmunity targeted so aggressively towards just the exocrine pancreas 
and submandibular salivary glands, yet no evidence of acceleration against other tissues 
such as the stomach.  
In this study, one hypothesis tested was that the organ-specificity is determined by the 
frequency of different T cells formed and positively selected in the T cell repertoire. 
Evidence supporting this hypothesis comes from experiments in NOD.Cd28-/- mice, 
where a depleted repertoire of Tregs was experimentally restored by adoptively 
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transferring islet-specific Tregs that had been expanded in culture (Meagher et al., 
2008). By manipulating the repertoire in this way, the accelerated insulitis and diabetes 
in the animals was suppressed while accelerated exocrine pancreatitis was unaffected 
and became the dominant clinical feature. Chapter 4 described two complimentary 
methods that were used to test if this kind of variation in the nascent T cell repertoire 
redirected autoimmunity in Aire-/-Cblb-/- mice to other organs. Firstly, the H2k haplotype 
(k alleles of Class II I-A & I-E and Class I molecules K, D & L) MHC upon which T 
cells were positively and negatively selected in the thymus was substituted with H2b (I-
Ab, I-Enull, Kb, Db, Lnull). This change did not alter the target organs but diminished the 
onset and incidence of the cachectic wasting, pancreatitis and sialoadenitis. The fact that 
these animals lived much longer argues against the possibility that the rapidly lethal 
course of pancreatic autoimmunity in H2k Aire-/-Cblb-/- mice obscured accelerated 
autoimmunity against other organs because the latter might require a few more weeks to 
develop.  A second approach was to keep the MHC constant but skew the repertoire to 
form high numbers of T cells bearing a HEL-specific TCR3A9 that recognized HEL in 
pancreatic islets. This also diminished the incidence and severity of exocrine 
pancreatitis in Aire-/-Cblb-/- TCR3A9-transgenic mice, but extensive exocrine pancreatitis 
still developed in a clear subgroup of the animals generated by bone marrow chimeras 
despite the skewing of the TCR repertoire towards recognizing the pancreatic islets. 
Moreover, there was no dramatic increase in the onset or incidence of diabetes 
compared to TCR3A9 × insHEL mice with single deficiency of either Aire or Cbl-b 
alone. Hence, these two approaches used to test the “repertoire/presentation 
hypothesis” failed to satisfactorily explain the organ specificity of the disease in the 
Aire- and Cblb-deficient mice. 
An alternative explanation for acinar-specific autoimmune destruction is that each 
peripheral organ is protected by a specific set of fail-safe mechanisms that control self-
reactive organ-specific T cells that escape negative selection in the thymus. In this view, 
different target organs would arise by combining Aire-deficiency with defects in 
different peripheral tolerance pathways regardless of the H2 haplotype (peripheral 
pathway hypothesis). This hypothesis is compatible with the observation that mice of 
various H2-types harbouring gene defects in Aire- or Cblb-related pathways displayed 
autoimmune exocrine pancreatitis or sialoadenitis as discussed in section 6.3. Further 
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support for this hypothesis comes from studies of NOD mice with unaltered MHC but 
lacking CD86 or congenic for two non-MHC chromosomal segments, wherein 
autoimmunity was redirected from the pancreatic islets to peripheral nerves or the 
biliary ducts (Irie et al., 2006; Salomon et al., 2001). Although preliminary data from 
breeding B10.BR mice with combinations of Aire-/- and either Faslgld/gld, Roquinsan/san or 
Card11unm/unm have not revealed co-operative autoimmunity, it would be of interest to 
test the effect of combining Aire-deficiency with defects in other peripheral tolerance 
pathways such as peripheral inhibition by PD-1 (Keir et al., 2007; Sharpe et al., 2007) 
or non-Aire dependent peripheral deletion (Cohen et al., 2010; Yip et al., 2009). It is 
also possible that most tissues are guarded by two or more peripheral tolerance failsafe 
mechanisms. To test this, it would be possible to breed Aire-deficient mice with defects 
in two different peripheral tolerance pathways – triple mutant mice, whereby the 
mutations could either occur in one or both copies of the tolerance gene (heterozygous 
or homozygous) and observe if any of these deficiencies could change the spectrum of 
organs targeted for autoimmune destruction. 
It is intriguing that two organs were targeted in combination and this may be attributed 
to common features present in both the organs. Since both the exocrine pancreas and 
salivary gland have similarities in structure and function (production of digestive 
enzymes), it is possible that the T cells from the Aire-/-Cblb-/- mice were targeting a 
shared autoantigen in the two organs, such as amylase (Meagher et al., 2008). However, 
the results of adoptive transfer assays in section 3 indicated that pancreatitis was both 
CD8- and CD4-dependent, while the sialoadenitis was predominantly CD4-dependent. 
Furthermore, the pattern of autoantibody detection from the sera of Aire-/-Cblb-/- seemed 
to be largely targeted towards the apical cytoplasmic granules of the pancreatic acinar 
cells, while a more diffused pattern was observed for the salivary gland acinar cells. An 
antigen-independent common feature of these organs is that they are sensitive to initial 
insult, promoting the secretion of pro-inflammatory cytokines including type I 
interferons, TNF-α and IL-1 mediating hastened destruction of the exocrine organs 
(Mavragani and Crow, 2010; Patel and Fine, 2005). This could explain the link between 
the destruction on both organs. Since the early destruction of both organs may be lethal 
due to the abolished production of digestive enzymes needed for nutrient absorption 
and/or the release of digestive enzymes and inflammatory cytokines from acute 
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pancreatic damage, the mice had to be sacrificed before other organs damage might 
have been observed. Prolonging the survival of the mice, perhaps by the introduction of 
exocrine pancreas specific Tregs (Meagher et al., 2008), may unveil autoimmunity in 
additional organs. 
6.4.2 Identifying the target antigen in Aire-/-Cblb-/- mice 
To further understand the autoimmune-specificity in Aire-/-Cblb-/- mice, a key next step 
will be to determine the target autoantigen(s) in both the pancreas and salivary glands. 
This could be achieved by testing the related TCRs isolated by PCR from multiple CD8 
T cells in the pancreas (chapter 5) and the distinct TCRs isolated from multiple CD4 T 
cells in the salivary gland (data from Singh, M. – PhD student in the laboratory) form 
the secondary adoptive transfer recipients of Aire-/-Cblb-/- mice. These TCRs could be 
tested for reactivity towards peptide-autoantigens by two approaches: a candidate 
autoantigen testing approach, or a screening and mass spectrometry approach. 
The candidate antigen testing approach would test pancreas-specific T cells isolated 
from retrogenic mice for their ability to proliferate and produce interleukin-2 following 
stimulation with antigen presenting cells expressing candidate autoantigens. As the 
pancreatitis was largely mediated by CD8 cells, the antigens would require MHC Class 
I-dependent presentation. To achieve this, the appropriate APCs could be generated by 
retroviral transduction of candidate autoantigen cDNAs into LPS-activated B cells or 
GM-CSF expanded bone marrow derived dendritic cells. In vitro cultures could be set 
up to determine reactivity of the retrogenic antigen-specific T cells. A good candidate 
autoantigen in the pancreas is the abundant endoplasmic reticulum protein, pancreas-
specific protein disulfide isomerase (PDIp, gene symbol Pdia2; (Ise et al., 2010; Niki et 
al., 2006)) that was identified as a causative autoantigen in Ctla4-deficient mice and in 
Aire-deficient NOD mice. Interestingly, a similar pattern of autoantibody reactivity with 
apical exocrine pancreatic cells to that described in NOD.Aire-/- mice (Niki et al., 2006) 
was observed in sera from Aire-/-Cblb-/- mice. Another likely candidate is pancreatic 
amylase expressed in the granules of the exocrine pancreas and also expressed in 
salivary gland, since this autoantigen was targeted by pancreatic autoimmunity in 
NOD.CD28-/- mice (Meagher et al., 2008). Other possible autoantigens that could be 
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tested are autoantigens identified based on high autoantibody titres in autoimmune 
pancreatitis patients such as lactoferrin (Jin et al., 2009), carbonic anhydrase (CA)-II 
(Aparisi et al., 2005), CA-IV (Nishimori et al., 2005), pancreatic secretory trypsin 
inhibitor (Asada et al., 2006), heat shock protein-10 (Takizawa et al., 2009) and 
plasminogen-binding protein (Frulloni et al., 2009). Besides these bona fide 
autoantigens, molecular mimicricy amongst microbes and target antigens could also 
result in a break down of tolerance. Commonly, Helicobacter pylori antigens have been 
shown to display cross reactivity with carbonic anhydrase (CA)-II and ubiquitin-protein 
ligase E3 component n-recognin 2 expressed in the acinar cells of the pancreas 
(Guarneri et al., 2005). 
A caveat in the candidate antigen testing strategy is that it is a biased approach and 
unlikely to unravel novel autoantigens. Thus, an unbiased strategy could be utilised to 
tackle the problem by screening pools of peptides from pancreas or salivary gland 
extracts for T cell stimulatory activity, followed by chromatographic separation and 
mass spectrometry to identify the reactive peptides. More specifically, the pathogenic 
TCR-of-interest could be co-transfected together with a nuclear factor of activated T-
cells (NFAT) transcription factor-reporter gene construct into the 58α–β- T cell 
hybridoma line. The line lacks endogenous TCR chains albeit carrying CD3 molecules 
needed to respond to TCR stimulation.  The system allows for the screening of 
candidate autoantigens with NFAT expression and IL-2 production as readouts for 
successful TCR-specific stimulation (Ise et al., 2010). The autoantigens could be 
presented to the pathogenic T cells as peptide libraries of fractionated pancreas or 
salivary gland extracts. The target antigen could then be identified via mass 
spectrometry to the reactive pool of autoantigens (Lieberman et al., 2003). Construction 
of retrogenic mouse models with immune cells specific for peptide autoantigens 
identified could shed light on how Aire and Cblb deficiencies contributes to the 
autoimmunity associated with bona fide autoantigens in vivo. 
6.4.3 Potential for pancreas- and salivary gland-specific targeted treatment  
Chapter 5 established that single cell multiplex sequencing coupled with the 
construction of retrogenic mice is a valuable tool for further understanding organ 
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specificity in the Aire-/-Cblb-/- mice. With the current technology, particular clones of 
self-reactive T cells that could be important in the pathogenesis of autoimmunity could 
be easily identified and targeted for tolerisation or selective deletion. Although it seems 
logical that autoreactive T cells clones that are clonally expanded in an organ-specific 
autoimmune disease would provide further insights about the disease, it has proved 
difficult to identify the driver clones. In humans, TCR bias has been observed in 
numerous diseases such as multiple sclerosis (Hong et al., 1999; Oksenberg et al., 1993; 
Wucherpfennig et al., 1990), inflammatory bowel disease (Saubermann et al., 1999), 
ulcerative colitis (Probert et al., 2001), Sjögren's Syndrome (Sasaki et al., 2000), 
systemic lupus erythematosus (Desai-Mehta et al., 1995) and rheumatoid arthritis (Sun 
et al., 2005). In most cases, however, only the TCRβ but not the TCRα chain was 
identified and the target of the TCR was unknown. With current technology readily 
available to provide a more complete analysis of TCR repertoire, it would be useful to 
revisit and mine for autoimmune-driving T cell clones in human diseases and study the 
behaviour of these clones when coupled with one or more deficiencies in tolerance 
genes. This may provide insights on how antigen-specific pathogenic T cell can be 
selectively identified and purged or tolerised in the repertoire using APC-coupled-
antigen treatment. 
By identifying the driver self-reactive T cells, targeted treatment could also be 
attempted using the specific autoantigen they recognised as exemplified by the progress 
that has been made in the type I diabetes field. One of the key autoantigens identified as 
a target of driver CD8 T cell clones in NOD mice was islet-specific glucose-6-
phosphatase catalytic subunit related protein (IGRP). Similar to the results in Aire-/-
Cblb-/- mice, recurrent clonal expansion of CD8 T cells with similar islet-specific TCRs 
was found and shown to cause pancreatic islet destruction in NOD mice. Many of these 
T cells expressed highly homologous T cell receptor chains (Valpha17-Jalpha42) that 
recognised the IGRP peptide sequence IGRP206−214 in the context of the MHC molecule 
Kd and were present on the earliest T cell infiltrates into the islets during the 
development of diabetes (Amrani et al., 2001; Anderson et al., 1999; DiLorenzo et al., 
1998; Lieberman et al., 2003; Santamaria et al., 1995; Verdaguer et al., 1997). 
Treatment of NOD mice with IGRP peptides that expand low affinity IGRP CD8 cells 
with suppressive activity was shown to be effective in reversing diabetes progression 
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(Han et al., 2005b; Tsai et al., 2010). In the human population, the IGRP-encoding gene 
resides in a TID susceptibility locus on chromosome 2 (Pociot and McDermott, 2002) 
and the effectiveness of this peptide for therapy for TID could be considered (Han et al., 
2005a). This example indicates that target antigens found in mice are translatable to 
human diseases.  
Indeed the Aire-deficient mice have started to unveil a list single autoantigens that can 
target specific organs for spontaneous destruction. The first to be identified was the 
Aire-dependent eye-specific interphotoreceptor retinoid-binding protein (IRBP) that 
trigger eye-specific autoimmunity (DeVoss et al., 2006). Transplantation of IRBP 
knockout thymi into athymic IRBP sufficient mice trigger spontaneous autoimmune 
uveitis demonstrating that expression of single eye antigen during T cell development in 
the thymus is crucial in preventing eye-specific autoimmunity (DeVoss et al., 2006). 
Similarly, single Aire-dependent self-antigens have been identified as targets for 
destruction in single organs such as the pancreas-specific PDIA2 (Niki et al., 2006), 
lacrimal gland odorant binding protein 1a (DeVoss et al., 2010), prostate seminal 
vesicle secretory protein 2 (Hou et al., 2009), stomach mucin 6 (Gavanescu et al., 2007) 
and H/Kβ subunit of the H+K+ ATPase (Laurie et al., 2004) and lung vemeromulin 
(Shum et al., 2009). The identification of particular organ-specific autoantigens targeted 
in the Aire-deficient mice is a useful tool for identifying clinically relevant autoantigens 
for diagnosis and treatment of organ-specific autoimmune diseases.  
As we continue to build upon this list of autoantigens and further understand how each 
of these antigens is controlled, it would help build clearer opportunities to target 
treatment more specifically in autoimmune diseases. There have already been attempts 
to treat autoimmune diseases using self-antigenic peptide to modulate autoimmune 
responses based on leads from mouse models. Originally identified in NOD mice 
(Daniel and Wegmann, 1996; Nakayama et al., 2005), the altered peptide ligand of the 
insulin B9-23 epitope, NBI-6024, that was recognised by the interferon-gamma TH1 
inflammatory cells, was used to modulate the T cell response in type I diabetes. The 
results of a phase I trial indicated that the peptide treatment cause a shift in TH1 
pathogenic immune response to a protective TH2 response (Alleva et al., 2006), 
although a phase II trial indicated that there were no significant effects on pancreatic 
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beta-cell function (Walter et al., 2009). Similarly, a two phase trial myelin basic 
protein83-99 altered peptide ligand for the treatment of multiple sclerosis was 
prematurely terminated because the treatment led to hypersensitive reaction and disease 
exacerbation (Bielekova et al., 2000; Kappos et al., 2000). It is possible that the little 
success in these trials could be attributed to ineffective dose delivery and the underlying 
altered peptide ligand-T cell specific precursor frequency, avidity, activation status, all 
of which would influence the outcome of a robust immune response that could also vary 
from patient to patient as autoimmune diseases are extremely heterogenous (Genain and 
Zamvil, 2000). Perhaps the full potential of this therapy could be realised by better 
understanding the mechanism that are involved in self-antigen regulation in the 
laboratory in in vitro models and animal models and considering tailored therapy for 
each patient depending on the state of the disease. Hence, augmenting the expression of 
autoantigens or administering doses of autoantigen that could induce tolerance could 
still be a valuable strategy for controlling autoimmunity towards the specific antigen, 
without inducing alternative autoimmune disorders by using broad-spectrum 
immunosupressions to treat autoimmunity that is only targeted towards one or two 
organs. However, there is still broad scope for research to understand the precise 
mechanism to create an effective immune response with this strategy. 
6.5 Aire-/-Cblb-/- mice as a mouse model for the human diseases autoimmune 
pancreatitis, Sjogren’s syndrome and Mikulicz disease 
6.5.1 Autoimmune pancreatitis, Sjögren's syndrome and Mikulicz disease share 
similar histopathological features as Aire-/-Cblb-/- mice 
The ultimate goal for using animal models to study autoimmunity is to characterise 
disease pathogenesis, allowing better understanding of the disease and targets for 
immunotherapies that can alter the course of disease. The features of the Aire-/-Cblb-/- 
mice are histopathologically most similar to the human conditions Sjögren's syndrome, 
Mikulicz disease and exocrine pancreatitis.  
Of the three, Sjögren's Syndrome or sicca syndrome is the most extensively studied 
(Goransson et al., 2006). It is an autoimmune disorder affecting the exocrine salivary 
and lacrimal glands, clinically characterized by xerostomia (dry mouth) and 
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keratoconjunctivitis sicca (dry eyes). The disease affects approximately 3.1 million 
people worldwide with 90% of patients being female (Helmick et al., 2008). It exists in 
two forms, either primary of secondary. Primary Sjögren's Syndrome affects salivary 
and/or lacrimal glands in the absence of other rheumatic diseases, while its more 
common secondary form occurs in the presence of other rheumatic diseases, such as 
systemic lupus erythematosus (Prabu et al., 2003), rheumatoid arthritis (Reader et al., 
1951), scleroderma (Kirkham, 1969), and primary biliary cirrhosis (Culp et al., 1982). 
The diagnosis of this syndrome includes detection of lymphocytes within the salivary 
glands (a feature of the Aire-/-Cblb-/- mouse model), ocular and oral dryness, and the 
presence of anti-SSA/Ro, anti-SSB/La and antinuclear antibodies in the serum (Vitali, 
2003). A similar disease to Sjögren's Syndrome, also characterized by infiltration in the 
salivary and lacrimal glands is Mikulicz's disease. The difference between the two 
diseases is that Mikulicz's disease exhibits a male dominance, no detection of anti-
SSA/Ro, anti-SSB/La antibodies, and demonstrates a good response to corticosteroid 
treatment (Yamamoto et al., 2005). Besides that, Mikulicz's disease is characterised by 
high concentrations of serum IgG4, a feature shared with autoimmune pancreatitis. 
Autoimmune pancreatitis is a rare condition twice as likely to develop in men compared 
to women. It is frequently associated with several autoimmune diseases including 
Sjögren's syndrome (Montefusco et al., 1984) and was only considered a separate 
disease when cases of pancreatitis without systemic autoimmunity were reported 
(Yoshida et al., 1995). The challenge in diagnosis is differentiating the disease from 
other forms of non-autoimmune pancreatitis (usually associated with chronic alcohol 
consumption or infections with Epstein-Barr virus, hepatitis virus or cytomegalovirus) 
and pancreatic cancer. The characteristic features include histological detection of 
pancreatic infiltration, hypergammaglobulinemia, elevated serum IgG4 levels, elevated 
plasma concentrations of carbonic anhydrase II and lactoferrin and antinuclear 
antibodies (Asada et al., 2006; Niki et al., 2006; Okazaki et al., 2001; Uchida et al., 
2002). In humans, the condition rarely proceeds to total pancreatic insufficiency, but it 
is a relatively common syndrome that proceeds to pancreatic insufficiency and 
malabsorption in dogs (Wiberg et al., 2000). Recently, there have been suggestions of a 
new clinical entity and classification – IgG4-related diseases that encompasses 
Mikulicz's disease and autoimmune pancreatitis (Takahashi et al., 2011).  
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There is still much to understand about the etiology and pathogenesis of these diseases 
and the emergence of new mouse models that accurately resemble the human diseases 
would be a valuable tool in the advancement of the field. As the histological features of 
the Aire-/-Cblb-/- mouse model fits with these diseases, exhibiting very specific 
destruction of the exocrine pancreas and salivary glands, it would be interesting to 
further investigate other key characteristics of the human disease in the mouse model. 
This would include the measurements of mouse-IgG1 antibodies (equivalent to human 
IgG4 (Hussain et al., 1995)) and detection of target antigens in the mouse that could 
unravel new biomarkers to be used for diagnosis of the disease or therapeutic treatment 
using coupled-cell-tolerance strategies (APCs coupled with autoantigens for tolerising 
autoreactive cell). 
Currently there is little evidence about a connection between Aire- and Cblb-
deficiencies in humans with pancreatitis/sialoadenitis. The well-characterized APECED 
disease has been associated with a simple monogenic recessive deficit in the Aire gene. 
It is notable that malabsorption and/or steatorrhoea occur as a secondary feature in 15-
22% of APECED patients, and pancreatic insufficiency has been demonstrated in a 
fraction of these individuals (Betterle et al., 1998; Perheentupa, 2006). On the other 
hand, single gene deficiencies in Cblb have been identified in type 1 diabetes (Hoyne et 
al., 2011b; Yokoi et al., 2007; Yokoi et al., 2002). Single nucleotide polymorphisms 
that are linked to the Cblb gene have also been identified in a range of polygenic 
autoimmune diseases such as multiple sclerosis (Corrado et al., 2010; Sanna et al., 
2010) and systemic lupus erythematosus (Doniz-Padilla et al., 2011). To date, there 
have not been reports of double deficiencies in both genes in autoimmune patients. 
Considering that many of the mouse models described in section 7.4 share deficiencies 
in Aire-dependent or Cblb-dependent tolerance pathways, this provides a compelling 
basis for analysing genetic variants within these pathways in Sjögren's syndrome 
syndrome, Mikulicz disease and exocrine pancreatitis autoimmune diseases. 
6.6 Comparing the multistep pathogenesis for autoimmune disease with cancer 
This study began by examining a multistep pathogenesis model to unravel a genetic 
basis for the clinical latency and heterogeneity in autoimmune diseases. Conventionally, 
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the latent phase in autoimmune disease have been attributed to environmental triggers. 
However, the presence of a latent phase in diabetes development in NOD mice (Alam et 
al., 2011) and autoimmunity in the MRL/lpr mice housed in germ-free conditions 
(Maldonado et al., 1999) provided scope for alternative explanations. Furthermore, 
NOD.Aire-/- mice housed in germ-free conditions developed comparable rates of 
exocrine pancreatitis to their specific-pathogen free-housed counterparts (Gray et al., 
2007), supporting the notion that environmental triggers cannot fully explain variations 
in tempo and progression of autoimmune disease.  
The co-operation between the two self-tolerance defects has striking parallels with the 
co-operative onset of cancer without a latent phase with combined defects in particular 
cancer checkpoints such as activation of an oncogene and inactivation of a failsafe 
tumor suppressor gene (Hanahan and Weinberg, 2000, 2011). Like the multi-step 
pathogenesis of different cancers, specific combinations of defects in compensating 
mechanisms of tolerance may be required to precipitate different autoimmune diseases. 
These findings provide a framework for understanding the latency and heterogeneity in 
clinical autoimmune disease and the complexity of its inheritance. There are several 
features that differ in the multistep model for autoimmunity to that of cancer 
pathogenesis. In cancer, multiple mutations accumulate in genes that regulate different 
pathways that control cell survival and growth in any cell type, resulting in multiple 
kinds of cancers able to metastasise to different areas. On the other hand, autoimmunity 
occurs as a results of multiple mutations occuring in genes involved in central of 
peripheral tolerance pathways and act either cell intrinsically or cell extrinsically on 
self-reactive lymphocyte clone(s), usually affecting haematopoietic progenitors of 
developing lymphocytes that are continuously produced throughout life. Cancer of the 
immune cells, or lymphoma (T and B cells) or leukaemia (myeloid cells), affect the 
immune cells but contrary to autoimmunity, these cancerous cells do not usually 
mediate severe destruction of specific organs. 
Intriguingly, there is an increased occurrence of lymphoma in individuals with pre-
existing autoimmune conditions such as lupus, rheumatoid arthritis and Sjögren's 
Syndrome (Bernatsky et al., 2005; Smedby et al., 2006; Zintzaras et al., 2005). As 
highlighted above, unifying features of the two diseases is that both are heterogenous in 
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nature, present with a latent phase (presumed to be a period of accumulating additional 
mutations) and result from inhibitions of normal pathways that keep cell growth/clonal 
expansion in check. These features suggest that the co-relation could be attributed to 
shared genetic defects between the two. A prominent example is that mutations in Fas, 
the molecule involved in apoptosis are associated with autoimmune diseases in mice 
and humans. Recent studies in chronic lymphocytic leukaemia demonstrated that 
monoclonal antibodies from the lymphoma react with autoantigens present in apoptotic 
cells and bacteria, providing preliminary indication that autoreactivity may play a role 
in lymphoma pathogenesis (Catera et al., 2008; Chu et al., 2010).  
As both lymphoma and autoimmunity share numerous similarities in etiology and 
pathogenesis, findings or concepts from lymphoma may be applied to autoimmunity, 
and vice versa. Similar therapeutic strategies could potentially be used to treat 
autoimmune diseases and lymphoma or leukaemia. Administration of ex vivo-generated 
antibodies, such as CD25-specific antibody (daclizumab) has been used to treat 
noninfectious autoimmune uveitis, multiple sclerosis and adult T cell leukaemia 
(Waldmann, 2007). Another example is the monoclonal CD20-specific antibody 
(rituximab) has been approved for treatment of non-Hodgkin lymphoma and chronic 
lymphocytic leukemia, as well as some non-malignant autoimmune conditions like 
rheumatoid arthritis (Keating, 2010).  
6.7 Concluding remarks 
This study highlights the importance of studying the synergistic interactions between 
two alleles as some combinations could prove more or less potent than predicted based 
on the knowledge of the individual gene function. Perhaps the easiest way to continue 
tackling this would be to construct a detailed map of gene groups and molecular 
pathways needed to execute each tolerance mechanisms based on autoimmune driver 
genes found in genome wide association studies. As genes within the same group could 
be considered functionally equivalent, synergistic effects between defects in two 
pathways could be easily tested. In time, it is hoped that these genes will be joined by 
many others to yield a detailed map of the gene groups or molecular pathways needed 
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to execute immune tolerance to particular organs and understand how each pathway 
interacts to prevent autoimmunity. 
Because of the potential collaborative nature of these tolerance defects, it could also be 
suggested that heterozygous mutations in tolerance genes may also contribute to 
pathogenesis and should be given more consideration. Deleterious inherited mutations 
are predicted to occur at a frequency of 1 in every 100 000 genes (Haag-Liautard et al., 
2007). As there are 25 000 genes in each individual, 1 in every 4 children are predicted 
to carry 1 deleterious mutations, that could easily occur in one of the many tolerance 
genes in a rapidly outbreeding population. There is thus a high likelihood that many 
carry deleterious mutations of tolerance genes in a heterozygous state. A second hit in 
the functional copy of the tolerance allele could easily occur given that 10-6 somatic 
mutations occur per gene per cell division (Araten et al., 2005) and lymphocytes are 
continuously produced. 
To summarise, organ-specific autoimmune disease is extremely complex in nature. As 
we continue to build a logical genetic framework for understanding the pathogenesis, it 
is important to not only draw information from genome wide association studies, but 
refine the information by strategically testing particular gene-gene combinations 
coupled with lymphocyte receptor reactivity to understand how these interactions 
orchestrate autoimmunity. A clearer picture of the genotypic contribution to 
autoimmune disease would not only provide insights to explain the mechanisms that 
account for human diseases but aid in predicting individual at risk of disease and 
effectively target treatments. 
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Chapter 7  
Appendix 
7.1 Supplementary figure and table for Chapter 3 
Appendix 3.1 Table shows the RAW DATA of litter sizes for the 9 breeder pairs, 
the number of offspring of each genotype from each breeder pair (TOTAL 
OBTAINED) and the expected Mendelian ratios of each genotype based on the 
genotype of the parent breeder (TOTAL EXPECTED). Summary is seen in Table 3.1. 
RAW DATA  TOTAL OBTAINED  TOTAL EXPECTED 
             
F4, Breeder pair 1           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 2 5  
Cblb
+/+ 8 17 5  
Cblb
+/+ 5.75 11.5 5.75 
2 2 5  
Cblb
+/- 6 27 12  
Cblb
+/- 11.5 23 11.5 
3 1    
Cblb-
/- 12 1 4  
Cblb-
/- 5.75 11.5 5.75 
4 6             
5 6 2           
6 5 5           
7 5 4           
8 2 7           
9 5 3           
10 8 5           
11 2 2           
12 1 1           
13 1 3           
14 3 5           
15   2           
16 Lost             
17 3             
             
F4, Breeder pair 2           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 Lost    
Cblb
+/+ 2 1 1  
Cblb
+/+ 0.88 1.75 0.88 
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2 4 2  
Cblb
+/- 1 3 4  
Cblb
+/- 1.75 3.51 1.75 
3 1 4  
Cblb-
/-   1 1  
Cblb-
/- 0.88 1.75 0.88 
4 2 4           
5 Lost             
             
F5, Breeder pair 1           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 5 2  
Cblb
+/+   6 6  
Cblb
+/+   5 5 
2 1 2  
Cblb
+/-   9 10  
Cblb
+/-   10 10 
3 1 3  
Cblb-
/-   6 3  
Cblb-
/-   5 5 
4   1           
5 2 3           
6 Lost             
7 2 4           
8 5 5           
9 3 3           
10 1 2           
             
RAW DATA  TOTAL OBTAINED  TOTAL EXPECTED 
             
F5, Breeder pair 2           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 3 5  
Cblb
+/+     4  
Cblb
+/+     3.75 
2 3 4  
Cblb
+/-     8  
Cblb
+/-     7.5 
3 Lost    
Cblb-
/-     3  
Cblb-
/-     3.75 
             
F5, Breeder pair 3           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 3 1  
Cblb
+/+   1 2  
Cblb
+/+   2.5 2.5 
2 2 5  
Cblb
+/-   3 1  
Cblb
+/-   2.5 2.5 
3 1 2  
Cblb-
/- 1 4 3  
Cblb-
/-   2.5 2.5 
             
F6, Breeder pair 2           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 2 1  
Cblb
+/+     6  
Cblb
+/+     3.25 
2 4 3  
Cblb
+/-     5  
Cblb
+/-     6.5 
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3 Lost    
Cblb-
/-     2  
Cblb-
/-     3.25 
4 1 2           
             
F6, Breeder pair 4           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 5 2  
Cblb
+/+   4    
Cblb
+/+ 3.65 3.65   
2 1 5  
Cblb
+/- 11 6    
Cblb
+/- 7.3 7.3   
3 5 6  
Cblb-
/-   8    
Cblb-
/- 3.65 3.65   
4 2 5           
             
F7, Breeder pair 1           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 4 5  
Cblb
+/+     1  
Cblb
+/+     4 
2 5 2  
Cblb
+/-     13  
Cblb
+/-     8 
    
Cblb-
/-     2  
Cblb-
/-     4 
             
F9, Breeder pair 1           
Litters Female Male  
Obta
ined 
Aire+
/+ 
Aire+
/- 
Aire-
/-  
Expe
cted 
Aire+
/+ 
Aire+
/- 
Aire-
/- 
1 Lost    
Cblb
+/+        
Cblb
+/+       
2 4 3  
Cblb
+/- 6 5    
Cblb
+/- 5.75 5.75   
3 3 8  
Cblb-
/- 7 5    
Cblb-
/- 5.75 5.75   
4 5 2           
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Appendix 3.2. Histology scores for histopathology.
Pancreas: (0) No pancreatitis detected; (1) Perivascular lymphocyte
infiltration; (2) Small patches of lymphocyte infiltration in the exocrine
tissue; (3) Extensive infiltration in the exocrine pancreatic tissue and
destruction of <50%  of the exocrine acinar tissue; (4) Extensive
infiltration in the exocrine pancreatic tissue and destruction of 50%-
90% of the exocrine acinar tissue; (5) Extensive infiltration in the
exocrine pancreatic tissue and complete absence of exocrine acinar
tissue. Original magnification: x100. Bars: 500 µm.
Submandibular salivary gland: (0) No sialoadenitis detected; (1)
Perivascular lymphocyte infiltration; (2) Small patches of lymphocyte
infiltration in the supporting tissue, decrease in mucous acini; (3)
Extensive lymphocytic infiltration and destruction of <50% of the
mucous acinar tissue; (4) Extensive lymphocytic infiltration and
destruction of 50%-90% of the mucous acinar tissue; (5) Extensive
lymphocytic infiltration and complete absence of mucous acinar tissue.
Original magnification: x400. Bars: 200 µm.
Varying lymphocytic infiltration in the stomach. Original magnification:
x200. Bars: 200 µm.
Histology 
scores
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7.2 Supplementary tables for Chapter 5 
Tables on the following pages show raw data from the multiplex RT-PCR sequencing 
of mRNA isolated from paired TCRα and β chains in Aire-/-Cblb-/- donors, adoptive 
transfer primary and secondary recipients. 
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Table 5.10 The analysis of CD4 clones in the spleen of original donors of WT1 mice (S0, Plate CT32). 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-4 YFCAV SANYNQGKL IFGQGTKLSIKP Traj23 9 Trbv20 YLCGA RDRANSD YTFGSGTRLLV Trbj1-2 7 1
Trav5D-4 YFCAA SSNNRIP FFGDGTQLVVK Traj31 7 Trbv3 YFCAS SPGTGYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav5D-4 YFCAA SEQGGSAKL IFGEGTKLTVSS Traj57 9 Trbv13-3 YFCAS SDGTGEKAP LFGEGTRLSVL Trbj1-5 9 1
Trav6? YFCAL LCGSFNKL TFGAGTRLAVCP Traj4 8 Trbv13-2 YFCAS GEQNTEV FFGKGTRLTVV Trbj1-1 7 1
Trav6-1, 2 YCVLA VSSNTNKV VFGTGTRLQVLP Traj34 8 Trbv13-2 YFCAS GDATGRDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6-1, 6-2 YYCVL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv29 YFCAS SSTGRNTEV FFGKGTRLTVV Trbj1-1 9 1
Trav6-3, 6D-3 YYCAM RDAYGSSGNKL IFGIGTLLSVKP Traj32 11 Trbv13-2 YFCAS GDAGQGYAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav6-4, 6D-4 YFCAL DYTGANTGKL TFGHGTILRVHP Traj52 10 Trbv13-2 YFCAS GDRNTGQL YFGEGSKLTVL Trbj2-2 8 1
Trav6-5, D-6, D-7, YYCAL GEGTGSKL SFGKGAKLTVSP Traj58 8 Trbv26 YLCAS SPLGPYYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav6-5, D-6, D-7, YYCAQ SGSFNKL TFGAGTRLAVCP Traj4 7 Trbv20 YLCGA RDNYAEQ FFGPGTRLTVL Trbj2-1 7 1
Trav6-6 YYCAL GASMNYNQGKL IFGQGTKLSIKP Traj23 11 Trbv31 YLCAW SLGGDQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav7? YLCAV NYNQGKL IFGQGTKLSIKP Traj23 7 Trbv31 YLCAW SSDWGGYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav7-1 YFCAV TDRGSALGRL HFGAGTQLIVIP Traj18 10 Trbv19 FLCAS RLGNQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav7-1 YFCAV RGMTTASLGKL QFGTGTQVVVTP Traj24 11 Trbv13-1 YFCAS SGPKDTQ YFGPGTRLLVL Trbj2-5 7 1
Trav7-2, 3, D-3 YLCAV SPGGSNAKL TFGKGTKLSVKS Traj42 9 Trbv13-1 YFCAS SGLTSQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav7-3 YLCAA SPGGNYKP TFGKGTSLVVHP Traj6 8 Trbv1 YCTCS AEAGDTGQL YFGEGSKLTVL Trbj2-2 9 1
Trav8-1, 8D-1 YFCAT NTNTGKL TFGDGTVLTVKP Traj27 7 Trbv31 YLCAW SLEGGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav9? YFCVL RMQQGTGSKL SFGKGAKLTVSP Traj58 10 Trbv13-2 YFCAS VLGGRGEQ YFGPGTRLTVL Trbv2-7 8 1
Trav9-3,D-3, 4 YFCAV SAGSNYNVL YFGSGTKLTVEP Traj21 9 Trbv1 YCTCS VQGNQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav9D-4 YFCVL SASGGSNAKL TFGKGTKLSVKS Traj42 10 Trbv13-2 YFCAS GALTGSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav10, 10D YFCAA RITGNTGKL IFGLGTTLQVQP Traj37 9 Trbv19 FLCAS SIWGAQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav11, 11D YICVVG DRGSALGRL HFGAGTQLIVIP Traj18 9 TRVB1 YCTCS ADRDTQ YFGPGTRLLVL Trbj2-5 6 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SRVGDNSKL IWGLGTSLVVNP Traj38 9 Trbv26 YLCAS SQDSGNT LYFGEGSRLIVV Trbj1-3 7 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL GANYGNEKI TFGAGTKLTIKP Traj48 9 Trbv2 YFCPS IQAGGGWRQ SFGPGTRLTVL Trbj2-1 9 1
Trav13-1, D-1 LCAM DQGGRAL IFGTGTTVSVSP Traj15 7 Trbv19 FLCAS SKRGAETL YFGSGTRLTVL Trbj2-3 8 1
Trav13-2 YFCAI ESSAGNKL TFGIGTRVLVRP Traj17 8 Trbv2 YFCAS SQDRDTQ YFGPGTRLLVL Trbj2-5 7 1
Trav13D-1 YLCAL EGNNNAP RFGAGTKLSVKP Traj43 7 Trbv5 YFCAS SQEGLGYAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav14-1 YFCAA RGSNAKL TFGKGTKLSVKS Traj42 7 Trbv4(2) YLCAS SSGQGYERL FFGHGTKLSVL Trbj1-4 9 1
Trav14-2 YFCAA SDTNTGKL TFGDGTVLTVKP Traj27 8 Trbv5 YFCAS SQAREGEQ YFGPGTRLTVL Trbv2-7 8 1
Trav14-2 YFCAA TSNTNKV VFGTGTRLQVLP Traj34 7 Trbv3 YFCAS SFDRGGSAETL YFGSGTRLTVL Trbj2-3 11 1
Trav14D-3/DV8 YFCAA SGGSALGRL HFGAGTQLIVIP Traj18 9 Trbv13-1 YFCAS SERTGTSAETL YFGSGTRLTVL Trbj2-3 11 1
Trav16, 16D/DV11 YFCAM REGRGYQNF YFGKGTSLTVIP Traj49 9 Trbv5 YFCAS SQDRGSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav21/DV12 YHCIL RNNNNAP RFGAGTKLSVKP Traj43 7 Trbv1 YCTCS ADTGGNTL YFGAGTRLSVL Trbj2-4 8 1
Trav21/DV12 YHCIL NSGYQNF YFGKGTSLTVIP Traj49 7 Trbv19 FLCAS SRQGEA YFGPGTRLTVL Trbv2-7 6 1
34
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Table 5.11 The analysis of CD4 clones in the spleen of WT1 primary recipient mice (S1, Plate CT43). 
 
Table 5.12 The analysis of CD4 clones in the spleen of WT1 secondary recipient mice (S2, Plate CT60). 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-3, D-3 YFCAA EANNAGAKL TFGGGTRLTVRP Traj39 9 Trbv1 LYCTC SDWGGNTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav7D-5 YLCAV SSNTGYQNF YFGKGTSLTVIP Traj49 9 Trbv4(2) YLCAS SDWGDQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav6D-4, Trav6D-6, Trav6D-
7 YFCAL STGNYKY VFGAGTRLKVIA Traj40 7 Trbv30 YFCSP YFGEGSKLTVL YFGEGSKLTVL Trbj2-2 11 1
Trav7-4, D-4 YFCAV SGGNMGYKL TFGTGTSLLVDP Traj9 9 Trbv2 YFCAS SQDGGLRGQNTL YFGAGTRLSVL Trbj2-4 12 1
Trav7D-2 YLCAA SMGTGSNRL TFGKGTKFSLIP Traj28 9 Trbv13-2 YFCAS GELGGDTQ YFGPGTRLLVL Trbj2-5 8 1
5
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
TRAV3-4 YFCAV SRNSGTYQ RFGTGTKLQVVP Traj13 8 Trbv4(2) YLCAS VLGNQDTQ YFGPGTRLLVL Trbj2-5 8 1
TRAV4-3, 4D-3 YFCAA ANMDYANKM IFGLGTILRVRP Traj47 9 Trbv1 LYCTC SADPTYSGNTL YFGEGSRLIVV Trbj1-3 11 1
TRAV7-5, 7D-5 YLCAD TGYQNF YFGKGTSLTVIP Traj49 6 Trbv3 YFCAS SLDQGGEV FFGKGTRLTVV Trbj1-1 8 1
TRAV7-6 or 7D-6 YLCAV RGNMGYKL TFGTGTSLLVDP Traj9 8 Trbv14 YLCAS SKTGINQAP LFGEGTRLSVL Trbj1-5 9 12
TRAV8-2 YFCAT DDTNTGKL TFGDGTVLTVKP Traj27 8 Trbv13-2 YFCAS GGTGGAETL YFGSGTRLTVL Trbj2-3 9 2
TRAV9-1, D-1, 2, D-2, 3, D-
3, 4, D-4 YFCVL SVTGSGGKL TLGAGTRLQVNL Traj44 9 Trbv13-1 YFCAS SDQDSAEQ FFGPGTRLTVL Trbj2-1 8 1
TRAV9-1, TRAV9D-3 YFCAV SSGTGGYKV VFGSGTRLLVSP Traj12 9 Trbv31 YLCAW SPLGGREQ YFGPGTRLTVL Trbv2-7 8 1
TRAV10, 10D YFCAA SNYGNEKI TFGAGTKLTIKP Traj48 8 Trbv5 YFCAS SPDRGGWEQ YFGPGTRLTVL Trbv2-7 9 2
TRAV13-2 YLCAL ERNNYAQGL TFGLGTRVSVFP Traj26(1) 9 Trbv20 YLCGA RDPGFDERL FFGHGTKLSVL Trbj1-4 9 1
TRAV14D-3/DV8 YFCAA KSAGNKL TFGIGTRVLVRP Traj17 7 Trbv20 YLCGA RDPGFDERL FFGHGTKLSVL Trbj1-4 9 1
TRAV14D-3/DV8 YFCAA SEGNMGYKL TFGTGTSLLVDP Traj9 9 Trbv2 YFCAS SPTGTNSD YTFGSGTRLLVI Trbj1-2 8 1
TRAV16, 16D/DV11 YFCAM REGRTGNYKY VFGAGTRLKVIA Traj40 10 Trbv13-2 YFCAS GGTGGAETL YFGSGTRLTVL Trbj2-3 9 1
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Table 5.13 The analysis of CD4 clones in the spleen of original donors of MUT1 mice (S0, Plate CT38). 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-4/DV10 YFCAA TGNTGKL IFGLGTTLQVQP Traj37 7 Trbv20 YLCGA STDNNQAP LFGEGTRLSVL Trbj1-5 8 1
Trav5-1 YFCSA GNYAQGL TFGLGTRVSVFP Traj26(1) 7 Trbv26 YLCAS RYWGGNQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav5D-4 YFCAA SENNNNAP RFGAGTKLSVKP Traj43 8 Trbv13-1 YFCAS SGGGAETL YFGSGTRLTVL Trbj2-3 8 1
Trav5D-4 YFCAA SGGSNAKL TFGKGTKLSVKS Traj42 8 Trbv17 YLCAS SGGTGGTQ YFGPGTRLLVL Trbj2-5 8 1
Trav6-1, 6-2, 6-4, 6D-4, 6-5, 
6D-5, 6, 6D-6, 6-7/DV9, 6D-
7 YYCAL GWAGSFNKL TFGAGTRLAVCP Traj4 9 Trbv13-3 YFCAS GTGGTNTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav6-5, 6D-5 YYCAL RFNYGNEKI TFGAGTKLTIKP Traj48 9 Trbv19 FLCAS SIVGLYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav6-7/DV9 YYCAL GNSGGSNYKL TFGKGTLLTVTP Traj53 10 Trbv5 YFCAS SPTGRNTS YFGAGTRLSVL Trbj2-4 8 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GVNTNTGKL TFGDGTVLTVKP Traj27 9 Trbv1 LYCTC SAGGSAETL YFGSGTRLTVL Trbj2-3 9 1
Trav7-5 YLCAV ENRGSALGRL HFGAGTQLIVIP Traj18 10 Trbv4(2) YLCAS TKDRRQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav7-6 YLCAV SSGSWQL IFGSGTQLTVMP Traj22 7 Trbv13-1 YFCAS SARDNSGNTL YFGEGSRLIVV Trbj1-3 10 1
Trav7-6 YLCAV GNNAGAKL TFGGGTRLTVRP Traj39 8 Trbv3 YFCAS SWDWGDAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav9-1, 9D-1, 9-2, 9D-3 YFCAA GNTRKL IFGLGTTLQVQP Traj37 6 Trbv20 YLCGA RVVGVQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav9-1, 9D-1, 9-2, 9D-3 YFCAV SAYGSSGNKL IFGIGTLLSVKP Traj32 10 Trbv3 YFCAS SSGAETL YFGSGTRLTVL Trbj2-3 7 1
Trav9-1, 9D-1, 9-2, 9D-3 YFCAV RDYSNNRL TLGKGTQVVVLP Traj7 8 Trbv4(2) YLCAS SPRGQNTL YFGAGTRLSVL Trbj2-4 8 1
Trav9-3, 9-4, 9D-4 YFCAV SALGSSGNKL IFGIGTLLSVKP Traj32 10 Trbv15 YLCAS SPDTSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav9-3, 9-4, 9D-4 YFCAV SIASSSFSKL VFGQGTSLSVVP Traj50 10 Trbv31 YLCAR RGGERL FFGHGTKLSVLGL Trbj1-4 6 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDNNAGAKL TFGGGTRLTVRP Traj39 9 Trbv13-1 YLCAS SPWGGSAETL YFGSGTRLTVL Trbj2-3 10 1
Trav13D-4 YLCAM ANTGYQNF YFGKGTSLTVIP Traj49 8 Trbv14 YLCAS SLGGNTGQL YFGEGSKLTVL Trbj2-2 9 1
Trav14-1 YFCAA SDYQGGRAL IFGTGTTVSVSP Traj15 9 Trbv13-1 YFCAS SDGTGGQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav14-1 YFCAA SGSQGGSAKL IFGEGTKLTVSS Traj57 10 Trbv31 YLCAW TGGTSAETL YFGSGTRLTVL Trbj2-3 9 1
Trav14-3 YFCAA MNYNQGKL IFGQGTKLSIKP Traj23 8 Trbv14 YLCAS SFRDSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav14-3 YFCAA SAGNTGKL IFGLGTTLQVQP Traj37 8 Trbv29 YFCAS SKGGLGGYEQ YFGPGTRLTVL Trbv2-7 10 1
Trav16, 16D/DV11 YFCAM REGTNTNKV VFGTGTRLQVLP Traj34 9 Trbv14 YLCAS SLGSSD YTFGSGTRLLVI Trbj1-2 6 1
Trav19 YLCAA GANTGYQNF YFGKGTSLTVIP Traj49 9 Trbv2 YFCAS SPQGNERL FFGHGTKLSVL Trbj1-4 8 1
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Table 5.14 The analysis of CD4 clones in the pancreas of original donors of MUT1 mice (P0, Plate CT25). 
Table 5.15 The analysis of CD4 clones in the pancreas of MUT1 primary recipient mice (P1). Note that no CD8 cells were 
identified (Plate CT40) 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-3, 4D-3 YFCAA MSGGSNYKL TFGKGTLLTVTP Traj53 9 Trbv2 YFCAS SQGNSD YTFGSGTRLLVI Trbj1-2 6 1
Trav5D-4 YFCAA TASLGKL QFGTGTQVVVTP Traj24 7 Trbv5 YFCAS SQGAQNTL YFGAGTRLSVL Trbj2-4 8 1
Trav6-4, 6D-4 YCVLG DLSSGSWQL 9 Trbv29 YFCAS SPRTGDTL YFGAGTRLSVL Trbj2-4 8 1
Trav6-4, 6D-4, 6-5, 6D-5, 6-
6, 6D-6, 6-7/DV9, 6D-7 YYCAL AYYAQGL TFGLGTRVSVFP Traj26(1) 7 Trbv1 LYCTC SANSAETL YFGSGTRLTVL Trbj2-3 8 1
Trav6-6, 6D-6 YYCAL SVVSGSFNKL TFGAGTRLAVCP Traj4 10 Trbv3 YFCAS SLGGGSAETL YFGSGTRLTVL Trbj2-3 10 1
Trav6-7, 6-7/DV9 YYCAL GVYNQGKL IFGQGTKLSIKP Traj23 8 Trbv13-2 YFCAS GDLGSSQNTL YFGAGTRLSVL Trbj2-4 10 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GDNNRI FFGDGTQLVVKP Traj31 6 Trbv29 YFCAS SFQTGNTL YFGEGSRLIVV Trbj1-3 8 1
Trav7-2, 7D-2 YLCAA SRGGSNAKL TFGKGTKLSVKS Traj42 9 Trbv19 FLCAS SRDREDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav7-4, 7D-4 YFCAA RAITGNTGKL IFGLGTTLQVQP Traj37 10 Trbv1 LYCTC SALTGGNSPL YFAAGTRLTVT Trbj1-6 10 1
Trav7D-5, 7-6 YFCAV SYSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-1 YFCAS SPSSYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav8-1, 8D-1 YFCAT TFGKGTLLTVTP TFGKGTLLTVTP Traj53 12 Trbv4 YLCAS SPTGGYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav13-2, 13D-2 YLCAM NGGSNYKL TFGKGTLLTVTP Traj53 8 Trbv5 YFCAS SQQGANERL FFGHGTKLSVL Trbj1-4 9 1
Trav13D-1, 13-2 YLCAL EQNAGAKL TFGGGTRLTVRP Traj39 8 Trbv20 YLCGA RDRGAEQ FFGPGTRLTVL Trbj2-1 7 1
Trav14-3 YFCAA NNNAGAKL TFGGGTRLTVRP Traj39 8 Trbv3 FCAS SLDRGREQ YFGPGTRLTVL Trbv2-7 8 1
Trav16, 16D/DV11 YFCAM REGSPGTGSNRL TFGKGTKFSLIP Traj28 12 Trbv13-2 GPQDSGNTL GPQDSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav16, 16D/DV11 YFCAM REGTGSGGKL TLGAGTRLQVNL Traj44 10 Trbv13-2 YFCAS GDPGQNSGNTL YFGEGSRLIVV Trbj1-3 11 1
Trav17 YFCAL DTNAYKV IFGKGTHLHVLP Traj30 7 Trbv5 YFCAS SQGWGGEYTQ YFGPGTRLLVL Trbj2-5 10 1
Trav19 YLCAA GEAGAKL TFGGGTRLTVRP Traj39 7 Trbv13-1 YFCAS SGTGQNTL YFGAGTRLSVL Trbj2-4 8 1
Trav21/DV12 YHCIL RVGGGSAKL IFGEGTKLTVSS Traj57 9 Trbv2 YFCAS SHRLGSSYEQ YFGPGTRLTVL Trbv2-7 10 1
19
ILGSGTQVTVMP
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav8-1, 8D-1 YFCAT DAAGYQNF YFGKGTSLTVIP Traj49 8 Trbv1 LYCTC SARAGNTL YFGEGSRLIVV Trbj1-3 8 1
Trav13-2, 13D-2 YFCAI DLNYNQGKL IFGQGTKLSIKP Traj23 9 Trbv20 YLCGA KRGPSYEQ YFGPGTRLTVL Trbv2-7 8 1
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Table 5.16 The analysis of CD4 clones in the spleen of MUT1 secondary recipient mice (S2<S1, Plate CT48). 
Table 5.17 The analysis of CD4 clones in the pancreas of MUT1 secondary recipient mice (P2<S1, Plate CT62, 63). 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-3 or D-3 YFCAV RNTGANTGKL TFGHGTILRVHP Traj52 10 Trbv5 YFCAS SLQNTEV FFGKGTRLTVV Trbj1-1 7 1
Trav5D-4 YFCAA SRNYNVL YFGSGTKLTVEP Traj21 7 Trbv3 YFCAS SSTGGQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav5D-4 YFCAA SRNYNVL YFGSGTKLTVEP Traj21 7 Trbv3 YFCAS SSTGGQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6-1, 6-2, 6-4, 6D-04, 6-
5, 6D-5, 6-6, 6D-6, 6-7/DV9 YYCVL ATGNTGKL IFGLGTTLQVQP Traj37 8 Trbv13-2 YFCAS GDAGLGDTGQL YFGEGSKLTVL Trbj2-2 11 3
Trav6-6 or D-6 YYCAL ARNNNNAP RFGAGTKLSVKP Traj43 8 Trbv19 FLCAS RTQGNTEV FFGKGTRLTVV Trbj1-1 8 2
Trav6D-6 YYCAL SDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-3 YFCAS SDLGQGDAETL YFGSGTRLTVL Trbj2-3 11 1
Trav7-5 or D-5 YLCAP LSSNTDKV VFGTGTRLQVSP Traj34 8 Trbv13-2 YFCAS GDRPGRAEV FFGKGTRLTVV Trbj1-1 9 2
Trav7-6 YLCAV KGNMGYKL TFGTGTSLLVDP Traj9 8 Trbv19 FLCAS SIRGLGGVNTGQL YFGEGSKLTVL Trbj2-2 13 1
Trav8-2 YFCAT DNNYAQGL TFGLGTRVSVFP Traj26(1) 8 Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 8 2
Trav9D-3 YFCAV SAQSNNRI FFGDGTQLVVKP Traj31 8 Trbv3 YFCAS SLRSSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SENYGNEKI TFGAGTKLTIKP Traj48 9 Trbv13-1 YFCAS TGTLSSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL DSGGSNAKL TFGKGTKLSVKS Traj42 9 Trbv13-2 YFCAS GDASANTEV FFGKGTRLTVV Trbj1-1 9 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDQGGSAKL IFGEGTKLTVSS Traj57 9 Trbv3 YFCAS SLGLGIQNTL YFGAGTRLSVL Trbj2-4 10 2
Trav14-1 YFCAA PSTGGNNKL TFGQGTVLSVIP Traj56 9 Trbv5 YFCAS SQDRANTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav14D-1 YFCAA SAIYGNEKI TFGAGTKLTIKP Traj48 9 Trbv13-1 YFCAS SEDRVEQ YFGPGTRLTVL Trbv2-7 7 1
Trav14D-3/DV8 YFCAA RMNYNQGKL IFGQGTKLSIKP Traj23 9 Trbv31 YLCAW SLPGGGEQ YFGPGTRLTVL Trbv2-7 8 1
Trav21/DV12 YHCIL RVAMATGGNNKL TFGQGTVLSVIP Traj56 12 Trbv13-2 YFCAS GDGWDWGDTQ YFGPGTRLLVL Trbj2-5 10 1
23
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav8-1 YFCAT DAAGYQNF YFGKGTSLTVIP Traj49 8 Trbv1 LYCTC SARAGNTL YFGEGSRLIVV Trbj1-3 8 1
Trav7-2, 7D-2 YLCAA LSGGN YKPTFGKGTSLVVHP Traj6 5 Trbv19 FLCAS SISGGLSYEQ YFGPGTRLTVL Trbv2-7 10 1
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Table 5.18 The analysis of CD4 clones in the spleen of MUT1 secondary recipient mice (S2<P1, Plate CT60). 
Table 5.19 The analysis of CD4 clones in the pancreas of MUT1 secondary recipient mice (P2<P1, Plate CT63, 64). 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-2 YFCAA HQGGRAL IFGTGTTVSVSP Traj15 7 Trbv20 YLCGA SDNSAETL YFGSGTRLTVL Trbj2-3 8 1
Trav4-3, 4D-3 YFCAA PSNYNVL YFGSGTKLTVEP Traj21 7 Trbv13-3 YFCAS RAGVAEQ FFGPGTRLTVL Trbj2-1 7 1
Trav5-1 YFCSA SGTGNYKY VFGAGTRLKVIA Traj40 8 Trbv13-3 YFCAS RAGVAEQ FFGPGTRLTVL Trbj2-1 7 6
Trav5-1 YFCSA KYSGTGNY VFGAGTRLKVIA Traj40 8 Trbv13-3 YFCAS RAGVAEQ FFGPGTRLTVL Trbj2-1 7 1
Trav6-2 YYCVL GETGNTGKL IFGLGTTLQVQP Traj37 9 Trbv24 YFCAS SPVRDRNSGNTL YFGEGSRLIVV Trbj1-3 12 1
Trav6-2 YYCVL GETGNTGKL IFGLGTTLQVQP Traj37 9 Trbv4(2) YLCAS SLQGASDY TFGSGTRLLVI Trbj1-2 8 1
Trav7-3, 7D-3 YLCAV SDNNNAPR FGAGTKLSVKP Traj43 8 Trbv13-2 YFCAS GDAGTGGYEQ YFGPGTRLTVL Trbv2-7 10 1
Trav7-3, 7D-3 YLCAV SDNNNAP RFGAGTKLSVKP Traj43 7 Trbv13-2 YFCAS GDAGTGGYEQ YFGPGTRLTVL Trbv2-7 10 2
Trav7-5, 7D-5 YLCAP LSSNTDKV VFGTGTRLQVSP Traj34 8 Trbv13-2 YFCAS GDRPGRAEV FFGKGTRLTVV Trbj1-1 9 2
Trav7D-2 YLCAA LSGGNYKP TFGKGTSLVVHP Traj6 8 Trbv19 FLCAS SISGGLSYEQ YFGPGTRLTVL Trbv2-7 10 1
Trav8-2 YFCAT DNNYAQGL TFGLGTRVSVFP Traj26(1) 8 Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 8 3
Trav9-1, 9D-3 YFCAV SAQSNNRI FFGDGTQLVVKP Traj31 8 Trbv3 YFCAS SLRSSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav10, 10D YFCAA RRTNAYKV IFGKGTHLHVLP Traj30 8 Trbv5 YFCAS SQGGANTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDQGGSAKL IFGEGTKLTVSS Traj57 9 Trbv3 YFCAS SLGLGIQNTL YFGAGTRLSVL Trbj2-4 10 3
Trav13-1 or 13D-4 YLCAM HQGGSAKL IFGEGTKLTVSS Traj57 8 Trbv13-2 YFCAS GGPGQGANERL FFGHGTKRSVL Trbj1-4 11 4
Trav13-2 YFCAI NYGSSGNKL IFGIGTLLSVKP Traj32 9 Trbv13-2 YFCAS GAGQSNTEV FFGKGTRLTVV Trbj1-1 9 2
Trav13D-1, 13-2 YLCAP RTGGYKV VFGSGTRLLVSP Traj12 7 Trbv19 FLCAS RTGDYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav14-2 YFCAA SSGGSNAKL TFGKGTKLSVKS Traj42 9 Trbv29 YFCAS SFANTEV FFGKGTRLTVV Trbj1-1 7 1
Trav16, 16D/DV11 YFCAM REGEGGSAKL IFGEGTKLTVSS Traj57 10 Trbv29 YFCAS SLDSEQ YFGPGTRLTVL Trbv2-7 6 1
34
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav5-1 YFCSA SGTGNYKY VFGAGTRLKVIA Traj40 8 Trbv13-3 YFCAS RAGVAEQ FFGPGTRLTVL Trbj2-1 7 2
Trav8-1, 8D-1 YFCAT DASGGNYKP TFGKGTSLVVHP Traj6 9 Trbv4(2) YLCAS LRSRDWGNTGQ YFGEGSKLTVL Trbj2-2 11 1
Trav8-1, 8D-1 YFCAT DASGGNYKP TFGKGTSLVVHP Traj6 9 Trbv4(2) YLCAS RSRDWGNTGQL YFGEGSKLTVL Trbj2-2 11 1
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Table 5.20 The analysis of CD4 clones in the spleen of original donors of WT2 mice (S0, Plate CT28). 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-4 YFCAV SAHYNQGKL IFGQGTKLSIKP Traj23 9 Trbv17 YLCAS SRQGNQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav4-4/DV10 YFCAA ENQGKL IFGQGTKLSIKP Traj23 6 Trbv1 LYCTCS ADRWGGSAETL YFGSGTRLTVL Trbj2-3 11 1
Trav5D-4 YFCAA RPSGTYQ RFGTGTKLQVVP Traj13 7 Trbv19 FLCAS SIGWGEDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6D-5 YYCAL RGSSGNKL IFGIGTLLSVKP Traj32 8 Trbv5 YFCAS SQEAGGYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav6D-5, 6-6, 6-7/DV9 YFCAL RGSALGRL HFGAGTQLIVIP Traj18 8 Trbv1 LYCTC SETDLSNERL FFGHGTKLSVL Trbj1-4 10 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GGNNNAP RFGAGTKLSVKP Traj43 7 Trbv20 YLCGA CRDWGGSNTGQL YFGEGSKLTVL Trbj2-2 12 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GDRNSAGNKL TFGIGTRVLVRP Traj17 10 Trbv3 YFCAS SLGTGVTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav6D-7 YYCAL SDWAYKV IFGKGTHLHVLP Traj30 7 Trbv13-2 YFCAS GDAGGSQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav7-2, 7D-2 YLCAA STASLGKL QFGTGTQVVVTP Traj24 8 Trbv1 LYCTC SAEWENTL YFGAGTRLSVL Trbj2-4 8 1
Trav7-3, 7D-3 YLCAV DYNVL YFGSGTKLTVEP Traj21 5 Trbv13-1 YFCAS SVDRGSNERL FFGHGTKLSVL Trbj1-4 10 1
Trav7-3, 7D-3 YLCAV AAGNTGKL IFGLGTTLQV Traj37 8 Trbv5 YFCAS SQDWEQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav7-4, 7D-4 YFCAA SMSNYNVL YFGSGTKLTVEP Traj21 8 Trbv20 YLCGV SRDSQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav7-5, 7D-5 YLCAA TSGGNYKP TFGKGTSLVVHP Traj6 8 Trbv31 YLCAW RSGGYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav7D-5 YLCAV RDSNYQL IWGSGTKLIIKP Traj33 7 Trbv1 LYCTC SADWGGDAETL YFGSGTRLTVL Trbj2-3 11 1
Trav8-1, 8D-1 YFCAT DDTNTGKL TFGDGTVLTVKP Traj27 8 Trbv1 LYCTC SSGLGGQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav8-1, 8D-1 YFCAT GANTGKL TFGHGTILRVHP Traj52 7 Trbv31 YLCAC FPGQSSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav8-1, 8D-1 YFCAT FNNNNAP RFGAGTKLSVKP Traj43 7 Trbv5 YFCAS SQEGGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav8-2 YFCAT DRGTASLGKL QFGTGTQVVVTP Traj24 10 Trbv13-2 YFCAS GDAGGEDTEV FFGKGTRLTVV Trbj1-1 10 1
Trav8-2 YFCAT DDDTNAYKV IFGKGTHLHVLP Traj30 9 Trbv31 YLCAW SLQNSYNSPL YFAAGTRLTVT Trbj1-6 10 1
Trav8D-2 YFCAT YQGGRAL IFGTGTTVSVSP Traj15 7 Trbv31 YLCAW SPGQGRGTL YFGSGTRLTVL Trbj2-3 9 1
Trav9D-3 YFCAV SYNAGAKL TFGGGTRLTVRP Traj39 8 Trbv4(2) YLCAS SLTGGSAETL YFGSGTRLTVL Trbj2-3 10 1
Trav10, 10D YFCAA SGTGNYKY VFGAGTRLKVIA Traj40 8 Trbv13-2 YFCAS GVGTGGSPL YFAAGTRLTVT Trbj1-6 9 1
Trav10,10D YFCAA SNSNNRI FFGDGTQLVVKP Traj31 7 Trbv5 YFCAS SRGTGIDERL FFGHGTKLSVL Trbj1-4 10 1
Trav11, 11D YICVV GATNTNKV VFGTGTRLQVLP Traj34 8 Trbv31 YLCAW SSGTGGFEQ YFGPGTRLTVL Trbv2-7 9 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL ILNTGNYKY VFGAGTRLKVIA Traj40 9 Trbv5 YFCAS SQGQGRAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav13-2 YLCAL DYSAGNKL TFGIGTRVLVRP Traj17 8 Trbv13-1 YFCAS SDADTQ YFGPGTRLLVL Trbj2-5 6 1
Trav14-1 YYCAL AYYAQGL TFGLGTRVSVFP Traj26(1) 7 Trbv1 LYCTC SANSAETL YFGSGTRLTVL Trbj2-3 8 1
Trav14-1 YFCAA SDTGNYKY VFGAGTRLKVIA Traj40 8 Trbv26 YLCAS SLTGGNSAETL YFGSGTRLTVL Trbj2-3 11 1
Trav14-3 YFCAA SRNNNAP RFGAGTKLSVKP Traj43 7 Trbv29 YFCAS SFSGLGSYEQ YFGPGTRLTVL Trbv2-7 10 1
Trav14-3 YFCAA SANTGNYKY VFGAGTRLKVIA Traj40 9 Trbv4(2) YLCAS SSTGANNQAP LFGEGTRLSVL Trbj1-5 10 1
Trav16, 16D/DV11 YFCAM REGSTGYQNF YFGKGTSLTVIP Traj49 10 Trbv15 YLCAS SLGVGGYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav16, 16D/DV11 YFCAM REGNSGGSNAKLTFGKGTKLSVKS Traj42 12 Trbv26 YLCAS SLGTGPGTGQL YFGEGSKLTVL Trbj2-2 11 1
Trav16, 16D/DV11 YFCAM REGGQGGRAL IFGTGTTVSVSP Traj15 10 Trbv5 YFCAS SQDLSYNYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav21/DV12 YHCIL NTGYQNF YFGKGTSLTVIP Traj49 7 Trbv19 FLCAS SRTGYNSPL YFAAGTRLTVT Trbj1-6 9 1
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Table 5.21 The analysis of CD4 clones in the spleen of WT2 primary recipient mice (S1, Plate CT42). 
Table 5.22 The analysis of CD4 clones in the spleen of WT2 secondary recipient mice (S2, Plate CT58). 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-3 YFCAA ERNTGKL IFGLGTTLQVQP Traj37 7 Trbv13-2 YFCAS GDRGGNSPL YFAAGTRLTVT Trbj1-6 9 1
Trav4-3 YFCAA GSGGSNAKL TFGKGTKLSVKS Traj42 8 Trbv19 FLCAS SIRVEQ YFGPGTRLTVL Trbv2-7 6 1
Trav6-3, 6D-3 YYCAM ITGNTGKL IFGLGTTLQVQP Traj37 8 Trbv31 YLCAW SLGTPNERL FFGHGTKRSVL Trbj1-4 9 1
Trav6-5, 6D-6, 6D-7 YFCAL SSNTNKV VFGTGTRLQVLP Traj34 7 Trbv1 YCTCS AETGNYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav8D-2 YFCAT DNTNTGKL TFGDGTVLTVKP Traj27 8 Trbv31 YLCAW IRDNQDTQ YFGPGTRLLVL Trbj2-5 8 2
Trav9-3, 4, 4-D YFCVL SANTGGLSGKL TFGEGTQVTVIS Traj2 11 Trbv29 YFCAS SRTGIAETL YFGSGTRLTVL Trbj2-3 9 1
Trav10, 10D YFCAA SISSNNR IFFGDGTQLVVKP Traj31 7 Trbv19 FLCASS SRDWGVEQ YFGPGTRLTVL Trbv2-7 8 1
Trav13-2 YLCAM ERSYGNEKI TFGAGTKLTIKP Traj48 9 Trbv20 YLCGA RWGHPYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav13D-1, 13-2, 13D-2 YLCAL NYGSSGNKL IFGIGTLLSVKP Traj32 9 Trbv5 YFCAS SQGRGGQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav14-2 YFCAA KATGGNNKL TFGQGTVLSVIP Traj56 9 Trbv20 YLCGA RGTYEQ YFGPGTRLTVL Trbv2-7 6 1
Trav14-2 YFCAA SRGGSAKL IFGEGTKLTVSS Traj57 8 Trbv20 YLCGA RELGNYAEQ FFGPGTRLTVL Trbj2-1 9 1
12
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav5D-4 YFCAA SERGSALGRL HFGAGTQLIVIP Traj18 10 Trbv13-3 YFCAS SNREGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav6-6, 6D-6 YYCAL GDTGNYKY VFGAGTRLKVIA Traj40 8 Trbv20 YLCGA RDRAQNTL YFGAGTRLSVL Trbj2-4 8 1
Trav6-6, 6D-6 YYCAL AKRNNNNAP RFGAGTKLSVKP Traj43 9 Trbv4(2) YLCAS SQDWGANQDTQ YFGPGTRLLVL Trbj2-5 11 1
Trav6-7/DV9, 6-7 YYCAR NSGGSNYKL TFGKGTLLTVTP Traj53 9 Trbv20 YLCGA SRDGNYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GETSSGQKL VFGQGTILKVYL Traj16 9 Trbv2 YFCAS SQDSGGTYEQ YFGPGTRLTVL Trbv2-7 10 1
Trav6D-6 YYCAL SENNNAP RFGAGTKLSVKP Traj43 7 Trbv4(2) YLCAS SLRTPNTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav6D-7 YYCAL AKRNNNNAP RFGAGTKLSVKP Traj43 9 Trbv4(2) YLCAS SQDWGANQDTQ YFGPGTRLLVL Trbj2-5 11 1
Trav7-4, 7D-4 YFCAA NTNAYKV IFGKGTHLHVLP Traj30 7 Trbv13-1 YFCAS SDFTSAETL YFGSGTRLTVL Trbj2-3 9 1
Trav7-4, 7D-4 YFCAA SEHNAGAKL TFGGGTRLTVRP Traj39 9 Trbv13-1 YFCAS RTGGASQNTL YFGAGTRLSVL Trbj2-4 10 1
Trav7D-2 YLCAA SIIAGGYKV VFGSGTRLLVSP Traj12 9 Trbv20 YLCGA REGGGSDY TFGSGTRLLVI Trbj1-2 8 1
Trav9-1, D-1, 2, D-3 YFLIT GNTGKL IFGLGTTLQVQP Traj37 6 Trbv20 YLCGA RDQGRNAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav10, 10D YFCAA SKAGTGSNRL TFGKGTKFSLIP Traj28 10 Trbv20 YLCGA REGGGSDY TFGSGTRLLVI Trbj1-2 8 1
Trav14-1 YFCAA YTGGLSGKL TFGEGTQVTVIS Traj2 9 Trbv31 YLCAW SPRDGSAETL YFGSGTRLTVL Trbj2-3 10 2
Trav14-3 YFCAA SSGTGSKL SFGKGAKLTVSP Traj58 8 Trbv4(2) YLCAS SLRTPNTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav16, 16D/DV11 YFCAM RDDTNAYKV IFGKGTHLHVLP Traj30 9 Trbv20 YLCGA RDQGRNAEQ FFGPGTRLTVL Trbj2-1 9 1
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Table 5.23 The analysis of CD4 clones in the spleen of original MUT2 donors (S0, Plate CT34). 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-3 or 4D-3 YFCAA EANNNAP RFGAGTKLSVKP Traj43 7 Trbv29 YFCAS SLVGQYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav5D-4 YFCAA STNSGGSNYKL TFGKGTLLTVTP Traj53 11 Trbv5 YFCAS SQARGAGEV LFGKGTRLTVV Trbj1-5 9 1
Trav6-2 YYCVL GYNTNTGKL TFGDGTVLTVKP Traj27 9 Trbv2 YFCAS SLDTGVYNSPL YFAAGTRLTVT Trbj1-6 11 1
Trav6-4 or 6D-4 YFCAL VDRTGYQNF YFGKGTSLTVIP Traj49 9 Trbv15 YLCAS SPGGGTEV FFGKGTRLTVV Trbj1-1 8 1
Trav6-6 YYCAL GDNTGANTGKLTFGHGTILRVHP Traj52 11 Trbv31 YLCAW SLLGVSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav6-7/DV9 or 6D-7 YYCAP YNTNTGKL TFGDGTVLTVKP Traj27 8 Trbv20 YLCGA GTGSDTQ YFGPGTRLLVL Trbj2-5 7 1
Trav6D-5 YYCAL TYNTNTGKL TFGDGTVLTVKP Traj27 9 Trbv29 YFCAS SIQDNNQAP LFGEGTRLSVL Trbj1-5 9 1
Trav7-3, 7D-3 YLCAV RRNYKY VFGAGTRLKVIA Traj40 6 Trbv31 YLCAW SKTSSQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav7D-2 YLCAA SGAGNTGKL IFGLGTTLQVQP Traj37 9 Trbv13-1 YFCAS SDAGRQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav8-1 or 8D-1 YFCAT DATNSAGNKL TFGIGTRVLVRP Traj17 10 Trbv13-2 YFCAS GDAGGAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav8-1 or 8D-1 YFCAS NSGGSNYKL TFGKGTLLTVTP Traj53 9 Trbv13-2 YFCAS GDGGDAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav8-1 or D-1 YFCAT QSGSFNKL TFGAGTRLAVCP 8 Trbv5 YFCAS SPQGANSD YTFGSGTRLLVI Trbj1-2 8 1
Trav9-1, D-1, 2, D-3 YFCAA SGNEKI TFGAGTKLTIKP Traj48 6 Trbv13-1 YFCAS SDTGGAHETL YFGSGTRLTVL Trbj2-3 10 1
Trav9D-2, 3, 4 YFCAV SNNNNAP RFGAGTKLSVKP Traj43 7 Trbv13-2 YFCAS GDRGEGSDY TFGSGTRLLVI Trbj1-2 9 1
Trav9D-2. 3. 4 YFCAV SLQGGSAKL IFGEGTKLTVSS Traj57 9 Trbv31 YLCAW SLGRGDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav11 or 11D YICVV GDRGSALGRL HFGAGTQLIVIP Traj18 10 Trbv13-2 YFCAS GDEGQINSD YTFGSGTRLLVI Trbj1-2 9 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL TWTGGYKV VFGSGTRLLVSP Traj12 8 Trbv5 YFCAS SQEGTGGGAETL YFGSGTRLTVL Trbj2-3 12 1
Trav13D-1 or 13-2 YLCAP SSNTNKV VFGTGTRLQVLP 7 Trbv13-2 YFCAS GDALGEDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav14-3 YFCAA SDTNAYKV IFGKGTHLHVLP Traj30 8 Trbv13-2 YFCAS GEWYSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav14-3 YFCAA VNTGNYKY VFGAGTRLKVIA Traj40 8 Trbv2 YFCAS SQDNYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav14-3 YFCAA SVVTGSGGKL TLGAGTRLQVNL Traj44 10 Trbv31 YLCAW SLGLGSEQ YFGPGTRLTVL Trbv2-7 8 1
Trav14D-1 YFCAA SEKSNNRI FFGDGTQLVVKP Traj31 8 Trbv1 LYCTC SADNYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav14D-1 YFCAA SRVYTGNYKY VFGAGTRLKVIA Traj40 10 Trbv13-3 YFCAS SDVGSDY TFGSGTRLLVI Trbj1-2 7 1
Trav14D-1 YFCAA SNYAQGL TFGLGTRVSVFP Traj26(1) 7 Trbv31 YLCAW SNYNNRAP LFGEGTRLSVL Trbj1-5 8 1
Trav14D-3/DV8 YFCAA ASSGSWQL IFGSGTQLTVMP Traj22 8 Trbv29 YFCAS SPGQGRERL FFGHGTKLSVL Trbj1-4 9 1
Trav16, 16D/DV11 YFCAM RNNNNAP RFGAGTKLSVKP Traj43 7 Trbv5 YFCAS SQDLTDQDTQ YFGPGTRLLVL Trbj2-5 10 1
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Table 5.24 The analysis of CD4 clones in the pancreas of original MUT2 donors (P0, Plate CT23). 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-3/Trav4D-3 YFCAA EVTGNTGKL IFGLGTTLQVQP Traj37 9 Trbv13-2 YFCAS GDRGQNTL YFGAGTRLSVL Trbj2-4 8 1
Trav5D-4 YFCAA SNTGYQNF YFGKGTSLTVIP Traj49 8 Trbv15 YLCAS SFGLYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav5D-4 YFCAA NSNNRI FFGDGTQLVVKP Traj31 6 Trbv20 YLCGA RDRGNQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav5D-4 YFCAA SLTGNTGKL IFGLGTTLQVQP Traj37 9 Trbv5 YFCAS SLLGGRYAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav6-2 YYCVL GYTGNYKY VFGAGTRLKVIA Traj40 8 Trbv2 YFCAS SQDWGSQNTL YFGAGTRLSVL Trbj2-4 10 1
Trav6-4/Trav6D-4 YFCAL VDQGGRAL IFGTGTTVSVSP Traj15 8 Trbv1 LYCTC SADRVVSSYEQ YFGPGTRLTVL Trbj2-7 11 1
Trav6-4/Trav6D-4 YFCAL VETGNTRKL IFGLGTTLQVQP Traj37 9 Trbv3 YFCAS SLVGWEDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6-6/Trav6-7/DV9 YYCAL GEGYAQGL TFGLGTRVSVFP Traj26 8 Trbv29 YFCAS TGTGKDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav6D-6 YYCAL ASSTGGNNKL TFGQGTVLSVIP Traj56 10 Trbv14 YLCAS SQVQAWNSPL YFAAGTRLTVT Trbj1-6 10 1
Trav6D-7 YYCAL SDLRGSNAKL TFGKGTKLSVKS Traj42 10 Trbv29 YFCAS SLSTGSQNTL YFGAGTRLSVL Trbj2-4 10 1
Trav7-1 YFCAV GTNTGKL TFGDGTVLTVKP Traj27 7 Trbv13-1 YFCAS SAWGLQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav7-4/7D-4 YFCAA YNTNTGKL TFGDGTVLTVKP Traj27 8 Trbv13-1 YFCAS SEGLGASQNTL YFGAGTRLSVL Trbj2-4 11 1
Trav8-1/Trav8D-1 YFCAT DAGGSNAKL TFGKGTKLSVKS Traj42 9 Trbv14 YLCAS SLSGGVNTL YFGAGTRLSVL Trbj2-4 9 1
Trav9-1/Trav9D-3 YFCAV SLNNYAQGL TFGLGTRVSVFP Traj26 9 Trbv19 FLCAS SIPGGYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav9D-4 YFCAL SGNMGYKL TFGTGTSLLVDP Traj9 8 Trbv26 YLCAS SLQGGEV FFGKGTRLTVV Trbj1-1 7 1
Trav11/Trav11-D YICVV GDRGSALGRL HFGAGTQLIVIP Traj18 10 Trbv1 LYCTC SADWGANYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav12D-1 YYCAL SEGTGGYKV VFGSGTRLLVSP Traj12 9 Trbv2 YFCAS SQDRGQGYEQ YFGPGTRLTVL Trbj2-7 10 1
Trav12D-1/Trav12-
2/Trav12D-2/Trav12-
3/Trav12D-3 YYCAL ALVISNTNKV VFGTGTRLQVLP Traj34 10 Trbv13-1 YFCAS SAASNTEV FFGKGTRLTVV Trbj1-1 8 1
Trav13-2 YLCAI SNTDKV VFGTGTRLQVSP Traj34 6 Trbv13-1 YFCAS SAQGADQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav13-2 YLCAI LNSGGSNAKL TFGKGTKLSVKS Traj42 10 Trbv3 YFCAS SPDSNYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav13D-4 YLCAM ANTGYQNF YFGKGTSLTVIP Traj49 8 Trbv14 YLCAS SLGGNTGQL YFGEGSKLTVL Trbj2-2 9 1
Trav14-1 YFCAA SLPGTGSNRL TFGKGTKFSLIP Traj28 10 Trbv13-2 YFCAS GGGTGGSQNTL YFGAGTRLSVL Trbj2-4 11 1
Trav14-1 YFCAA SRGQGGSAKL IFGEGTKLTVSS Traj57 10 Trbv2 YFCAS SQVPNTGQL YFGEGSKLTVL Trbj2-2 9 1
Trav14-3 YFCAA RDMQQGTGSKLSFGKGAKLTVSP Traj58 11 Trbv13-1 YFCAS SDGQSSYEQ YFGPGTRLTVL Trbj2-7 9 1
Trav14-3 YFCAA SAGSGYNKL TFGKGTVLLVSP Traj11 9 Trbv20 YLCGA RDSAETL YFGSGTRLTVL Trbj2-3 7 1
Trav14-3 YFCAA KSAGNTRKL IFGLGTTLQVQP Traj37 Trbv29 YFCAS SLYRGQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav14-3 YFCAA SKPGYQNF YFGKGTSLTVIP Traj49 8 Trbv3 YFCAS SLGQYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav19 YLCAA GSANTGANTGKLTFGHGTILRVHP Traj52 12 Trbv5 YFCAS SLDWGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav3-1 YFCAA NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv12-1 YFCAS SPLQGRVQKRM YFGSGTRLTVL Trbj2-3 11 1
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Table 5.25 The analysis of CD4 clones in the spleen of MUT2 secondary recipient mice (S2<S1, Plate CT44). 
 
Table 5.26 The analysis of CD4 clones in the spleen of MUT2 secondary recipient mice (S2<P1, Plate CT46). 
 
 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency 
Trav4-3 or 4D-3 YFCAA ENYAQGL TFGLGTRVSVFP Traj26 7 Trbv3 YFCAS SLQGRAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav4-3 or 4D-3 YFCAA ENYAQGL TFGLGTRVSVFP Traj26 7 Trbv5 YFCAS SQDRGQDTEV FFGKGTRLTVV Trbj1-1 10 1
Trav6D-7, 6-5 YFCAL SKGHKCLP-HPEPRTCCA Trbv5 YFCAS SQDRGQDTEV FFGKGTRLTVV Trbj1-1 10 17
Trav9-1, Trav9D-3 YFCAV SAHSNNRI FFGDGTQLVVKP Traj31 8 Trbv26 YLCAS SPGTAEQ YFGPGTRLTVL Trbv2-7 7 1
20
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency 
Trav4-3 or 4D-3 YFCAA ENYAQGL TFGLGTRVSVFP Traj26(1) 7 Trbv5 YFCAS SQDRGQDTDV FFGKGTRLTVV Trbj1-1 10 10
Trav6D-7, 6-5 YFCAL SKGHKCLP-HPEPRTCCA Trbv5 YFCAS SQDRGQDTEV FFGKGTRLTVV Trbj1-1 10 13
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Table 5.27 The analysis of CD8 clones in the spleen of original WT1 donor mice (S0, Plate CT33). 
 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav5-1 YFCSA TSGGNYKP TFGKGTSLVVHP Traj6 8 Trbv13-1 YFCAS SDADWGQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav6-1 YFCAL VDYANKM IFGLGTILRVRP Traj47 7 Trbv19 FLCAS SRQGSNSDY TFGSGTRLLVI Trbj1-2 9 1
Trav6-5 YYCAL SDLNYNQGKL IFGQGTKLSIKP Traj23 10 Trbv2 YFCAS SQELWGQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav6-6 YYCAL GDSVGDNSKL IWGLGTSLVVNP Traj38 10 Trbv20 YLCGA RGTLNSPL YFAAGTRLTVT Trbj1-6 8 1
Trav6-7/DV9 YYCAL GDTNAYKV IFGKGTHLHVLP Traj30 8 Trbv14 YLCAS SYRGNTEV FFGKGTRLTVV Trbj1-1 8 1
Trav6D-5, 6,6-7/DV9 YYCAL GDKDTNAYKV IFGKGTHLHVLP Traj30 10 Trbv1 YCTCS GDRGNTQ YFGPGTRLLVL Trbj2-5 7 1
Trav6D-5, 6,6-7/DV9 YYCAL GEPSGSWQL IFGSGTQLTVMP Traj22 9 Trbv5 YFCAS SQEGGPGQNTL YFGAGTRLSVL Trbj2-4 11 1
Trav6D-7 YYCAL SDRDYANKM IFGLGTILRVRP Traj47 9 Trbv19 FLCAS SISSSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav7-3, 7D-3 YLCAV SNGNAYKV IFGKGTHLHVLP Traj30 8 Trbv14 YLCAS SPTEVV FFGKGTRLTV Trbj1-1 6 1
Trav7-3, 7D-3 YLCAV NNAGAKL TFGGGTRLTVRP Traj39 7 Trbv29 YFCAS SLQGNYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav7D-2 YLCAA STGNTGKL IFGLGTTLQVQP Traj37 8 Trbv13-3 YFCAS SQGFTEV FFGKGTRLTVV Trbj1-1 7 1
Trav9? YFCVL SASSGSWQL IFGSGTQLTVMP Traj22 9 Trbv29 YFCAS RTGAQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav9-1 YFCAV SVTSGSWQL IFGSGTQLTVMP Traj22 9 Trbv23 YLCSS SQYSEWGGNYAEQFFGPGTRLTVL Trbj2-1 13 1
Trav9-1 YFCAV SADMGYKL TFGTGTSLLVDP Traj9 8 Trbv13-2 YFCAS GDGTEV FFGKGTRLTVV Trbj1-1 6 1
Trav9-1 YFCAV SAASSGQKL VFGQGTILKVYL Traj16 9 YFCAS RLRDWGGYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav9D-4 YFCVL SANTGKL TFGDGTVLTVKP Traj27 7 Trbv13-2 YFCAS GDRVEDTQ YFGPGTRLLVL Trbj2-5 8 1
TRAC12D-1, 2, D-2, 3, D-3 YYCAL LSSGSWQL IFGSGTQLTVMP Traj22 8 Trbv19 FLCAS SNWGNTL YFGAGTRLSVL Trbj2-4 7 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL DYANKM IFGLGTILRVRP Traj37 6 Trbv2 YFCAS SQQGSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SDSNYQL IWGSGTKLIIKP Traj33 7 Trbv29 YFCAS SLTDQAP LFGEGTRLSVL Trbj1-5 7 1
Trav13-1, D-4 YLCAM DSGTYQ RFGTGTKLQVVP Traj13 6 Trbv3 YFCAS SPNQDTQ YFGPGTRLLVL Trbj2-5 7 1
Trav13D-1 YLCAL EGASSSFSKL VFGQGTSLSVVP Traj50 10 Trbv13-3 YFCAS SGDNYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav13D-1 YLCAL EVPGYQNF YFGKGTSLTVIP Traj49 8 Trbv19 FLCAS SMGGEQ YFGPGTRLTVL Trbv2-7 6 1
Trav13D-1, 13-2 YFCAT YTNTGKL TFGDGTVLTVKP Traj27 7 Trbv29 YFCAS SQGARDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav14-1 YFCAA SRAYQ RFGTGTKLQVVP Traj13 5 Trbv29 YFCAS SSTTSAETL YFGSGTRLTVL Trbj2-3 9 1
Trav14-1 YFCAA RPSSSFSKL VFGQGTSLSVVP Traj50 9 Trbv5 YFCAS SQGVYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav15D-1/DV6D-1 YFCAL WELNSNNRI FFGDGTQLVVKP Traj31 9 Trbv31 YLCAW SRLGGRGAETL YFGSGTRLTVL Trbj2-3 11 1
Trav16, 16D/DV11 YFCAN NNNAP RFGAGTKLSVKP Traj43 5 Trbv17 YLCAS SRVWGGYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav16, 16D/DV11 YFCAM REGTSGGNYKP TFGKGTSLVV Traj6 11 Trbv13-3 YFCAS SGDNYEQ YFGPGTRLTL Trbj2-5 7 1
Trav17 YFCAL EEQGTGSKL SFGKGAKLTVSP Traj58 9 Trbv14 YLCAS SFRGAETL YFGSGTRLTVL Trbj2-3 8 1
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Table 5.28 The analysis of CD8 clones in the spleen of WT1 primary recipient mice (S1, Plate CT43). 
Table 5.29 The analysis of CD8 clones in the spleen of WT1 secondary recipient mice (S2, Plate CT61). 
 
 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav9-3, Trav9-4, D-4 YFCAV DTNAYKV IFGKGTHLHVLP Traj30 7 Trbv3 YFCAS SLVWGAHEQ YFGPGTRLTVL Trbv2-7 9 1
Trav12D-1, Trav12-2 
Trav12D-2, Trav12-3, 
Trav12D-3 YYCAL SDFLLLQQAGVWAGDILISRSKHPEPRTCCVPV 10 Trbv17 YLCAS GGYEQ YFGPGTRLTVL Trbv2-7 5 1
2
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-1 YFCAV GNSGGSNAKL TFGKGTKLSVKS Traj42 10 Trbv13-3 YFCAS RDRDTQ YFGPGTRLLVL Trbj2-5 6 9
Trav3-1 YFCAV GNSGGSNAKL TFGKGTKLSVKS Traj42 10 Trbv13-2 YFCAS GEGGANTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav7D-5 HLCAV ETNAYKV IFGKGTHLHVLP Traj30 7 Trbv16 YLCAS SSWGGNQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav10, 10D YFCAA SMSNNRI FFGDGTQLVVKP Traj31 7 Trbv31 DLCAW SPQTNTDV FFGKGTRLTTV Trbj1-1 8 1
Trav10, 10D YFCAA SRGNNNAP RFGAGTKLSVKP Traj43 8 Trbv1 LYCTC SAHRGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav10, 10D YFCAA SNMGYKL TFGTGTSLLVDP Traj9 7 Trbv3 YFCAS SPQGQDTQ YFGPGTRLLVL Trbj2-5 8 2
Trav14D-3/DV8 YFCAA SGSGSWQL IFGSGTQLTVMP Traj22 8 Trbv13-1 YFCAS SDEQGD YTFGSGTRLLVI Trbj1-2 6 1
Trav14D-3/DV8 YFCAA SGSGSWQL IFGSGTQLTVMP Traj22 8 Trbv13-1 YFCAS SDEQGD YTFGSGTRLLVI Trbj1-2 6 1
Trav16, Trav16D/DV11 YFCAM REGRTGNYKY VFGAGTRLKVIA Traj40 10 Trbv13-2 YFCAS GGTGGAETL YFGSGTRLTVL Trbj2-3 9 1
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Table 5.30 The analysis of CD8 clones in the spleen of original MUT1 donor mice (S0, Plate CT39). 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-1 YFCAV SHSNNRI FFGDGTQLVVKP Traj31 7 Trbv29 YFCAS SSGTNYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav3-3, 3D-3 YFCAV SVDSNYQL IWGSGTKLIIKP Traj33 8 Trbv13-3 YFCAS SNRGPGAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav3-3, 3D-3 YFCAV SDTGGADRL TFGKGTQLII 9 Trbv5 YFCAS SQGTENTEV FFGKGTRLTVV Trbj1-1 9 1
Trav5D-4 YFCAA SGANTGKL TFGHGTILRVHP Traj52 8 Trbv31 YLCAW SLGGRQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav6-4 6D-4 YFCAL DNNNRI FFGDGTQLVVKP Traj31 6 Trbv14 YLCAS SFSGVQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav6-4 6D-4 YYCVL GWDYSNNRL TLGKGTQVVVLP Traj7 9 Trbv29 YFCAS SPGHNSD YTFGSGTRLLV Trbj1-2 7 1
Trav6-4, 6D-4 YFCAL VANNYAQGL TFGLGTRVSVFP Traj26(1) 9 Trbv13-2, 13-3YFCAS GDWDNSGNTL YFGEGSRLIVV Trbj1-3 10 1
Trav6-5, 6-6, 6D-7 YFCAL SENSNNRI FFGDGTQLVVKP Traj31 8 Trbv1 LYCTC SAAGGDAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GFNYAQGL TFGLGTRVSVFP Traj26(1) 8 Trbv2 YFCAS SQDYEQ YFGPGTRLTVL Trbv2-7 6 1
Trav7-3, D-3 YLCAA NSGTYQ RFGTGTKLQVVP Traj13 6 Trbv1 LYCTC SADSTGGYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav7-3,7D-3 YLCAK ASSGSWQL IFGSGTQLTVMP Traj22 8 Trbv1 LYCTC SAGGGVNQDTQ YFGPGTRLLVL Trbj2-5 11 1
Trav7-3,7D-3 YLCAV SNYGNEKI TFGAGTKLTIKP Traj48 8 Trbv19 FLCAS SIGDTNSGNTL YFGEGSRLIVV Trbj1-3 11 1
Trav7-4, D-4 YFCAA RNYAQGL TFGLGTRVSVFP Traj26(1) 7 Trbv1 LYCTC SADDRNSDY TFGSGTRLLVI Trbj1-2 9 1
Trav7-4, D-4 YFCAA STEGADRL TFGKGTQLIIQP Traj45 8 Trbv13-2 YFCAS GDDNERL FFGHGTKLSVL Trbj1-4 7 1
Trav7-4, D-4 YFCAA SDEGYQNF YFGKGTSLTVIP Traj49 8 Trbv19 FLCAS SIGQQAP LFGEGTRLSVL Trbj1-5 7 1
Trav7D-5 YLCAV STASLGKL QFGTGTQVVVTP Traj24 8 Trbv13-2 YFCAS GDWGDNQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav8D-2 YFCAT EGSNAKL TFGKGTKLSVKS Traj42 7 Trbv31 YLCAW TGPSAETL YFGSGTRLTVL Trbj2-3 8 1
Trav9D-4 YFCAL SPHMGYKL TFGTGTSLLVDP Traj9 8 Trbv3 YFCAS SLELGASQNTL YFGAGTRLSVL Trbj2-4 11 1
Trav10,10D YFCAA SEDNNRI FFGDGTQLVVKP Traj31 7 Trbv13-1 YFCAS SDAGIEQ YFGPGTRLTVL Trbv2-7 7 1
Trav10,10D YFCAA SNTGYQNF YFGKGTSLTVIP Traj49 8 Trbv19 FLCAS SIANQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav11, 11D YICVV GAAGNTGKL IFGLGTTLQVQP Traj37 9 Trbv13-2 YFCAS DTGQL YFGEGSKLTVL Trbj2-2 5 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDSAYKV IFGKGTHLHVLP Traj30 7 Trbv5 YFCAS SQGGSGNTL YFGEGSRLIVV Trbj1-3 9 2
Trav14-1 YFCAA DYANKM IFGLGTILRVRP Traj47 6 Trbv12-2 YFCAS SLGLGGRAAETL YFGSGTRLTVL Trbj2-3 12 1
Trav16,16D/DV11 YFCAM RERDTGYQNF YFGKGTSLTVIP Traj49 10 Trbv13-1 YFCAS SVRTGYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav16,16D/DV11 YFCAM RGPTASLGKL QFGTGTQVVVTP Traj24 10 Trbv13-3 YFCAS SDPGISNERL FFGHGTKLSVL Trbj1-4 10 1
Trav17 YFCAL EGNYAQGL TFGLGTRVSVFP Traj26(1) 8 Trbv31 YLCAW SPGGSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav18 YFCAR DTGANTGKL TFGHGTILRVHP Traj52 9 Trbv13-1 YFCAS SDLGFNQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav19 YLCAA GQGGSAKL IFGEGTKLTVSS Traj57 8 Trbv19 FLCAS SIGGARERL FFGHGTKLSVL Trbj1-4 9 1
Trav21/DV12 YHCIL RVGGSGGSNYKL TFGKGTLLTVTP Traj53 12 Trbv13-3 YFCAS SERRKNTL YFGAGTRLSVL Trbj2-4 8 1
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Table 5.31 The analysis of CD8 clones in the pancreas of original MUT1 donor mice (P0, Plate CT25). 
 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav6-4, 6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav6-6, 6D-6, 6D-7 YYCAL GNTGYQNF YFGKGTSLTVIP Traj49 8 Trbv17 YLCAS SHWGRSAETL YFGSGTRLTVL Trbj2-3 10 1
Trav7-3, 7D-3 YLCAV RAMGYKL TFGTGTSLLVDP Traj9 7 Trbv1 LYCTC SADNSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav7-6 YLCAV RRNSNNRL 8 Trbv1 LYCTC RDISYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav9-1, 9D-3 YFCAV ISSGSWQL IFGSGTQLTVMP Traj22 8 Trbv13-1 YFCAS SDASSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav9D-2, 9-4 YFCAV SIEGTGSKL SFGKGAKLTVSP Traj58 9 Trbv13-3 YFCAS SDLGGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL MGNYQL IWGSGTKLIIKP Traj33 6 Trbv12-2 YFCAS SPTGEDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDTEGADRL TFGKGTQLIIQP Traj45 9 Trbv15 YLCAS RPGHANSDY TFGSGTRLLVI Trbj1-2 9 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDSAYKV IFGKGTHLHVLP Traj30 7 Trbv5 YFCAS SQGGSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav13-1, 13-4/DV7, 13D-4 YLCAM EQDRGSALGRL HFGAGTQLIVIP Traj18 11 Trbv29 YFCAS SLGAGTGQL YFGEGSKLTVL Trbj2-2 9 1
Trav13-2 YFCAI DTEGADRL TFGKGTQLIIQP Traj45 8 Trbv13-3 YFCAS SQGFTEV FFGKGTRLTVV Trbj1-1 7 1
Trav14-1 YFCAA S-YRKLQIR 9 Trbv19 FLCAS SIGTPNERL FFGHGTKLSVL Trbj1-4 9 1
Trav14-1, 14-2, 14D-2 YFCAA HNYAQGL 7 Trbv19 FLCAS SLTASGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav16, 16D/DV11 YFCAM RDTNAYKV IFGKGTHLHVLP Traj30 8 Trbv31 YLCAW SRDRDNSPL YFAAGTRLTVT Trbj1-6 9 1
Trav21/DV12 YHCIL RGRLCKCAD 9 Trbv13-3 YFCAS SLGRGGYAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav21/DV12 YHCIP PNYGNEKI TFGAGTKLTIKP Traj48 8 Trbv3 YFCAS SLRTGNTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav6-4, 6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav6-6, 6D-6, 6D-7 YYCAL GNTGYQNF YFGKGTSLTVIP Traj49 8 Trbv17 YLCAS SHWGRSAETL YFGSGTRLTVL Trbj2-3 10 1
Trav7-3, 7D-3 YLCAV RAMGYKL TFGTGTSLLVDP Traj9 7 Trbv1 LYCTC SADNSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav7-6 YLCAV RRNSNNRL 8 Trbv1 LYCTC RDISYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav9-1, 9D-3 YFCAV ISSGSWQL IFGSGTQLTVMP Traj22 8 Trbv13-1 YFCAS SDASSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav9D-2, 9-4 YFCAV SIEGTGSKL SFGKGAKLTVSP Traj58 9 Trbv13-3 YFCAS SDLGGQNTL YFGAGTRLSVL Trbj2-4 9 1
22
FFGDGTQLAVKP
FFGDGTQLAVKP
LWSRYQTEGYST
TFGVGTRVLVFP
IWIWHKSHSM
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Table 5.32 The analysis of CD8 clones in the spleen of MUT1 secondary recipient mice (S2<S1, Plate CT49). 
Table 5.33 The analysis of CD8 clones in the pancreas of MUT1 secondary recipient mice (P2<S1, Plate CT51). 
Table 5.34 The analysis of CD8 clones in the spleen of MUT1 secondary recipient mice (S2<P1). 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-4 YFCAV SGPGYQNF YFGKGTSLTVIP Traj49 8 Trbv17 YLCAS RTGGGTQ YFGPGTRLLVL Trbj2-5 7 1
Trav6-4, 6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 8 2
Trav7-1 YFCAV SSSGSWQL IFGSGTQLTVMP Traj22 8 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 9 1
Trav7-3, 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 9 14
Trav7-4., 7D-4 YFCAA SDANKM IFGLGTILRVRP Traj47 6 Trbv19 FLCAS RKLGNQDTQ YFGPGTRLLVL Trbj2-5 9 8
Trav8-1 or 8D-1 YFCAT ANSGGSNAKL TFGKGTKLSVKS Traj42 10 Trbv14 YLCAS SLGSGIQDTQ YFGPGTRLLVL Trbj2-5 10 2
Trav8-2 YFCAT DNNYAQGL TFGLGTRVSVFP Traj26(1) 8 Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 8 8
Trav8-2 YFCAT DNNYAQGL TFGLGTRVCVFP Traj26 8 Trbv5 YFCAS SQDRANTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav14-1 YFCAA SSNTDKV VFGTGTRLQVSP Traj34 7 Trbv19 FLCAS CIAGGSGNTL YFGEGSRLIVV Trbj1-3 10 1
38
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav2 YYCIV TVNTEGADRL TFGKGTQLIIQP Traj45 10 Trbv13-1 YFCAS SDPFSNERL FFGHGTKRSVL 9 1
Trav7-1 YFCAV RVGDNSKL IWGLGTSLVVNP Traj38 8 Trbv1 LYCTC SADRGGNTL YFGEGSRLIVV Trbj1-3 9 4
Trav7-3, 7D-3 YLCAV IDYANKM IFGLGTILRVRP Traj47 7 Trbv13-1 YFCAS TGQNYAEQ FFGPGTRLTVL Trbj2-1 8 25
Trav7-3, 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 9 21
51
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav6-4, 6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav6D-6 YYCAL SDSGGSNAKL TFGKGTKLSVKS Traj42 10 Trbv13-3 YFCAS SDGNSDY TFGSGTRLLVI Trbj1-2 7 1
Trav7-3, 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 9 5
Trav7-3, 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv13-2 YFCAS GDNNERL FFGHGTKLSVL Trbj1-4 7 1
Trav8-2 YFCAT DNNYAQGL TFGLGTRVSVFP Traj26(1) 8 Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 8 6
Trav9-3,9-4, 9D-4 YFCVL TINSAGNKL TFGIGTRVLVRP Traj17 9 Trbv13-2 YFCAS GDNNERL FFGHGTKLSVL Trbj1-4 7 15
Trav9-3,9-4, 9D-4 YFCVL TINSAGNKL TFGIGTRVLVRP Traj17 9 Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 8 1
Trav12-1 YFCAL SEDGSALGRL HFGAGTQLIVIP Traj18 10 Trbv13-2 YFCAS GDRGGSAETL YFGSGTRLTVL Trbj2-3 10 1
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Table 5.35 The analysis of CD8 clones in the pancreas of MUT1 secondary recipient mice (P2<P1, Plate CT63, 64). 
Table 5.36 The analysis of CD8 clones in the spleen of original donors of WT2 mice (S0, Plate CT29). 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav6-4, 6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 8 30
Trav7-3, 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 8 42
Trav13-1 YLCAM HQGGSAKL IFGEGTKLTVSS Traj57 8 Trbv13-2 YFCAS GGPGQGANERL FFGHGTKLSVL Trbj1-4 11 1
73
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav4-3, 4D-3 YFCAG ASSGSWQL IFGSGTQLTVMP Traj22 8 Trbv13-2 YFCAS GWGDYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav5D-4 YFCAA RQGGRAL IFGTGTTVSVSP Traj15 7 Trbv13-2 YFCAS GGGALYNSPL YFAAGTRLTVT Trbj1-6 10 1
Trav5D-4 YFCAA SDTNAYKV IFGKGTHLHVLP Traj30 8 Trbv17 YLCAS SSGNQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav5D-4 YFCAA SATEGADRL TFGKGTQLIIQP Traj45 9 Trbv31 YLCAW TGGTGQL YFGEGSKLTVL Trbj2-2 7 1
Trav6-3, 6D-3 YYCAM RDTEGADRL TFGKGTQLIIQP Traj45 9 Trbv13-3 YFCAS SDAGLQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6-4, 6D-4 YFCAL VATGGNNKL TFGQGTVLSVIP Traj56 9 Trbv26 YLCAS SPDREDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav6-5 YYCAL SDTNAYKV IFGKGTHLHVLP Traj30 8 Trbv19 FLCAS SIDRENTL YFGAGTRLSVL Trbj2-4 8 1
Trav6-5, 6D-6, 6D-7 YFCAL SMTNSAGNKL TFGIGTRVLVRP Traj17 10 Trbv19 FLCAS SIGWGEDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6D-7 YYCAL SDGNEKI TFGAGTKLTIKP Traj48 8 Trbv5 YFCAS SQEGGARDTL YFGAGTRLSVL Trbj2-4 10 1
Trav6D-7 YYCAL SDQESSSFSKL VFGQGTSLSVVP Traj50 11 Trbv19 FLCAS SIWGGYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav7D-2 YLCAA SNGSSGNKL IFGIGTLLSVKP Traj32 9 Trbv13-3 YFCAS SDAGQVSNERL FFGHGTKLSVL Trbj1-4 11 1
Trav7D-5 YLCAV TGGYKV VFGSGTRLLVSP Traj12 6 Trbv14 YLCAS SFAGEGTETL YFGSGTRLTVL Trbj2-3 10 1
Trav12-1 YYCAL TTASLGKL QFGTGTQVVVTP Traj24 8 Trbv16 YLCAS RLDTGRAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL DYSNNRL TLGKGTQVVVLP Traj7 7 Trbv13-2 YFCAS GDAGQAEV FFGKGTRLTVV Trbj1-1 8 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL DYSNNRL TLGKGTQVVVLP Traj7 7 Trbv19 FLCAS SIQNTL YFGEGSRLIVV Trbj1-3 6 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL SDQDNMGYKL TFGTGTSLLVDP Traj9 10 Trbv1 LYCTC SADQGGQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav13-1 YLCAM VNQGGSAKL IFGEGTKLTVSS Traj57 9 Trbv14 YLCAS RPGQNYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav13-2, 13D-2 YLCAI DHQGGRAL IFGTGTTVSVSP Traj15 8 Trbv16 YLCAS SPGTANTEV FFGKGTRLTVV Trbj1-1 9 1
Trav13-2, 13D-2 YLCAF GQGGSAKL IFGEGTKLTVSS Traj57 8 Trbv30 YFCSS IGTGGGEQ YFGPGTRLTVL Trbv2-7 8 1
Trav13-4/DV7 YLCAM ERGNEKI TFGAGTKLTIKP Traj48 7 Trbv16 YLCAS SFRLGVNQDTQ YFGPGTRLLVL Trbj2-5 11 1
Trav13D-4 YLCAM ESPSGSWQL IFGSGTQLTVMP Traj22 9 Trbv4(2) YLCAS SYTANSDY TFGSGTRLLVI Trbj1-2 8 1
Trav14-1 YFCAA SSDYGNEKI TFGAGTKLTIKP Traj48 9 Trbv1 LYCTC TYRGERL FFGHGTKLSVL Trbj1-4 7 1
Trav14-3 YFCAA SVTGSGGKL TLGAGTRLQVNL Traj44 9 Trbv13-3 YFCAS SWTGGATEV FFGKGTRLTVV Trbj1-1 9 1
Trav14D-3/DV8 YFCAA SDDSNNRI FFGDGTQLVVKP Traj31 8 Trbv3 YFCAS SHRGLAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav16, 16D/DV11 YFCAM REGANNNAP RFGAGTKLSVKP Traj43 9 Trbv13-1 YFCAS SDRQGLSNERL FFGHGTKLSVL Trbj1-4 11 1
Trav21/DV12 YHCIL RVRETGANTGKL TFGHGTILRVHP Traj52 12 Trbv13-3 YFCAS SHRGLSAETL YFGSGTRLTVL Trbj2-3 10 1
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Table 5.37 The analysis of CD8 clones in the spleen of WT2 primary recipient mice (S1, Plate CT42). 
Table 5.38 The analysis of CD8 clones in the spleen of WT2 secondary recipient mice (S2, Plate CT59). 
 
 
 
 
 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-1 YFCAV TGANTGKL TFGHGTILRVHP Traj52 8 Trbv14 YLCAS SWAGNSDY TFGSGTRLLVI Trbj1-2 8 1
Trav7-4, &-4D YFCAA SEQSTGNYKY VFGAGTRLKVIA Traj40 10 Trbv3 YFCAS SLAGEGDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav7-5 YLCAM TTASLGKL QFGTGTQVVVTP Traj24 8 Trbv2 YFCAS SQETVNTEV FFGKGTRLTVV Trbj1-1 9 1
Trav7D-3 YLCAV SLNNAGAKL TFGGGTRLTVRP Traj39 9 Trbv13-3 YFCAS GGDWGGTYEQ YFGPGTRLTVL Trbv2-7 10 1
Trav9-3, 4, 4-D YFCVF MATGGNNKL TFGQGTVLSVIP Traj56 9 Trbv13-3 YFCAS SETLSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav9D-3 YFCAV SGNSNNRI FFGDGTQLVVKP Traj31 8 Trbv16 YLCAS SSWGGNQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SGTNYAQGL TFGLGTRVSVFP Traj26 9 Trbv1 YCTCS ADRGPYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav13-2, 13D-2 YFCAI DGANTGKL TFGHGTILRVHP Traj52 8 Trbv13-3 YFCAS SWTGGQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav21/D12 YHCIL NPSGGNYKP TFGKGTSLVVHP Traj6 9 Trbv3 YFCAS SLAGEGDTQ YFGPGTRLLVL Trbj2-5 9 1
9
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav6-6 YYCAL GDYGNEKI TFGAGTKLTIKP Traj48 8 Trbv29 YFCAS SRQGNTGQL YFGEGSKLTVL Trbj2-2 9 2
Trav6-6, 6D-6 YYCAL AKRNNNNAP RFGAGTKLSVKP Traj43 9 Trbv4(2) YLCAS SQDWGANQDTQ YFGPGTRLLVL Trbj2-5 11 1
Trav13-2 YLCAL ELDYANKM IFGLGTILRVRP Traj47 8 Trbv13-3 YFCAS SDAGGANERL FFGHGTKLSVL Trbj1-4 10 2
Trav14-3 YFCAA DSSSGSWQL IFGSGTQLTVMP Traj22 9 Trbv3 YFCAS SLGARGERL FFGHGTKLSVL Trbj1-4 9 1
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Table 5.39 The analysis of CD8 clones in the spleen of original MUT2 donor mice (S0, Plate CT35). 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav1 YLCAE NQGGRAL IFGTGTTVSVSP Traj15 7 Trbv29 YFCAS SSTGQGAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav3-1 YFCAV SADSGSWQL IFGSGTQLTVMP Traj22 9 Trbv13-2 YFCAS GGLGGRGAETL YFGSGTRLTVL Trbj2-3 11 1
Trav5D-4 YFCAA SGGTGNYK YVFGAGTRLKVIA Traj40 8 Trbv13-3 YFCAS REQGANSD YTFGSGTRLLVI Trbj1-2 8 1
Trav6-1, 2, 3, D-3, 4, D-4, 5, 
D-5, 6, D-6, 7, D-7 YYCVL GEGTGGYKV VFGSGTRLLVSP Traj12 9 Trbv13-3 YFCAS RDFSAETL YFGSGTRLTVL Trbj2-3 8 1
Trav6-1, 2, 3, D-3, 4, D-4, 5, 
D-5, 6, D-6, 7, D-7 YFCAV SMNYNQGKL IFGQGTKLSIKP Traj23 9 Trbv26 YLCAS SLSQGGDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6-1, 2, 3, D-3, 4, D-4, 5, 
D-5, 6, D-6, 7, D-7 YFCAV NMGYKL TFGTGTSLLVDP Traj9 6 Trbv31 YLCAW SPGHLNTEV FFGKGTRLTVV Trbj1-1 9 1
Trav6-2 YYCVL GDTGGLSGKL TFGEGTQVTVIS Traj2 10 Trbv13-2 YFCAS GDMGGYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav6-5, D-5 YYCAL NNYAQGL TFGLGTRVSVFP Traj26(1) 7 Trbv31 YLCAW SEEV FFGKGTRLTVV Trbj1-1 4 1
Trav6D-7 YYCAL SEDNNAP RFGAGTKLSVKP Traj43 7 Trbv16 YLCASS LWGSSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav7-4 or D-4 YFCAA SDYGNEKI TFGAGTKLTIKP Traj48 8 Trbv29 YFCAS SLSQSQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav7D-5 YLCAV SDTGN YKYVFGA Traj40 5 Trbv1 LYCTC SADQDTEV FFGKGTRLTVV Trbj1-1 8 1
Trav7D-5 YLCAV SSNNNAGAKL TFGGGTRLTVRP Traj39 10 Trbv5 YFCAS SQYWGGYAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav9-3, 4, D-4 YFCVL SVDSNYQL IWGSGTKLIIKP Traj33 8 Trbv13-3 YFCAS SDGGEDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav9-3, 9-4 YFCVL SASNYNVL YFGSGTKLTVEP Traj21 8 Trbv31 YLCAW SHGNTEV FFGKGTRLTVV Trbj1-1 7 1
Trav9D-3, 4, D-4 YFCAV SSNYNQGKL IFGQGTKLSIKP Traj23 9 Trbv5 YFCAS SQDGGAQEQ YFGPGTRLTVL Trbv2-7 9 1
Trav10, 10D YFCAA SMDNNNAP RFGAGTKLSVKP Traj43 8 Trbv20 YLCGA RDSWDQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav12-1, D-1, 2, D-2, 3, D-3 YYCAL SGTGGLSGKL TFGEGTQVTVIS Traj2 10 Trbv1 LYCTC SAGREQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL STNAYKV IFGKGTHLHVLP Traj30 7 Trbv13-2 YFCAS GGQEDTQ YFGPGTRLLVL Trbj2-5 7 1
Trav13-1, D-1 YLCAL EQTGFASAL TFGSGTKVIPCLP Traj35 9 Trbv13-3 YFCAS SGDRTGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav13-1, D-1 YLCAM ASNTNKV VFGTGTRLQVLP 7 Trbv26 YLCAS SLYRGEDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav13-2 YLCAI RDSNYQL IWGSGTKLIIKP Traj33 7 YFCSS RPGLGAEQ YFGPGTRLTVL Trbv2-7 8 1
Trav14-3 YFCAA TSSGQKL VFGQGTILKVYL Traj16 7 Trbv13-2 YFCAS GDKNYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav16, 16D/DV11 YFCAM REGDGANTGKL TFGHGTILRVHP Traj52 11 Trbv13-3 YFCAS SDSGISNERL FFGHGTKLSVL Trbj1-4 10 1
Trav16, 16D/DV11 YFCAM REGNYGSSGNKL IFGIGTLLSVKP Traj32 12 Trbv19 FLCAS SMGLGYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav16, 16D/DV11 YFCAM REGNYGNEKI TFGAGTKLTIKP Traj48 10 Trbv19 FLCAS DSQNTL YFGAGTRLSVL Trbj2-4 6 1
Trav21/DV12 YHCIV RVDTGYQKF YFGKGTSLTVIP Traj49 9 Trbv1 LYCTC SAVLGTSAETL YFGSGTRLTVL Trbj2-3 11 1
Trav21/DV12 YHCIL RVRQQGTGSKL SFGKGAKLTVSP Traj58 11 Trbv1 LYCTC SARTGSSAETL YFGSGTRLTVL Trbj2-3 11 1
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Table 5.40 The analysis of CD8 clones in the pancreas of original MUT2 donor mice (P0, Plate CT24). 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav3-4 YFCAV SADTNAYKV IFGKGTHLHVLP Traj30 9 Trbv16 YLCAS SLGPTGTANTGQLYFGEGSKLTVL Trbj2-2 13 1
Trav3-4 YFCAV SGQMLTKSSLEKGH IFMFSLTSRTQ 14 Trbv4 YLCAS SSGTPSQNTL YFGAGTRLSVL Trbj2-4 10 1
Trav3-4 YFCAV IDSNYQL IWGSGTKLIIKP Traj33 7 Trbv3 YFCAS SLGSGDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav5D-4 YFCAA SEHYGNEKI TFGAGTKLTIKP Traj48 9 Trbv2 YFCAS SQDSQNTL YFGAGTRLSVL Trbj2-4 8 1
Trav5D-4 YFCAA SPNTNKV VFGTGTRLQVLP 7 Trbv19 FLCAS SIGNTEV FFGKGTRLTVV Trbj1-1 7 1
Trav6-3, 6D-3 YYCAM RDPSGGSNYKL TFGKGTLLTVTP Traj53 11 Trbv29 YFCAS SFQGSTGQL YFGEGSKLTVL Trbj2-2 9 1
Trav6-7/DV9 YYCAL GDSGYNKL TFGKGTVLLVSP Traj11 8 Trbv1 LYCTC SAATGGNAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GTGGNNKL TFGQGTVLSVIP Traj56 8 Trbv13-3 YFCAS SDAGSQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav7-4 or 7D-4 YFCAA SDVDYANKM IFGLGTILRVRP Traj47 9 Trbv13-2 YFCAS GERGVSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav7-4 or Trav7D-4 YFCAA SDVGDNSKL IWGLGTSLVVNP Traj38 9 Trbv26 YLCAS SLDREDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav7-4 or Trav7D-4 YFCAV SELSNYNVL YFGSGTKLTVEP Traj21 9 Trbv2 YFCAS SQEDRGYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav7-4, Trav7D-4 YFCAA SDVDYANKM IFGLGTILRVRP Traj47 9 Trbv13-2 YFCAS GERGVSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav7D-2 YLCAA SMDNMGYKL TFGTGTSLLVDP Traj9 9 Trbv19 FLCAS STGGTYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav7D-5 YLCAV SMKYRQINLWGWDRAHSEAKHPEPRT 8 Trbv19 FLCAS SIHTEV FFGKGTRLTVV Trbj1-1 6 1
Trav8-2 YFCAK DGNYAQGL TFGLGTRVSVFP Traj26(1) 8 Trbv29 YFCAS STGDAGQL YFGEGSKLTVL Trbj2-2 8 1
Trav9-1, D-1, 2, D-4 YFCAY NYAQGL TFGLGTRVSVFP Traj26(1) 6 Trbv19 FLCAS SIGGTNTGQL YFGEGSKLTVL Trbj2-2 10 1
Trav9-3 or 9-4 YFCAV STNAYKV IFGKGTHLHVLP Traj30 7 Trbv1 LYCTC SAEGTGGEYEQ YFGPGTRLTVL Trbv2-7 11 1
Trav9D-2, 2, 4 YFCAV ANYGNEKI TFGAGTKLTIKP Traj48 8 Trbv1 LYCTC SAGGQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav9D-3 YFCAV SANYNQGKL IFGQGTKLSIKP Traj23 9 Trbv5 YFCAS SQDGGNQNTL YFGAGTRLSVL Trbj2-4 10 2
,Trav14D-1 YFCAA SEDTGNYKY VFGAGTRLKVIA Traj40 9 Trbv31 YLCAW SPGLGGSNTGQLYFGEGSKLTVL Trbj2-2 12 1
Trav10 or 10D YFCAA SPQSNYKVL YFGSGTKLTVE 9 Trbv2 YFCAS SQEPNSGNTL YFGEGSRLIVV Trbj1-3 10 1
Trav12D-1, 2, D-2, 3, D-3 YYCAP NSNNRI FFGDGTQLVVKP Traj31 6 Trbv13-2 YFCAS GDWGSSQNTL YFGAGTRLSVL Trbj2-4 10 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SDSAYKV IFGKGTHLHVLP Traj30 7 Trbv5 YFCAS SQGGSGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SVTGNTGKL IFGLGTTLQVQP Traj37 9 Trbv14 YLCAS SSGGTQ YFGPGTRLLVL Trbj2-5 6 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SDRGTGSKL SFGKGAKLTVSP Traj58 9 Trbv31 YLCAW SRDWGYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SVGGSNYKL TFGKGTLLTVTP Traj53 9 Trbv13-1 YFCAS SEIGNEQ YFGPGTRLTVL Trbv2-7 7 1
Trav12D-1, 2, D-2, 3, D-3 YYCAL SEWGTGGYKV VFGSGTRLLVSP Traj12 10 Trbv31 YLCAW SELGGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav12D-1, 2, D-2, 3, D-3 YYCNY NVL YFGSGTKLTVEP Traj21 3 YLCAS SLGGGRAQNTLYFGAGTRLSVL Trbj2-4 11 1
Trav13-1 or ,Trav13D-4 YLCAM QGTGSKL SFGKGAKLTVSP Traj58 7 Trbv2 YFCAS SRDWGAAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav13-1 or Trav13D-4 YLCAM ENTGYQNF YFGKGTSLTVIP Traj49 8 Trbv4(2) YLCAS SLLGGLGTL YFGAGTRLSVL Trbj2-4 9 1
Trav13D-1 YLCAL ERGDSNYQL IWGSGTKLIIKP Traj33 9 Trbv31 YLCAW TGGTSAETL YFGSGTRLTVL Trbj2-3 9 1
Trav14-1 YFCAA SGNEKI TFGAGTKLTIKP Traj48 6 Trbv31 YLCAW SRGNQDTQ YFGPGTRLLVL Trbj2-5 8 1
Trav14-2 YFCAA SATSGSWQL IFGSGTQLTVMP Traj22 9 Trbv19 FLCAS SIPGAGNTL YFGEGSRLIVV Trbj1-3 9 1
Trav14-2 YFCAA SAQVVGQL TFGRGTRLQVYA Traj5 8 Trbv1 LYCTC LSADRHSNER FFGHGTERSVL Trbj1-4 10 1
Trav16 or Trav16D/DV11 YFCAM RENNNAGAKL TFGGGTRLTVRP Traj39 10 Trbv13-3 YFCAS RQGAVNSPL YSAAGTRLTV Trbj1-6 9 1
Trav16 or Trav16D/DV11 YFCAM RERDTGYQNF YFGKGTSLTVIP Traj49 10 Trbv13-1 YFCAS SVRTGYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav19 YLCAA GTGSKL SFGKGAKLTVSP Traj58 6 Trbv4(2) YLCAS SYLGGRQDTQ YFGPGTRLLVL Trbj2-5 10 1
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Table 5.41 The analysis of CD8 clones in the pancreas of MUT2 primary recipient mice (P1, Plate CT40). 
Table 5.42 The analysis of CD8 clones in the spleen of MUT2 secondary recipient mice (S2<S1, Plate CT45). 
Table 5.43 The analysis of CD8 clones in the spleen of MUT2 secondary recipient mice (S2<P1, Plate CT47). 
 
 
 
 
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa
Trav6-4, 6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 8 8
8
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav6-4 or Trav6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 8 3
3
Trav  Va N Ja Traj Length, aa Trbv  Vb N Jb Trbj Length, aa Frequency
Trav6-4 or Trav6D-4 YFCAL VDSNYQL IWGSGTKLIIKP Traj33 7 Trbv13-2 YFCAS GGNSSYEQ YFGPGTRLTVL Trbv2-7 9 1
Trav7-3 or 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv1 LYCTC SADREGHEQ YFGPGTRLTVL Trbv2-7 9 2
Trav7-3 or 7D-3 YLCAV NTGANTGKL TFGHGTILRVHP Traj52 9 Trbv5 YFCAS SQDRGQDTEV FFGKGTRLTV Trbj1-1 10 2
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Table 5.44 The analysis of CD4 clones in the spleen of WT3 secondary recipient mice (S2<S1, Plate CT22). 
Trav  Va  CDR3a Ja Traj Length, aa Trbv  Vb  CDR3b Jb Trbj Length, aa Frequency
Trav3-1, 3-4 YFCAV GTGNYKY VFGAGTRLKVIA Traj40 7 Trbv31 YLCAW SLGTGGVKETL YFGSGTRLTVL Trbj2-3 11 1
Trav4-2 YFCAA GTGGYKV VFGSGTRLLVSP Traj12 7 Trbv1 YCTCS ADWEGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav4-2 YFCAA GTGGYKV VFGSGTRLLVSP Traj12 7 Trbv1 YCTCS ADWEGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav4-2 YFCAA EASTNAYKV IFGKGTHLHVLP Traj30 9 Trbv19 FLCAS SPGTGDEQ YFGPGTRLTVL Trbv2-7 8 1
Trav4D-2 YFFAA ASSGSRQL IFGSGTQLTVMP Traj22 8 Trbv2 YFCAS SHGTVNSDY TFGSGTRLLVI Trbj1-2 9 1
Trav4D-2 YFCAA EASTNAYKV IFGKGTHLHVLP Traj30 9 Trbv5 YFCAS SQGDRTNTGQL YFGEGSKLTVL Trbj2-2 11 1
Trav4D-2 YFCAA DTNAYKV IFGKGTHLHVLP Traj30 7 Trbv31 YLCAW SQLGGGYAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav4D-2 YFCAA EAPNTNKV VFGTGTRLQVLP Traj34 8 Trbv19 FLCAS SPDWGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav5D-4 YFCAA SPNAYKV IFGKGTHLHVLP Traj30 7 Trbv2 YFCAS SQAGTGRDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav5D-4 YFCAA SPNAYKV IFGKGTHLHVLP Traj30 7 Trbv5 YFCAS SQGDRTNTGQL YFGEGSKLTVL Trbj2-2 11 1
Trav5D-4 YFCAA SGGDSNYKL TFGKGTLLTVTP Traj53 9 Trbv12-2 YFCAS SLGGSQDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav6-5 YYCAL LGSNMGYKL TFGTGTSLLVDP Traj9 9 Trbv23 YLCSS GTASAETL YFGSGTRLTVL Trbj2-3 8 1
Trav6-6 YYCAL GMSXHNL LYFGSGTKLT Traj21 7 Trbv15 YLCAS TGEGYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav6-6, 6D-6 YYCAL GDQSSSFSKL VFGQGTSLSVVP Traj50 10 Trbv2 YFCAS SQAGTGRDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav6-7/DV9, Trav6D-7 YYCAL RLTGSGGKL TLGAGTRLQVNL Traj44 9 Trbv20 YLCGA RSGGAAETL YFGSGTRLTVL Trbj2-3 9 1
Trav6D-4, 6-5, 6D-5, 6-66D-
6, 6-7/DV9, 6D-7 YCARG
SNMGYKL
TFGTGTSLLVDP Traj9 7 Trbv23
YLCSS
GTASAETL YFGSGTRLTVL Trbj2-3 8 1
Trav6D-5 YYCAL GSNMGYKL TFGTGTSLLVDP Traj9 8 Trbv23 YLCSS GTASAETL YFGSGTRLTVL Trbj2-3 8 1
Trav6D-5, 6-6, 6-7/DV9 YYCAL GMNTEGADRL TFGKGTQLIIQP Traj45 10 Trbv4 YLCAS SYYNSPL YFAAGTRLTVT Trbj1-6 1
Trav10, 10D YFCAA SINNRI FFGDGTQLVVKP Traj31 6 Trbv26 YLCAS SLTGGNTEV FFGKGTRLTVV Trbj1-1 9 1
Trav12-1 YYCAL SVTNTGKL TFGDGTVLTVKP Traj27 8 Trbv13-2 YFCAS GDAWGDGEQ YFGPGTRLTVL Trbv2-7 9 1
Trav12-1 YFCAF SGGNYKP TFGKGTSLVVHP Traj6 7 Trbv1 YCTCS ADWEGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav12-1 YFCAF SGGNYKP TFGKGTSLVVHP Traj6 7 Trbv16 YLCAS SLDWGNYAEQ FFGPGTRLTVL Trbj2-1 10 1
Trav12D-1, 12-2, 12D-2, 12-
3, 12D-3 YYCAL
SGGGGGNNKL
TFGQGTVLSVIP Traj56 10 Trbv31
YLCAR
SLSRGENSPL YFAAGTRLTVT Trbj1-6 10 1
Trav13-2 YLCAL ERGGSGGKL TLGAGTRLQVNL Traj44 9 Trbv13-2 YFCAS GDAQGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav13-4/DV7 YLCAM DTGYQNF YFGKGTSLTVIP Traj48 7 Trbv20 YLCGA QTGAYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav14-1 YFCAA SSTGNYKY VFGAGTRLKVIA Traj40 8 Trbv26 YLCAS LSLQGTNER FFGHGTKLSVL Trbj1-4 9 1
Trav14-1 YFCAA SRNNNAP RFGAGTKLSVKP Traj43 7 Trbv2 YFCAS SQDSNTEV FFGKGTRLTVV Trbj1-1 8 1
Trav14-1 YFCAA SGVSGGSNYKL TFGKGTLLTVTP Traj53 11 Trbv26 YLCAS SQGSQNTL YFGAGTRLSVL Trbj2-4 8 2
Trav14-2 YFCAA SESNNRI FFGDGTQLVVKP Traj31 7 Trbv31 YLWAW SLPRGGGEQ SFGPGTRLTVL Trbj2-1/7 9 1
Trav14-2 YFCAA SSTGNYKY VFGAGTRLKVI Traj40 8 Trbv26 YLCAS SLQGTNERL FFGHGTKLSV Trbj1-4 9 2
Trav14-3 YFCAA SGSNNRI FFGDGTQLVVKP Traj31 7 Trbv16 YLCAS SLDFGGXRGQNTL YFGAGTRLSVL Trbj2-4 13 1
Trav14D-3/DV8 YFCAA NYGNEKI TFGAGTKLTIKP Traj48 7 Trbv19 FLCAS SRTHSGNT YFGEGSRLIVV Trbj1-3 8 1
Trav16, 16D/DV11 YFCAM RGTSGRAL IFGTGTTVSVSP Traj15 8 Trbv19 FLCAS SPDKYEQ YFGPGTRLTVL Trbv2-7 7 1
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Table 5.45 The analysis of CD4 clones in the spleen of MUT3 secondary recipients receiving pancreas-infiltrating lymphocytes 
(S2<P1, Plate CT20). 
 
 
 
 
 
 
 
Trav  Va  CDR3a Ja Traj Length, aa Trbv  Vb  CDR3b Jb Trbj Length, aa Frequency
Trav1 YLCAV RDPTNAYKV IFGKXTHLHVLP Traj30 9 Trbv5 YFCAS SQDRTAYEQ YFGPGTRLTVL Trbj2-5 9 1
Trav3-3, Trav3D-3 YFCAV SEGNNNRI FFGDGTQLVVKP Traj31 8 Trbv20 YLCGA RYRDWGGFEQ YFGPGTRLTVL Trbv2-7 10 1
Trav4-3, 4D-3 YFCAA EANYGNEKI TFGAGTKLTIKP Traj48 9 Trbv20 YLCGA QGNYAEQ FFGPGTRLTVL Trbj2-1 7 1
Trav4-4/DV10 YFCAA EGSSNTDKV VFGTGTRLQVSP Traj34 9 Trbv20 YLCGA IQGYEQ YFGPGTRLTVL Trbv2-7 6 1
Trav4-4/DV10 YFCAA VNNNNAP RFGAGTKLTVKP Traj43 7 Trbv13-2 YFCAS GTGGYNSPL YFAAATRLTVT Trbj1-6 9 1
Trav4D-2, 4-3, 4D-3, 
4/DV10 YFCAA EANYGNEKI TFGAGTKLTIKP Traj48 9 Trbv20 YLCGA QGNYAEQ FFGPGTRLTVL Trbj2-1 7 1
Trav7-5 YLCAM SMRGGSALGRL HFGAGTQLIVIP Traj18 11 Trbv31 YLCAW SLGLGGRYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav7D-5 YXCAV SAHYGSSGNKL IFGIGTLLSVKP Traj32 11 Trbv13-2 YFCAS GDPGLGNYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav8-1, 8D-1 YFCAT GGSNAKL TFGKGTKLSVKS Traj42 7 Trbv5 YFCAS SQEGQGQDTQ YFGPGTRLLVL Trbj2-5 10 1
Trav8-2 YFCAT DKRNSNNRI FFGDGTQLVVKP Traj31 9 Trbv13-2 YFCAS GPQGYAEQ FFGPGTRLTVL Trbj2-1 8 1
Trav13D-1 YLCAM GDNNAGAKL TFGGGTRLTVRP Traj39 9 Trbv20 YLCGA RDNYAEQ FFGPGTRLTVL Trbj2-1 7 3
Trav14-1 YXCAA SAGXGGGGKL TLGAGTRLQVNL Traj44 10 Trbv20 YLCGA SDWGYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav14-2 YFCAA SPNNNNAP RFGAGTKLTVKP Traj43 8 Trbv13-1 YFCAS SAGTGGNSDY TFGSGTRLLVI Trbj1-2 10 1
Trav16, 16D/DV11 YFCAM RAWTGGYKV VFGSGTRLLVSP Traj12 9 Trbv26 YLCAS TPGQGANSDY TFGSGXRLLVI Trbj1-2 10 1
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Table 5.46 The analysis of CD4 clones in the pancreas of MUT3 secondary recipients receiving pancreas-infiltrating 
lymphocytes (P2<P1, Plate CT17). 
 
 
 
 
 
 
 
Trav  Va  CDR3a Ja Traj Length, aa Trbv  Vb  CDR3b Jb Trbj Length, aa Frequency
Trav6-3, D-3 YYCAM RENNAGAKL TFGGGTRLTVRP Traj39 9 Trbv13-3 YFCAS SPDRDSDF TFGSGTRLXVI Trbj1-2 8 1
Trav6D-5 YYCAL LGSNMGYK TFGTGTSLLVDP Traj9 8 Trbv23 YLCSS GTASAETL YFGSGTRLTVL Trbj2-3 8 1
Trav7-3, D-3 YLCAV SIFGGSNAKL TFGKGTKLSVKS Traj42 10 Trbv31 YLCAW SLYSSAETL YFGSGTRLTVL Trbj2-3 11 1
Trav7-4, 7D-4 YFCAA SEPNSGGSNAKL TFGKGTKLSVKS Traj42 12 Trbv5 YFCAS SQTENTL YFGAGTRLSVL Trbj2-4 7 1
Trav7-5 YLCAG SNTGANTGKL TFGHGTILRVHP Traj52 10 Trbv20 YLCGA RQGSYEQ YFGPGTRLTVL Trbv2-7 7 1
Trav7D-5 YLCAG SNTGANTGKL TFGHGTILRVHP Traj52 10 Trbv20 YLCGG ARQGSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav8-1, 8D-1 YFCAT GGNYAQGL TFGLGTRVSVFP Traj26 8 Trbv1 YCTCS ADWEGQNTL YFGAGTRLSVL Trbj2-4 9 1
Trav13D-1 YLCAM GDNNAGAKL TFGGGTRLTVRP Traj39 9 Trbv20 YLCGG ARQGSYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav14-1 YFCAA SGVSGGSNYKL TFGKGTLLTV Traj53 11 Trbv26 YLCAS SQGSQNTL YFGAGTRLSVL Trbj2-4 8 1
Trav14-3 YFCAA TGANTGKL TFGHGTILRVHP Traj52 8 Trbv4 YLCAS SPRQIYEQ YFGPGTRLTVL Trbv2-7 8 1
Trav14D-3/DV8 YFCAA SANSGTYQ RFGTGTKLQVVP Traj13 8 Trbv5 YFCAS SPGANSDY TFGSGTRLLV Trbj1-2 8 1
Trav16, 16D/DV11 YFCAM RAWTGGYKV VFGSGTRLLVSP Traj12 Trbv26 YLCAS SPGQGANSDV YTFGSGTRLL Trbj1-2 10 1
Trav21/DV12 YHCIL RANSGGS NYKLTFGKGTLLTVTP Traj53 7 Trbv31 YLCAW SYNYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav21/DV12 YHCIL RANSGGSNYKL TFGKGTLLTVTP Traj53 11 Trbv31 YLCAW SYNYAEQ FFGPGTRLTVL Trbj2-1 7 2
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Table 5.47 The analysis of CD8 clones in the spleen of WT3 secondary recipients (S2<S1, Plate CT21). 
 
 
 
Trav  Va  CDR3a Ja Traj Length, aa Trbv  Vb  CDR3b Jb Trbj Length, aa Frequency
Trav3-1 YFCAV SAGRASNTNKV VFGTGTRLQVLP Traj34 11 Trbv13-3 YLCAS SDEGAGTGQL YFGEGSKL Trbj2-2 10 1
Trav4-2 or Trav4D-2 YFCAA ASGGSNYKL TFGKGTLLTVTP Traj53 9 Trbv17 YLCAS SRKGGEQ YFGPGTRLTVL Trbv2-7 7 1
Trav4-3 or Trav4D-3 YFCAA EGGSAKL IFGEGTKLTVSS Traj57 7 Trbv19 FLCAS SMGLGYEQ YFGPGTRLTV Trbv2-7 8 5
Trav4-3 YFCAA EGGSAKL IFGEGTKLTVSS Traj57 7 Trbv19 FLCAS SMGLGYEQY FGPGTRLTVL Trbj2-1 8 1
Trav4-3 YFCAA EGGSAKL IFGEGTKLTVSS Traj57 7 Trbv19 VFLCAS SMGLGYEQ YFGPGTRLTV Trbv2-7 8 1
Trav6-2 YYCVL GFTGSGGKLT LGAGTRLQVNL Traj44 10 Trbv13-2 YFCAS GDAWGVSAETL YFGSGTRL Trbj2-3 11 1
Trav6-6 YYCAL GDANSAGNKL TFGIGTRVLVRP Traj17 10 Trbv13-1 YFCAS SGTGGYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav6-6 YCAL GNSNNRI FFGDGTQLVVKP Traj31 7 Trbv17 YLCAS KQGARDTQ YFGPGTRLLV Trbj2-5 8 1
Trav6D-6 YYCAL GDANSAGNKL TFGIGTRVLVRP Traj17 10 Trbv13-1 YFCAS SGTGGYAEQ FFGPGTRLT Trbj2-1 9 1
Trav7-1 YFCAV SSSGSWQL IFGSGTQLTV Traj22 8 Trbv1 YCTCS GDSSGNTL YFGEGSRLIVV Trbj1-3 8 1
Trav7D-5 YLCAV GASSSFSKL VFGQGTSLSVVP Traj50 9 Trbv1 YCTCS AHRGSYNSPL YFAAGTRLTV Trbj1-6 10 1
Trav8-1 or Trav8D-1 YFCAT PSNTNKV VFGTGTRLQVLP Traj34 7 Trbv19 FLCAS SDWGGYEQ YFGPGTRLTV Trbv2-7 8 1
Trav8-2 YFCAT DFNTNKV VFGTGTRLQV Traj34 7 Trbv13-3 YFCAS RTGGAYEQ YFGPGTRLTV Trbv2-7 8 1
Trav10 or Trav10D YFCAA SSTGGYKV VFGSGTRLLVSP Traj12 8 Trbv13-2 YFCAS GDAGVQDTQ YFGPGTXLLVL Trbj2-5 9 1
Trav13-1 YLCAM ESSSGSWQL IFGSGTQLT Traj22 Trbv13-2 YFCAS GDGRGSYEQ YFGPGTRLTV Trbv2-7 9 1
Trav13-2 YLCAI SGSFNKLT FGAGTRLAVCP Traj40 8 Trbv5 YFCAS SQGETL YFGSGTRLTV Trbj2-3 6 1
Trav13-4/DV7 YLCAM DQGGSAKL IFGEGTKLTVSS Traj57 8 Trbv14 YLCAS RQVNQDTQ YFGPGTRLLV Trbj2-5 8 1
Trav16 or Trav16D YFCAM REGDQGGRAL IFGTGTTV Traj15 10 Trbv13-2 YFCAS GDGRGSYEQ YFGPGTRLTV Trbv2-7 9 1
Trav16 or Trav16D YFCAM REGDQGGRAL IFGTGTTVSV Traj15 Trbv13-1 YFCAS SDGGAREQ YFGPGTRLTV Trbv2-7 8 1
Trav19 YLCAA GTGGNNKL TFGQGTVLSVIP Traj56 8 Trbv14 YLCAS RQVNQDTQ YFGPGTRLLV Trbj2-5 8 1
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Table 5.48 The analysis of CD8 clones in the spleen of MUT3 secondary recipients receiving pancreas-infiltrating lymphocytes 
(S2<P1, Plate CT19). 
Table 5.49 The analysis of CD8 clones in the pancreas of MUT3 secondary recipients receiving pancreas-infiltrating 
lymphocytes (P2<P1, Plate CT16). 
 
Trav  Va  CDR3a Ja Traj Length, aa Trbv  Vb  CDR3b Jb Trbj Length, aa Frequency
Trav7-1 YFCAV SSSGSWQL IFGSGTQLTVMP Traj22 8 Trbv1 YCTCS GDSSGNTL YFGEGSRLIVV Trbj1-3 8 12
Trav7-1 YFCAV SGGSNYQL IWGSGTKLIIKP Traj33 8 Trbv1 YCTCS GDRGGNTL YFGEGSRLIVV Trbj1-3 8 8
Trav12D-1, 2, D-2, 3 YYCAL SDTSSGQKL VFGQGTILKVYL Traj16 9 Trbv14 YLCAS SFGTGAYAEQ FFGPGTRLTVL Trbj2-1 10 7
Trav1 YLCAV RPNSGTYQ RFGTGTKLQVVP Traj13 8 Trbv13-3 YFCAS SGTDRASQNTL YFGAGTRLSVL Trbj2-4 11 1
Trav4-3, 4D-3 YFCAA EGYQNF YFGKGTSLTVIP Traj49 6 Trbv31 YLCAW SLAYEQ YFGPGTRLTVL Trbv2-7 6 1
Trav7-1 YFCAV SSSGSWQL IFGSGTQLTVMP Traj22 8 Trbv19 FLCAS SIQNSYNSPL YFAAGTRLTVT Trbj1-6 10 1
Trav7-1 YLCAV TSGGNYKP TFGKGTSLVVHP Traj6 8 Trbv13-1 YFCAS SDERTGSYAEQ FFGPGTRLTVL Trbj2-1 11 1
Trav7-1 YFCAV SSSGSWQL IFGSGTQLTVMP Traj22 8 Trbv13-1 YFCAS SDERTGSYAEQ FFGPGTRLTVL Trbj2-4 11 1
Trav7D-2 YLCAA SNYSNNRL TLGKGTQVVVLP Traj7 8 Trbv13-1 YFCAS SEGQNTL YFGAGTRLSVL Trbj2-4 7 1
Trav8D-2 XFCAT DYNQGKL IFGQGTKLSIKP Traj23 7 Trbv17 YLCAS SRAGGEDTQ YFGPGTRLLVL Trbj2-5 9 1
Trav12-1 YFCAL SEGGPGRQSSD IWNRNHGISQP 11 Trbv1 YCTCS GDRGGNTL YFGEGSRLIVV Trbj1-3 8 1
Trav12D-1, 2, D-2, 3 YYCAL SGNTGYQNF YFGKGTSLTVIP Traj49 9 Trbv1 LYCTC SGDRGGNTL YFGEGSRLIVV Trbj1-3 8 1
Trav14-3 YFCAA SRGTQVVGQL TFGRGTRLQVYA Traj5 10 Trbv26 YLCAS SLWDWSSYEQ YFGPGTRLTVL Trbv2-7 10 1
37
Trav  Va  CDR3a Ja Traj Length, aa Trbv  Vb  CDR3b Jb Trbj Length, aa Frequency
Trav7-1 YFCAV SSSGSWQL IFGSGTQLT Traj22 8 Trbv1 YCTCS GDSSGNTL YFGEGSRLIVV Trbj1-3 8 29
Trav7-1 YFCAV SGGSNYQL IWGSGTKL Traj33 8 Trbv1 YCTCS GDSSGNTL YFGEGSRLIVV Trbj1-3 8 9
Trav1 YLCAV RPNSGTYQ RFGTGTKLQV Traj13 8 Trbv13-3 YFCAS SGTDRASQNTL YFGAGTRLSVL Trbj2-4 11 1
Trav6-6 YCAL GLNNYAQGL TFGLGTRVSV Traj26 9 Trbv13-1 YFCAS SADRNYAEQ FFGPGTRLTVL Trbj2-1 9 1
Trav12D-1, 2, D-2, 3 YYCAL SGNTGYQNF YFGKGTSLTV Traj49 9 Trbv1 YCTCS DRANSPL YFAAGTRLTVT Trbj1-6 7 1
Trav14D-1 YFCAA SRDDSAGNKL TFGIGTRV Traj17 10 Trbv16 YLCAS SLAGGRFAETL YFGSGTRL Trbj2-3 11 1
42
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